CD19-binding polypeptides, compositions comprising the same, and methods for use thereof

Abstract

As described below, the present disclosure features polypeptides capable of binding a cluster of differentiation 19 (CD19) antigen and polynucleotides encoding said CD19-binding polypeptides, compositions comprising the same, and methods for use thereof. The disclosure also features lipid nanoparticles comprising the CD19-binding polypeptides and methods for use thereof for delivery of a polynucleotide (e.g., a polynucleotide encoding a chimeric antigen receptor) to a T cell in vivo.

Description

[0001] CD19-BINDING POLYPEPTIDES, COMPOSITIONS COMPRISING THE SAME, AND METHODS FOR USE THEREOF CROSS REFERENCE TO RELATED APPLICATIONS The present application claims priority to U.S. Provisional Application No.63 / 612,146 filed December 19, 2023, the entire contents of which are hereby incorporated by reference in their entirety. SEQUENCE LISTING This application contains a Sequence Listing which has been submitted electronically in XML format and is hereby incorporated by reference in its entirety. The Sequence Listing XML file, was created on December 6, 2024, is named 180802-056302PCT_SL.xml, and is 1,876,629 bytes in size. BACKGROUND Autologous and allogeneic immunotherapies are neoplasia treatment approaches in which immune cells expressing chimeric antigen receptors are administered to a subject. To generate an immune cell that expresses a chimeric antigen receptor (CAR), an immune cell of a subject (autologous) or from a donor separate from the subject receiving treatment (allogeneic) is genetically modified to express the chimeric antigen receptor. The cells may be genetically modified within the subject or modified in vitro and subsequently administered to the subject. The resulting cell expresses the chimeric antigen receptor on its cell surface (e.g., CAR-T cell) and the chimeric antigen receptor binds to an antigen expressed by a pathogenic cell in the subject, such as a neoplastic cell. This interaction with the antigen activates the CAR-T cell, which then kills the neoplastic cell. There are various challenges to be overcome when administering an autologous or allogeneic immunotherapy to a subject. For example, autologous cell therapies traditionally have disadvantages associated with having to usually obtain the starting material from the patient to be treated, including long manufacturing times and the requirement that the patient cells are suitable despite previous therapies or disease state. Further, for allogeneic cell therapy, graft-versus-host disease (GVHD) and host rejection of CAR-T cells provide additional challenges. Thus, there is a significant need for improved methods and compositions for use in autologous and allogeneic immunotherapies. SUMMARY As described below, the present disclosure features polypeptides capable of binding a cluster of differentiation 19 (CD19) antigen and polynucleotides encoding said CD19-binding polypeptides, compositions comprising the same, and methods for use thereof. The disclosure also features lipid nanoparticles comprising the CD19-binding polypeptides and methods for use thereof for delivery of a polynucleotide (e.g., a polynucleotide encoding a chimeric antigen receptor) to a T cell in vivo. In one aspect, the disclosure features a VHH antibody or an antigen binding fragment thereof that specifically binds to a cluster of differentiation 19 (CD19) polypeptide. The VHH antibody contains three Complementarity Determining Regions (CDRs): CDR1, CDR2 and CDR3, that are structurally positioned between four camelid VHH framework (FR) regions (FR1-FR4) as follows: FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4. CDR1 is selected from one or more of:FYSIG (SEQ ID NO: 543),GYTIG (SEQ ID NO: 544),SYTIG (SEQ ID NO: 545), FNFMA (SEQ ID NO: 546),FNTMG (SEQ ID NO: 547),IDDMG (SEQ ID NO: 548),IDAMA (SEQ ID NO: 549),MNAMG (SEQ ID NO: 550),INAMA (SEQ ID NO: 551),PNDMG (SEQ ID NO: 552),VNDMG (SEQ ID NO: 553),GWQMG (SEQ ID NO: 554),NHGMG (SEQ ID NO: 594), SFAID (SEQ ID NO: 595),DYSMD (SEQ ID NO: 596),STIMG (SEQ ID NO: 597),TMA, GHGMG (SEQ ID NO: 598),NTMA (SEQ ID NO: 1195),NYGMM (SEQ ID NO: 599),LYAMA (SEQ ID NO: 600),GYYMS (SEQ ID NO: 601),SYTMG (SEQ ID NO: 602),INNIN (SEQ ID NO: 603),SYAMG (SEQ ID NO: 604),TYTMG (SEQ ID NO: 605), and NYAMG (SEQ ID NO: 643). CDR2 is selected from one or more of: CITWSGERTNYKDSVKG (SEQ ID NO: 555), CISRSDTSTKYADSVKG (SEQ ID NO: 556),CISRSTSDARYADSVKG (SEQ ID NO: 557), SITGGSRLSYIDSVKG (SEQ ID NO: 558),RITMSGIPNYADSVKG (SEQ ID NO: 559), TITAGGIANYADSAKG (SEQ ID NO: 560),SITAGGITKYADSAKG (SEQ ID NO: 561), TITAGGITNYASSAKG (SEQ ID NO: 562),TITAGGITKYGDSAKG (SEQ ID NO: 563), SITAGRITKYADSAKG (SEQ ID NO: 564),TITAGGITNYADSAKG (SEQ ID NO: 565), TITAGGITKYADSAKG (SEQ ID NO: 566),SITAGGITNYADSAKG (SEQ ID NO: 567), FSSSGGITNYADSVKG (SEQ ID NO: 568),TITDNDFTYYAASVKD (SEQ ID NO: 569), VITSGGSTNYADSVKG (SEQ ID NO: 570),IITDGGITNYAATVKG (SEQ ID NO: 571), ASYSGGSTNYADSVKG (SEQ ID NO: 572),AIYSGGSTNYADSVKG (SEQ ID NO: 573), SISMSDGSTSYQDSVKG (SEQ ID NO: 574),GSYTDGSTYYADSVKG (SEQ ID NO: 606), AINRGGDRTYYSDSVKG (SEQ ID NO: 607),AINRNGGSTYYAESMKG (SEQ ID NO: 608), ISARSGDSESYASSVKD (SEQ ID NO: 609),AITWSGGLTYYEDSVKG (SEQ ID NO: 610), AISWSGGLTYYGDSVKG (SEQ ID NO: 611),AISWSGGLTYYADSVKG (SEQ ID NO: 612), AIAWNSGLTYYGDSVKG (SEQ ID NO: 613),AISWSGVSTAYADSVKG (SEQ ID NO: 614), YIDSGGGSTYYTDSVRG (SEQ ID NO: 615),DISNGGVTTRYADSVKG (SEQ ID NO: 616), SIYSDDSNTYYADSVKG (SEQ ID NO: 617),AVNWDNVKNYADPVKG (SEQ ID NO: 618), TTRWRGDSTYYADSVAG (SEQ ID NO: 619),TISLSGGSTFYSDSAKG (SEQ ID NO: 620), TISLSGGSTFYSGSAKG (SEQ ID NO: 621),AISSSGDSTYYTDSVKG (SEQ ID NO:622), AITWSGGSTYYANSVKG (SEQ ID NO: 644),AISWSGGSTYYANSVKG (SEQ ID NO: 645), DISWSGGTTNYANSVKG (SEQ ID NO: 646),AINWSGGRIYYTDSVKG (SEQ ID NO: 647), AIRWSGGSTYYGDSVKG (SEQ ID NO: 648),AISWSGGRIYYADSVKG (SEQ ID NO: 649), AISWSGGSIYYADSVKG (SEQ ID NO: 650),AISWSGGSTYYADSVKG (SEQ ID NO: 651), AISWRGVNTYYADSVKG (SEQ ID NO: 652), and AISWSGGGTYYADSVKG (SEQ ID NO: 653). CDR3 is selected from one or more of:DSGYPCYGSSWSSVGYDF (SEQ ID NO: 575), SLQSGLLSRFLLPRQYDH (SEQ ID NO: 576),SRQTGLLSTFLLPRQYDH (SEQ ID NO: 577), SSPFAGEF (SEQ ID NO: 578),EHSGY (SEQ ID NO: 579),IRRYYPRFDY (SEQ ID NO: 580), VRRYYPRFDY (SEQ ID NO: 581),IRKYYPRFDY (SEQ ID NO: 582),VRKYYPRFDY (SEQ ID NO: 583),IRRSYPRFDY (SEQ ID NO: 584),IRKFYPRFDY (SEQ ID NO: 585),IRRFYPRFDY (SEQ ID NO: 586),DILQSGWYTY (SEQ ID NO: 587),DGIYSGGRYYPSS (SEQ ID NO: 588), DLVYYSGNPGDYGMDY (SEQ ID NO: 589),NIPYPRVSS (SEQ ID NO: 590), DLVVVTTTPPSFPMPYRFLEV (SEQ ID NO: 591),DIVVVTTTPPSFPMPYRFLEV (SEQ ID NO: 592),RSRFGFEY (SEQ ID NO: 779),RQYYRSGYVDY (SEQ ID NO: 623), GGRVSADGKKWEYDY (SEQ ID NO: 624),NTGAGTI (SEQ ID NO: 625), RSTFRTALVNTVTAYDT (SEQ ID NO: 626),RTTFRTGLIVTVTAYDT (SEQ ID NO: 627), RRTFRTALINTVTAYDT (SEQ ID NO:628),RRTFRTALINTITAYDT (SEQ ID NO: 629), RRTFRTGLINTVTAYDT (SEQ ID NO: 630),RRTFRTGLIDTVTAYDT (SEQ ID NO: 631), GLYSRPTTERREYIY (SEQ ID NO: 632),GLYSRPTTERRDYIY (SEQ ID NO: 633), AIGVVSGSLEV (SEQ ID NO: 634),TTTGWRA (SEQ ID NO: 635),SATLRGRDTRFDY (SEQ ID NO: 636),GTNLPTRGSGS (SEQ ID NO: 637),GTNLPTIESGS (SEQ ID NO: 638), KGGVDV (SEQ ID NO: 639),RPVLISRSSTDYAY (SEQ ID NO: 640),RPVLISRSSIDYAY (SEQ ID NO: 641),GEEVAGKYFRALYDY (SEQ ID NO: 642), GEEVAGKYFRPLYDY (SEQ ID NO: 654),GEEVAGKYFRQLYDY (SEQ ID NO: 655),GEEVDGKYFRPLYDY (SEQ ID NO: 656), GTNWSIPPDY (SEQ ID NO: 657),DPIGLGYEMGEYDY (SEQ ID NO: 658),DDFERTMTEVRY (SEQ ID NO: 659),DGTLRTPMNLIHY (SEQ ID NO: 660),DPSLSRTMDEIGS (SEQ ID NO: 661), and GPLGATMSEIGS (SEQ ID NO: 662). In another aspect, the disclosure features a chimeric antigen receptor (CAR) polypeptide containing the VHH antibody of any aspect or embodiment of the disclosure, or an antigen- binding fragment thereof. In another aspect, the disclosure features an immunoconjugate containing the VHH antibody of any aspect or embodiment of the disclosure. In another aspect, the disclosure features a polynucleotide encoding the VHH antibody or the CAR of any aspect or embodiment of the disclosure. In another aspect, the disclosure features a vector containing the polynucleotide of any aspect or embodiment of the disclosure. In another aspect, the disclosure features a cell expressing the VHH antibody, the CAR, the polynucleotide, or the vector of any aspect or embodiment of the disclosure. In another aspect, the disclosure features a lipid nanoparticle containing the VHH antibody or the polynucleotide of any aspect or embodiment of the disclosure. In another aspect, the disclosure features a composition containing the VHH antibody, the chimeric antigen receptor, the immunoconjugate, the polynucleotide, the vector of claim 15, the cell, or the lipid nanoparticle of any aspect or embodiment of the disclosure, and a carrier or excipient. In another aspect, the disclosure features a method for treating a disease in a subject in need thereof. The method involves administering to the subject the lipid nanoparticle of any aspect or embodiment of the disclosure. In another aspect, the disclosure features a chimeric antigen receptor (CAR) containing an amino acid sequence having at least 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to a sequence selected from one or more of, or a fragment thereof: MALPVTALLLPLALLLHAARPEVQLVESGGGLVQPGGSLRLSCAASGFALDGYTIGWFRQAPGK EREGVACISRSDTSTKYADSVKGRFTISRDNAKRTVSLQMNSLKPEDTAVYYCAASLQSGLLSR FLLPRQYDHWGQGTQVTVSSTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFAC DIYIWAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGG CELRVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNE LQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR (SEQ ID NO: 785); MALPVTALLLPLALLLHAARPQLQLVESGGGLVQPGGSLRLSCVASGFALDSYTIGWFRQAPGK EREGLSCISRSTSDARYADSVKGRFTISRDNAKTTVSLLMSSLKPEDTAVYYCAASRQTGLLST FLLPRQYDHWGQGTQVTVSSTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFAC DIYIWAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGG CELRVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNE LQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR (SEQ ID NO: 786); MALPVTALLLPLALLLHAARPQVQLVESGGGLVQPGGSLRLSCAASGFSLDFYSIGWFRQAPGK EREGVSCITWSGERTNYKDSVKGRFTISRDDAKATVFLQMNNLKPEDTAVYYCAADSGYPCYGS SWSSVGYDFWGQGTQVTVSSTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFAC DIYIWAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGG CELRVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNE LQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR (SEQ ID NO: 787); MALPVTALLLPLALLLHAARPQVQLVESGGGSVEPGGSLRLSCATSGLILSNHGMGWARQVPGK EVEWVSGSYTDGSTYYADSVKGRFTISRDNVKNTVYLQMNSLKPEDTAVYYCAARQYYRSGYVD YWGQGTQVTVSSTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPL AGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVKFS RSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAE AYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR (SEQ ID NO: 788); MALPVTALLLPLALLLHAARPQVQLVESGGGKVQPGGSLRLSCAASGFTFSNYGMMWVRQAPGK GLEWVSYIDSGGGSTYYTDSVRGRFTISRDNAKNTVYLQMNSLKPEDTAVYYCAKAIGVVSGSL EVWGQGTLVTVSSTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAP LAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVKF SRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMA EAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR (SEQ ID NO: 789); MALPVTALLLPLALLLHAARPQVQLVESGGGLVQAGGSLRLSCAASGRTFTSYAMGWFRQAPGK EREFVAAISWRGVNTYYADSVKGRFTISRENAKNTVYLQMISLKPEDTAVYYCAAGPLGATMSE IGSWGQGTQVTVSSTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWA PLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVK FSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKM AEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR (SEQ ID NO: 790); MALPVTALLLPLALLLHAARPEVQLVESGGGLVQAGGSLRLSCAASGRTFSNYAMGWFRQAPGK EREFVSAISWSGGSTYYADSVKGRFTISRDNAKNTVYLQMISLKPEDTAVYYCAAGPLGATMSE IGSWGQGTQVTVSSTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWA PLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVK FSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKM AEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR (SEQ ID NO: 791); MALPVTALLLPLALLLHAARPQVQLVESGGGLVQAGGSLRLSCAASGRTVSSYAMGWFRQAPGK EREFVAAISWSGGGTYYADSVKGRFTISRDNAKNTVYLQMISLKPEDTAVYYCAAGPLGATMSE IGSWGQGTQVTVSSTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWA PLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVK FSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKM AEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR (SEQ ID NO: 792); MALPVTALLLPLALLLHAARPQVQLVESGGGLVQAGGSLRLSCAASGRTVSSYAMGWFRQAPGK EREFVAAISWSGGSTYYADSVKGRFTISRDNAKNTVYLQMISLKPEDTAVYYCAAGPLGATMSE IGSWGQGTQVTVSSTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWA PLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVK FSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKM AEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR (SEQ ID NO: 793); MALPVTALLLPLALLLHAARPEVQLVESGGGLAQPGGSLRLSCVASGFAFGSFAIDWVRQPPGK GPEWVSAINRGGDRTYYSDSVKGRFTISRDNAKNTLYLQLNSLKPEDTAVYLCAAGGRVSADGK KWEYDYWGQGTQVTVSSTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIY IWAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCEL RVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQK DKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR (SEQ ID NO: 794); MALPVTALLLPLALLLHAARPEVQLVESGGGLVHAGGSLRLSCAASGRTFNTMAWFRQAPGKER EFVAAIAWNSGLTYYGDSVKGRFTIFRDNAKNLAYLQMNSLKPEDTAVYSCAARRTFRTGLINT VTAYDTWGQGTQVTVSSTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIY IWAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCEL RVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQK DKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR (SEQ ID NO: 795); MALPVTALLLPLALLLHAARPEVQLVESGGGLVHAGGSLRLSCVASGRTFNTMAWFRQAPGKER EFVAAISWSGGLTYYGDSVKGRFTIFRDNAKNLAYLQMNSLKPEDTAVYSCAARRTFRTALINT ITAYDTWGQGTQVTVSSTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIY IWAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCEL RVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQK DKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR (SEQ ID NO: 796); MALPVTALLLPLALLLHAARPEVQLVESGGGLVQAGGSLRLSCAASGNIVDIDDMGWYRQAPGR DLVASITAGGITKYADSAKGRFTISRDNVKNTVYLQMNSLKPEDTATYYCYAVRRYYPRFDYWG QGTQVTVSSTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGT CGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVKFSRSA DAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYS EIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR (SEQ ID NO: 797); MALPVTALLLPLALLLHAARPEVQLVESGGGLVQAGGSLRLSCAASGNIVEIDDMGWYRQAPGK QRDLVATITAGGITNYASSAKGRFTISRDNVKNTVYLQMNSLKPEDTATYYCYAIRKYYPRFDY WGQGTQVTVSSTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLA GTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVKFSR SADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEA YSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR (SEQ ID NO: 798); MALPVTALLLPLALLLHAARPEVQLVESGGGLVQAGGSLRLSCAASGRTFRSYAMGWFRQAPGK EREFVAAISWSGGRIYYADSVKGRFTISRDNAKNTVYLQMNSLKPEDTAVYYCAADDFERTMTE VRYWGQGTQVTVSSTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWA PLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVK FSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKM AEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR (SEQ ID NO: 799); MALPVTALLLPLALLLHAARPEVQLVESGGGLVQPGGSLRLSCAASGFTFSGYYMSWVRQAPGK GLEWVSSIYSDDSNTYYADSVKGRFTISRDNAKNTVYLQMNSLKPEDTAVYYCAASATLRGRDT RFDYWGQGTQVTVSSTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIW APLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRV KFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDK MAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR (SEQ ID NO: 800); MALPVTALLLPLALLLHAARPEVQLVESGGGLVQPGGSLRLSCSASGFPFDDYSMDWVRQAPGK GLEWVSAINRNGGSTYYAESMKGRFTISRDNAKNTLYLQMSSLKPEDTGVYLCAAGGRVSADGK KWEYDYWGQGTQVTVSSTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIY IWAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCEL RVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQK DKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR (SEQ ID NO: 801); MALPVTALLLPLALLLHAARPQLQLVESGGGLVQAGGSLRLSCAASDPIVTFNTMGWYRQAPGK QRELVARITMSGIPNYADSVKGRFTISRDNAKNTLYLQMNSLKPEDSAVYYCRAEHSGYWGQGT QVTVSSTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGV LLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVKFSRSADAP AYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIG MKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR (SEQ ID NO: 802); MALPVTALLLPLALLLHAARPQLQLVESGGGLVQAGGSLRLSCAASGNIVDIDDMGWYRQAPGK QRDLVATITAGGIANYADSAKGRFTISRDNAKNTVYLQMNSLKPEDTATYYCYAIRRYYPRFDY WGQGAQVTVSSTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLA GTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVKFSR SADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEA YSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR (SEQ ID NO: 803); MALPVTALLLPLALLLHAARPQLQLVESGGGLVQAGGSLRLSCAASGRTVSSYAMGWFRQAPGK EREFVAAISWSGGSTYYADSVKGRFTISRDNAKNTVYLQMNSLKPEDTAVYYCAADPSLSRTMD EIGSWGQGTQVTVSSTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIW APLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRV KFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDK MAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR (SEQ ID NO: 804); MALPVTALLLPLALLLHAARPQLQLVESGGGLVQTGGSLNLSCAASGAFVSIDAMAWYRQAPGK ARELVAFSSSGGITNYADSVKGRFTITRDNAKNTVYLQMNSLKPEDTAVYYCNADILQSGWYTY WGQGTQVTVSSTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLA GTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVKFSR SADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEA YSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR (SEQ ID NO: 805); MALPVTALLLPLALLLHAARPQLQLVESGGGLVRAGGSLRLSCVLSGRTFSSYAMGWFRQAPGK EREFVSTISLSGGSTFYSDSAKGRFTISRDNAKNTVYLQMNSLKPEDAAVYYCAARPVLISRSS TDYAYWGPGTQVTVSSTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYI WAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELR VKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKD KMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR (SEQ ID NO: 806); MALPVTALLLPLALLLHAARPQLQLVESGGGLVRAGGSLRLSCVLSGRTFSSYAMGWFRQAPGK EREFVSTISLSGGSTFYSDSAKGRFTISRDNAKNTVYLQMNSLKPEDTAVYYCAARPVLISRSS IDYAYWGPGTQVTVSSTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYI WAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELR VKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKD KMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR (SEQ ID NO: 807); MALPVTALLLPLALLLHAARPQVQLQESGGGLVQAGETLGLSCVHSGRAFSGHGMGWFRQAPGK EREFVAAISWSGVSTAYADSVKGRFTISRVNADNTVSLQMNSLKPEDTAVYFCAAGLYSRPTTE RREYIYWGQGTQVTVSSTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIY IWAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCEL RVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQK DKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR (SEQ ID NO: 808); MALPVTALLLPLALLLHAARPQVQLQESGGGLVQAGGSLRLSCAASGNSVDIDDMGWYRQAPGK QRDLVATITAGGITKYGDSAKGRFTISRDNVKNTVYLQMNSLKPEDTATYYCYAVRRYYPRFDY WGQGTQVTVSSTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLA GTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVKFSR SADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEA YSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR (SEQ ID NO: 809); MALPVTALLLPLALLLHAARPQVQLQESGGGLVQPGGSLRLSCAASGSIFSMNAMGWYRQAPGK QRELVATITDNDFTYYAASVKDRFTISRGNAKNTVYLQMNSLTPEDTAVYYCNADGIYSGGRYY PSSWGQGTQVTVSSTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWA PLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVK FSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKM AEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR (SEQ ID NO: 810); MALPVTALLLPLALLLHAARPQVQLQESGGGLVQPGGSLRLSCAASGSIFSVNDMGWYRQAPGK QRELVAASYSGGSTNYADSVKGRFTISRDNAKNTVYLQMNSLLPEDTAVYYCNADLVVVTTTPP SFPMPYRFLEVWGQGTLVTVSSTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDF ACDIYIWAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEE GGCELRVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLY NELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR (SEQ ID NO: 811); MALPVTALLLPLALLLHAARPQVQLVESGGGLVHAGGSLRLSCAASGRTFNTMAWFRQAPGKER EFVAAISWSGGLTYYADSVKGRFTIFRDNAKGLAYLQMDSLKPEDTAVYSCAARRTFRTALINT VTAYDTWGQGTQVTVSSTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIY IWAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCEL RVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQK DKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR (SEQ ID NO: 812); MALPVTALLLPLALLLHAARPQVQLVESGGGLVHAGGSLRLSCAASGRTFNTMAWFRQAPGKER EFVAAISWSGGLTYYGDSVKGRFTIFRDNAKNLAYLQMNSLKPEDTAVYSCAARRTFRTGLIDT VTAYDTWGQGTQVTVSSTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIY IWAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCEL RVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQK DKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR (SEQ ID NO: 813); MALPVTALLLPLALLLHAARPQVQLVESGGGLVQAGDSLRLSCAAASGRALSGWQMGWYRQAPG KEREFVASISMSDGSTSYQDSVKGRFTISRDNALSTMSLRMNSLKSEDTAIYYCQGRSRFGFEY WGQGTQVTVSSTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLA GTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVKFSR SADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEA YSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR (SEQ ID NO: 814); MALPVTALLLPLALLLHAARPQVQLVESGGGLVQAGESLRLSCVASGRALSGHGMGWFRQAPGK EREFVAAISWSGVSTAYADSVKGRFTISRVNAENTVSVSLQMNSLKPDDTAVYFCAAGLYSRPT TERRDYIYWGQGTQVTVSSTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACD IYIWAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGC ELRVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNEL QKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR (SEQ ID NO: 815); MALPVTALLLPLALLLHAARPQVQLVESGGGLVQAGGSLRLSCAAASHTFDSYTMGWFRQAPGK EREFVAAVNWDNVKNYADPVKGRFTISRDNVKNRVYLQMNSLKPEDTAVYYCAAGTNLPTRGSG SWGQGTQVTVSSTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPL AGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVKFS RSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAE AYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR (SEQ ID NO: 816); MALPVTALLLPLALLLHAARPQVQLVESGGGLVQAGGSLRLSCAAASLTFDSYTMGWFRQAPGK EREFVAAVNWDNVKNYADPVKGRFTISRDNVKNTVYLQMNSLKPEDTAVYYCAAGTNLPTIESG SWGQGTQVTVSSTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPL AGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVKFS RSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAE AYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR (SEQ ID NO: 817); MALPVTALLLPLALLLHAARPQVQLVESGGGLVQAGGSLRLSCAASGNGVDIDDMGWYRQAPGK QRDLVASITAGGITKYADSAKGRFTISRDNVKNTVYLQMNSLKPEDTATYYCYAIRRFYPRFDY WGQGTQVTVSSTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLA GTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVKFSR SADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEA YSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR (SEQ ID NO: 818); MALPVTALLLPLALLLHAARPQVQLVESGGGLVQAGGSLRLSCAASGNGVDIDDMGWYRQAPGK QRDLVASITAGGITNYADSAKGRFTISRDNVKNTVYLQMNSLKPEDTATYYCYAIRRFYPRFDY WGQGTQVTVSSTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLA GTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVKFSR SADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEA YSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR (SEQ ID NO: 819); MALPVTALLLPLALLLHAARPQVQLVESGGGLVQAGGSLRLSCAASGNGVDIDDMGWYRQAPGK QRDLVATITAGGITKYADSAKGRFTISRDNVKNTVYLQMNSLKPEDTATYYCYAIRRFYPRFDY WGQGTQVTVSSTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLA GTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVKFSR SADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEA YSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR (SEQ ID NO: 820); MALPVTALLLPLALLLHAARPQVQLVESGGGLVQAGGSLRLSCAASGNGVDIDDMGWYRQAPGK QRDLVATITAGGITNYADSAKGRFTISRDNVKNTVYLQMNSLKPEDTGTYYCYAIRKFYPRFDY WGQGTQVTVSSTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLA GTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVKFSR SADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEA YSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR (SEQ ID NO: 821); MALPVTALLLPLALLLHAARPQVQLVESGGGLVQAGGSLRLSCAASGNIVDIDDMGWYRQAPGK QRDLVASITAGGITKYADSAKGRFTISRDNVKNTVSLQMNSLKPEDTATYYCYAVRKYYPRFDY WGQGTQVTVSSTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLA GTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVKFSR SADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEA YSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR (SEQ ID NO: 822); MALPVTALLLPLALLLHAARPQVQLVESGGGLVQAGGSLRLSCAASGNIVDIDDMGWYRQAPGK QRDLVASITAGRITKYADSAKGRFTISRDNVKNTVYLQMNSLKPEDTATYYCYAIRRSYPRFDY WGQGTQVTVSSTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLA GTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVKFSR SADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEA YSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR (SEQ ID NO: 823); MALPVTALLLPLALLLHAARPQVQLVESGGGLVQAGGSLRLSCAASGRTFSNYAMGWFRQAPGK EREFVAAINWSGGRIYYTDSVKGRFTISRDNAKNTVYLQMNSLKPEDTAVYYCAAGTNWSIPPD YWGQGTQVTVSSTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPL AGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVKFS RSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAE AYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR (SEQ ID NO: 824); MALPVTALLLPLALLLHAARPQVQLVESGGGLVQAGGSLRLSCAASGRTFSSYAMGWFRQAPGK EREFVAAIRWSGGSTYYGDSVKGRFTISRDNAKNTVYLQMNSLKPEDTAVYYCAADPIGLGYEM GEYDYWGQGTQVTVSSTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYI WAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELR VKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKD KMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR (SEQ ID NO: 825); MALPVTALLLPLALLLHAARPQVQLVESGGGLVQAGGSLRLSCAASGRTFSSYAMGWFRQAPGK EREFVAAISWSGGSIYYADSVKGRFTISRDNAKNTVSLQMNSLKPEDTAVYYCAADGTLRTPMN LIHYWGQGTQVTVSSTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIW APLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRV KFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDK MAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR (SEQ ID NO: 826); MALPVTALLLPLALLLHAARPQVQLVESGGGLVQAGGSLRLSCAASGRTFSSYAMGWFRQAPGK EREFVAAISWSGGSTYYANSVKGRFTISRDNAKNTVYLQMNSLKPEDTAVYYCAPGEEVAGKYF RQLYDYWGQGTQVTVSSTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIY IWAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCEL RVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQK DKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR (SEQ ID NO: 827); MALPVTALLLPLALLLHAARPQVQLVESGGGLVQAGGSLRLSCAASGRTFSSYAMGWFRQAPGK EREFVADISWSGGTTNYANSVKGRFTISRDNAKNTVYLQMNSLKPEDTAVYYCAPGEEVDGKYF RPLYDYWGQGTQVTVSSTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIY IWAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCEL RVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQK DKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR (SEQ ID NO: 828); MALPVTALLLPLALLLHAARPQVQLVESGGGLVQAGGSLRLSCAASGRTFSTYTMGWFRQAPGK ERQFVAAISSSGDSTYYTDSVKGRFTISRDNAKNTVYLQMDSLKPEDTAVYYCAPGEEVAGKYF RALYDYWGQGTQVTVSSTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIY IWAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCEL RVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQK DKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR (SEQ ID NO: 829); MALPVTALLLPLALLLHAARPQVQLVESGGGLVQAGGSLRLSCAASGSIFSINAMAWYRQAPGK QRELVAVITSGGSTNYADSVKGRFTISRDNAKNTVYLQMNSLKPEDTAVYYCNADLVYYSGNPG DYGMDYWGKGTLVTVSSTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIY IWAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCEL RVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQK DKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR (SEQ ID NO: 830); MALPVTALLLPLALLLHAARPQVQLVESGGGLVQAGGSLRLSCVASGRTFSINNINWYRQAPGK EREFVATTRWRGDSTYYADSVAGRFTISRDSAKNTVYLQMNSLKPEDTAIYYCNAKGGVDVWGQ GTQVTVSSTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTC GVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVKFSRSAD APAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSE IGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR (SEQ ID NO: 831); MALPVTALLLPLALLLHAARPQVQLVESGGGLVQPGGSLRLSCAASGFLFSLYAMAWVRQAPGK GLEWVSDISNGGVTTRYADSVKGRFTISRDNAKNTLYLQMDSLTPGDTAVYYCAVTTTGWRARG QGTQVTVSSTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGT CGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVKFSRSA DAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYS EIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR (SEQ ID NO: 832); MALPVTALLLPLALLLHAARPQVQLVESGGGLVQPGGSLRLSCAASGSIFRPNDMGWYRQAPGK QRELVAIITDGGITNYAATVKGRFTISRDNAKNTVYLQMNSLKPEDTAVYYCNLNIPYPRVSSW GQGTQVTVSSTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAG TCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVKFSRS ADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAY SEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR (SEQ ID NO: 833); MALPVTALLLPLALLLHAARPQVQLVESGGGLVQPGGSLRLSCAASGSIFSVNDMGWYRQAPGK QRELVAAIYSGGSTNYADSVKGRFTISRDNAKNTVYLQMNSLKPEDTAVYYCNADIVVVTTTPP SFPMPYRFLEVWGQGTLVTVSSTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDF ACDIYIWAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEE GGCELRVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLY NELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR (SEQ ID NO: 834); MALPVTALLLPLALLLHAARPQVQLVESGGGLVQPGGSLRLSCAASGSTFNTMAWFRQAPGKER EFVAAISWSGGLTYYGDSVKGRFTIFRDNAKNLGYLQMNSLKPEDTAVYSCAARTTFRTGLIVT VTAYDTWGQGTQVTVSSTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIY IWAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCEL RVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQK DKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR (SEQ ID NO: 842); MALPVTALLLPLALLLHAARPQVQLVESGGGLVQPGGSLRLSCVLSGRTFSSYAMGWFRQAPGK EREFVSTISLSGGSTFYSGSAKGRFTISRDNAKNTVYLQMNSLKPEDTAVYYCAARPVLISRSS TDYAYWGPGTQVTVSSTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYI WAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELR VKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKD KMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR (SEQ ID NO: 843); MALPVTALLLPLALLLHAARPQVQLVESGGGLVQTGGSLRLSCAASGRTFSSYAMGWFRQAPGK EREFVAAITWSGGSTYYANSVKGRFTISRDNAKNTVDLQMNSLKPEDTAVYYCTPGEEVAGKYF RPLYDYWGQGTQVTVSSTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIY IWAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCEL RVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQK DKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR (SEQ ID NO: 844); MALPVTALLLPLALLLHAARPQVQLVESGGGLVQVGGSLRLSCSISRSIAIFNFMAWYREAEGK QRELVASITGGSRLSYIDSVKGRFTVSKDTANNTLDLQMNSLRPEDTAVYRCAASSPFAGEFWG QGTQVTVSSTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGT CGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVKFSRSA DAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYS EIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR (SEQ ID NO: 845); MALPVTALLLPLALLLHAARPQVQLVESGGRLVQAGGSLRLSCAASGRTFNTMAWFRQAPGKER EFVAAITWSGGLTYYEDSVKGRFTIFRDNAKNLAYLQLNSLKPEDTAVYSCAARSTFRTALVNT VTAYDTWGQGTQVTVSSTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIY IWAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCEL RVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQK DKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR (SEQ ID NO: 846); MALPVTALLLPLALLLHAARPQVQLVESGGGLVQPGGSLRLSCTASGRTIASTIMGWYRQTPGK EREFVAISARSGDSESYASSVKDRFTISRDNAKNTVYLQMNNLKPEDTAIYYCYWNTGAGTIWG QGTQVTVSSTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGT CGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVKFSRSA DAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYS EIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR (SEQ ID NO: 847). In another aspect, the disclosure features a polynucleotide encoding the CAR of any aspect or embodiment of the disclosure, where the polynucleotide contains a sequence having at least 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to a sequence selected from one or more of: ATGGCCCTGCCCGTTACCGCCCTACTCCTGCCCCTGGCCCTCCTGCTCCACGCCGCCAGGCCCG AGGTGCAATTGGTCGAGAGCGGTGGCGGGTTGGTTCAACCAGGTGGTTCTTTGCGGCTGTCATG TGCAGCCTCTGGCTTTGCTCTGGACGGATACACAATAGGGTGGTTTCGCCAAGCTCCGGGTAAA GAGCGGGAGGGAGTGGCATGTATCAGTCGATCTGATACTTCCACGAAGTACGCAGATTCAGTTA AGGGGAGGTTTACGATTAGTCGAGATAACGCCAAAAGAACTGTCTCTCTTCAAATGAACTCTCT CAAGCCGGAGGACACGGCGGTTTATTATTGTGCCGCCTCACTTCAATCTGGACTGCTTTCCAGA TTTCTCTTGCCTCGCCAGTATGACCACTGGGGACAGGGTACTCAGGTTACTGTTAGCAGCACCA CCACCCCTGCCCCCAGGCCCCCCACCCCCGCCCCCACCATCGCCAGCCAGCCCCTGTCCCTGCG GCCCGAGGCCTGCCGGCCCGCCGCCGGCGGCGCCGTGCACACCCGGGGCCTGGACTTCGCCTGC GACATCTACATCTGGGCCCCCCTGGCCGGAACCTGCGGCGTGCTGCTGCTGTCCCTGGTGATCA CCCTGTACTGCAAGCGGGGCCGGAAGAAGCTGCTGTACATCTTCAAGCAGCCCTTCATGCGCCC CGTGCAGACCACCCAGGAGGAGGACGGCTGCAGCTGCAGGTTCCCCGAGGAGGAGGAGGGGGGC TGCGAGCTGCGGGTGAAGTTCAGCAGGAGCGCCGACGCCCCTGCTTACCAGCAGGGCCAGAATC AGCTGTACAACGAGCTGAATCTGGGCCGGAGGGAGGAGTACGACGTGCTGGACAAGCGGAGGGG CAGGGACCCCGAGATGGGCGGCAAGCCCAGGCGGAAGAACCCCCAGGAGGGGCTGTACAACGAG CTGCAGAAGGACAAGATGGCCGAGGCCTACTCCGAGATCGGCATGAAGGGCGAGAGGCGGAGAG GCAAGGGCCATGACGGCCTGTACCAGGGCCTGTCCACCGCCACCAAGGACACCTACGACGCCCT GCACATGCAGGCCCTGCCCCCCCGC (SEQ ID NO: 904); ATGGCCCTGCCCGTTACCGCCCTACTCCTGCCCCTGGCCCTCCTGCTCCACGCCGCCAGGCCCC AACTTCAACTCGTTGAGTCAGGAGGGGGGCTCGTCCAGCCTGGAGGTAGTCTGCGGCTCTCCTG CGTAGCTTCCGGTTTTGCACTTGACTCATATACTATTGGGTGGTTCCGGCAAGCACCAGGTAAA GAACGGGAGGGGCTTTCCTGTATATCCAGGTCAACCTCCGATGCTAGATATGCGGACTCTGTTA AAGGACGGTTCACGATATCTCGGGATAATGCGAAGACTACCGTAAGCCTGTTGATGAGCTCCCT CAAACCCGAGGACACTGCCGTCTATTATTGCGCTGCCAGTAGACAAACTGGCCTCCTCTCCACT TTCCTTCTTCCGCGCCAGTACGATCACTGGGGCCAGGGAACGCAAGTAACTGTCTCCAGCACCA CCACCCCTGCCCCCAGGCCCCCCACCCCCGCCCCCACCATCGCCAGCCAGCCCCTGTCCCTGCG GCCCGAGGCCTGCCGGCCCGCCGCCGGCGGCGCCGTGCACACCCGGGGCCTGGACTTCGCCTGC GACATCTACATCTGGGCCCCCCTGGCCGGAACCTGCGGCGTGCTGCTGCTGTCCCTGGTGATCA CCCTGTACTGCAAGCGGGGCCGGAAGAAGCTGCTGTACATCTTCAAGCAGCCCTTCATGCGCCC CGTGCAGACCACCCAGGAGGAGGACGGCTGCAGCTGCAGGTTCCCCGAGGAGGAGGAGGGGGGC TGCGAGCTGCGGGTGAAGTTCAGCAGGAGCGCCGACGCCCCTGCTTACCAGCAGGGCCAGAATC AGCTGTACAACGAGCTGAATCTGGGCCGGAGGGAGGAGTACGACGTGCTGGACAAGCGGAGGGG CAGGGACCCCGAGATGGGCGGCAAGCCCAGGCGGAAGAACCCCCAGGAGGGGCTGTACAACGAG CTGCAGAAGGACAAGATGGCCGAGGCCTACTCCGAGATCGGCATGAAGGGCGAGAGGCGGAGAG GCAAGGGCCATGACGGCCTGTACCAGGGCCTGTCCACCGCCACCAAGGACACCTACGACGCCCT GCACATGCAGGCCCTGCCCCCCCGC (SEQ ID NO: 905); ATGGCCCTGCCCGTTACCGCCCTACTCCTGCCCCTGGCCCTCCTGCTCCACGCCGCCAGGCCCC AAGTTCAACTGGTTGAAAGTGGTGGCGGCTTGGTTCAGCCGGGCGGGTCCCTTCGCCTTTCATG TGCAGCGTCAGGCTTTTCCCTTGACTTTTATTCAATCGGATGGTTCAGACAAGCCCCTGGTAAA GAAAGGGAAGGAGTCTCTTGTATAACATGGTCAGGAGAGCGAACGAATTACAAGGATAGCGTAA AAGGTCGATTCACAATAAGCAGGGACGATGCTAAGGCGACGGTTTTTTTGCAGATGAATAATCT GAAACCGGAAGATACAGCAGTCTACTACTGTGCAGCGGATTCTGGCTACCCGTGTTATGGGTCC TCCTGGTCCTCTGTAGGCTATGATTTTTGGGGCCAGGGGACGCAAGTTACAGTCTCTTCAACCA CCACCCCTGCCCCCAGGCCCCCCACCCCCGCCCCCACCATCGCCAGCCAGCCCCTGTCCCTGCG GCCCGAGGCCTGCCGGCCCGCCGCCGGCGGCGCCGTGCACACCCGGGGCCTGGACTTCGCCTGC GACATCTACATCTGGGCCCCCCTGGCCGGAACCTGCGGCGTGCTGCTGCTGTCCCTGGTGATCA CCCTGTACTGCAAGCGGGGCCGGAAGAAGCTGCTGTACATCTTCAAGCAGCCCTTCATGCGCCC CGTGCAGACCACCCAGGAGGAGGACGGCTGCAGCTGCAGGTTCCCCGAGGAGGAGGAGGGGGGC TGCGAGCTGCGGGTGAAGTTCAGCAGGAGCGCCGACGCCCCTGCTTACCAGCAGGGCCAGAATC AGCTGTACAACGAGCTGAATCTGGGCCGGAGGGAGGAGTACGACGTGCTGGACAAGCGGAGGGG CAGGGACCCCGAGATGGGCGGCAAGCCCAGGCGGAAGAACCCCCAGGAGGGGCTGTACAACGAG CTGCAGAAGGACAAGATGGCCGAGGCCTACTCCGAGATCGGCATGAAGGGCGAGAGGCGGAGAG GCAAGGGCCATGACGGCCTGTACCAGGGCCTGTCCACCGCCACCAAGGACACCTACGACGCCCT GCACATGCAGGCCCTGCCCCCCCGC (SEQ ID NO: 906); ATGGCCCTGCCCGTTACCGCCCTACTCCTGCCCCTGGCCCTCCTGCTCCACGCCGCCAGGCCCC AGGTGCAACTCGTTGAAAGCGGTGGAGGGAGTGTGGAACCCGGCGGGAGCCTCAGATTGAGCTG CGCCACCTCTGGGCTTATCCTCAGTAATCACGGCATGGGGTGGGCCAGACAGGTTCCCGGCAAA GAAGTTGAATGGGTTTCCGGAAGCTACACCGACGGAAGCACGTATTATGCGGATAGTGTTAAGG GCCGCTTTACCATTAGCCGGGATAATGTCAAGAATACAGTTTATCTTCAAATGAATAGTCTTAA ACCCGAAGACACTGCCGTCTACTACTGTGCCGCAAGGCAATATTATCGCTCCGGCTATGTGGAC TATTGGGGGCAAGGAACCCAAGTGACGGTGTCATCTACCACCACCCCTGCCCCCAGGCCCCCCA CCCCCGCCCCCACCATCGCCAGCCAGCCCCTGTCCCTGCGGCCCGAGGCCTGCCGGCCCGCCGC CGGCGGCGCCGTGCACACCCGGGGCCTGGACTTCGCCTGCGACATCTACATCTGGGCCCCCCTG GCCGGAACCTGCGGCGTGCTGCTGCTGTCCCTGGTGATCACCCTGTACTGCAAGCGGGGCCGGA AGAAGCTGCTGTACATCTTCAAGCAGCCCTTCATGCGCCCCGTGCAGACCACCCAGGAGGAGGA CGGCTGCAGCTGCAGGTTCCCCGAGGAGGAGGAGGGGGGCTGCGAGCTGCGGGTGAAGTTCAGC AGGAGCGCCGACGCCCCTGCTTACCAGCAGGGCCAGAATCAGCTGTACAACGAGCTGAATCTGG GCCGGAGGGAGGAGTACGACGTGCTGGACAAGCGGAGGGGCAGGGACCCCGAGATGGGCGGCAA GCCCAGGCGGAAGAACCCCCAGGAGGGGCTGTACAACGAGCTGCAGAAGGACAAGATGGCCGAG GCCTACTCCGAGATCGGCATGAAGGGCGAGAGGCGGAGAGGCAAGGGCCATGACGGCCTGTACC AGGGCCTGTCCACCGCCACCAAGGACACCTACGACGCCCTGCACATGCAGGCCCTGCCCCCCCG C (SEQ ID NO: 907); ATGGCCCTGCCCGTTACCGCCCTACTCCTGCCCCTGGCCCTCCTGCTCCACGCCGCCAGGCCCC AGGTCCAACTGGTAGAAAGCGGCGGAGGCAAAGTGCAACCCGGAGGTTCCCTTCGGCTTTCATG TGCCGCGAGCGGATTTACGTTTTCCAACTACGGTATGATGTGGGTGAGACAAGCTCCAGGCAAA GGGTTGGAGTGGGTTAGCTATATTGACAGCGGCGGTGGATCCACCTACTACACCGACTCTGTAC GAGGGAGGTTTACAATTAGTAGAGACAACGCTAAAAACACAGTCTACCTCCAAATGAATAGTCT CAAGCCAGAGGACACAGCCGTGTACTACTGCGCAAAAGCGATAGGTGTTGTCTCTGGCTCCTTG GAAGTATGGGGACAAGGGACGCTGGTCACAGTAAGCTCTACCACCACCCCTGCCCCCAGGCCCC CCACCCCCGCCCCCACCATCGCCAGCCAGCCCCTGTCCCTGCGGCCCGAGGCCTGCCGGCCCGC CGCCGGCGGCGCCGTGCACACCCGGGGCCTGGACTTCGCCTGCGACATCTACATCTGGGCCCCC CTGGCCGGAACCTGCGGCGTGCTGCTGCTGTCCCTGGTGATCACCCTGTACTGCAAGCGGGGCC GGAAGAAGCTGCTGTACATCTTCAAGCAGCCCTTCATGCGCCCCGTGCAGACCACCCAGGAGGA GGACGGCTGCAGCTGCAGGTTCCCCGAGGAGGAGGAGGGGGGCTGCGAGCTGCGGGTGAAGTTC AGCAGGAGCGCCGACGCCCCTGCTTACCAGCAGGGCCAGAATCAGCTGTACAACGAGCTGAATC TGGGCCGGAGGGAGGAGTACGACGTGCTGGACAAGCGGAGGGGCAGGGACCCCGAGATGGGCGG CAAGCCCAGGCGGAAGAACCCCCAGGAGGGGCTGTACAACGAGCTGCAGAAGGACAAGATGGCC GAGGCCTACTCCGAGATCGGCATGAAGGGCGAGAGGCGGAGAGGCAAGGGCCATGACGGCCTGT ACCAGGGCCTGTCCACCGCCACCAAGGACACCTACGACGCCCTGCACATGCAGGCCCTGCCCCC CCGC (SEQ ID NO: 908); ATGGCCCTGCCCGTTACCGCCCTACTCCTGCCCCTGGCCCTCCTGCTCCACGCCGCCAGGCCCC AGGTTCAGCTTGTTGAAAGCGGAGGAGGACTGGTTCAGGCAGGGGGCAGCTTGCGACTCTCATG CGCCGCCAGCGGGCGGACCTTCACAAGTTATGCTATGGGGTGGTTTAGACAAGCACCGGGAAAA GAGAGAGAATTCGTAGCAGCCATTTCATGGCGGGGCGTAAATACCTATTATGCCGATAGCGTGA AAGGAAGGTTTACCATTAGCAGAGAAAACGCAAAAAATACGGTGTACTTGCAAATGATCAGTCT GAAGCCGGAGGATACAGCGGTGTATTACTGTGCCGCAGGTCCATTGGGCGCGACCATGTCTGAG ATCGGTTCTTGGGGGCAGGGGACACAAGTCACCGTGTCTTCCACCACCACCCCTGCCCCCAGGC CCCCCACCCCCGCCCCCACCATCGCCAGCCAGCCCCTGTCCCTGCGGCCCGAGGCCTGCCGGCC CGCCGCCGGCGGCGCCGTGCACACCCGGGGCCTGGACTTCGCCTGCGACATCTACATCTGGGCC CCCCTGGCCGGAACCTGCGGCGTGCTGCTGCTGTCCCTGGTGATCACCCTGTACTGCAAGCGGG GCCGGAAGAAGCTGCTGTACATCTTCAAGCAGCCCTTCATGCGCCCCGTGCAGACCACCCAGGA GGAGGACGGCTGCAGCTGCAGGTTCCCCGAGGAGGAGGAGGGGGGCTGCGAGCTGCGGGTGAAG TTCAGCAGGAGCGCCGACGCCCCTGCTTACCAGCAGGGCCAGAATCAGCTGTACAACGAGCTGA ATCTGGGCCGGAGGGAGGAGTACGACGTGCTGGACAAGCGGAGGGGCAGGGACCCCGAGATGGG CGGCAAGCCCAGGCGGAAGAACCCCCAGGAGGGGCTGTACAACGAGCTGCAGAAGGACAAGATG GCCGAGGCCTACTCCGAGATCGGCATGAAGGGCGAGAGGCGGAGAGGCAAGGGCCATGACGGCC TGTACCAGGGCCTGTCCACCGCCACCAAGGACACCTACGACGCCCTGCACATGCAGGCCCTGCC CCCCCGC (SEQ ID NO: 909); ATGGCCCTGCCCGTTACCGCCCTACTCCTGCCCCTGGCCCTCCTGCTCCACGCCGCCAGGCCCG AGGTGCAGTTGGTTGAATCCGGGGGAGGGCTTGTCCAAGCTGGAGGTTCTCTCAGACTCAGTTG TGCAGCTAGTGGACGCACCTTTAGTAACTATGCTATGGGATGGTTCCGCCAGGCTCCTGGTAAA GAACGAGAGTTCGTATCAGCGATTTCTTGGTCCGGTGGGTCCACCTATTACGCGGACAGCGTCA AAGGTCGATTTACCATTTCTCGAGATAATGCGAAAAATACCGTCTATCTGCAAATGATATCTCT CAAGCCCGAGGATACTGCTGTGTACTATTGCGCGGCTGGTCCGCTCGGAGCAACAATGTCAGAA ATTGGAAGTTGGGGCCAAGGGACGCAAGTTACCGTATCCTCTACCACCACCCCTGCCCCCAGGC CCCCCACCCCCGCCCCCACCATCGCCAGCCAGCCCCTGTCCCTGCGGCCCGAGGCCTGCCGGCC CGCCGCCGGCGGCGCCGTGCACACCCGGGGCCTGGACTTCGCCTGCGACATCTACATCTGGGCC CCCCTGGCCGGAACCTGCGGCGTGCTGCTGCTGTCCCTGGTGATCACCCTGTACTGCAAGCGGG GCCGGAAGAAGCTGCTGTACATCTTCAAGCAGCCCTTCATGCGCCCCGTGCAGACCACCCAGGA GGAGGACGGCTGCAGCTGCAGGTTCCCCGAGGAGGAGGAGGGGGGCTGCGAGCTGCGGGTGAAG TTCAGCAGGAGCGCCGACGCCCCTGCTTACCAGCAGGGCCAGAATCAGCTGTACAACGAGCTGA ATCTGGGCCGGAGGGAGGAGTACGACGTGCTGGACAAGCGGAGGGGCAGGGACCCCGAGATGGG CGGCAAGCCCAGGCGGAAGAACCCCCAGGAGGGGCTGTACAACGAGCTGCAGAAGGACAAGATG GCCGAGGCCTACTCCGAGATCGGCATGAAGGGCGAGAGGCGGAGAGGCAAGGGCCATGACGGCC TGTACCAGGGCCTGTCCACCGCCACCAAGGACACCTACGACGCCCTGCACATGCAGGCCCTGCC CCCCCGC (SEQ ID NO: 910); ATGGCCCTGCCCGTTACCGCCCTACTCCTGCCCCTGGCCCTCCTGCTCCACGCCGCCAGGCCCC AAGTTCAATTGGTCGAAAGTGGAGGCGGCTTGGTACAAGCGGGTGGATCACTGAGACTTAGCTG CGCTGCCTCAGGTAGGACCGTGTCAAGTTATGCTATGGGCTGGTTCAGGCAGGCGCCTGGCAAG GAACGAGAATTTGTCGCCGCAATTTCATGGTCCGGCGGAGGCACTTACTATGCTGATTCCGTCA AGGGCCGGTTTACTATCAGCCGGGATAACGCAAAAAACACGGTGTACCTGCAAATGATTTCCCT GAAGCCCGAAGATACAGCAGTGTATTATTGTGCGGCGGGACCGCTTGGTGCGACGATGAGTGAG ATCGGGAGCTGGGGACAGGGCACACAAGTAACGGTGTCCAGCACCACCACCCCTGCCCCCAGGC CCCCCACCCCCGCCCCCACCATCGCCAGCCAGCCCCTGTCCCTGCGGCCCGAGGCCTGCCGGCC CGCCGCCGGCGGCGCCGTGCACACCCGGGGCCTGGACTTCGCCTGCGACATCTACATCTGGGCC CCCCTGGCCGGAACCTGCGGCGTGCTGCTGCTGTCCCTGGTGATCACCCTGTACTGCAAGCGGG GCCGGAAGAAGCTGCTGTACATCTTCAAGCAGCCCTTCATGCGCCCCGTGCAGACCACCCAGGA GGAGGACGGCTGCAGCTGCAGGTTCCCCGAGGAGGAGGAGGGGGGCTGCGAGCTGCGGGTGAAG TTCAGCAGGAGCGCCGACGCCCCTGCTTACCAGCAGGGCCAGAATCAGCTGTACAACGAGCTGA ATCTGGGCCGGAGGGAGGAGTACGACGTGCTGGACAAGCGGAGGGGCAGGGACCCCGAGATGGG CGGCAAGCCCAGGCGGAAGAACCCCCAGGAGGGGCTGTACAACGAGCTGCAGAAGGACAAGATG GCCGAGGCCTACTCCGAGATCGGCATGAAGGGCGAGAGGCGGAGAGGCAAGGGCCATGACGGCC TGTACCAGGGCCTGTCCACCGCCACCAAGGACACCTACGACGCCCTGCACATGCAGGCCCTGCC CCCCCGC (SEQ ID NO: 911); ATGGCCCTGCCCGTTACCGCCCTACTCCTGCCCCTGGCCCTCCTGCTCCACGCCGCCAGGCCCC AAGTCCAACTTGTTGAATCTGGGGGTGGGCTCGTGCAAGCTGGGGGGAGTCTTCGGTTGTCATG CGCCGCGTCAGGACGCACTGTATCAAGCTACGCCATGGGATGGTTTAGGCAGGCACCTGGTAAG GAGCGGGAGTTCGTCGCGGCGATTTCCTGGTCAGGTGGAAGCACGTACTACGCAGACTCAGTGA AAGGTAGATTCACGATCTCACGGGATAATGCCAAAAATACCGTCTACCTCCAGATGATCTCTCT TAAACCTGAAGATACAGCCGTGTACTATTGCGCCGCTGGGCCACTCGGTGCTACGATGAGTGAA ATTGGGAGTTGGGGCCAGGGCACGCAGGTCACTGTTTCAAGCACCACCACCCCTGCCCCCAGGC CCCCCACCCCCGCCCCCACCATCGCCAGCCAGCCCCTGTCCCTGCGGCCCGAGGCCTGCCGGCC CGCCGCCGGCGGCGCCGTGCACACCCGGGGCCTGGACTTCGCCTGCGACATCTACATCTGGGCC CCCCTGGCCGGAACCTGCGGCGTGCTGCTGCTGTCCCTGGTGATCACCCTGTACTGCAAGCGGG GCCGGAAGAAGCTGCTGTACATCTTCAAGCAGCCCTTCATGCGCCCCGTGCAGACCACCCAGGA GGAGGACGGCTGCAGCTGCAGGTTCCCCGAGGAGGAGGAGGGGGGCTGCGAGCTGCGGGTGAAG TTCAGCAGGAGCGCCGACGCCCCTGCTTACCAGCAGGGCCAGAATCAGCTGTACAACGAGCTGA ATCTGGGCCGGAGGGAGGAGTACGACGTGCTGGACAAGCGGAGGGGCAGGGACCCCGAGATGGG CGGCAAGCCCAGGCGGAAGAACCCCCAGGAGGGGCTGTACAACGAGCTGCAGAAGGACAAGATG GCCGAGGCCTACTCCGAGATCGGCATGAAGGGCGAGAGGCGGAGAGGCAAGGGCCATGACGGCC TGTACCAGGGCCTGTCCACCGCCACCAAGGACACCTACGACGCCCTGCACATGCAGGCCCTGCC CCCCCGC (SEQ ID NO: 912); ATGGCCCTGCCCGTTACCGCCCTACTCCTGCCCCTGGCCCTCCTGCTCCACGCCGCCAGGCCCG AAGTTCAGTTGGTAGAATCTGGCGGTGGCCTGGCTCAACCTGGGGGATCACTCAGACTCAGTTG TGTAGCGTCCGGCTTTGCCTTCGGCTCCTTCGCTATAGATTGGGTGCGACAACCGCCCGGAAAG GGACCTGAATGGGTATCTGCGATCAACCGGGGAGGGGATCGCACATACTATAGTGATAGCGTAA AGGGTCGATTTACAATCTCCCGCGATAACGCCAAGAATACACTCTATCTGCAATTGAACAGTCT TAAACCGGAGGACACGGCGGTTTATCTGTGTGCTGCTGGAGGGCGCGTGTCTGCTGATGGAAAA AAGTGGGAGTACGACTATTGGGGTCAGGGCACGCAAGTGACCGTATCTTCCACCACCACCCCTG CCCCCAGGCCCCCCACCCCCGCCCCCACCATCGCCAGCCAGCCCCTGTCCCTGCGGCCCGAGGC CTGCCGGCCCGCCGCCGGCGGCGCCGTGCACACCCGGGGCCTGGACTTCGCCTGCGACATCTAC ATCTGGGCCCCCCTGGCCGGAACCTGCGGCGTGCTGCTGCTGTCCCTGGTGATCACCCTGTACT GCAAGCGGGGCCGGAAGAAGCTGCTGTACATCTTCAAGCAGCCCTTCATGCGCCCCGTGCAGAC CACCCAGGAGGAGGACGGCTGCAGCTGCAGGTTCCCCGAGGAGGAGGAGGGGGGCTGCGAGCTG CGGGTGAAGTTCAGCAGGAGCGCCGACGCCCCTGCTTACCAGCAGGGCCAGAATCAGCTGTACA ACGAGCTGAATCTGGGCCGGAGGGAGGAGTACGACGTGCTGGACAAGCGGAGGGGCAGGGACCC CGAGATGGGCGGCAAGCCCAGGCGGAAGAACCCCCAGGAGGGGCTGTACAACGAGCTGCAGAAG GACAAGATGGCCGAGGCCTACTCCGAGATCGGCATGAAGGGCGAGAGGCGGAGAGGCAAGGGCC ATGACGGCCTGTACCAGGGCCTGTCCACCGCCACCAAGGACACCTACGACGCCCTGCACATGCA GGCCCTGCCCCCCCGC (SEQ ID NO: 913); ATGGCCCTGCCCGTTACCGCCCTACTCCTGCCCCTGGCCCTCCTGCTCCACGCCGCCAGGCCCG AGGTGCAACTTGTCGAGAGCGGAGGAGGTCTTGTTCATGCGGGAGGTTCTCTGCGCCTGAGCTG CGCCGCGAGCGGACGGACATTCAATACCATGGCTTGGTTCCGGCAGGCGCCTGGCAAGGAGAGA GAATTCGTAGCCGCCATAGCATGGAATTCAGGTCTTACCTACTATGGGGACAGTGTAAAGGGGC GCTTCACCATCTTTCGAGACAATGCGAAGAATCTGGCCTACCTCCAGATGAACTCCTTGAAACC TGAGGATACTGCGGTCTATTCCTGCGCTGCACGACGGACGTTCCGCACCGGACTGATCAACACT GTCACCGCGTATGATACATGGGGTCAGGGGACACAAGTCACCGTCTCATCAACCACCACCCCTG CCCCCAGGCCCCCCACCCCCGCCCCCACCATCGCCAGCCAGCCCCTGTCCCTGCGGCCCGAGGC CTGCCGGCCCGCCGCCGGCGGCGCCGTGCACACCCGGGGCCTGGACTTCGCCTGCGACATCTAC ATCTGGGCCCCCCTGGCCGGAACCTGCGGCGTGCTGCTGCTGTCCCTGGTGATCACCCTGTACT GCAAGCGGGGCCGGAAGAAGCTGCTGTACATCTTCAAGCAGCCCTTCATGCGCCCCGTGCAGAC CACCCAGGAGGAGGACGGCTGCAGCTGCAGGTTCCCCGAGGAGGAGGAGGGGGGCTGCGAGCTG CGGGTGAAGTTCAGCAGGAGCGCCGACGCCCCTGCTTACCAGCAGGGCCAGAATCAGCTGTACA ACGAGCTGAATCTGGGCCGGAGGGAGGAGTACGACGTGCTGGACAAGCGGAGGGGCAGGGACCC CGAGATGGGCGGCAAGCCCAGGCGGAAGAACCCCCAGGAGGGGCTGTACAACGAGCTGCAGAAG GACAAGATGGCCGAGGCCTACTCCGAGATCGGCATGAAGGGCGAGAGGCGGAGAGGCAAGGGCC ATGACGGCCTGTACCAGGGCCTGTCCACCGCCACCAAGGACACCTACGACGCCCTGCACATGCA GGCCCTGCCCCCCCGC (SEQ ID NO: 914); ATGGCCCTGCCCGTTACCGCCCTACTCCTGCCCCTGGCCCTCCTGCTCCACGCCGCCAGGCCCG AAGTACAACTTGTCGAGAGCGGCGGCGGGCTCGTACATGCTGGCGGCTCATTGCGCCTTAGCTG CGTAGCAAGCGGGAGGACTTTTAACACTATGGCCTGGTTTAGACAAGCTCCTGGTAAAGAAAGA GAATTTGTCGCGGCAATTTCCTGGAGCGGAGGGCTCACGTACTACGGGGATAGCGTTAAGGGGC GATTCACGATATTCAGAGACAACGCTAAAAACCTGGCCTACCTTCAAATGAATAGCTTGAAACC AGAAGACACTGCCGTATATTCATGTGCAGCCCGCCGGACGTTCCGGACAGCCCTCATCAACACT ATCACAGCCTATGATACCTGGGGTCAAGGAACTCAAGTGACTGTCAGCTCCACCACCACCCCTG CCCCCAGGCCCCCCACCCCCGCCCCCACCATCGCCAGCCAGCCCCTGTCCCTGCGGCCCGAGGC CTGCCGGCCCGCCGCCGGCGGCGCCGTGCACACCCGGGGCCTGGACTTCGCCTGCGACATCTAC ATCTGGGCCCCCCTGGCCGGAACCTGCGGCGTGCTGCTGCTGTCCCTGGTGATCACCCTGTACT GCAAGCGGGGCCGGAAGAAGCTGCTGTACATCTTCAAGCAGCCCTTCATGCGCCCCGTGCAGAC CACCCAGGAGGAGGACGGCTGCAGCTGCAGGTTCCCCGAGGAGGAGGAGGGGGGCTGCGAGCTG CGGGTGAAGTTCAGCAGGAGCGCCGACGCCCCTGCTTACCAGCAGGGCCAGAATCAGCTGTACA ACGAGCTGAATCTGGGCCGGAGGGAGGAGTACGACGTGCTGGACAAGCGGAGGGGCAGGGACCC CGAGATGGGCGGCAAGCCCAGGCGGAAGAACCCCCAGGAGGGGCTGTACAACGAGCTGCAGAAG GACAAGATGGCCGAGGCCTACTCCGAGATCGGCATGAAGGGCGAGAGGCGGAGAGGCAAGGGCC ATGACGGCCTGTACCAGGGCCTGTCCACCGCCACCAAGGACACCTACGACGCCCTGCACATGCA GGCCCTGCCCCCCCGC (SEQ ID NO: 915); ATGGCCCTGCCCGTTACCGCCCTACTCCTGCCCCTGGCCCTCCTGCTCCACGCCGCCAGGCCCG AAGTTCAACTCGTCGAGTCAGGTGGTGGCCTTGTCCAAGCCGGGGGAAGCCTCCGATTGTCTTG CGCTGCAAGTGGGAATATTGTTGATATAGACGACATGGGATGGTACCGGCAGGCACCTGGACGC GACTTGGTCGCTTCTATAACGGCTGGCGGGATTACAAAGTACGCTGATTCAGCGAAGGGCAGGT TCACTATCTCCCGCGATAACGTTAAAAACACCGTGTATCTGCAAATGAACAGTCTTAAACCTGA AGATACGGCGACGTACTACTGTTATGCAGTGAGACGGTACTACCCTCGATTTGATTATTGGGGC CAGGGCACACAAGTGACAGTGTCCAGTACCACCACCCCTGCCCCCAGGCCCCCCACCCCCGCCC CCACCATCGCCAGCCAGCCCCTGTCCCTGCGGCCCGAGGCCTGCCGGCCCGCCGCCGGCGGCGC CGTGCACACCCGGGGCCTGGACTTCGCCTGCGACATCTACATCTGGGCCCCCCTGGCCGGAACC TGCGGCGTGCTGCTGCTGTCCCTGGTGATCACCCTGTACTGCAAGCGGGGCCGGAAGAAGCTGC TGTACATCTTCAAGCAGCCCTTCATGCGCCCCGTGCAGACCACCCAGGAGGAGGACGGCTGCAG CTGCAGGTTCCCCGAGGAGGAGGAGGGGGGCTGCGAGCTGCGGGTGAAGTTCAGCAGGAGCGCC GACGCCCCTGCTTACCAGCAGGGCCAGAATCAGCTGTACAACGAGCTGAATCTGGGCCGGAGGG AGGAGTACGACGTGCTGGACAAGCGGAGGGGCAGGGACCCCGAGATGGGCGGCAAGCCCAGGCG GAAGAACCCCCAGGAGGGGCTGTACAACGAGCTGCAGAAGGACAAGATGGCCGAGGCCTACTCC GAGATCGGCATGAAGGGCGAGAGGCGGAGAGGCAAGGGCCATGACGGCCTGTACCAGGGCCTGT CCACCGCCACCAAGGACACCTACGACGCCCTGCACATGCAGGCCCTGCCCCCCCGC (SEQ ID NO: 916); ATGGCCCTGCCCGTTACCGCCCTACTCCTGCCCCTGGCCCTCCTGCTCCACGCCGCCAGGCCCG AGGTTCAACTTGTGGAAAGTGGCGGGGGGCTCGTGCAAGCGGGTGGGAGCCTCCGGCTGTCTTG CGCAGCCAGCGGGAACATCGTTGAAATCGACGACATGGGGTGGTATAGACAAGCACCAGGAAAA CAGCGGGACCTTGTTGCCACAATTACAGCTGGAGGCATTACGAATTATGCATCTTCAGCTAAAG GGAGGTTTACGATCTCCCGAGATAACGTAAAGAACACAGTCTATTTGCAAATGAACTCCCTGAA ACCGGAGGATACCGCAACGTACTACTGCTATGCCATACGAAAGTATTACCCACGATTCGATTAT TGGGGTCAAGGCACTCAGGTGACCGTGTCAAGTACCACCACCCCTGCCCCCAGGCCCCCCACCC CCGCCCCCACCATCGCCAGCCAGCCCCTGTCCCTGCGGCCCGAGGCCTGCCGGCCCGCCGCCGG CGGCGCCGTGCACACCCGGGGCCTGGACTTCGCCTGCGACATCTACATCTGGGCCCCCCTGGCC GGAACCTGCGGCGTGCTGCTGCTGTCCCTGGTGATCACCCTGTACTGCAAGCGGGGCCGGAAGA AGCTGCTGTACATCTTCAAGCAGCCCTTCATGCGCCCCGTGCAGACCACCCAGGAGGAGGACGG CTGCAGCTGCAGGTTCCCCGAGGAGGAGGAGGGGGGCTGCGAGCTGCGGGTGAAGTTCAGCAGG AGCGCCGACGCCCCTGCTTACCAGCAGGGCCAGAATCAGCTGTACAACGAGCTGAATCTGGGCC GGAGGGAGGAGTACGACGTGCTGGACAAGCGGAGGGGCAGGGACCCCGAGATGGGCGGCAAGCC CAGGCGGAAGAACCCCCAGGAGGGGCTGTACAACGAGCTGCAGAAGGACAAGATGGCCGAGGCC TACTCCGAGATCGGCATGAAGGGCGAGAGGCGGAGAGGCAAGGGCCATGACGGCCTGTACCAGG GCCTGTCCACCGCCACCAAGGACACCTACGACGCCCTGCACATGCAGGCCCTGCCCCCCCGC (SEQ ID NO: 917); ATGGCCCTGCCCGTTACCGCCCTACTCCTGCCCCTGGCCCTCCTGCTCCACGCCGCCAGGCCCG AGGTTCAACTCGTTGAAAGTGGAGGAGGGCTCGTCCAGGCGGGCGGGAGTCTGAGGCTTTCTTG CGCCGCGAGCGGTAGAACTTTCCGATCCTATGCTATGGGCTGGTTCAGACAGGCTCCCGGAAAA GAGAGAGAATTTGTGGCGGCCATATCTTGGTCCGGTGGGCGGATATACTATGCAGACAGCGTCA AGGGGAGATTCACGATAAGCCGAGATAATGCAAAGAATACGGTATACCTGCAGATGAACTCCCT TAAACCCGAGGACACCGCAGTATATTATTGTGCCGCTGATGATTTTGAGAGGACCATGACGGAA GTACGGTATTGGGGGCAGGGCACTCAAGTCACCGTGTCTTCAACCACCACCCCTGCCCCCAGGC CCCCCACCCCCGCCCCCACCATCGCCAGCCAGCCCCTGTCCCTGCGGCCCGAGGCCTGCCGGCC CGCCGCCGGCGGCGCCGTGCACACCCGGGGCCTGGACTTCGCCTGCGACATCTACATCTGGGCC CCCCTGGCCGGAACCTGCGGCGTGCTGCTGCTGTCCCTGGTGATCACCCTGTACTGCAAGCGGG GCCGGAAGAAGCTGCTGTACATCTTCAAGCAGCCCTTCATGCGCCCCGTGCAGACCACCCAGGA GGAGGACGGCTGCAGCTGCAGGTTCCCCGAGGAGGAGGAGGGGGGCTGCGAGCTGCGGGTGAAG TTCAGCAGGAGCGCCGACGCCCCTGCTTACCAGCAGGGCCAGAATCAGCTGTACAACGAGCTGA ATCTGGGCCGGAGGGAGGAGTACGACGTGCTGGACAAGCGGAGGGGCAGGGACCCCGAGATGGG CGGCAAGCCCAGGCGGAAGAACCCCCAGGAGGGGCTGTACAACGAGCTGCAGAAGGACAAGATG GCCGAGGCCTACTCCGAGATCGGCATGAAGGGCGAGAGGCGGAGAGGCAAGGGCCATGACGGCC TGTACCAGGGCCTGTCCACCGCCACCAAGGACACCTACGACGCCCTGCACATGCAGGCCCTGCC CCCCCGC (SEQ ID NO: 918); ATGGCCCTGCCCGTTACCGCCCTACTCCTGCCCCTGGCCCTCCTGCTCCACGCCGCCAGGCCCG AGGTGCAACTGGTTGAGAGTGGCGGGGGTCTTGTCCAGCCAGGGGGATCACTTAGGCTGTCATG TGCGGCTAGCGGCTTTACCTTCAGCGGGTATTACATGAGTTGGGTCCGCCAGGCTCCAGGAAAG GGACTTGAGTGGGTAAGTAGTATATATAGCGATGATTCAAACACTTATTATGCGGATTCAGTTA AGGGTAGATTTACGATTAGCAGAGATAATGCAAAGAACACTGTCTATCTCCAAATGAACAGCCT TAAACCAGAGGACACTGCAGTTTACTATTGTGCAGCAAGCGCGACACTTAGAGGCCGCGATACC AGGTTCGATTACTGGGGCCAGGGAACACAAGTCACTGTCAGCTCCACCACCACCCCTGCCCCCA GGCCCCCCACCCCCGCCCCCACCATCGCCAGCCAGCCCCTGTCCCTGCGGCCCGAGGCCTGCCG GCCCGCCGCCGGCGGCGCCGTGCACACCCGGGGCCTGGACTTCGCCTGCGACATCTACATCTGG GCCCCCCTGGCCGGAACCTGCGGCGTGCTGCTGCTGTCCCTGGTGATCACCCTGTACTGCAAGC GGGGCCGGAAGAAGCTGCTGTACATCTTCAAGCAGCCCTTCATGCGCCCCGTGCAGACCACCCA GGAGGAGGACGGCTGCAGCTGCAGGTTCCCCGAGGAGGAGGAGGGGGGCTGCGAGCTGCGGGTG AAGTTCAGCAGGAGCGCCGACGCCCCTGCTTACCAGCAGGGCCAGAATCAGCTGTACAACGAGC TGAATCTGGGCCGGAGGGAGGAGTACGACGTGCTGGACAAGCGGAGGGGCAGGGACCCCGAGAT GGGCGGCAAGCCCAGGCGGAAGAACCCCCAGGAGGGGCTGTACAACGAGCTGCAGAAGGACAAG ATGGCCGAGGCCTACTCCGAGATCGGCATGAAGGGCGAGAGGCGGAGAGGCAAGGGCCATGACG GCCTGTACCAGGGCCTGTCCACCGCCACCAAGGACACCTACGACGCCCTGCACATGCAGGCCCT GCCCCCCCGC (SEQ ID NO: 919); ATGGCCCTGCCCGTTACCGCCCTACTCCTGCCCCTGGCCCTCCTGCTCCACGCCGCCAGGCCCG AGGTTCAACTCGTCGAATCCGGAGGGGGATTGGTGCAACCCGGCGGATCACTTAGGCTTTCCTG TAGTGCATCTGGCTTCCCTTTCGACGATTACAGTATGGACTGGGTCAGGCAGGCACCGGGGAAA GGCTTGGAATGGGTGAGTGCCATCAACAGGAACGGGGGATCAACGTATTACGCCGAGTCCATGA AGGGGAGGTTCACGATCAGCCGGGATAATGCCAAAAACACGCTGTATCTCCAGATGTCCAGTCT TAAACCAGAAGATACCGGGGTCTATCTCTGTGCTGCGGGGGGCAGGGTGTCCGCAGATGGTAAG AAATGGGAATATGATTATTGGGGTCAGGGGACCCAAGTTACGGTTTCTAGCACCACCACCCCTG CCCCCAGGCCCCCCACCCCCGCCCCCACCATCGCCAGCCAGCCCCTGTCCCTGCGGCCCGAGGC CTGCCGGCCCGCCGCCGGCGGCGCCGTGCACACCCGGGGCCTGGACTTCGCCTGCGACATCTAC ATCTGGGCCCCCCTGGCCGGAACCTGCGGCGTGCTGCTGCTGTCCCTGGTGATCACCCTGTACT GCAAGCGGGGCCGGAAGAAGCTGCTGTACATCTTCAAGCAGCCCTTCATGCGCCCCGTGCAGAC CACCCAGGAGGAGGACGGCTGCAGCTGCAGGTTCCCCGAGGAGGAGGAGGGGGGCTGCGAGCTG CGGGTGAAGTTCAGCAGGAGCGCCGACGCCCCTGCTTACCAGCAGGGCCAGAATCAGCTGTACA ACGAGCTGAATCTGGGCCGGAGGGAGGAGTACGACGTGCTGGACAAGCGGAGGGGCAGGGACCC CGAGATGGGCGGCAAGCCCAGGCGGAAGAACCCCCAGGAGGGGCTGTACAACGAGCTGCAGAAG GACAAGATGGCCGAGGCCTACTCCGAGATCGGCATGAAGGGCGAGAGGCGGAGAGGCAAGGGCC ATGACGGCCTGTACCAGGGCCTGTCCACCGCCACCAAGGACACCTACGACGCCCTGCACATGCA GGCCCTGCCCCCCCGC (SEQ ID NO: 920); ATGGCCCTGCCCGTTACCGCCCTACTCCTGCCCCTGGCCCTCCTGCTCCACGCCGCCAGGCCCC AACTCCAGCTGGTCGAGTCTGGAGGTGGTTTGGTCCAGGCTGGGGGGAGCCTTCGCCTGTCATG CGCTGCGAGTGACCCCATCGTTACCTTCAACACTATGGGATGGTATAGACAAGCGCCTGGCAAG CAGAGAGAACTTGTTGCGAGAATTACCATGTCTGGCATTCCCAACTACGCGGATTCCGTAAAAG GGCGGTTTACCATATCCCGAGATAACGCGAAAAATACGCTGTATCTTCAAATGAACTCTTTGAA GCCCGAGGATAGTGCCGTTTACTATTGTCGAGCTGAGCATTCTGGCTATTGGGGGCAGGGAACT CAGGTTACTGTAAGCAGCACCACCACCCCTGCCCCCAGGCCCCCCACCCCCGCCCCCACCATCG CCAGCCAGCCCCTGTCCCTGCGGCCCGAGGCCTGCCGGCCCGCCGCCGGCGGCGCCGTGCACAC CCGGGGCCTGGACTTCGCCTGCGACATCTACATCTGGGCCCCCCTGGCCGGAACCTGCGGCGTG CTGCTGCTGTCCCTGGTGATCACCCTGTACTGCAAGCGGGGCCGGAAGAAGCTGCTGTACATCT TCAAGCAGCCCTTCATGCGCCCCGTGCAGACCACCCAGGAGGAGGACGGCTGCAGCTGCAGGTT CCCCGAGGAGGAGGAGGGGGGCTGCGAGCTGCGGGTGAAGTTCAGCAGGAGCGCCGACGCCCCT GCTTACCAGCAGGGCCAGAATCAGCTGTACAACGAGCTGAATCTGGGCCGGAGGGAGGAGTACG ACGTGCTGGACAAGCGGAGGGGCAGGGACCCCGAGATGGGCGGCAAGCCCAGGCGGAAGAACCC CCAGGAGGGGCTGTACAACGAGCTGCAGAAGGACAAGATGGCCGAGGCCTACTCCGAGATCGGC ATGAAGGGCGAGAGGCGGAGAGGCAAGGGCCATGACGGCCTGTACCAGGGCCTGTCCACCGCCA CCAAGGACACCTACGACGCCCTGCACATGCAGGCCCTGCCCCCCCGC (SEQ ID NO: 921; ATGGCCCTGCCCGTTACCGCCCTACTCCTGCCCCTGGCCCTCCTGCTCCACGCCGCCAGGCCCC AACTCCAACTTGTTGAGTCTGGGGGCGGCTTGGTTCAAGCTGGTGGCTCCTTGCGACTCTCTTG CGCCGCTAGCGGGAACATTGTTGATATAGACGACATGGGATGGTATCGCCAGGCACCGGGAAAA CAGCGCGATCTGGTCGCCACCATCACGGCGGGTGGGATTGCCAACTATGCCGATTCAGCGAAAG GGAGGTTTACGATAAGCCGCGACAACGCTAAGAACACAGTGTACCTGCAAATGAACTCTCTCAA ACCAGAGGACACTGCAACATATTACTGTTACGCAATCCGGCGGTACTACCCTAGATTCGATTAT TGGGGGCAAGGAGCCCAAGTTACAGTATCCTCCACCACCACCCCTGCCCCCAGGCCCCCCACCC CCGCCCCCACCATCGCCAGCCAGCCCCTGTCCCTGCGGCCCGAGGCCTGCCGGCCCGCCGCCGG CGGCGCCGTGCACACCCGGGGCCTGGACTTCGCCTGCGACATCTACATCTGGGCCCCCCTGGCC GGAACCTGCGGCGTGCTGCTGCTGTCCCTGGTGATCACCCTGTACTGCAAGCGGGGCCGGAAGA AGCTGCTGTACATCTTCAAGCAGCCCTTCATGCGCCCCGTGCAGACCACCCAGGAGGAGGACGG CTGCAGCTGCAGGTTCCCCGAGGAGGAGGAGGGGGGCTGCGAGCTGCGGGTGAAGTTCAGCAGG AGCGCCGACGCCCCTGCTTACCAGCAGGGCCAGAATCAGCTGTACAACGAGCTGAATCTGGGCC GGAGGGAGGAGTACGACGTGCTGGACAAGCGGAGGGGCAGGGACCCCGAGATGGGCGGCAAGCC CAGGCGGAAGAACCCCCAGGAGGGGCTGTACAACGAGCTGCAGAAGGACAAGATGGCCGAGGCC TACTCCGAGATCGGCATGAAGGGCGAGAGGCGGAGAGGCAAGGGCCATGACGGCCTGTACCAGG GCCTGTCCACCGCCACCAAGGACACCTACGACGCCCTGCACATGCAGGCCCTGCCCCCCCGC (SEQ ID NO: 922); ATGGCCCTGCCCGTTACCGCCCTACTCCTGCCCCTGGCCCTCCTGCTCCACGCCGCCAGGCCCC AACTCCAACTTGTGGAATCAGGAGGGGGTCTCGTACAGACAGGAGGATCACTCAACTTGAGTTG TGCCGCCTCTGGAGCTTTTGTGTCTATAGATGCCATGGCGTGGTATCGACAGGCTCCCGGCAAG GCTCGGGAGCTTGTCGCCTTTTCAAGCAGCGGTGGGATAACAAATTATGCGGACAGTGTCAAGG GCCGATTTACCATTACTAGGGATAACGCGAAAAATACTGTTTATCTCCAAATGAATTCCCTTAA ACCAGAGGATACGGCTGTGTACTATTGCAACGCAGACATCTTGCAATCAGGTTGGTACACGTAC TGGGGACAAGGAACTCAGGTGACAGTGTCTAGCACCACCACCCCTGCCCCCAGGCCCCCCACCC CCGCCCCCACCATCGCCAGCCAGCCCCTGTCCCTGCGGCCCGAGGCCTGCCGGCCCGCCGCCGG CGGCGCCGTGCACACCCGGGGCCTGGACTTCGCCTGCGACATCTACATCTGGGCCCCCCTGGCC GGAACCTGCGGCGTGCTGCTGCTGTCCCTGGTGATCACCCTGTACTGCAAGCGGGGCCGGAAGA AGCTGCTGTACATCTTCAAGCAGCCCTTCATGCGCCCCGTGCAGACCACCCAGGAGGAGGACGG CTGCAGCTGCAGGTTCCCCGAGGAGGAGGAGGGGGGCTGCGAGCTGCGGGTGAAGTTCAGCAGG AGCGCCGACGCCCCTGCTTACCAGCAGGGCCAGAATCAGCTGTACAACGAGCTGAATCTGGGCC GGAGGGAGGAGTACGACGTGCTGGACAAGCGGAGGGGCAGGGACCCCGAGATGGGCGGCAAGCC CAGGCGGAAGAACCCCCAGGAGGGGCTGTACAACGAGCTGCAGAAGGACAAGATGGCCGAGGCC TACTCCGAGATCGGCATGAAGGGCGAGAGGCGGAGAGGCAAGGGCCATGACGGCCTGTACCAGG GCCTGTCCACCGCCACCAAGGACACCTACGACGCCCTGCACATGCAGGCCCTGCCCCCCCGC (SEQ ID NO: 9); ATGGCCCTGCCCGTTACCGCCCTACTCCTGCCCCTGGCCCTCCTGCTCCACGCCGCCAGGCCCC AGTTGCAACTTGTGGAGAGCGGTGGAGGCCTGGTTCGGGCAGGAGGTAGTCTCCGGTTGTCTTG TGTATTGTCAGGGAGGACATTTTCCAGTTACGCGATGGGATGGTTCAGGCAGGCTCCTGGGAAA GAACGAGAATTCGTTTCAACTATTTCTCTGTCCGGCGGATCAACCTTCTATAGCGATTCCGCCA AGGGTCGCTTTACCATAAGTCGGGACAACGCCAAAAACACCGTTTATCTGCAAATGAATAGTCT GAAGCCAGAGGACGCGGCGGTGTACTACTGTGCTGCACGGCCCGTGTTGATTAGTCGCAGTTCC ACGGACTACGCTTATTGGGGGCCTGGAACCCAGGTGACCGTCAGCTCTACCACCACCCCTGCCC CCAGGCCCCCCACCCCCGCCCCCACCATCGCCAGCCAGCCCCTGTCCCTGCGGCCCGAGGCCTG CCGGCCCGCCGCCGGCGGCGCCGTGCACACCCGGGGCCTGGACTTCGCCTGCGACATCTACATC TGGGCCCCCCTGGCCGGAACCTGCGGCGTGCTGCTGCTGTCCCTGGTGATCACCCTGTACTGCA AGCGGGGCCGGAAGAAGCTGCTGTACATCTTCAAGCAGCCCTTCATGCGCCCCGTGCAGACCAC CCAGGAGGAGGACGGCTGCAGCTGCAGGTTCCCCGAGGAGGAGGAGGGGGGCTGCGAGCTGCGG GTGAAGTTCAGCAGGAGCGCCGACGCCCCTGCTTACCAGCAGGGCCAGAATCAGCTGTACAACG AGCTGAATCTGGGCCGGAGGGAGGAGTACGACGTGCTGGACAAGCGGAGGGGCAGGGACCCCGA GATGGGCGGCAAGCCCAGGCGGAAGAACCCCCAGGAGGGGCTGTACAACGAGCTGCAGAAGGAC AAGATGGCCGAGGCCTACTCCGAGATCGGCATGAAGGGCGAGAGGCGGAGAGGCAAGGGCCATG ACGGCCTGTACCAGGGCCTGTCCACCGCCACCAAGGACACCTACGACGCCCTGCACATGCAGGC CCTGCCCCCCCGC (SEQ ID NO: 924); ATGGCCCTGCCCGTTACCGCCCTACTCCTGCCCCTGGCCCTCCTGCTCCACGCCGCCAGGCCCC AGCTTCAGCTCGTTGAATCTGGGGGAGGCCTGGTTCGCGCTGGAGGCAGCCTTCGCCTCTCCTG CGTGCTTTCAGGACGAACTTTTTCAAGCTATGCGATGGGTTGGTTTAGGCAGGCGCCTGGAAAA GAGCGGGAATTTGTCAGTACGATAAGCCTTAGCGGGGGTAGTACATTTTACTCAGATAGCGCGA AAGGCCGATTTACTATATCCCGAGATAATGCGAAAAATACGGTCTATTTGCAGATGAATAGTCT GAAACCAGAGGATACTGCCGTCTATTACTGCGCTGCGAGGCCCGTACTTATTTCCCGGAGCTCC ATAGACTATGCTTACTGGGGTCCGGGCACACAGGTAACGGTCTCCAGTACCACCACCCCTGCCC CCAGGCCCCCCACCCCCGCCCCCACCATCGCCAGCCAGCCCCTGTCCCTGCGGCCCGAGGCCTG CCGGCCCGCCGCCGGCGGCGCCGTGCACACCCGGGGCCTGGACTTCGCCTGCGACATCTACATC TGGGCCCCCCTGGCCGGAACCTGCGGCGTGCTGCTGCTGTCCCTGGTGATCACCCTGTACTGCA AGCGGGGCCGGAAGAAGCTGCTGTACATCTTCAAGCAGCCCTTCATGCGCCCCGTGCAGACCAC CCAGGAGGAGGACGGCTGCAGCTGCAGGTTCCCCGAGGAGGAGGAGGGGGGCTGCGAGCTGCGG GTGAAGTTCAGCAGGAGCGCCGACGCCCCTGCTTACCAGCAGGGCCAGAATCAGCTGTACAACG AGCTGAATCTGGGCCGGAGGGAGGAGTACGACGTGCTGGACAAGCGGAGGGGCAGGGACCCCGA GATGGGCGGCAAGCCCAGGCGGAAGAACCCCCAGGAGGGGCTGTACAACGAGCTGCAGAAGGAC AAGATGGCCGAGGCCTACTCCGAGATCGGCATGAAGGGCGAGAGGCGGAGAGGCAAGGGCCATG ACGGCCTGTACCAGGGCCTGTCCACCGCCACCAAGGACACCTACGACGCCCTGCACATGCAGGC CCTGCCCCCCCGC (SEQ ID NO: 925); ATGGCCCTGCCCGTTACCGCCCTACTCCTGCCCCTGGCCCTCCTGCTCCACGCCGCCAGGCCCC AGGTCCAACTTCAGGAAAGCGGTGGGGGTTTGGTACAGGCAGGAGAAACGCTGGGACTTAGTTG CGTACACAGTGGACGCGCGTTCTCAGGCCATGGTATGGGGTGGTTTCGCCAGGCCCCTGGAAAA GAAAGGGAGTTTGTGGCGGCTATAAGTTGGTCAGGCGTCTCAACTGCCTATGCCGACTCTGTAA AAGGTCGATTCACCATCTCTAGAGTGAACGCTGACAACACGGTGTCACTTCAAATGAATAGTCT GAAACCCGAGGACACAGCCGTTTACTTCTGCGCGGCGGGCCTCTACTCTCGACCAACCACTGAA CGCAGGGAATACATATACTGGGGTCAGGGAACTCAGGTAACAGTTAGCAGCACCACCACCCCTG CCCCCAGGCCCCCCACCCCCGCCCCCACCATCGCCAGCCAGCCCCTGTCCCTGCGGCCCGAGGC CTGCCGGCCCGCCGCCGGCGGCGCCGTGCACACCCGGGGCCTGGACTTCGCCTGCGACATCTAC ATCTGGGCCCCCCTGGCCGGAACCTGCGGCGTGCTGCTGCTGTCCCTGGTGATCACCCTGTACT GCAAGCGGGGCCGGAAGAAGCTGCTGTACATCTTCAAGCAGCCCTTCATGCGCCCCGTGCAGAC CACCCAGGAGGAGGACGGCTGCAGCTGCAGGTTCCCCGAGGAGGAGGAGGGGGGCTGCGAGCTG CGGGTGAAGTTCAGCAGGAGCGCCGACGCCCCTGCTTACCAGCAGGGCCAGAATCAGCTGTACA ACGAGCTGAATCTGGGCCGGAGGGAGGAGTACGACGTGCTGGACAAGCGGAGGGGCAGGGACCC CGAGATGGGCGGCAAGCCCAGGCGGAAGAACCCCCAGGAGGGGCTGTACAACGAGCTGCAGAAG GACAAGATGGCCGAGGCCTACTCCGAGATCGGCATGAAGGGCGAGAGGCGGAGAGGCAAGGGCC ATGACGGCCTGTACCAGGGCCTGTCCACCGCCACCAAGGACACCTACGACGCCCTGCACATGCA GGCCCTGCCCCCCCGC (SEQ ID NO: 926); ATGGCCCTGCCCGTTACCGCCCTACTCCTGCCCCTGGCCCTCCTGCTCCACGCCGCCAGGCCCC AAGTACAGCTGCAAGAGAGTGGGGGCGGGCTCGTCCAAGCCGGGGGATCTTTGCGGCTCAGTTG CGCGGCCTCTGGTAATTCCGTTGACATTGACGACATGGGATGGTACCGACAGGCTCCTGGCAAG CAACGAGATTTGGTCGCGACTATCACCGCAGGAGGCATCACCAAGTATGGTGACTCTGCGAAAG GCAGGTTCACAATAAGCAGAGATAACGTGAAGAATACCGTGTACTTGCAGATGAATAGCCTGAA GCCTGAGGACACCGCAACCTACTACTGTTATGCCGTCCGGCGCTATTACCCACGCTTCGACTAT TGGGGCCAGGGTACGCAAGTAACAGTAAGTAGTACCACCACCCCTGCCCCCAGGCCCCCCACCC CCGCCCCCACCATCGCCAGCCAGCCCCTGTCCCTGCGGCCCGAGGCCTGCCGGCCCGCCGCCGG CGGCGCCGTGCACACCCGGGGCCTGGACTTCGCCTGCGACATCTACATCTGGGCCCCCCTGGCC GGAACCTGCGGCGTGCTGCTGCTGTCCCTGGTGATCACCCTGTACTGCAAGCGGGGCCGGAAGA AGCTGCTGTACATCTTCAAGCAGCCCTTCATGCGCCCCGTGCAGACCACCCAGGAGGAGGACGG CTGCAGCTGCAGGTTCCCCGAGGAGGAGGAGGGGGGCTGCGAGCTGCGGGTGAAGTTCAGCAGG AGCGCCGACGCCCCTGCTTACCAGCAGGGCCAGAATCAGCTGTACAACGAGCTGAATCTGGGCC GGAGGGAGGAGTACGACGTGCTGGACAAGCGGAGGGGCAGGGACCCCGAGATGGGCGGCAAGCC CAGGCGGAAGAACCCCCAGGAGGGGCTGTACAACGAGCTGCAGAAGGACAAGATGGCCGAGGCC TACTCCGAGATCGGCATGAAGGGCGAGAGGCGGAGAGGCAAGGGCCATGACGGCCTGTACCAGG GCCTGTCCACCGCCACCAAGGACACCTACGACGCCCTGCACATGCAGGCCCTGCCCCCCCGC (SEQ ID NO: 927); ATGGCCCTGCCCGTTACCGCCCTACTCCTGCCCCTGGCCCTCCTGCTCCACGCCGCCAGGCCCC AGGTTCAGTTGCAAGAAAGCGGGGGAGGCCTCGTTCAGCCGGGTGGCTCATTGAGGTTGTCATG CGCCGCTTCAGGTTCTATATTCTCTATGAACGCGATGGGATGGTATAGACAAGCCCCCGGCAAA CAACGCGAACTTGTGGCGACTATTACAGATAATGACTTTACTTACTATGCAGCCTCCGTGAAAG ATCGGTTTACAATTTCTCGGGGGAACGCCAAGAACACTGTGTATCTTCAGATGAACAGTCTGAC GCCTGAAGATACGGCGGTCTACTATTGCAATGCGGATGGCATCTACTCCGGTGGAAGATATTAC CCATCTTCATGGGGACAGGGTACACAAGTCACAGTAAGCAGCACCACCACCCCTGCCCCCAGGC CCCCCACCCCCGCCCCCACCATCGCCAGCCAGCCCCTGTCCCTGCGGCCCGAGGCCTGCCGGCC CGCCGCCGGCGGCGCCGTGCACACCCGGGGCCTGGACTTCGCCTGCGACATCTACATCTGGGCC CCCCTGGCCGGAACCTGCGGCGTGCTGCTGCTGTCCCTGGTGATCACCCTGTACTGCAAGCGGG GCCGGAAGAAGCTGCTGTACATCTTCAAGCAGCCCTTCATGCGCCCCGTGCAGACCACCCAGGA GGAGGACGGCTGCAGCTGCAGGTTCCCCGAGGAGGAGGAGGGGGGCTGCGAGCTGCGGGTGAAG TTCAGCAGGAGCGCCGACGCCCCTGCTTACCAGCAGGGCCAGAATCAGCTGTACAACGAGCTGA ATCTGGGCCGGAGGGAGGAGTACGACGTGCTGGACAAGCGGAGGGGCAGGGACCCCGAGATGGG CGGCAAGCCCAGGCGGAAGAACCCCCAGGAGGGGCTGTACAACGAGCTGCAGAAGGACAAGATG GCCGAGGCCTACTCCGAGATCGGCATGAAGGGCGAGAGGCGGAGAGGCAAGGGCCATGACGGCC TGTACCAGGGCCTGTCCACCGCCACCAAGGACACCTACGACGCCCTGCACATGCAGGCCCTGCC CCCCCGC (SEQ ID NO: 928); ATGGCCCTGCCCGTTACCGCCCTACTCCTGCCCCTGGCCCTCCTGCTCCACGCCGCCAGGCCCC AGGTACAGCTTCAGGAATCTGGCGGTGGCCTGGTCCAGCCAGGAGGAAGCCTGAGATTGAGCTG TGCGGCATCCGGCAGCATTTTTTCTGTAAATGATATGGGCTGGTACAGACAGGCTCCAGGGAAG CAACGCGAATTGGTGGCGGCCTCATACTCTGGTGGGTCAACGAATTATGCCGATAGTGTTAAGG GACGGTTTACGATTAGCAGGGATAATGCAAAAAACACTGTGTATTTGCAAATGAATTCTCTTCT CCCCGAAGATACAGCTGTGTATTATTGTAATGCCGATTTGGTCGTAGTTACGACTACGCCGCCT AGTTTCCCCATGCCGTACCGATTCCTTGAGGTGTGGGGTCAGGGTACGCTGGTTACCGTCAGCA GCACCACCACCCCTGCCCCCAGGCCCCCCACCCCCGCCCCCACCATCGCCAGCCAGCCCCTGTC CCTGCGGCCCGAGGCCTGCCGGCCCGCCGCCGGCGGCGCCGTGCACACCCGGGGCCTGGACTTC GCCTGCGACATCTACATCTGGGCCCCCCTGGCCGGAACCTGCGGCGTGCTGCTGCTGTCCCTGG TGATCACCCTGTACTGCAAGCGGGGCCGGAAGAAGCTGCTGTACATCTTCAAGCAGCCCTTCAT GCGCCCCGTGCAGACCACCCAGGAGGAGGACGGCTGCAGCTGCAGGTTCCCCGAGGAGGAGGAG GGGGGCTGCGAGCTGCGGGTGAAGTTCAGCAGGAGCGCCGACGCCCCTGCTTACCAGCAGGGCC AGAATCAGCTGTACAACGAGCTGAATCTGGGCCGGAGGGAGGAGTACGACGTGCTGGACAAGCG GAGGGGCAGGGACCCCGAGATGGGCGGCAAGCCCAGGCGGAAGAACCCCCAGGAGGGGCTGTAC AACGAGCTGCAGAAGGACAAGATGGCCGAGGCCTACTCCGAGATCGGCATGAAGGGCGAGAGGC GGAGAGGCAAGGGCCATGACGGCCTGTACCAGGGCCTGTCCACCGCCACCAAGGACACCTACGA CGCCCTGCACATGCAGGCCCTGCCCCCCCGC (SEQ ID NO: 929); ATGGCCCTGCCCGTTACCGCCCTACTCCTGCCCCTGGCCCTCCTGCTCCACGCCGCCAGGCCCC AAGTACAACTTGTAGAATCTGGAGGGGGTCTCGTACACGCGGGCGGTTCTCTCCGCCTTTCTTG CGCTGCCAGTGGAAGGACATTCAACACGATGGCATGGTTCCGCCAAGCACCAGGAAAAGAGCGA GAATTTGTCGCGGCTATATCATGGTCCGGAGGTCTCACTTATTACGCGGACTCCGTGAAGGGGC GATTCACCATTTTTCGGGACAATGCGAAGGGTCTGGCCTACCTCCAAATGGATTCATTGAAGCC AGAAGATACGGCAGTGTACTCATGCGCCGCGAGAAGGACCTTCAGAACAGCGCTGATTAACACT GTAACGGCTTACGACACCTGGGGCCAGGGAACTCAGGTCACTGTCTCAAGTACCACCACCCCTG CCCCCAGGCCCCCCACCCCCGCCCCCACCATCGCCAGCCAGCCCCTGTCCCTGCGGCCCGAGGC CTGCCGGCCCGCCGCCGGCGGCGCCGTGCACACCCGGGGCCTGGACTTCGCCTGCGACATCTAC ATCTGGGCCCCCCTGGCCGGAACCTGCGGCGTGCTGCTGCTGTCCCTGGTGATCACCCTGTACT GCAAGCGGGGCCGGAAGAAGCTGCTGTACATCTTCAAGCAGCCCTTCATGCGCCCCGTGCAGAC CACCCAGGAGGAGGACGGCTGCAGCTGCAGGTTCCCCGAGGAGGAGGAGGGGGGCTGCGAGCTG CGGGTGAAGTTCAGCAGGAGCGCCGACGCCCCTGCTTACCAGCAGGGCCAGAATCAGCTGTACA ACGAGCTGAATCTGGGCCGGAGGGAGGAGTACGACGTGCTGGACAAGCGGAGGGGCAGGGACCC CGAGATGGGCGGCAAGCCCAGGCGGAAGAACCCCCAGGAGGGGCTGTACAACGAGCTGCAGAAG GACAAGATGGCCGAGGCCTACTCCGAGATCGGCATGAAGGGCGAGAGGCGGAGAGGCAAGGGCC ATGACGGCCTGTACCAGGGCCTGTCCACCGCCACCAAGGACACCTACGACGCCCTGCACATGCA GGCCCTGCCCCCCCGC (SEQ ID NO: 930); ATGGCCCTGCCCGTTACCGCCCTACTCCTGCCCCTGGCCCTCCTGCTCCACGCCGCCAGGCCCC AAGTTCAACTGGTTGAATCCGGGGGCGGGCTGGTGCATGCGGGCGGTTCTCTTCGACTCTCTTG CGCCGCCTCAGGTAGAACCTTCAATACGATGGCTTGGTTTCGGCAAGCACCGGGTAAGGAGCGG GAGTTCGTGGCGGCAATTAGCTGGTCAGGTGGACTGACCTATTACGGAGATTCTGTGAAGGGCC GCTTCACTATATTCCGGGACAATGCGAAGAATCTGGCGTATCTTCAAATGAACTCACTGAAGCC CGAGGACACTGCTGTGTACTCCTGCGCTGCTCGAAGGACTTTCAGGACGGGACTTATAGATACG GTTACAGCGTACGATACTTGGGGGCAGGGAACCCAGGTTACGGTTTCTAGCACCACCACCCCTG CCCCCAGGCCCCCCACCCCCGCCCCCACCATCGCCAGCCAGCCCCTGTCCCTGCGGCCCGAGGC CTGCCGGCCCGCCGCCGGCGGCGCCGTGCACACCCGGGGCCTGGACTTCGCCTGCGACATCTAC ATCTGGGCCCCCCTGGCCGGAACCTGCGGCGTGCTGCTGCTGTCCCTGGTGATCACCCTGTACT GCAAGCGGGGCCGGAAGAAGCTGCTGTACATCTTCAAGCAGCCCTTCATGCGCCCCGTGCAGAC CACCCAGGAGGAGGACGGCTGCAGCTGCAGGTTCCCCGAGGAGGAGGAGGGGGGCTGCGAGCTG CGGGTGAAGTTCAGCAGGAGCGCCGACGCCCCTGCTTACCAGCAGGGCCAGAATCAGCTGTACA ACGAGCTGAATCTGGGCCGGAGGGAGGAGTACGACGTGCTGGACAAGCGGAGGGGCAGGGACCC CGAGATGGGCGGCAAGCCCAGGCGGAAGAACCCCCAGGAGGGGCTGTACAACGAGCTGCAGAAG GACAAGATGGCCGAGGCCTACTCCGAGATCGGCATGAAGGGCGAGAGGCGGAGAGGCAAGGGCC ATGACGGCCTGTACCAGGGCCTGTCCACCGCCACCAAGGACACCTACGACGCCCTGCACATGCA GGCCCTGCCCCCCCGC (SEQ ID NO: 931); ATGGCCCTGCCCGTTACCGCCCTACTCCTGCCCCTGGCCCTCCTGCTCCACGCCGCCAGGCCCC AGGTCCAGCTTGTGGAATCCGGCGGCGGGTTGGTGCAAGCCGGTGATAGCCTGCGCCTTTCTTG CGCGGCTGCTAGTGGGCGCGCTTTGAGCGGCTGGCAAATGGGTTGGTATCGGCAGGCGCCGGGG AAGGAAAGAGAGTTTGTTGCATCCATTTCCATGTCCGATGGGAGTACTAGCTACCAAGATTCTG TCAAGGGGAGATTTACGATCAGCCGCGACAATGCACTTAGTACAATGTCTTTGAGAATGAACAG TCTTAAATCCGAGGACACTGCTATTTACTACTGCCAGGGGCGGTCTAGGTTCGGGTTTGAGTAT TGGGGTCAAGGCACTCAAGTCACAGTCTCTAGTACCACCACCCCTGCCCCCAGGCCCCCCACCC CCGCCCCCACCATCGCCAGCCAGCCCCTGTCCCTGCGGCCCGAGGCCTGCCGGCCCGCCGCCGG CGGCGCCGTGCACACCCGGGGCCTGGACTTCGCCTGCGACATCTACATCTGGGCCCCCCTGGCC GGAACCTGCGGCGTGCTGCTGCTGTCCCTGGTGATCACCCTGTACTGCAAGCGGGGCCGGAAGA AGCTGCTGTACATCTTCAAGCAGCCCTTCATGCGCCCCGTGCAGACCACCCAGGAGGAGGACGG CTGCAGCTGCAGGTTCCCCGAGGAGGAGGAGGGGGGCTGCGAGCTGCGGGTGAAGTTCAGCAGG AGCGCCGACGCCCCTGCTTACCAGCAGGGCCAGAATCAGCTGTACAACGAGCTGAATCTGGGCC GGAGGGAGGAGTACGACGTGCTGGACAAGCGGAGGGGCAGGGACCCCGAGATGGGCGGCAAGCC CAGGCGGAAGAACCCCCAGGAGGGGCTGTACAACGAGCTGCAGAAGGACAAGATGGCCGAGGCC TACTCCGAGATCGGCATGAAGGGCGAGAGGCGGAGAGGCAAGGGCCATGACGGCCTGTACCAGG GCCTGTCCACCGCCACCAAGGACACCTACGACGCCCTGCACATGCAGGCCCTGCCCCCCCGC (SEQ ID NO: 932); ATGGCCCTGCCCGTTACCGCCCTACTCCTGCCCCTGGCCCTCCTGCTCCACGCCGCCAGGCCCC AGGTACAACTCGTAGAAAGCGGTGGGGGCCTTGTTCAGGCAGGGGAGAGCCTCCGGTTGTCTTG CGTCGCTAGCGGTCGAGCCTTGTCAGGACACGGTATGGGGTGGTTCCGACAAGCGCCAGGGAAG GAAAGAGAGTTCGTAGCTGCTATCAGTTGGAGTGGGGTGTCAACTGCTTACGCAGACTCCGTAA AAGGTCGCTTCACGATCAGTAGGGTTAATGCGGAAAACACAGTGTCTGTATCCTTGCAGATGAA CTCACTGAAGCCAGATGATACAGCAGTCTATTTCTGCGCCGCTGGGTTGTATTCCCGCCCGACA ACGGAGCGACGCGACTACATATACTGGGGACAGGGAACACAGGTTACCGTGAGCAGCACCACCA CCCCTGCCCCCAGGCCCCCCACCCCCGCCCCCACCATCGCCAGCCAGCCCCTGTCCCTGCGGCC CGAGGCCTGCCGGCCCGCCGCCGGCGGCGCCGTGCACACCCGGGGCCTGGACTTCGCCTGCGAC ATCTACATCTGGGCCCCCCTGGCCGGAACCTGCGGCGTGCTGCTGCTGTCCCTGGTGATCACCC TGTACTGCAAGCGGGGCCGGAAGAAGCTGCTGTACATCTTCAAGCAGCCCTTCATGCGCCCCGT GCAGACCACCCAGGAGGAGGACGGCTGCAGCTGCAGGTTCCCCGAGGAGGAGGAGGGGGGCTGC GAGCTGCGGGTGAAGTTCAGCAGGAGCGCCGACGCCCCTGCTTACCAGCAGGGCCAGAATCAGC TGTACAACGAGCTGAATCTGGGCCGGAGGGAGGAGTACGACGTGCTGGACAAGCGGAGGGGCAG GGACCCCGAGATGGGCGGCAAGCCCAGGCGGAAGAACCCCCAGGAGGGGCTGTACAACGAGCTG CAGAAGGACAAGATGGCCGAGGCCTACTCCGAGATCGGCATGAAGGGCGAGAGGCGGAGAGGCA AGGGCCATGACGGCCTGTACCAGGGCCTGTCCACCGCCACCAAGGACACCTACGACGCCCTGCA CATGCAGGCCCTGCCCCCCCGC (SEQ ID NO: 933); ATGGCCCTGCCCGTTACCGCCCTACTCCTGCCCCTGGCCCTCCTGCTCCACGCCGCCAGGCCCC AGGTGCAACTGGTAGAAAGTGGCGGGGGCCTGGTACAAGCGGGAGGCAGCTTGCGGCTCTCTTG CGCGGCGGCGTCCCACACGTTCGATTCTTATACGATGGGTTGGTTCCGACAGGCTCCGGGAAAA GAAAGGGAGTTCGTGGCTGCTGTGAATTGGGATAATGTGAAGAACTACGCAGATCCGGTTAAAG GGCGGTTCACAATCTCTCGAGACAATGTGAAAAACCGCGTGTATTTGCAGATGAATAGCTTGAA ACCCGAAGATACGGCAGTCTACTATTGTGCGGCAGGTACCAATCTGCCGACGAGAGGAAGCGGA TCTTGGGGGCAGGGTACACAAGTTACTGTCTCAAGTACCACCACCCCTGCCCCCAGGCCCCCCA CCCCCGCCCCCACCATCGCCAGCCAGCCCCTGTCCCTGCGGCCCGAGGCCTGCCGGCCCGCCGC CGGCGGCGCCGTGCACACCCGGGGCCTGGACTTCGCCTGCGACATCTACATCTGGGCCCCCCTG GCCGGAACCTGCGGCGTGCTGCTGCTGTCCCTGGTGATCACCCTGTACTGCAAGCGGGGCCGGA AGAAGCTGCTGTACATCTTCAAGCAGCCCTTCATGCGCCCCGTGCAGACCACCCAGGAGGAGGA CGGCTGCAGCTGCAGGTTCCCCGAGGAGGAGGAGGGGGGCTGCGAGCTGCGGGTGAAGTTCAGC AGGAGCGCCGACGCCCCTGCTTACCAGCAGGGCCAGAATCAGCTGTACAACGAGCTGAATCTGG GCCGGAGGGAGGAGTACGACGTGCTGGACAAGCGGAGGGGCAGGGACCCCGAGATGGGCGGCAA GCCCAGGCGGAAGAACCCCCAGGAGGGGCTGTACAACGAGCTGCAGAAGGACAAGATGGCCGAG GCCTACTCCGAGATCGGCATGAAGGGCGAGAGGCGGAGAGGCAAGGGCCATGACGGCCTGTACC AGGGCCTGTCCACCGCCACCAAGGACACCTACGACGCCCTGCACATGCAGGCCCTGCCCCCCCG C (SEQ ID NO: 934); ATGGCCCTGCCCGTTACCGCCCTACTCCTGCCCCTGGCCCTCCTGCTCCACGCCGCCAGGCCCC AAGTCCAACTCGTCGAGTCAGGAGGTGGGCTCGTTCAGGCAGGCGGGAGCCTGAGGTTGAGTTG TGCCGCCGCAAGTCTTACCTTTGATTCATATACTATGGGATGGTTTAGACAGGCGCCAGGTAAA GAAAGAGAGTTCGTAGCAGCAGTTAACTGGGACAACGTAAAGAATTATGCAGATCCAGTAAAGG GTCGCTTTACCATCTCAAGAGATAATGTCAAAAATACGGTGTACCTCCAAATGAACAGTCTGAA GCCTGAGGATACAGCCGTATACTATTGCGCCGCCGGGACCAACCTCCCCACTATAGAGTCAGGG AGTTGGGGGCAGGGCACTCAAGTAACTGTGAGTAGTACCACCACCCCTGCCCCCAGGCCCCCCA CCCCCGCCCCCACCATCGCCAGCCAGCCCCTGTCCCTGCGGCCCGAGGCCTGCCGGCCCGCCGC CGGCGGCGCCGTGCACACCCGGGGCCTGGACTTCGCCTGCGACATCTACATCTGGGCCCCCCTG GCCGGAACCTGCGGCGTGCTGCTGCTGTCCCTGGTGATCACCCTGTACTGCAAGCGGGGCCGGA AGAAGCTGCTGTACATCTTCAAGCAGCCCTTCATGCGCCCCGTGCAGACCACCCAGGAGGAGGA CGGCTGCAGCTGCAGGTTCCCCGAGGAGGAGGAGGGGGGCTGCGAGCTGCGGGTGAAGTTCAGC AGGAGCGCCGACGCCCCTGCTTACCAGCAGGGCCAGAATCAGCTGTACAACGAGCTGAATCTGG GCCGGAGGGAGGAGTACGACGTGCTGGACAAGCGGAGGGGCAGGGACCCCGAGATGGGCGGCAA GCCCAGGCGGAAGAACCCCCAGGAGGGGCTGTACAACGAGCTGCAGAAGGACAAGATGGCCGAG GCCTACTCCGAGATCGGCATGAAGGGCGAGAGGCGGAGAGGCAAGGGCCATGACGGCCTGTACC AGGGCCTGTCCACCGCCACCAAGGACACCTACGACGCCCTGCACATGCAGGCCCTGCCCCCCCG C (SEQ ID NO: 935); ATGGCCCTGCCCGTTACCGCCCTACTCCTGCCCCTGGCCCTCCTGCTCCACGCCGCCAGGCCCC AAGTACAACTTGTTGAGAGCGGGGGAGGATTGGTGCAGGCCGGAGGTTCCCTCCGGCTGTCCTG CGCTGCGTCAGGAAATGGGGTAGATATAGACGACATGGGTTGGTACAGACAGGCACCCGGCAAA CAAAGGGACCTGGTAGCATCTATTACTGCTGGAGGAATTACTAAATACGCCGATTCTGCAAAAG GACGGTTTACGATCAGTCGGGACAACGTAAAGAACACTGTTTACCTCCAGATGAATTCCCTGAA GCCGGAGGACACAGCGACTTACTATTGTTACGCTATCAGACGATTCTACCCTCGCTTCGACTAC TGGGGCCAGGGTACGCAGGTTACGGTTTCATCTACCACCACCCCTGCCCCCAGGCCCCCCACCC CCGCCCCCACCATCGCCAGCCAGCCCCTGTCCCTGCGGCCCGAGGCCTGCCGGCCCGCCGCCGG CGGCGCCGTGCACACCCGGGGCCTGGACTTCGCCTGCGACATCTACATCTGGGCCCCCCTGGCC GGAACCTGCGGCGTGCTGCTGCTGTCCCTGGTGATCACCCTGTACTGCAAGCGGGGCCGGAAGA AGCTGCTGTACATCTTCAAGCAGCCCTTCATGCGCCCCGTGCAGACCACCCAGGAGGAGGACGG CTGCAGCTGCAGGTTCCCCGAGGAGGAGGAGGGGGGCTGCGAGCTGCGGGTGAAGTTCAGCAGG AGCGCCGACGCCCCTGCTTACCAGCAGGGCCAGAATCAGCTGTACAACGAGCTGAATCTGGGCC GGAGGGAGGAGTACGACGTGCTGGACAAGCGGAGGGGCAGGGACCCCGAGATGGGCGGCAAGCC CAGGCGGAAGAACCCCCAGGAGGGGCTGTACAACGAGCTGCAGAAGGACAAGATGGCCGAGGCC TACTCCGAGATCGGCATGAAGGGCGAGAGGCGGAGAGGCAAGGGCCATGACGGCCTGTACCAGG GCCTGTCCACCGCCACCAAGGACACCTACGACGCCCTGCACATGCAGGCCCTGCCCCCCCGC (SEQ ID NO: 936); ATGGCCCTGCCCGTTACCGCCCTACTCCTGCCCCTGGCCCTCCTGCTCCACGCCGCCAGGCCCC AGGTACAGCTCGTCGAATCCGGGGGAGGCTTGGTCCAGGCGGGCGGAAGTCTTAGATTGTCTTG TGCCGCATCTGGGAACGGCGTTGATATTGACGATATGGGGTGGTATCGACAGGCGCCCGGTAAG CAGCGCGATCTGGTTGCCAGCATCACGGCAGGAGGAATCACTAATTATGCGGATAGTGCCAAAG GAAGGTTTACCATCTCTCGGGACAACGTCAAAAATACAGTATATCTTCAGATGAACTCCCTTAA ACCAGAGGATACTGCGACCTATTATTGCTACGCAATACGCCGGTTTTACCCTCGGTTTGACTAC TGGGGTCAAGGGACGCAGGTGACAGTATCATCAACCACCACCCCTGCCCCCAGGCCCCCCACCC CCGCCCCCACCATCGCCAGCCAGCCCCTGTCCCTGCGGCCCGAGGCCTGCCGGCCCGCCGCCGG CGGCGCCGTGCACACCCGGGGCCTGGACTTCGCCTGCGACATCTACATCTGGGCCCCCCTGGCC GGAACCTGCGGCGTGCTGCTGCTGTCCCTGGTGATCACCCTGTACTGCAAGCGGGGCCGGAAGA AGCTGCTGTACATCTTCAAGCAGCCCTTCATGCGCCCCGTGCAGACCACCCAGGAGGAGGACGG CTGCAGCTGCAGGTTCCCCGAGGAGGAGGAGGGGGGCTGCGAGCTGCGGGTGAAGTTCAGCAGG AGCGCCGACGCCCCTGCTTACCAGCAGGGCCAGAATCAGCTGTACAACGAGCTGAATCTGGGCC GGAGGGAGGAGTACGACGTGCTGGACAAGCGGAGGGGCAGGGACCCCGAGATGGGCGGCAAGCC CAGGCGGAAGAACCCCCAGGAGGGGCTGTACAACGAGCTGCAGAAGGACAAGATGGCCGAGGCC TACTCCGAGATCGGCATGAAGGGCGAGAGGCGGAGAGGCAAGGGCCATGACGGCCTGTACCAGG GCCTGTCCACCGCCACCAAGGACACCTACGACGCCCTGCACATGCAGGCCCTGCCCCCCCGC (SEQ ID NO: 937); ATGGCCCTGCCCGTTACCGCCCTACTCCTGCCCCTGGCCCTCCTGCTCCACGCCGCCAGGCCCC AGGTTCAACTGGTCGAGTCCGGTGGAGGCTTGGTGCAAGCGGGTGGTAGTCTGCGGCTGAGCTG CGCTGCTAGTGGTAACGGTGTCGACATCGACGACATGGGATGGTACAGACAGGCACCAGGGAAG CAGAGGGACCTTGTTGCTACAATCACAGCCGGCGGGATAACCAAATACGCAGATTCTGCAAAGG GTCGGTTTACAATTTCACGAGATAATGTAAAGAATACCGTCTATTTGCAGATGAACAGCCTTAA ACCCGAAGATACTGCCACATATTATTGTTACGCCATAAGGCGATTCTATCCCCGCTTCGACTAT TGGGGTCAGGGGACTCAAGTTACTGTTAGCTCCACCACCACCCCTGCCCCCAGGCCCCCCACCC CCGCCCCCACCATCGCCAGCCAGCCCCTGTCCCTGCGGCCCGAGGCCTGCCGGCCCGCCGCCGG CGGCGCCGTGCACACCCGGGGCCTGGACTTCGCCTGCGACATCTACATCTGGGCCCCCCTGGCC GGAACCTGCGGCGTGCTGCTGCTGTCCCTGGTGATCACCCTGTACTGCAAGCGGGGCCGGAAGA AGCTGCTGTACATCTTCAAGCAGCCCTTCATGCGCCCCGTGCAGACCACCCAGGAGGAGGACGG CTGCAGCTGCAGGTTCCCCGAGGAGGAGGAGGGGGGCTGCGAGCTGCGGGTGAAGTTCAGCAGG AGCGCCGACGCCCCTGCTTACCAGCAGGGCCAGAATCAGCTGTACAACGAGCTGAATCTGGGCC GGAGGGAGGAGTACGACGTGCTGGACAAGCGGAGGGGCAGGGACCCCGAGATGGGCGGCAAGCC CAGGCGGAAGAACCCCCAGGAGGGGCTGTACAACGAGCTGCAGAAGGACAAGATGGCCGAGGCC TACTCCGAGATCGGCATGAAGGGCGAGAGGCGGAGAGGCAAGGGCCATGACGGCCTGTACCAGG GCCTGTCCACCGCCACCAAGGACACCTACGACGCCCTGCACATGCAGGCCCTGCCCCCCCGC (SEQ ID NO: 938); ATGGCCCTGCCCGTTACCGCCCTACTCCTGCCCCTGGCCCTCCTGCTCCACGCCGCCAGGCCCC AGGTGCAACTCGTTGAAAGCGGGGGAGGACTCGTGCAAGCGGGAGGATCACTCCGACTGAGTTG TGCTGCTTCAGGGAATGGCGTTGATATAGACGACATGGGTTGGTATCGACAGGCACCCGGAAAG CAACGGGATTTGGTCGCGACTATTACAGCGGGGGGTATTACTAACTATGCGGATAGCGCCAAGG GGCGATTCACTATCTCACGCGATAACGTGAAAAACACCGTATATCTTCAGATGAACAGTTTGAA ACCAGAAGACACCGGTACATACTATTGTTACGCTATCAGAAAATTTTACCCCAGATTTGATTAC TGGGGGCAGGGAACGCAGGTTACGGTCAGTAGCACCACCACCCCTGCCCCCAGGCCCCCCACCC CCGCCCCCACCATCGCCAGCCAGCCCCTGTCCCTGCGGCCCGAGGCCTGCCGGCCCGCCGCCGG CGGCGCCGTGCACACCCGGGGCCTGGACTTCGCCTGCGACATCTACATCTGGGCCCCCCTGGCC GGAACCTGCGGCGTGCTGCTGCTGTCCCTGGTGATCACCCTGTACTGCAAGCGGGGCCGGAAGA AGCTGCTGTACATCTTCAAGCAGCCCTTCATGCGCCCCGTGCAGACCACCCAGGAGGAGGACGG CTGCAGCTGCAGGTTCCCCGAGGAGGAGGAGGGGGGCTGCGAGCTGCGGGTGAAGTTCAGCAGG AGCGCCGACGCCCCTGCTTACCAGCAGGGCCAGAATCAGCTGTACAACGAGCTGAATCTGGGCC GGAGGGAGGAGTACGACGTGCTGGACAAGCGGAGGGGCAGGGACCCCGAGATGGGCGGCAAGCC CAGGCGGAAGAACCCCCAGGAGGGGCTGTACAACGAGCTGCAGAAGGACAAGATGGCCGAGGCC TACTCCGAGATCGGCATGAAGGGCGAGAGGCGGAGAGGCAAGGGCCATGACGGCCTGTACCAGG GCCTGTCCACCGCCACCAAGGACACCTACGACGCCCTGCACATGCAGGCCCTGCCCCCCCGC (SEQ ID NO: 939); ATGGCCCTGCCCGTTACCGCCCTACTCCTGCCCCTGGCCCTCCTGCTCCACGCCGCCAGGCCCC AGGTCCAGCTGGTTGAAAGCGGTGGGGGGCTGGTCCAAGCCGGCGGTTCTCTTAGACTTAGCTG CGCCGCGTCTGGTAACATTGTTGACATCGACGACATGGGGTGGTATAGGCAGGCTCCAGGTAAA CAACGAGATTTGGTTGCCTCAATCACAGCGGGGGGTATAACCAAATATGCAGATTCAGCTAAGG GACGATTCACCATTAGCCGAGACAATGTAAAGAACACTGTTAGTTTGCAGATGAACTCACTGAA ACCTGAAGATACGGCGACATATTATTGTTATGCAGTTAGAAAGTATTACCCCAGATTTGACTAT TGGGGCCAAGGCACTCAAGTGACCGTATCCTCTACCACCACCCCTGCCCCCAGGCCCCCCACCC CCGCCCCCACCATCGCCAGCCAGCCCCTGTCCCTGCGGCCCGAGGCCTGCCGGCCCGCCGCCGG CGGCGCCGTGCACACCCGGGGCCTGGACTTCGCCTGCGACATCTACATCTGGGCCCCCCTGGCC GGAACCTGCGGCGTGCTGCTGCTGTCCCTGGTGATCACCCTGTACTGCAAGCGGGGCCGGAAGA AGCTGCTGTACATCTTCAAGCAGCCCTTCATGCGCCCCGTGCAGACCACCCAGGAGGAGGACGG CTGCAGCTGCAGGTTCCCCGAGGAGGAGGAGGGGGGCTGCGAGCTGCGGGTGAAGTTCAGCAGG AGCGCCGACGCCCCTGCTTACCAGCAGGGCCAGAATCAGCTGTACAACGAGCTGAATCTGGGCC GGAGGGAGGAGTACGACGTGCTGGACAAGCGGAGGGGCAGGGACCCCGAGATGGGCGGCAAGCC CAGGCGGAAGAACCCCCAGGAGGGGCTGTACAACGAGCTGCAGAAGGACAAGATGGCCGAGGCC TACTCCGAGATCGGCATGAAGGGCGAGAGGCGGAGAGGCAAGGGCCATGACGGCCTGTACCAGG GCCTGTCCACCGCCACCAAGGACACCTACGACGCCCTGCACATGCAGGCCCTGCCCCCCCGC (SEQ ID NO: 940); ATGGCCCTGCCCGTTACCGCCCTACTCCTGCCCCTGGCCCTCCTGCTCCACGCCGCCAGGCCCC AGGTACAACTTGTCGAATCAGGTGGAGGACTCGTGCAGGCTGGGGGGTCCCTGCGCTTGAGTTG CGCCGCTAGTGGTAGGACATTTTCCAATTACGCCATGGGTTGGTTTAGACAAGCTCCTGGGAAG GAGCGCGAATTCGTGGCTGCAATTAACTGGTCCGGCGGACGCATTTACTATACAGACTCCGTGA AAGGTCGATTTACAATCAGTAGAGACAACGCCAAGAATACGGTTTATCTTCAGATGAACAGTCT TAAACCGGAAGATACTGCCGTGTACTATTGCGCTGCGGGGACGAATTGGTCAATACCACCTGAT TACTGGGGTCAGGGGACGCAGGTAACCGTGAGCTCCACCACCACCCCTGCCCCCAGGCCCCCCA CCCCCGCCCCCACCATCGCCAGCCAGCCCCTGTCCCTGCGGCCCGAGGCCTGCCGGCCCGCCGC CGGCGGCGCCGTGCACACCCGGGGCCTGGACTTCGCCTGCGACATCTACATCTGGGCCCCCCTG GCCGGAACCTGCGGCGTGCTGCTGCTGTCCCTGGTGATCACCCTGTACTGCAAGCGGGGCCGGA AGAAGCTGCTGTACATCTTCAAGCAGCCCTTCATGCGCCCCGTGCAGACCACCCAGGAGGAGGA CGGCTGCAGCTGCAGGTTCCCCGAGGAGGAGGAGGGGGGCTGCGAGCTGCGGGTGAAGTTCAGC AGGAGCGCCGACGCCCCTGCTTACCAGCAGGGCCAGAATCAGCTGTACAACGAGCTGAATCTGG GCCGGAGGGAGGAGTACGACGTGCTGGACAAGCGGAGGGGCAGGGACCCCGAGATGGGCGGCAA GCCCAGGCGGAAGAACCCCCAGGAGGGGCTGTACAACGAGCTGCAGAAGGACAAGATGGCCGAG GCCTACTCCGAGATCGGCATGAAGGGCGAGAGGCGGAGAGGCAAGGGCCATGACGGCCTGTACC AGGGCCTGTCCACCGCCACCAAGGACACCTACGACGCCCTGCACATGCAGGCCCTGCCCCCCCG C (SEQ ID NO: 941); ATGGCCCTGCCCGTTACCGCCCTACTCCTGCCCCTGGCCCTCCTGCTCCACGCCGCCAGGCCCC AAGTACAGCTCGTGGAGTCAGGTGGTGGACTCGTTCAGGCGGGTGGTTCCCTTAGGTTGTCCTG TGCTGCGTCAGGTCGCACGTTCAGCTCCTATGCTATGGGCTGGTTCAGGCAGGCACCGGGGAAG GAGCGAGAATTTGTAGCGGCAATACGATGGAGTGGAGGCTCTACTTATTACGGAGATAGTGTTA AAGGGAGGTTCACTATTTCTAGAGATAATGCGAAAAACACCGTGTATCTCCAAATGAACAGCCT CAAACCTGAAGATACGGCAGTCTACTACTGTGCGGCTGACCCCATTGGCCTCGGATACGAAATG GGAGAGTATGATTACTGGGGTCAAGGTACGCAGGTTACTGTATCAAGTACCACCACCCCTGCCC CCAGGCCCCCCACCCCCGCCCCCACCATCGCCAGCCAGCCCCTGTCCCTGCGGCCCGAGGCCTG CCGGCCCGCCGCCGGCGGCGCCGTGCACACCCGGGGCCTGGACTTCGCCTGCGACATCTACATC TGGGCCCCCCTGGCCGGAACCTGCGGCGTGCTGCTGCTGTCCCTGGTGATCACCCTGTACTGCA AGCGGGGCCGGAAGAAGCTGCTGTACATCTTCAAGCAGCCCTTCATGCGCCCCGTGCAGACCAC CCAGGAGGAGGACGGCTGCAGCTGCAGGTTCCCCGAGGAGGAGGAGGGGGGCTGCGAGCTGCGG GTGAAGTTCAGCAGGAGCGCCGACGCCCCTGCTTACCAGCAGGGCCAGAATCAGCTGTACAACG AGCTGAATCTGGGCCGGAGGGAGGAGTACGACGTGCTGGACAAGCGGAGGGGCAGGGACCCCGA GATGGGCGGCAAGCCCAGGCGGAAGAACCCCCAGGAGGGGCTGTACAACGAGCTGCAGAAGGAC AAGATGGCCGAGGCCTACTCCGAGATCGGCATGAAGGGCGAGAGGCGGAGAGGCAAGGGCCATG ACGGCCTGTACCAGGGCCTGTCCACCGCCACCAAGGACACCTACGACGCCCTGCACATGCAGGC CCTGCCCCCCCGC (SEQ ID NO: 942); ATGGCCCTGCCCGTTACCGCCCTACTCCTGCCCCTGGCCCTCCTGCTCCACGCCGCCAGGCCCC AGGTACAGCTTGTCGAAAGCGGGGGCGGTCTGGTTCAGGCCGGTGGAAGTTTGAGGCTCAGTTG TGCAGCGAGCGGGAGAACCTTCTCCAGTTACGCGATGGGGTGGTTCCGACAGGCGCCAGGGAAG GAGAGAGAATTCGTGGCAGCAATCTCATGGTCCGGCGGAAGCATTTATTATGCGGACTCTGTAA AGGGGCGATTTACAATATCCCGAGACAACGCGAAGAACACAGTATCCCTCCAAATGAATAGCCT GAAGCCTGAAGACACGGCTGTGTACTATTGTGCCGCAGACGGAACGCTCCGCACGCCCATGAAC CTTATTCATTATTGGGGGCAGGGAACCCAAGTGACTGTATCTTCTACCACCACCCCTGCCCCCA GGCCCCCCACCCCCGCCCCCACCATCGCCAGCCAGCCCCTGTCCCTGCGGCCCGAGGCCTGCCG GCCCGCCGCCGGCGGCGCCGTGCACACCCGGGGCCTGGACTTCGCCTGCGACATCTACATCTGG GCCCCCCTGGCCGGAACCTGCGGCGTGCTGCTGCTGTCCCTGGTGATCACCCTGTACTGCAAGC GGGGCCGGAAGAAGCTGCTGTACATCTTCAAGCAGCCCTTCATGCGCCCCGTGCAGACCACCCA GGAGGAGGACGGCTGCAGCTGCAGGTTCCCCGAGGAGGAGGAGGGGGGCTGCGAGCTGCGGGTG AAGTTCAGCAGGAGCGCCGACGCCCCTGCTTACCAGCAGGGCCAGAATCAGCTGTACAACGAGC TGAATCTGGGCCGGAGGGAGGAGTACGACGTGCTGGACAAGCGGAGGGGCAGGGACCCCGAGAT GGGCGGCAAGCCCAGGCGGAAGAACCCCCAGGAGGGGCTGTACAACGAGCTGCAGAAGGACAAG ATGGCCGAGGCCTACTCCGAGATCGGCATGAAGGGCGAGAGGCGGAGAGGCAAGGGCCATGACG GCCTGTACCAGGGCCTGTCCACCGCCACCAAGGACACCTACGACGCCCTGCACATGCAGGCCCT GCCCCCCCGC (SEQ ID NO: 943); ATGGCCCTGCCCGTTACCGCCCTACTCCTGCCCCTGGCCCTCCTGCTCCACGCCGCCAGGCCCC AAGTCCAACTGGTAGAGAGTGGCGGTGGGCTCGTCCAAGCCGGGGGCTCTCTCAGGTTGTCCTG TGCCGCGTCCGGCAGGACCTTCTCAAGTTATGCGATGGGATGGTTCCGACAGGCACCAGGAAAA GAGAGGGAGTTTGTCGCAGCTATTTCATGGTCTGGCGGTAGCACGTATTATGCCAATAGCGTGA AAGGGCGGTTCACGATTAGTCGGGACAATGCGAAAAACACCGTTTATCTGCAAATGAATTCCCT GAAGCCTGAGGACACCGCTGTGTACTACTGCGCTCCTGGCGAAGAAGTAGCAGGCAAGTATTTC CGCCAACTCTATGACTACTGGGGGCAGGGCACACAAGTTACAGTGAGTTCCACCACCACCCCTG CCCCCAGGCCCCCCACCCCCGCCCCCACCATCGCCAGCCAGCCCCTGTCCCTGCGGCCCGAGGC CTGCCGGCCCGCCGCCGGCGGCGCCGTGCACACCCGGGGCCTGGACTTCGCCTGCGACATCTAC ATCTGGGCCCCCCTGGCCGGAACCTGCGGCGTGCTGCTGCTGTCCCTGGTGATCACCCTGTACT GCAAGCGGGGCCGGAAGAAGCTGCTGTACATCTTCAAGCAGCCCTTCATGCGCCCCGTGCAGAC CACCCAGGAGGAGGACGGCTGCAGCTGCAGGTTCCCCGAGGAGGAGGAGGGGGGCTGCGAGCTG CGGGTGAAGTTCAGCAGGAGCGCCGACGCCCCTGCTTACCAGCAGGGCCAGAATCAGCTGTACA ACGAGCTGAATCTGGGCCGGAGGGAGGAGTACGACGTGCTGGACAAGCGGAGGGGCAGGGACCC CGAGATGGGCGGCAAGCCCAGGCGGAAGAACCCCCAGGAGGGGCTGTACAACGAGCTGCAGAAG GACAAGATGGCCGAGGCCTACTCCGAGATCGGCATGAAGGGCGAGAGGCGGAGAGGCAAGGGCC ATGACGGCCTGTACCAGGGCCTGTCCACCGCCACCAAGGACACCTACGACGCCCTGCACATGCA GGCCCTGCCCCCCCGC (SEQ ID NO: 944); ATGGCCCTGCCCGTTACCGCCCTACTCCTGCCCCTGGCCCTCCTGCTCCACGCCGCCAGGCCCC AAGTTCAACTTGTTGAGTCCGGGGGTGGCCTCGTCCAAGCAGGAGGGTCCCTCCGGCTGTCATG CGCGGCTAGCGGTCGGACATTTAGCAGTTATGCGATGGGGTGGTTCCGGCAAGCACCAGGTAAG GAAAGGGAGTTTGTGGCAGACATTTCATGGAGTGGAGGTACGACAAATTATGCAAACAGCGTTA AGGGGCGCTTTACGATTTCCCGAGACAATGCAAAAAACACAGTATATCTGCAGATGAACTCACT CAAGCCGGAAGATACGGCGGTTTACTACTGTGCGCCTGGAGAAGAAGTGGACGGCAAATATTTC CGCCCTCTCTATGATTACTGGGGGCAGGGAACTCAGGTAACCGTAAGCAGTACCACCACCCCTG CCCCCAGGCCCCCCACCCCCGCCCCCACCATCGCCAGCCAGCCCCTGTCCCTGCGGCCCGAGGC CTGCCGGCCCGCCGCCGGCGGCGCCGTGCACACCCGGGGCCTGGACTTCGCCTGCGACATCTAC ATCTGGGCCCCCCTGGCCGGAACCTGCGGCGTGCTGCTGCTGTCCCTGGTGATCACCCTGTACT GCAAGCGGGGCCGGAAGAAGCTGCTGTACATCTTCAAGCAGCCCTTCATGCGCCCCGTGCAGAC CACCCAGGAGGAGGACGGCTGCAGCTGCAGGTTCCCCGAGGAGGAGGAGGGGGGCTGCGAGCTG CGGGTGAAGTTCAGCAGGAGCGCCGACGCCCCTGCTTACCAGCAGGGCCAGAATCAGCTGTACA ACGAGCTGAATCTGGGCCGGAGGGAGGAGTACGACGTGCTGGACAAGCGGAGGGGCAGGGACCC CGAGATGGGCGGCAAGCCCAGGCGGAAGAACCCCCAGGAGGGGCTGTACAACGAGCTGCAGAAG GACAAGATGGCCGAGGCCTACTCCGAGATCGGCATGAAGGGCGAGAGGCGGAGAGGCAAGGGCC ATGACGGCCTGTACCAGGGCCTGTCCACCGCCACCAAGGACACCTACGACGCCCTGCACATGCA GGCCCTGCCCCCCCGC (SEQ ID NO: 945); ATGGCCCTGCCCGTTACCGCCCTACTCCTGCCCCTGGCCCTCCTGCTCCACGCCGCCAGGCCCC AGGTACAACTGGTGGAATCAGGTGGGGGGTTGGTCCAGGCTGGAGGATCATTGCGACTCAGTTG CGCCGCATCAGGGCGAACTTTTTCTACCTATACGATGGGATGGTTTCGGCAAGCCCCCGGTAAA GAACGACAGTTTGTCGCAGCCATTAGTTCCTCAGGAGACTCAACCTACTACACTGATTCCGTGA AAGGCCGGTTTACCATTTCCAGAGATAATGCCAAGAACACTGTTTATCTGCAGATGGACAGCCT GAAGCCCGAGGACACAGCGGTGTATTACTGCGCACCGGGTGAAGAAGTAGCTGGAAAATACTTC CGCGCACTGTATGATTACTGGGGCCAGGGCACTCAAGTTACCGTCTCTAGTACCACCACCCCTG CCCCCAGGCCCCCCACCCCCGCCCCCACCATCGCCAGCCAGCCCCTGTCCCTGCGGCCCGAGGC CTGCCGGCCCGCCGCCGGCGGCGCCGTGCACACCCGGGGCCTGGACTTCGCCTGCGACATCTAC ATCTGGGCCCCCCTGGCCGGAACCTGCGGCGTGCTGCTGCTGTCCCTGGTGATCACCCTGTACT GCAAGCGGGGCCGGAAGAAGCTGCTGTACATCTTCAAGCAGCCCTTCATGCGCCCCGTGCAGAC CACCCAGGAGGAGGACGGCTGCAGCTGCAGGTTCCCCGAGGAGGAGGAGGGGGGCTGCGAGCTG CGGGTGAAGTTCAGCAGGAGCGCCGACGCCCCTGCTTACCAGCAGGGCCAGAATCAGCTGTACA ACGAGCTGAATCTGGGCCGGAGGGAGGAGTACGACGTGCTGGACAAGCGGAGGGGCAGGGACCC CGAGATGGGCGGCAAGCCCAGGCGGAAGAACCCCCAGGAGGGGCTGTACAACGAGCTGCAGAAG GACAAGATGGCCGAGGCCTACTCCGAGATCGGCATGAAGGGCGAGAGGCGGAGAGGCAAGGGCC ATGACGGCCTGTACCAGGGCCTGTCCACCGCCACCAAGGACACCTACGACGCCCTGCACATGCA GGCCCTGCCCCCCCGC (SEQ ID NO: 946); ATGGCCCTGCCCGTTACCGCCCTACTCCTGCCCCTGGCCCTCCTGCTCCACGCCGCCAGGCCCC AAGTCCAGCTTGTAGAAAGCGGTGGCGGTCTCGTTCAAGCCGGTGGAAGCCTCCGGCTTTCATG TGCGGCATCAGGTTCAATTTTCTCCATTAACGCGATGGCATGGTATAGGCAAGCCCCTGGTAAG CAGCGCGAGCTCGTGGCTGTTATCACATCAGGAGGGAGTACTAACTACGCGGATTCTGTTAAAG GAAGATTTACCATTTCCCGCGATAATGCTAAGAATACAGTCTACCTCCAAATGAACTCCCTGAA GCCTGAAGACACTGCCGTGTATTATTGCAATGCTGATCTGGTCTACTACTCAGGCAATCCTGGA GACTATGGTATGGACTACTGGGGAAAGGGGACATTGGTGACTGTCAGTAGTACCACCACCCCTG CCCCCAGGCCCCCCACCCCCGCCCCCACCATCGCCAGCCAGCCCCTGTCCCTGCGGCCCGAGGC CTGCCGGCCCGCCGCCGGCGGCGCCGTGCACACCCGGGGCCTGGACTTCGCCTGCGACATCTAC ATCTGGGCCCCCCTGGCCGGAACCTGCGGCGTGCTGCTGCTGTCCCTGGTGATCACCCTGTACT GCAAGCGGGGCCGGAAGAAGCTGCTGTACATCTTCAAGCAGCCCTTCATGCGCCCCGTGCAGAC CACCCAGGAGGAGGACGGCTGCAGCTGCAGGTTCCCCGAGGAGGAGGAGGGGGGCTGCGAGCTG CGGGTGAAGTTCAGCAGGAGCGCCGACGCCCCTGCTTACCAGCAGGGCCAGAATCAGCTGTACA ACGAGCTGAATCTGGGCCGGAGGGAGGAGTACGACGTGCTGGACAAGCGGAGGGGCAGGGACCC CGAGATGGGCGGCAAGCCCAGGCGGAAGAACCCCCAGGAGGGGCTGTACAACGAGCTGCAGAAG GACAAGATGGCCGAGGCCTACTCCGAGATCGGCATGAAGGGCGAGAGGCGGAGAGGCAAGGGCC ATGACGGCCTGTACCAGGGCCTGTCCACCGCCACCAAGGACACCTACGACGCCCTGCACATGCA GGCCCTGCCCCCCCGC (SEQ ID NO: 947); ATGGCCCTGCCCGTTACCGCCCTACTCCTGCCCCTGGCCCTCCTGCTCCACGCCGCCAGGCCCC AGGTTCAGTTGGTAGAATCCGGCGGTGGATTGGTGCAGGCTGGAGGGTCCTTGAGACTTTCCTG TGTTGCGAGCGGGAGGACGTTTTCAATCAATAACATTAACTGGTATAGACAGGCCCCTGGCAAG GAGCGAGAGTTCGTTGCCACTACCAGATGGCGGGGAGACAGCACTTACTACGCTGACTCTGTGG CCGGTCGATTTACCATATCAAGAGACTCAGCTAAAAATACCGTGTACCTCCAAATGAACTCACT GAAACCAGAGGATACTGCTATATACTATTGCAATGCTAAGGGCGGCGTTGATGTCTGGGGTCAA GGAACCCAGGTAACGGTTTCCAGTACCACCACCCCTGCCCCCAGGCCCCCCACCCCCGCCCCCA CCATCGCCAGCCAGCCCCTGTCCCTGCGGCCCGAGGCCTGCCGGCCCGCCGCCGGCGGCGCCGT GCACACCCGGGGCCTGGACTTCGCCTGCGACATCTACATCTGGGCCCCCCTGGCCGGAACCTGC GGCGTGCTGCTGCTGTCCCTGGTGATCACCCTGTACTGCAAGCGGGGCCGGAAGAAGCTGCTGT ACATCTTCAAGCAGCCCTTCATGCGCCCCGTGCAGACCACCCAGGAGGAGGACGGCTGCAGCTG CAGGTTCCCCGAGGAGGAGGAGGGGGGCTGCGAGCTGCGGGTGAAGTTCAGCAGGAGCGCCGAC GCCCCTGCTTACCAGCAGGGCCAGAATCAGCTGTACAACGAGCTGAATCTGGGCCGGAGGGAGG AGTACGACGTGCTGGACAAGCGGAGGGGCAGGGACCCCGAGATGGGCGGCAAGCCCAGGCGGAA GAACCCCCAGGAGGGGCTGTACAACGAGCTGCAGAAGGACAAGATGGCCGAGGCCTACTCCGAG ATCGGCATGAAGGGCGAGAGGCGGAGAGGCAAGGGCCATGACGGCCTGTACCAGGGCCTGTCCA CCGCCACCAAGGACACCTACGACGCCCTGCACATGCAGGCCCTGCCCCCCCGC (SEQ ID NO: 948); ATGGCCCTGCCCGTTACCGCCCTACTCCTGCCCCTGGCCCTCCTGCTCCACGCCGCCAGGCCCC AGGTACAGCTTGTTGAGTCCGGCGGGGGTCTCGTACAGCCGGGCGGCTCCTTGCGCCTCAGTTG TGCGGCGAGTGGATTCTTGTTCTCACTCTACGCTATGGCATGGGTCCGGCAAGCCCCAGGCAAA GGTCTGGAGTGGGTAAGTGATATAAGCAACGGAGGTGTTACCACAAGATACGCGGATTCAGTAA AAGGCCGGTTTACAATTTCACGAGATAATGCGAAAAATACGTTGTATCTTCAAATGGATAGTCT GACGCCGGGGGATACTGCGGTCTATTACTGTGCTGTTACAACCACGGGCTGGCGGGCAAGAGGC CAAGGGACCCAAGTGACTGTCTCCTCCACCACCACCCCTGCCCCCAGGCCCCCCACCCCCGCCC CCACCATCGCCAGCCAGCCCCTGTCCCTGCGGCCCGAGGCCTGCCGGCCCGCCGCCGGCGGCGC CGTGCACACCCGGGGCCTGGACTTCGCCTGCGACATCTACATCTGGGCCCCCCTGGCCGGAACC TGCGGCGTGCTGCTGCTGTCCCTGGTGATCACCCTGTACTGCAAGCGGGGCCGGAAGAAGCTGC TGTACATCTTCAAGCAGCCCTTCATGCGCCCCGTGCAGACCACCCAGGAGGAGGACGGCTGCAG CTGCAGGTTCCCCGAGGAGGAGGAGGGGGGCTGCGAGCTGCGGGTGAAGTTCAGCAGGAGCGCC GACGCCCCTGCTTACCAGCAGGGCCAGAATCAGCTGTACAACGAGCTGAATCTGGGCCGGAGGG AGGAGTACGACGTGCTGGACAAGCGGAGGGGCAGGGACCCCGAGATGGGCGGCAAGCCCAGGCG GAAGAACCCCCAGGAGGGGCTGTACAACGAGCTGCAGAAGGACAAGATGGCCGAGGCCTACTCC GAGATCGGCATGAAGGGCGAGAGGCGGAGAGGCAAGGGCCATGACGGCCTGTACCAGGGCCTGT CCACCGCCACCAAGGACACCTACGACGCCCTGCACATGCAGGCCCTGCCCCCCCGC (SEQ ID NO: 949); ATGGCCCTGCCCGTTACCGCCCTACTCCTGCCCCTGGCCCTCCTGCTCCACGCCGCCAGGCCCC AGGTCCAACTTGTTGAATCAGGCGGAGGACTCGTTCAGCCTGGAGGCAGCCTGAGGCTTTCTTG CGCCGCTTCAGGAAGCATATTCAGACCAAACGACATGGGCTGGTACCGACAGGCGCCCGGTAAA CAAAGGGAACTCGTGGCAATCATAACGGACGGGGGTATCACAAATTACGCTGCAACGGTAAAGG GGAGGTTTACGATTAGTCGAGACAATGCCAAAAATACAGTGTACCTTCAAATGAACAGCCTCAA ACCGGAGGACACGGCGGTTTATTATTGCAACCTTAATATCCCGTACCCTCGCGTTTCCTCATGG GGCCAGGGAACGCAGGTCACAGTCTCATCTACCACCACCCCTGCCCCCAGGCCCCCCACCCCCG CCCCCACCATCGCCAGCCAGCCCCTGTCCCTGCGGCCCGAGGCCTGCCGGCCCGCCGCCGGCGG CGCCGTGCACACCCGGGGCCTGGACTTCGCCTGCGACATCTACATCTGGGCCCCCCTGGCCGGA ACCTGCGGCGTGCTGCTGCTGTCCCTGGTGATCACCCTGTACTGCAAGCGGGGCCGGAAGAAGC TGCTGTACATCTTCAAGCAGCCCTTCATGCGCCCCGTGCAGACCACCCAGGAGGAGGACGGCTG CAGCTGCAGGTTCCCCGAGGAGGAGGAGGGGGGCTGCGAGCTGCGGGTGAAGTTCAGCAGGAGC GCCGACGCCCCTGCTTACCAGCAGGGCCAGAATCAGCTGTACAACGAGCTGAATCTGGGCCGGA GGGAGGAGTACGACGTGCTGGACAAGCGGAGGGGCAGGGACCCCGAGATGGGCGGCAAGCCCAG GCGGAAGAACCCCCAGGAGGGGCTGTACAACGAGCTGCAGAAGGACAAGATGGCCGAGGCCTAC TCCGAGATCGGCATGAAGGGCGAGAGGCGGAGAGGCAAGGGCCATGACGGCCTGTACCAGGGCC TGTCCACCGCCACCAAGGACACCTACGACGCCCTGCACATGCAGGCCCTGCCCCCCCGC (SEQ ID NO: 950); ATGGCCCTGCCCGTTACCGCCCTACTCCTGCCCCTGGCCCTCCTGCTCCACGCCGCCAGGCCCC AGGTGCAGCTCGTCGAGTCTGGGGGAGGCCTTGTCCAGCCTGGTGGCTCCCTTCGCCTGAGTTG TGCAGCATCTGGGAGTACATTTAACACCATGGCCTGGTTCCGGCAAGCGCCGGGAAAGGAGCGC GAATTCGTGGCGGCCATATCATGGAGCGGCGGATTGACCTATTATGGTGATTCCGTCAAGGGAA GATTCACCATATTCAGGGATAACGCGAAGAATTTGGGCTATCTCCAGATGAATTCCCTTAAACC GGAAGATACTGCGGTATATAGTTGCGCCGCGAGGACAACTTTCCGAACCGGTTTGATCGTAACC GTAACAGCCTATGATACATGGGGTCAAGGTACACAAGTGACAGTCAGTTCCACCACCACCCCTG CCCCCAGGCCCCCCACCCCCGCCCCCACCATCGCCAGCCAGCCCCTGTCCCTGCGGCCCGAGGC CTGCCGGCCCGCCGCCGGCGGCGCCGTGCACACCCGGGGCCTGGACTTCGCCTGCGACATCTAC ATCTGGGCCCCCCTGGCCGGAACCTGCGGCGTGCTGCTGCTGTCCCTGGTGATCACCCTGTACT GCAAGCGGGGCCGGAAGAAGCTGCTGTACATCTTCAAGCAGCCCTTCATGCGCCCCGTGCAGAC CACCCAGGAGGAGGACGGCTGCAGCTGCAGGTTCCCCGAGGAGGAGGAGGGGGGCTGCGAGCTG CGGGTGAAGTTCAGCAGGAGCGCCGACGCCCCTGCTTACCAGCAGGGCCAGAATCAGCTGTACA ACGAGCTGAATCTGGGCCGGAGGGAGGAGTACGACGTGCTGGACAAGCGGAGGGGCAGGGACCC CGAGATGGGCGGCAAGCCCAGGCGGAAGAACCCCCAGGAGGGGCTGTACAACGAGCTGCAGAAG GACAAGATGGCCGAGGCCTACTCCGAGATCGGCATGAAGGGCGAGAGGCGGAGAGGCAAGGGCC ATGACGGCCTGTACCAGGGCCTGTCCACCGCCACCAAGGACACCTACGACGCCCTGCACATGCA GGCCCTGCCCCCCCGC (SEQ ID NO: 951); ATGGCCCTGCCCGTTACCGCCCTACTCCTGCCCCTGGCCCTCCTGCTCCACGCCGCCAGGCCCC AGGTGCAGTTGGTAGAGTCCGGAGGAGGTCTCGTGCAGCCCGGAGGTTCACTCAGACTTTCATG TGTGTTGAGTGGGCGGACGTTTTCTAGTTATGCAATGGGATGGTTCCGGCAAGCGCCGGGCAAA GAAAGAGAGTTCGTGAGTACAATCTCCTTGTCCGGGGGAAGCACATTTTACTCAGGGAGTGCGA AAGGGCGGTTCACGATAAGTAGAGATAACGCCAAAAACACCGTTTATCTCCAGATGAACTCCTT GAAGCCTGAAGACACTGCGGTGTACTACTGCGCTGCACGACCTGTTCTTATTAGCCGGAGCTCA ACAGACTACGCCTATTGGGGTCCGGGAACTCAAGTTACAGTTAGCTCAACCACCACCCCTGCCC CCAGGCCCCCCACCCCCGCCCCCACCATCGCCAGCCAGCCCCTGTCCCTGCGGCCCGAGGCCTG CCGGCCCGCCGCCGGCGGCGCCGTGCACACCCGGGGCCTGGACTTCGCCTGCGACATCTACATC TGGGCCCCCCTGGCCGGAACCTGCGGCGTGCTGCTGCTGTCCCTGGTGATCACCCTGTACTGCA AGCGGGGCCGGAAGAAGCTGCTGTACATCTTCAAGCAGCCCTTCATGCGCCCCGTGCAGACCAC CCAGGAGGAGGACGGCTGCAGCTGCAGGTTCCCCGAGGAGGAGGAGGGGGGCTGCGAGCTGCGG GTGAAGTTCAGCAGGAGCGCCGACGCCCCTGCTTACCAGCAGGGCCAGAATCAGCTGTACAACG AGCTGAATCTGGGCCGGAGGGAGGAGTACGACGTGCTGGACAAGCGGAGGGGCAGGGACCCCGA GATGGGCGGCAAGCCCAGGCGGAAGAACCCCCAGGAGGGGCTGTACAACGAGCTGCAGAAGGAC AAGATGGCCGAGGCCTACTCCGAGATCGGCATGAAGGGCGAGAGGCGGAGAGGCAAGGGCCATG ACGGCCTGTACCAGGGCCTGTCCACCGCCACCAAGGACACCTACGACGCCCTGCACATGCAGGC CCTGCCCCCCCGC (SEQ ID NO: 952); ATGGCCCTGCCCGTTACCGCCCTACTCCTGCCCCTGGCCCTCCTGCTCCACGCCGCCAGGCCCC AGGTTCAACTCGTTGAGTCCGGCGGCGGCCTTGTCCAACCTGGTGGGAGTTTGCGGTTGTCCTG TGTACTTAGCGGCAGAACCTTTAGCTCATACGCGATGGGATGGTTTCGCCAAGCGCCGGGTAAA GAGCGAGAGTTCGTATCAACTATCAGCTTGTCTGGCGGATCAACGTTCTATAGCGGTTCTGCCA AAGGACGGTTCACCATTTCAAGAGACAATGCGAAAAACACTGTATATCTGCAGATGAATAGTCT CAAACCTGAGGACACTGCCGTCTACTATTGTGCTGCTCGGCCAGTTTTGATAAGCCGAAGTAGC ACCGATTATGCCTACTGGGGACCTGGTACTCAGGTGACCGTTTCCAGTACCACCACCCCTGCCC CCAGGCCCCCCACCCCCGCCCCCACCATCGCCAGCCAGCCCCTGTCCCTGCGGCCCGAGGCCTG CCGGCCCGCCGCCGGCGGCGCCGTGCACACCCGGGGCCTGGACTTCGCCTGCGACATCTACATC TGGGCCCCCCTGGCCGGAACCTGCGGCGTGCTGCTGCTGTCCCTGGTGATCACCCTGTACTGCA AGCGGGGCCGGAAGAAGCTGCTGTACATCTTCAAGCAGCCCTTCATGCGCCCCGTGCAGACCAC CCAGGAGGAGGACGGCTGCAGCTGCAGGTTCCCCGAGGAGGAGGAGGGGGGCTGCGAGCTGCGG GTGAAGTTCAGCAGGAGCGCCGACGCCCCTGCTTACCAGCAGGGCCAGAATCAGCTGTACAACG AGCTGAATCTGGGCCGGAGGGAGGAGTACGACGTGCTGGACAAGCGGAGGGGCAGGGACCCCGA GATGGGCGGCAAGCCCAGGCGGAAGAACCCCCAGGAGGGGCTGTACAACGAGCTGCAGAAGGAC AAGATGGCCGAGGCCTACTCCGAGATCGGCATGAAGGGCGAGAGGCGGAGAGGCAAGGGCCATG ACGGCCTGTACCAGGGCCTGTCCACCGCCACCAAGGACACCTACGACGCCCTGCACATGCAGGC CCTGCCCCCCCGC (SEQ ID NO: 953); ATGGCCCTGCCCGTTACCGCCCTACTCCTGCCCCTGGCCCTCCTGCTCCACGCCGCCAGGCCCC AGGTGCAACTCGTAGAAAGCGGGGGTGGGTTGGTTCAAACCGGTGGCTCATTGCGATTGTCCTG CGCGGCATCTGGAAGAACGTTTAGTTCTTATGCGATGGGTTGGTTTAGGCAGGCTCCTGGAAAG GAACGGGAATTTGTCGCCGCAATCACCTGGTCAGGTGGATCCACCTATTACGCAAACAGTGTAA AGGGGCGCTTTACAATCTCTCGGGACAACGCTAAAAATACAGTGGATTTGCAAATGAACAGTCT CAAGCCCGAGGACACAGCAGTCTATTATTGCACTCCTGGAGAAGAAGTAGCCGGTAAGTATTTT AGACCTCTGTATGATTATTGGGGGCAAGGGACGCAAGTTACCGTTTCATCAACCACCACCCCTG CCCCCAGGCCCCCCACCCCCGCCCCCACCATCGCCAGCCAGCCCCTGTCCCTGCGGCCCGAGGC CTGCCGGCCCGCCGCCGGCGGCGCCGTGCACACCCGGGGCCTGGACTTCGCCTGCGACATCTAC ATCTGGGCCCCCCTGGCCGGAACCTGCGGCGTGCTGCTGCTGTCCCTGGTGATCACCCTGTACT GCAAGCGGGGCCGGAAGAAGCTGCTGTACATCTTCAAGCAGCCCTTCATGCGCCCCGTGCAGAC CACCCAGGAGGAGGACGGCTGCAGCTGCAGGTTCCCCGAGGAGGAGGAGGGGGGCTGCGAGCTG CGGGTGAAGTTCAGCAGGAGCGCCGACGCCCCTGCTTACCAGCAGGGCCAGAATCAGCTGTACA ACGAGCTGAATCTGGGCCGGAGGGAGGAGTACGACGTGCTGGACAAGCGGAGGGGCAGGGACCC CGAGATGGGCGGCAAGCCCAGGCGGAAGAACCCCCAGGAGGGGCTGTACAACGAGCTGCAGAAG GACAAGATGGCCGAGGCCTACTCCGAGATCGGCATGAAGGGCGAGAGGCGGAGAGGCAAGGGCC ATGACGGCCTGTACCAGGGCCTGTCCACCGCCACCAAGGACACCTACGACGCCCTGCACATGCA GGCCCTGCCCCCCCGC (SEQ ID NO: 954); ATGGCCCTGCCCGTTACCGCCCTACTCCTGCCCCTGGCCCTCCTGCTCCACGCCGCCAGGCCCC AGGTGCAACTGGTTGAGTCCGGCGGTGGCTTGGTACAGCCCGGCGGCAGTCTCCGACTTAGTTG TACGGCGTCAGGTCGCACAATTGCGAGCACGATTATGGGCTGGTACAGACAAACGCCCGGCAAA GAACGGGAATTTGTCGCTATCAGCGCTAGGAGCGGCGATTCCGAATCCTATGCAAGTTCAGTGA AGGATAGGTTTACCATCAGTCGCGATAATGCGAAAAATACCGTCTACCTCCAGATGAACAATTT GAAACCTGAGGACACTGCTATATATTACTGCTACTGGAATACGGGAGCAGGAACCATCTGGGGG CAGGGAACACAAGTGACTGTCTCTTCCACCACCACCCCTGCCCCCAGGCCCCCCACCCCCGCCC CCACCATCGCCAGCCAGCCCCTGTCCCTGCGGCCCGAGGCCTGCCGGCCCGCCGCCGGCGGCGC CGTGCACACCCGGGGCCTGGACTTCGCCTGCGACATCTACATCTGGGCCCCCCTGGCCGGAACC TGCGGCGTGCTGCTGCTGTCCCTGGTGATCACCCTGTACTGCAAGCGGGGCCGGAAGAAGCTGC TGTACATCTTCAAGCAGCCCTTCATGCGCCCCGTGCAGACCACCCAGGAGGAGGACGGCTGCAG CTGCAGGTTCCCCGAGGAGGAGGAGGGGGGCTGCGAGCTGCGGGTGAAGTTCAGCAGGAGCGCC GACGCCCCTGCTTACCAGCAGGGCCAGAATCAGCTGTACAACGAGCTGAATCTGGGCCGGAGGG AGGAGTACGACGTGCTGGACAAGCGGAGGGGCAGGGACCCCGAGATGGGCGGCAAGCCCAGGCG GAAGAACCCCCAGGAGGGGCTGTACAACGAGCTGCAGAAGGACAAGATGGCCGAGGCCTACTCC GAGATCGGCATGAAGGGCGAGAGGCGGAGAGGCAAGGGCCATGACGGCCTGTACCAGGGCCTGT CCACCGCCACCAAGGACACCTACGACGCCCTGCACATGCAGGCCCTGCCCCCCCGC (SEQ ID NO: 955); ATGGCCCTGCCCGTTACCGCCCTACTCCTGCCCCTGGCCCTCCTGCTCCACGCCGCCAGGCCCC AGCTTCAGCTTGTGGAAAGCGGAGGGGGCCTGGTGCAAGCAGGTGGCAGTCTTCGACTCTCATG TGCGGCGTCAGGACGGACTGTCAGTTCATACGCCATGGGCTGGTTCAGGCAGGCACCGGGCAAA GAAAGGGAGTTTGTCGCGGCCATTAGTTGGTCTGGGGGGAGCACTTACTATGCCGATAGTGTTA AGGGTAGATTTACTATTAGTCGCGATAACGCTAAGAACACCGTTTATTTGCAGATGAACTCACT TAAACCAGAGGATACAGCAGTGTACTATTGCGCTGCCGACCCCAGCCTGAGTCGCACCATGGAC GAGATAGGCTCCTGGGGTCAAGGAACGCAGGTCACGGTTTCCTCTACCACCACCCCTGCCCCCA GGCCCCCCACCCCCGCCCCCACCATCGCCAGCCAGCCCCTGTCCCTGCGGCCCGAGGCCTGCCG GCCCGCCGCCGGCGGCGCCGTGCACACCCGGGGCCTGGACTTCGCCTGCGACATCTACATCTGG GCCCCCCTGGCCGGAACCTGCGGCGTGCTGCTGCTGTCCCTGGTGATCACCCTGTACTGCAAGC GGGGCCGGAAGAAGCTGCTGTACATCTTCAAGCAGCCCTTCATGCGCCCCGTGCAGACCACCCA GGAGGAGGACGGCTGCAGCTGCAGGTTCCCCGAGGAGGAGGAGGGGGGCTGCGAGCTGCGGGTG AAGTTCAGCAGGAGCGCCGACGCCCCTGCTTACCAGCAGGGCCAGAATCAGCTGTACAACGAGC TGAATCTGGGCCGGAGGGAGGAGTACGACGTGCTGGACAAGCGGAGGGGCAGGGACCCCGAGAT GGGCGGCAAGCCCAGGCGGAAGAACCCCCAGGAGGGGCTGTACAACGAGCTGCAGAAGGACAAG ATGGCCGAGGCCTACTCCGAGATCGGCATGAAGGGCGAGAGGCGGAGAGGCAAGGGCCATGACG GCCTGTACCAGGGCCTGTCCACCGCCACCAAGGACACCTACGACGCCCTGCACATGCAGGCCCT GCCCCCCCGC (SEQ ID NO: 956); ATGGCCCTGCCCGTTACCGCCCTACTCCTGCCCCTGGCCCTCCTGCTCCACGCCGCCAGGCCCC AGGTCCAGTTGGTGGAGAGCGGCGGTGGGTTGGTTCAGGCGGGAGGGTCTCTCAGGCTGAGCTG TGCTGCAAGTGGGAATATCGTCGACATCGACGATATGGGTTGGTACCGCCAAGCACCTGGGAAG CAACGAGATTTGGTTGCATCTATAACCGCAGGCAGAATAACCAAATATGCTGATAGCGCGAAAG GAAGGTTTACAATATCTAGGGATAATGTTAAAAATACCGTTTATCTCCAGATGAACTCACTGAA GCCAGAAGATACCGCGACTTATTACTGTTACGCAATAAGGCGGTCATACCCAAGGTTCGACTAC TGGGGACAGGGGACACAGGTCACAGTGTCAAGCACCACCACCCCTGCCCCCAGGCCCCCCACCC CCGCCCCCACCATCGCCAGCCAGCCCCTGTCCCTGCGGCCCGAGGCCTGCCGGCCCGCCGCCGG CGGCGCCGTGCACACCCGGGGCCTGGACTTCGCCTGCGACATCTACATCTGGGCCCCCCTGGCC GGAACCTGCGGCGTGCTGCTGCTGTCCCTGGTGATCACCCTGTACTGCAAGCGGGGCCGGAAGA AGCTGCTGTACATCTTCAAGCAGCCCTTCATGCGCCCCGTGCAGACCACCCAGGAGGAGGACGG CTGCAGCTGCAGGTTCCCCGAGGAGGAGGAGGGGGGCTGCGAGCTGCGGGTGAAGTTCAGCAGG AGCGCCGACGCCCCTGCTTACCAGCAGGGCCAGAATCAGCTGTACAACGAGCTGAATCTGGGCC GGAGGGAGGAGTACGACGTGCTGGACAAGCGGAGGGGCAGGGACCCCGAGATGGGCGGCAAGCC CAGGCGGAAGAACCCCCAGGAGGGGCTGTACAACGAGCTGCAGAAGGACAAGATGGCCGAGGCC TACTCCGAGATCGGCATGAAGGGCGAGAGGCGGAGAGGCAAGGGCCATGACGGCCTGTACCAGG GCCTGTCCACCGCCACCAAGGACACCTACGACGCCCTGCACATGCAGGCCCTGCCCCCCCGC (SEQ ID NO: 957); ATGGCCCTGCCCGTTACCGCCCTACTCCTGCCCCTGGCCCTCCTGCTCCACGCCGCCAGGCCCC AAGTTCAATTGGTAGAGTCCGGTGGAGGACTGGTCCAACCGGGAGGGTCTTTGCGGTTGTCATG CGCCGCCTCTGGCAGCATTTTTTCTGTGAATGATATGGGTTGGTATCGACAAGCGCCTGGTAAG CAACGGGAACTCGTAGCCGCGATATATTCCGGTGGCTCTACAAATTACGCGGATAGTGTAAAAG GCCGGTTTACCATCTCCCGAGATAATGCTAAGAATACCGTCTATCTTCAAATGAACAGCTTGAA GCCCGAGGACACAGCAGTGTATTATTGCAACGCCGACATTGTAGTGGTCACGACTACCCCTCCG AGTTTCCCTATGCCCTATCGGTTCTTGGAGGTATGGGGTCAGGGAACGCTTGTTACTGTAAGTT CTACCACCACCCCTGCCCCCAGGCCCCCCACCCCCGCCCCCACCATCGCCAGCCAGCCCCTGTC CCTGCGGCCCGAGGCCTGCCGGCCCGCCGCCGGCGGCGCCGTGCACACCCGGGGCCTGGACTTC GCCTGCGACATCTACATCTGGGCCCCCCTGGCCGGAACCTGCGGCGTGCTGCTGCTGTCCCTGG TGATCACCCTGTACTGCAAGCGGGGCCGGAAGAAGCTGCTGTACATCTTCAAGCAGCCCTTCAT GCGCCCCGTGCAGACCACCCAGGAGGAGGACGGCTGCAGCTGCAGGTTCCCCGAGGAGGAGGAG GGGGGCTGCGAGCTGCGGGTGAAGTTCAGCAGGAGCGCCGACGCCCCTGCTTACCAGCAGGGCC AGAATCAGCTGTACAACGAGCTGAATCTGGGCCGGAGGGAGGAGTACGACGTGCTGGACAAGCG GAGGGGCAGGGACCCCGAGATGGGCGGCAAGCCCAGGCGGAAGAACCCCCAGGAGGGGCTGTAC AACGAGCTGCAGAAGGACAAGATGGCCGAGGCCTACTCCGAGATCGGCATGAAGGGCGAGAGGC GGAGAGGCAAGGGCCATGACGGCCTGTACCAGGGCCTGTCCACCGCCACCAAGGACACCTACGA CGCCCTGCACATGCAGGCCCTGCCCCCCCGC (SEQ ID NO: 958); ATGGCCCTGCCCGTTACCGCCCTACTCCTGCCCCTGGCCCTCCTGCTCCACGCCGCCAGGCCCC AGGTTCAGTTGGTTGAATCTGGAGGTGGTCTCGTACAGGTCGGCGGGTCATTGCGGCTGTCCTG CTCTATTAGCAGGAGCATTGCAATTTTTAATTTTATGGCCTGGTATAGGGAGGCCGAAGGGAAG CAGCGGGAACTCGTCGCCTCCATCACTGGCGGGAGTCGACTGTCATATATTGATAGTGTTAAGG GACGCTTCACGGTCAGTAAGGACACAGCTAACAATACACTCGATCTCCAAATGAACTCCCTGCG ACCAGAGGACACCGCCGTGTATCGATGCGCGGCGTCTAGTCCGTTTGCTGGTGAGTTCTGGGGC CAAGGGACCCAGGTAACTGTGTCTTCAACCACCACCCCTGCCCCCAGGCCCCCCACCCCCGCCC CCACCATCGCCAGCCAGCCCCTGTCCCTGCGGCCCGAGGCCTGCCGGCCCGCCGCCGGCGGCGC CGTGCACACCCGGGGCCTGGACTTCGCCTGCGACATCTACATCTGGGCCCCCCTGGCCGGAACC TGCGGCGTGCTGCTGCTGTCCCTGGTGATCACCCTGTACTGCAAGCGGGGCCGGAAGAAGCTGC TGTACATCTTCAAGCAGCCCTTCATGCGCCCCGTGCAGACCACCCAGGAGGAGGACGGCTGCAG CTGCAGGTTCCCCGAGGAGGAGGAGGGGGGCTGCGAGCTGCGGGTGAAGTTCAGCAGGAGCGCC GACGCCCCTGCTTACCAGCAGGGCCAGAATCAGCTGTACAACGAGCTGAATCTGGGCCGGAGGG AGGAGTACGACGTGCTGGACAAGCGGAGGGGCAGGGACCCCGAGATGGGCGGCAAGCCCAGGCG GAAGAACCCCCAGGAGGGGCTGTACAACGAGCTGCAGAAGGACAAGATGGCCGAGGCCTACTCC GAGATCGGCATGAAGGGCGAGAGGCGGAGAGGCAAGGGCCATGACGGCCTGTACCAGGGCCTGT CCACCGCCACCAAGGACACCTACGACGCCCTGCACATGCAGGCCCTGCCCCCCCGC (SEQ ID NO: 959); and ATGGCCCTGCCCGTTACCGCCCTACTCCTGCCCCTGGCCCTCCTGCTCCACGCCGCCAGGCCCC AGGTGCAGCTGGTGGAATCAGGGGGACGCTTGGTTCAAGCAGGGGGTAGCCTTAGGTTGTCTTG TGCGGCAAGTGGGCGGACGTTTAATACAATGGCCTGGTTTCGACAGGCACCTGGAAAGGAAAGG GAATTTGTAGCTGCCATCACCTGGTCCGGGGGGTTGACATACTACGAGGATAGCGTAAAAGGGA GGTTTACAATTTTTCGAGACAACGCAAAAAATTTGGCATACCTTCAGCTCAACTCATTGAAACC CGAGGATACAGCTGTATATTCTTGTGCCGCCCGATCAACTTTTAGGACTGCCCTGGTTAATACT GTTACGGCGTATGACACTTGGGGACAAGGCACCCAAGTGACGGTAAGCTCAACCACCACCCCTG CCCCCAGGCCCCCCACCCCCGCCCCCACCATCGCCAGCCAGCCCCTGTCCCTGCGGCCCGAGGC CTGCCGGCCCGCCGCCGGCGGCGCCGTGCACACCCGGGGCCTGGACTTCGCCTGCGACATCTAC ATCTGGGCCCCCCTGGCCGGAACCTGCGGCGTGCTGCTGCTGTCCCTGGTGATCACCCTGTACT GCAAGCGGGGCCGGAAGAAGCTGCTGTACATCTTCAAGCAGCCCTTCATGCGCCCCGTGCAGAC CACCCAGGAGGAGGACGGCTGCAGCTGCAGGTTCCCCGAGGAGGAGGAGGGGGGCTGCGAGCTG CGGGTGAAGTTCAGCAGGAGCGCCGACGCCCCTGCTTACCAGCAGGGCCAGAATCAGCTGTACA ACGAGCTGAATCTGGGCCGGAGGGAGGAGTACGACGTGCTGGACAAGCGGAGGGGCAGGGACCC CGAGATGGGCGGCAAGCCCAGGCGGAAGAACCCCCAGGAGGGGCTGTACAACGAGCTGCAGAAG GACAAGATGGCCGAGGCCTACTCCGAGATCGGCATGAAGGGCGAGAGGCGGAGAGGCAAGGGCC ATGACGGCCTGTACCAGGGCCTGTCCACCGCCACCAAGGACACCTACGACGCCCTGCACATGCA GGCCCTGCCCCCCCGC (SEQ ID NO: 960). In another aspect, the disclosure features a VHH antibody or an antigen binding fragment thereof that specifically binds to a cluster of differentiation 19 (CD19) polypeptide. The VHH antibody contains three Complementarity Determining Regions (CDRs): CDR1, CDR2 and CDR3, that are structurally positioned between four camelid VHH framework (FR) regions (FR1-FR4) as follows: FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4. CDR1, CDR2, and CDR3 are selected from those sequences listed in Table 1B. In some embodiments, CDR1, CDR2, and CDR3 are selected from the same row of Table 1B. In any aspect or embodiment of the disclosure, the CDRs are calculated using a Chothia, AbM, Kabat, Contact, or IMGT numbering scheme. In any aspect or embodiment of the disclosure: a) CDR1 contains the amino acid sequence FYSIG (SEQ ID NO: 543), CDR2 contains the amino acid sequenceCITWSGERTNYKDSVKG (SEQ ID NO: 555), and CDR3 contains the amino acid sequence DSGYPCYGSSWSSVGYDF (SEQ ID NO: 575); b) CDR1 contains the amino acid sequence GYTIG (SEQ ID NO: 544), CDR2 contains the amino acid sequenceCISRSDTSTKYADSVKG (SEQ ID NO: 556), and CDR3 contains the amino acid sequence SLQSGLLSRFLLPRQYDH (SEQ ID NO: 576); c) CDR1 contains the amino acid sequence SYTIG (SEQ ID NO: 545), CDR2 contains the amino acid sequenceCISRSTSDARYADSVKG (SEQ ID NO: 557), and CDR3 contains the amino acid sequence SRQTGLLSTFLLPRQYDH (SEQ ID NO: 577); d) CDR1 contains the amino acid sequence FNFMA (SEQ ID NO: 546), CDR2 contains the amino acid sequenceSITGGSRLSYIDSVKG (SEQ ID NO: 558), and CDR3 contains the amino acid sequence SSPFAGEF (SEQ ID NO: 578); e) CDR1 contains the amino acid sequence FNTMG (SEQ ID NO: 547), CDR2 contains the amino acid sequenceRITMSGIPNYADSVKG (SEQ ID NO: 559), and CDR3 contains the amino acid sequence EHSGY (SEQ ID NO: 579); f) CDR1 contains the amino acid sequence IDDMG (SEQ ID NO: 548), CDR2 contains the amino acid sequenceTITAGGIANYADSAKG (SEQ ID NO: 560), and CDR3 contains the amino acid sequence IRRYYPRFDY (SEQ ID NO: 580); g) CDR1 contains the amino acid sequence IDDMG (SEQ ID NO: 548), CDR2 contains the amino acid sequenceSITAGGITKYADSAKG (SEQ ID NO: 561), and CDR3 contains the amino acid sequence VRRYYPRFDY (SEQ ID NO: 581); h) CDR1 contains the amino acid sequence IDDMG (SEQ ID NO: 548), CDR2 contains the amino acid sequenceTITAGGITNYASSAKG (SEQ ID NO: 562), and CDR3 contains the amino acid sequence IRKYYPRFDY (SEQ ID NO: 582); i) CDR1 contains the amino acid sequence IDDMG (SEQ ID NO: 548), CDR2 contains the amino acid sequenceSITAGGITKYADSAKG (SEQ ID NO: 561), and CDR3 contains the amino acid sequence VRKYYPRFDY (SEQ ID NO: 583); j) CDR1 contains the amino acid sequence IDDMG (SEQ ID NO: 548), CDR2 contains the amino acid sequenceTITAGGITKYGDSAKG (SEQ ID NO: 563), and CDR3 contains the amino acid sequence VRRYYPRFDY (SEQ ID NO: 581); k) CDR1 contains the amino acid sequence IDDMG (SEQ ID NO: 548), CDR2 contains the amino acid sequenceSITAGRITKYADSAKG (SEQ ID NO: 564), and CDR3 contains the amino acid sequence IRRSYPRFDY (SEQ ID NO: 584); l) CDR1 contains the amino acid sequence IDDMG (SEQ ID NO: 548), CDR2 contains the amino acid sequenceTITAGGITNYADSAKG (SEQ ID NO: 565), and CDR3 contains the amino acid sequence IRKFYPRFDY (SEQ ID NO: 585); m) CDR1 contains the amino acid sequence IDDMG (SEQ ID NO: 548), CDR2 contains the amino acid sequenceTITAGGITKYADSAKG (SEQ ID NO: 566), and CDR3 contains the amino acid sequence IRRFYPRFDY (SEQ ID NO: 586); n) CDR1 contains the amino acid sequence IDDMG (SEQ ID NO: 548), CDR2 contains the amino acid sequenceSITAGGITKYADSAKG (SEQ ID NO: 561), and CDR3 contains the amino acid sequence IRRFYPRFDY (SEQ ID NO: 586); o) CDR1 contains the amino acid sequence IDDMG (SEQ ID NO: 548), CDR2 contains the amino acid sequenceSITAGGITNYADSAKG (SEQ ID NO: 567), and CDR3 contains the amino acid sequence IRRFYPRFDY (SEQ ID NO: 586); p) CDR1 contains the amino acid sequence IDAMA (SEQ ID NO: 549), CDR2 contains the amino acid sequenceFSSSGGITNYADSVKG (SEQ ID NO: 568), and CDR3 contains the amino acid sequence DILQSGWYTY (SEQ ID NO: 587); q) CDR1 contains the amino acid sequence MNAMG (SEQ ID NO: 550), CDR2 contains the amino acid sequenceTITDNDFTYYAASVKD (SEQ ID NO: 569), and CDR3 contains the amino acid sequence DGIYSGGRYYPSS (SEQ ID NO: 588); r) CDR1 contains the amino acid sequence INAMA (SEQ ID NO: 551), CDR2 contains the amino acid sequenceVITSGGSTNYADSVKG (SEQ ID NO: 570), and CDR3 contains the amino acid sequence DLVYYSGNPGDYGMDY (SEQ ID NO: 589); s) CDR1 contains the amino acid sequence PNDMG (SEQ ID NO: 552), CDR2 contains the amino acid sequenceIITDGGITNYAATVKG (SEQ ID NO: 571), and CDR3 contains the amino acid sequence NIPYPRVSS (SEQ ID NO: 590); t) CDR1 contains the amino acid sequence VNDMG (SEQ ID NO: 553), CDR2 contains the amino acid sequenceASYSGGSTNYADSVKG (SEQ ID NO: 572), and CDR3 contains the amino acid sequence DLVVVTTTPPSFPMPYRFLEV (SEQ ID NO: 591); u) CDR1 contains the amino acid sequence VNDMG (SEQ ID NO: 553), CDR2 contains the amino acid sequenceAIYSGGSTNYADSVKG (SEQ ID NO: 573), and CDR3 contains the amino acid sequence DIVVVTTTPPSFPMPYRFLEV (SEQ ID NO: 592); v) CDR1 contains the amino acid sequence GWQMG (SEQ ID NO: 554), CDR2 contains the amino acid sequenceSISMSDGSTSYQDSVKG (SEQ ID NO: 574), and CDR3 contains the amino acid sequence RSRFGFEY (SEQ ID NO: 779); w) CDR1 contains the amino acid sequence NHGMG (SEQ ID NO: 594), CDR2 contains the amino acid sequenceGSYTDGSTYYADSVKG (SEQ ID NO: 606), and CDR3 contains the amino acid sequence RQYYRSGYVDY (SEQ ID NO: 623); x) CDR1 contains the amino acid sequence SFAID (SEQ ID NO: 595), CDR2 contains the amino acid sequenceAINRGGDRTYYSDSVKG (SEQ ID NO: 607), and CDR3 contains the amino acid sequence GGRVSADGKKWEYDY (SEQ ID NO: 624); y) CDR1 contains the amino acid sequence DYSMD (SEQ ID NO: 596), CDR2 contains the amino acid sequenceAINRNGGSTYYAESMKG (SEQ ID NO: 608), and CDR3 contains the amino acid sequence GGRVSADGKKWEYDY (SEQ ID NO: 624); z) CDR1 contains the amino acid sequence STIMG (SEQ ID NO: 597), CDR2 contains the amino acid sequenceISARSGDSESYASSVKD (SEQ ID NO: 609), and CDR3 contains the amino acid sequence NTGAGTI (SEQ ID NO: 625); aa) CDR1 contains the amino acid sequenceTMA orNTMA (SEQ ID NO: 1195) CDR2 contains the amino acid sequence AITWSGGLTYYEDSVKG (SEQ ID NO: 610), and CDR3 contains the amino acid sequence RSTFRTALVNTVTAYDT (SEQ ID NO: 626); ab) CDR1 contains the amino acid sequence TMA or NTMA (SEQ ID NO: 1195) CDR2 contains the amino acid sequence AISWSGGLTYYGDSVKG (SEQ ID NO: 611), and CDR3 contains the amino acid sequence RTTFRTGLIVTVTAYDT (SEQ ID NO: 627); ac) CDR1 contains the amino acid sequenceTMA orNTMA (SEQ ID NO: 1195) CDR2 contains the amino acid sequence AISWSGGLTYYADSVKG (SEQ ID NO: 612), and CDR3 contains the amino acid sequence RRTFRTALINTVTAYDT (SEQ ID NO: 628); ad) CDR1 contains the amino acid sequence TMA or NTMA (SEQ ID NO: 1195) CDR2 contains the amino acid sequence AISWSGGLTYYGDSVKG (SEQ ID NO: 611), and CDR3 contains the amino acid sequence RRTFRTALINTITAYDT (SEQ ID NO: 629); ae) CDR1 contains the amino acid sequenceTMA orNTMA (SEQ ID NO: 1195) CDR2 contains the amino acid sequence AIAWNSGLTYYGDSVKG (SEQ ID NO: 613), and CDR3 contains the amino acid sequence RRTFRTGLINTVTAYDT (SEQ ID NO: 630); af) CDR1 contains the amino acid sequence TMA orNTMA (SEQ ID NO: 1195) CDR2 contains the amino acid sequence AISWSGGLTYYGDSVKG (SEQ ID NO: 611), and CDR3 contains the amino acid sequence RRTFRTGLIDTVTAYDT (SEQ ID NO: 631); ag) CDR1 contains the amino acid sequence GHGMG (SEQ ID NO: 598), CDR2 contains the amino acid sequenceAISWSGVSTAYADSVKG (SEQ ID NO: 614), and CDR3 contains the amino acid sequence GLYSRPTTERREYIY (SEQ ID NO: 632); ah) CDR1 contains the amino acid sequence GHGMG (SEQ ID NO: 598), CDR2 contains the amino acid sequenceAISWSGVSTAYADSVKG (SEQ ID NO: 614), and CDR3 contains the amino acid sequence GLYSRPTTERRDYIY (SEQ ID NO: 633); ai) CDR1 contains the amino acid sequence NYGMM (SEQ ID NO: 599), CDR2 contains the amino acid sequenceYIDSGGGSTYYTDSVRG (SEQ ID NO: 615), and CDR3 contains the amino acid sequence AIGVVSGSLEV (SEQ ID NO: 634); aj) CDR1 contains the amino acid sequence LYAMA (SEQ ID NO: 600), CDR2 contains the amino acid sequenceDISNGGVTTRYADSVKG (SEQ ID NO: 616), and CDR3 contains the amino acid sequence TTTGWRA (SEQ ID NO: 635); ak) CDR1 contains the amino acid sequence GYYMS (SEQ ID NO: 601), CDR2 contains the amino acid sequenceSIYSDDSNTYYADSVKG (SEQ ID NO: 617), and CDR3 contains the amino acid sequence SATLRGRDTRFDY (SEQ ID NO: 636); al) CDR1 contains the amino acid sequence SYTMG (SEQ ID NO: 602), CDR2 contains the amino acid sequenceAVNWDNVKNYADPVKG (SEQ ID NO: 618), and CDR3 contains the amino acid sequence GTNLPTRGSGS (SEQ ID NO: 637); am) CDR1 contains the amino acid sequence SYTMG (SEQ ID NO: 602), CDR2 contains the amino acid sequenceAVNWDNVKNYADPVKG (SEQ ID NO: 618), and CDR3 contains the amino acid sequence GTNLPTIESGS (SEQ ID NO: 638); an) CDR1 contains the amino acid sequence INNIN (SEQ ID NO: 603), CDR2 contains the amino acid sequenceTTRWRGDSTYYADSVAG (SEQ ID NO:619), and CDR3 contains the amino acid sequence KGGVDV (SEQ ID NO: 639); ao) CDR1 contains the amino acid sequence SYAMG (SEQ ID NO: 604), CDR2 contains the amino acid sequenceTISLSGGSTFYSDSAKG (SEQ ID NO: 620), and CDR3 contains the amino acid sequence RPVLISRSSTDYAY (SEQ ID NO: 640); ap) CDR1 contains the amino acid sequence SYAMG (SEQ ID NO: 604), CDR2 contains the amino acid sequenceTISLSGGSTFYSDSAKG (SEQ ID NO: 620), and CDR3 contains the amino acid sequence RPVLISRSSIDYAY (SEQ ID NO: 641); aq) CDR1 contains the amino acid sequence SYAMG (SEQ ID NO: 604), CDR2 contains the amino acid sequenceTISLSGGSTFYSGSAKG (SEQ ID NO:621), and CDR3 contains the amino acid sequence RPVLISRSSTDYAY (SEQ ID NO: 640); ar) CDR1 contains the amino acid sequence TYTMG (SEQ ID NO: 605), CDR2 contains the amino acid sequenceAISSSGDSTYYTDSVKG (SEQ ID NO: 622), and CDR3 contains the amino acid sequence GEEVAGKYFRALYDY (SEQ ID NO: 642); as) CDR1 contains the amino acid sequence SYAMG (SEQ ID NO: 604), CDR2 contains the amino acid sequenceAITWSGGSTYYANSVKG (SEQ ID NO: 644), and CDR3 contains the amino acid sequence GEEVAGKYFRPLYDY (SEQ ID NO: 654); at) CDR1 contains the amino acid sequence SYAMG (SEQ ID NO: 604), CDR2 contains the amino acid sequenceAISWSGGSTYYANSVKG (SEQ ID NO: 645), and CDR3 contains the amino acid sequence GEEVAGKYFRQLYDY (SEQ ID NO: 655); au) CDR1 contains the amino acid sequence SYAMG (SEQ ID NO: 604), CDR2 contains the amino acid sequenceDISWSGGTTNYANSVKG (SEQ ID NO: 646), and CDR3 contains the amino acid sequence GEEVDGKYFRPLYDY (SEQ ID NO: 656); av) CDR1 contains the amino acid sequence NYAMG (SEQ ID NO: 643), CDR2 contains the amino acid sequenceAINWSGGRIYYTDSVKG (SEQ ID NO: 647), and CDR3 contains the amino acid sequence GTNWSIPPDY (SEQ ID NO: 657); aw) CDR1 contains the amino acid sequenceSYAMG (SEQ ID NO: 604), CDR2 contains the amino acid sequenceAIRWSGGSTYYGDSVKG (SEQ ID NO: 648), and CDR3 contains the amino acid sequence DPIGLGYEMGEYDY (SEQ ID NO: 658); ax) CDR1 contains the amino acid sequence SYAMG (SEQ ID NO: 604), CDR2 contains the amino acid sequenceAISWSGGRIYYADSVKG (SEQ ID NO: 649), and CDR3 contains the amino acid sequence DDFERTMTEVRY (SEQ ID NO: 659); ay) CDR1 contains the amino acid sequence SYAMG (SEQ ID NO: 604), CDR2 contains the amino acid sequenceAISWSGGSIYYADSVKG (SEQ ID NO: 650), and CDR3 contains the amino acid sequence DGTLRTPMNLIHY (SEQ ID NO: 660); az) CDR1 contains the amino acid sequenceSYAMG (SEQ ID NO: 604), CDR2 contains the amino acid sequenceAISWSGGSTYYADSVKG (SEQ ID NO: 651), and CDR3 contains the amino acid sequence DPSLSRTMDEIGS (SEQ ID NO: 661); ba) CDR1 contains the amino acid sequence SYAMG (SEQ ID NO: 604), CDR2 contains the amino acid sequenceAISWRGVNTYYADSVKG (SEQ ID NO: 652), and CDR3 contains the amino acid sequence GPLGATMSEIGS (SEQ ID NO: 662); bb) CDR1 contains the amino acid sequence NYAMG (SEQ ID NO: 643), CDR2 contains the amino acid sequenceAISWSGGSTYYADSVKG (SEQ ID NO: 651), and CDR3 contains the amino acid sequence GPLGATMSEIGS (SEQ ID NO: 662); bc) CDR1 contains the amino acid sequence SYAMG (SEQ ID NO: 604), CDR2 contains the amino acid sequenceAISWSGGGTYYADSVKG (SEQ ID NO: 653), and CDR3 contains the amino acid sequence GPLGATMSEIGS (SEQ ID NO: 662); or bd) CDR1 contains the amino acid sequence SYAMG (SEQ ID NO: 604), CDR2 contains the amino acid sequenceAISWSGGSTYYADSVKG (SEQ ID NO: 651), and CDR3 contains the amino acid sequence GPLGATMSEIGS (SEQ ID NO: 662). In any aspect or embodiment of the disclosure: a) FR1 contains the following amino acid sequence: X1X2QLX3ESGGX4X5X6X7X8GX9X10LX11LSCAX12X13X14X15X15X17X18X19(SEQ ID NO: 781), where X1is E or Q; X2is L or V; X3is V or Q; X4is G or R; X5is K, L, or S; X6is A or V; X7is E, H, Q, or R; X8is A, P, T, or V; X9is D, E, or G; X10is S or T; X11is G, N, or R; X12is A or null; X13is A, H, I, L, or T; X14is A or S; X15is D, G, R, or S; X15is A, F, H, L, N, P, R, or S; X17is A, F, G, I, L, P, S, or T; X18is A, F, I, L, or V; and X19is A, D, E, G, I, N, R, S, or T; b) FR2 contains the amino acid sequence: WX20RX21X22X23GX24X25X26X27X28X29X30, where X20is A, F, V, or Y; X21is E or Q; X22is A, P, T, or V; X23is E or P; X24is K or null; X25is A, E, G, null, or Q; X26is L, P, R, or V; X27is D, E, or Q; X28is F, G, L, or W; X29is L or V; and X30is A or S; c) FR3 contains the amino acid sequence: RFTX31X32X33X34X35X36X37X38X39X40X41X42X43LX44X45X46X47LX48X49X50DX51X52X53YX54CX55X56(SEQ ID NO: 782), where X31is I or V; X32is F, S, or T; X33is K or R; X34is D, E, G, or V; X35is D, N, S, or T; X36is A or V; X37is D, E, K, L, or N; X38is A, G, N, R, S, or T; X39is L, R, or T; X40is A, G, L, M, or V; X41is null or S; X42is null or V; X43is D, F, S, or Y; X44is Q or R; X45is L or M; X46is D, I, N, or S; X47is N or S; X48is K, L, R, or T; X49is P or S; X50is D, E, or G; X51is A, S, or T; X52is A or G; X53is I, T, or V; X54is F, L, R, S, or Y; X55is A, N, Q, R, T, or Y; and X56is A, G, K, L, P, V, or W; and / or d) FR4 contains the amino acid sequence: X57G X58GX59X60VTVSS (SEQ ID NO: 783), where X57is R or W; X58is K, P, or Q; X59is A or T; and X60is L or Q. In any aspect or embodiment of the disclosure: a) FR1 contains an amino acid sequence selected from one or more of: QVQLVESGGGLVQPGGSLRLSCAASGFSLD (SEQ ID NO: 663), EVQLVESGGGLVQPGGSLRLSCAASGFALD (SEQ ID NO: 664), QLQLVESGGGLVQPGGSLRLSCVASGFALD (SEQ ID NO: 665), QVQLVESGGGLVQVGGSLRLSCSISRSIAI (SEQ ID NO:673 ), QLQLVESGGGLVQAGGSLRLSCAASDPIVT (SEQ ID NO: 674 ), QLQLVESGGGLVQAGGSLRLSCAASGNIVD (SEQ ID NO: 675 ), EVQLVESGGGLVQAGGSLRLSCAASGNIVD (SEQ ID NO: 676), EVQLVESGGGLVQAGGSLRLSCAASGNIVE (SEQ ID NO: 677), QVQLVESGGGLVQAGGSLRLSCAASGNIVD (SEQ ID NO: 678 ), QVQLQESGGGLVQAGGSLRLSCAASGNSVD (SEQ ID NO:679 ), QVQLVESGGGLVQAGGSLRLSCAASGNGVD (SEQ ID NO: 691), QLQLVESGGGLVQTGGSLNLSCAASGAFVS (SEQ ID NO: 692), QVQLQESGGGLVQPGGSLRLSCAASGSIFS (SEQ ID NO: 693), QVQLVESGGGLVQAGGSLRLSCAASGSIFS (SEQ ID NO: 694), QVQLVESGGGLVQPGGSLRLSCAASGSIFR (SEQ ID NO: 695), QVQLVESGGGLVQPGGSLRLSCAASGSIFS (SEQ ID NO: 696), QVQLVESGGGLVQAGDSLRLSCAAASGRALS (SEQ ID NO: 697), QVQLVESGGGSVEPGGSLRLSCATSGLILS (SEQ ID NO: 698), EVQLVESGGGLAQPGGSLRLSCVASGFAFG (SEQ ID NO: 699), EVQLVESGGGLVQPGGSLRLSCSASGFPFD (SEQ ID NO: 700), QVQLVESGGGLVQPGGSLRLSCTASGRTIA (SEQ ID NO: 701), QVQLVESGGRLVQAGGSLRLSCAASGRTFN (SEQ ID NO: 702), QVQLVESGGGLVQPGGSLRLSCAASGSTFN (SEQ ID NO: 703), QVQLVESGGGLVHAGGSLRLSCAASGRTFN (SEQ ID NO: 706), EVQLVESGGGLVHAGGSLRLSCVASGRTFN (SEQ ID NO: 704), EVQLVESGGGLVHAGGSLRLSCAASGRTFN (SEQ ID NO: 705), QVQLQESGGGLVQAGETLGLSCVHSGRAFS (SEQ ID NO: 707), QVQLVESGGGLVQAGESLRLSCVASGRALS (SEQ ID NO: 708), QVQLVESGGGKVQPGGSLRLSCAASGFTFS (SEQ ID NO: 709), QVQLVESGGGLVQPGGSLRLSCAASGFLFS (SEQ ID NO: 710), EVQLVESGGGLVQPGGSLRLSCAASGFTFS (SEQ ID NO: 711), QVQLVESGGGLVQAGGSLRLSCAAASHTFD (SEQ ID NO: 780), QVQLVESGGGLVQAGGSLRLSCAAASLTFD (SEQ ID NO: 715), QVQLVESGGGLVQAGGSLRLSCVASGRTFS (SEQ ID NO: 716), QLQLVESGGGLVRAGGSLRLSCVLSGRTFS (SEQ ID NO: 712), QVQLVESGGGLVQPGGSLRLSCVLSGRTFS (SEQ ID NO: 717), QVQLVESGGGLVQAGGSLRLSCAASGRTFS (SEQ ID NO: 714), QVQLVESGGGLVQTGGSLRLSCAASGRTFS (SEQ ID NO: 713), EVQLVESGGGLVQAGGSLRLSCAASGRTFR (SEQ ID NO: 718), QLQLVESGGGLVQAGGSLRLSCAASGRTVS (SEQ ID NO: 719), QVQLVESGGGLVQAGGSLRLSCAASGRTFT (SEQ ID NO: 720), EVQLVESGGGLVQAGGSLRLSCAASGRTFS (SEQ ID NO: 721), and QVQLVESGGGLVQAGGSLRLSCAASGRTVS (SEQ ID NO: 722); b) FR2 contains an amino acid sequence selected from one or more of: WFRQAPGKEREGVS (SEQ ID NO: 666),WFRQAPGKEREGVA (SEQ ID NO: 667), WFRQAPGKEREGLS (SEQ ID NO: 668),WYREAEGKQRELVA (SEQ ID NO: 680), WYRQAPGKQRELVA (SEQ ID NO: 681),WYRQAPGKQRDLVA (SEQ ID NO: 682), WYRQAPGRDLVA (SEQ ID NO: 683),WYRQAPGKARELVA (SEQ ID NO: 723), WYRQAPGKEREFVA (SEQ ID NO: 724),WARQVPGKEVEWVS (SEQ ID NO: 725), WVRQPPGKGPEWVS (SEQ ID NO: 726),WVRQAPGKGLEWVS (SEQ ID NO: 727), WYRQTPGKEREFVA (SEQ ID NO: 728),WFRQAPGKEREFVA (SEQ ID NO: 729), WFRQAPGKEREFVS (SEQ ID NO: 730), andWFRQAPGKERQFVA (SEQ ID NO: 731); c) FR3 contains an amino acid sequence selected from one or more of: RFTISRDDAKATVFLQMNNLKPEDTAVYYCAA (SEQ ID NO: 669), RFTISRDNAKRTVSLQMNSLKPEDTAVYYCAA (SEQ ID NO: 670), RFTISRDNAKTTVSLLMSSLKPEDTAVYYCAA (SEQ ID NO: 671), RFTVSKDTANNTLDLQMNSLRPEDTAVYRCAA (SEQ ID NO: 684), RFTISRDNAKNTLYLQMNSLKPEDSAVYYCRA (SEQ ID NO: 685), RFTISRDNAKNTVYLQMNSLKPEDTATYYCYA (SEQ ID NO: 686), RFTISRDNVKNTVYLQMNSLKPEDTATYYCYA (SEQ ID NO: 687), RFTISRDNVKNTVSLQMNSLKPEDTATYYCYA (SEQ ID NO: 688), RFTISRDNVKNTVYLQMNSLKPEDTGTYYCYA (SEQ ID NO: 689), RFTITRDNAKNTVYLQMNSLKPEDTAVYYCNA (SEQ ID NO: 732), RFTISRGNAKNTVYLQMNSLTPEDTAVYYCNA (SEQ ID NO: 733), RFTISRDNAKNTVYLQMNSLKPEDTAVYYCNA (SEQ ID NO: 734), RFTISRDNAKNTVYLQMNSLKPEDTAVYYCNL (SEQ ID NO: 735), RFTISRDNAKNTVYLQMNSLLPEDTAVYYCNA (SEQ ID NO: 736), RFTISRDNALSTMSLRMNSLKSEDTAIYYCQG (SEQ ID NO: 737), RFTISRDNVKNTVYLQMNSLKPEDTAVYYCAA (SEQ ID NO: 738), RFTISRDNAKNTLYLQLNSLKPEDTAVYLCAA (SEQ ID NO: 739), RFTISRDNAKNTLYLQMSSLKPEDTGVYLCAA (SEQ ID NO: 740), RFTISRDNAKNTVYLQMNNLKPEDTAIYYCYW (SEQ ID NO: 741), RFTIFRDNAKNLAYLQLNSLKPEDTAVYSCAA (SEQ ID NO: 742), RFTIFRDNAKNLGYLQMNSLKPEDTAVYSCAA (SEQ ID NO: 743), RFTIFRDNAKGLAYLQMDSLKPEDTAVYSCAA (SEQ ID NO: 744), RFTIFRDNAKNLAYLQMNSLKPEDTAVYSCAA (SEQ ID NO: 745), RFTISRVNADNTVSLQMNSLKPEDTAVYFCAA (SEQ ID NO: 746), RFTISRVNAENTVSVSLQMNSLKPDDTAVYFCAA (SEQ ID NO: 747), RFTISRDNAKNTVYLQMNSLKPEDTAVYYCAK (SEQ ID NO: 748), RFTISRDNAKNTLYLQMDSLTPGDTAVYYCAV (SEQ ID NO: 749), RFTISRDNAKNTVYLQMNSLKPEDTAVYYCAA (SEQ ID NO: 750), RFTISRDNVKNRVYLQMNSLKPEDTAVYYCAA (SEQ ID NO: 751), RFTISRDSAKNTVYLQMNSLKPEDTAIYYCNA (SEQ ID NO: 752), RFTISRDNAKNTVYLQMNSLKPEDAAVYYCAA (SEQ ID NO: 753), RFTISRDNAKNTVYLQMDSLKPEDTAVYYCAP (SEQ ID NO: 754), RFTISRDNAKNTVDLQMNSLKPEDTAVYYCTP (SEQ ID NO: 755), RFTISRDNAKNTVYLQMNSLKPEDTAVYYCAP (SEQ ID NO: 756 ), RFTISRDNAKNTVSLQMNSLKPEDTAVYYCAA (SEQ ID NO: 757), RFTISRENAKNTVYLQMISLKPEDTAVYYCAA (SEQ ID NO: 758), and RFTISRDNAKNTVYLQMISLKPEDTAVYYCAA (SEQ ID NO: 759); and / or d) FR4 contains an amino acid sequence selected from one or more of:WGQGTQVTVSS (SEQ ID NO: 542), WGQGAQVTVSS (SEQ ID NO: 690), WGKGTLVTVSS (SEQ ID NO: 760), WGQGTLVTVSS (SEQ ID NO: 761), RGQGTQVTVSS (SEQ ID NO: 762), and WGPGTQVTVSS (SEQ ID NO: 763). In any aspect or embodiment of the disclosure: a) FR1 contains the amino acid sequenceQVQLVESGGGLVQPGGSLRLSCAASGFSLD (SEQ ID NO: 663), FR2 contains the amino acid sequenceWFRQAPGKEREGVS (SEQ ID NO: 666), FR3 contains the amino acid sequence RFTISRDDAKATVFLQMNNLKPEDTAVYYCAA (SEQ ID NO: 669), and FR4 contains the amino acid sequence WGQGTQVTVSS (SEQ ID NO: 542); b) FR1 contains the amino acid sequenceEVQLVESGGGLVQPGGSLRLSCAASGFALD (SEQ ID NO: 664), FR2 contains the amino acid sequenceWFRQAPGKEREGVA (SEQ ID NO: 667), FR3 contains the amino acid sequence RFTISRDNAKRTVSLQMNSLKPEDTAVYYCAA (SEQ ID NO: 670), and FR4 contains the amino acid sequence WGQGTQVTVSS (SEQ ID NO: 542); c) FR1 contains the amino acid sequenceQLQLVESGGGLVQPGGSLRLSCVASGFALD (SEQ ID NO: 665), FR2 contains the amino acid sequenceWFRQAPGKEREGLS (SEQ ID NO: 668), FR3 contains the amino acid sequence RFTISRDNAKTTVSLLMSSLKPEDTAVYYCAA (SEQ ID NO: 671), and FR4 contains the amino acid sequence WGQGTQVTVSS (SEQ ID NO: 542); d) FR1 contains the amino acid sequenceQVQLVESGGGLVQVGGSLRLSCSISRSIAI (SEQ ID NO: 673), FR2 contains the amino acid sequenceWYREAEGKQRELVA (SEQ ID NO: 680), FR3 contains the amino acid sequence RFTVSKDTANNTLDLQMNSLRPEDTAVYRCAA (SEQ ID NO: 684), and FR4 contains the amino acid sequence WGQGTQVTVSS (SEQ ID NO: 542); e) FR1 contains the amino acid sequenceQLQLVESGGGLVQAGGSLRLSCAASDPIVT (SEQ ID NO: 674), FR2 contains the amino acid sequenceWYRQAPGKQRELVA (SEQ ID NO: 681), FR3 contains the amino acid sequence RFTISRDNAKNTLYLQMNSLKPEDSAVYYCRA (SEQ ID NO: 685), and FR4 contains the amino acid sequence WGQGTQVTVSS (SEQ ID NO: 542); f) FR1 contains the amino acid sequence QLQLVESGGGLVQAGGSLRLSCAASGNIVD (SEQ ID NO: 675), FR2 contains the amino acid sequenceWYRQAPGKQRDLVA (SEQ ID NO: 682), FR3 contains the amino acid sequence RFTISRDNAKNTVYLQMNSLKPEDTATYYCYA (SEQ ID NO: 686), and FR4 contains the amino acid sequenceWGQGAQVTVSS (SEQ ID NO: 690); g) FR1 contains the amino acid sequenceEVQLVESGGGLVQAGGSLRLSCAASGNIVD (SEQ ID NO: 676), FR2 contains the amino acid sequenceWYRQAPGRDLVA (SEQ ID NO: 683), FR3 contains the amino acid sequence RFTISRDNVKNTVYLQMNSLKPEDTATYYCYA (SEQ ID NO: 687), and FR4 contains the amino acid sequence WGQGTQVTVSS (SEQ ID NO: 542); h) FR1 contains the amino acid sequenceEVQLVESGGGLVQAGGSLRLSCAASGNIVE (SEQ ID NO: 677 ), FR2 contains the amino acid sequence WYRQAPGKQRDLVA (SEQ ID NO: 682), FR3 contains the amino acid sequence RFTISRDNVKNTVYLQMNSLKPEDTATYYCYA (SEQ ID NO: 687), and FR4 contains the amino acid sequence WGQGTQVTVSS (SEQ ID NO: 542); i) FR1 contains the amino acid sequence QVQLVESGGGLVQAGGSLRLSCAASGNIVD (SEQ ID NO: 678 ), FR2 contains the amino acid sequence WYRQAPGKQRDLVA (SEQ ID NO: 682), FR3 contains the amino acid sequence RFTISRDNVKNTVSLQMNSLKPEDTATYYCYA (SEQ ID NO: 688), and FR4 contains the amino acid sequence WGQGTQVTVSS (SEQ ID NO: 542); j) FR1 contains the amino acid sequence QVQLQESGGGLVQAGGSLRLSCAASGNSVD (SEQ ID NO: 679 ), FR2 contains the amino acid sequence WYRQAPGKQRDLVA (SEQ ID NO: 682), FR3 contains the amino acid sequence RFTISRDNVKNTVYLQMNSLKPEDTATYYCYA (SEQ ID NO: 687), and FR4 contains the amino acid sequence WGQGTQVTVSS (SEQ ID NO: 542); k) FR1 contains the amino acid sequenceQVQLVESGGGLVQAGGSLRLSCAASGNIVD (SEQ ID NO: 678 ), FR2 contains the amino acid sequence WYRQAPGKQRDLVA (SEQ ID NO: 682), FR3 contains the amino acid sequence RFTISRDNVKNTVYLQMNSLKPEDTATYYCYA (SEQ ID NO: 687), and FR4 contains the amino acid sequence WGQGTQVTVSS (SEQ ID NO: 542); l) FR1 contains the amino acid sequence QVQLVESGGGLVQAGGSLRLSCAASGNGVD (SEQ ID NO: 780), FR2 contains the amino acid sequenceWYRQAPGKQRDLVA (SEQ ID NO: 682), FR3 contains the amino acid sequence RFTISRDNVKNTVYLQMNSLKPEDTGTYYCYA (SEQ ID NO: 689), and FR4 contains the amino acid sequenceWGQGTQVTVSS (SEQ ID NO: 542); m) FR1 contains the amino acid sequence QVQLVESGGGLVQAGGSLRLSCAASGNGVD (SEQ ID NO: 780), FR2 contains the amino acid sequenceWYRQAPGKQRDLVA (SEQ ID NO: 682), FR3 contains the amino acid sequence RFTISRDNVKNTVYLQMNSLKPEDTATYYCYA (SEQ ID NO: 687), and FR4 contains the amino acid sequenceWGQGTQVTVSS (SEQ ID NO: 542); n) FR1 contains the amino acid sequenceQVQLVESGGGLVQAGGSLRLSCAASGNGVD (SEQ ID NO: 780), FR2 contains the amino acid sequenceWYRQAPGKQRDLVA (SEQ ID NO: 682), FR3 contains the amino acid sequence RFTISRDNVKNTVYLQMNSLKPEDTATYYCYA (SEQ ID NO: 687), and FR4 contains the amino acid sequenceWGQGTQVTVSS (SEQ ID NO: 542); o) FR1 contains the amino acid sequenceQVQLVESGGGLVQAGGSLRLSCAASGNGVD (SEQ ID NO: 780), FR2 contains the amino acid sequenceWYRQAPGKQRDLVA (SEQ ID NO: 682), FR3 contains the amino acid sequence RFTISRDNVKNTVYLQMNSLKPEDTATYYCYA (SEQ ID NO: 687), and FR4 contains the amino acid sequenceWGQGTQVTVSS (SEQ ID NO: 542); p) FR1 contains the amino acid sequenceQLQLVESGGGLVQTGGSLNLSCAASGAFVS (SEQ ID NO: 692), FR2 contains the amino acid sequenceWYRQAPGKARELVA (SEQ ID NO: 723), FR3 contains the amino acid sequence RFTITRDNAKNTVYLQMNSLKPEDTAVYYCNA (SEQ ID NO: 732), and FR4 contains the amino acid sequence WGQGTQVTVSS (SEQ ID NO: 542); q) FR1 contains the amino acid sequenceQVQLQESGGGLVQPGGSLRLSCAASGSIFS (SEQ ID NO: 693), FR2 contains the amino acid sequenceWYRQAPGKQRELVA (SEQ ID NO: 681), FR3 contains the amino acid sequence RFTISRGNAKNTVYLQMNSLTPEDTAVYYCNA (SEQ ID NO: 733), and FR4 contains the amino acid sequence WGQGTQVTVSS (SEQ ID NO: 542); r) FR1 contains the amino acid sequence QVQLVESGGGLVQAGGSLRLSCAASGSIFS (SEQ ID NO: 694), FR2 contains the amino acid sequenceWYRQAPGKQRELVA (SEQ ID NO: 681), FR3 contains the amino acid sequence RFTISRDNAKNTVYLQMNSLKPEDTAVYYCNA (SEQ ID NO: 734), and FR4 contains the amino acid sequence WGKGTLVTVSS (SEQ ID NO: 760); s) FR1 contains the amino acid sequenceQVQLVESGGGLVQPGGSLRLSCAASGSIFR (SEQ ID NO: 695), FR2 contains the amino acid sequenceWYRQAPGKQRELVA (SEQ ID NO: 681), FR3 contains the amino acid sequence RFTISRDNAKNTVYLQMNSLKPEDTAVYYCNL (SEQ ID NO: 735), and FR4 contains the amino acid sequence WGQGTQVTVSS (SEQ ID NO: 542); t) FR1 contains the amino acid sequence QVQLQESGGGLVQPGGSLRLSCAASGSIFS (SEQ ID NO: 693), FR2 contains the amino acid sequenceWYRQAPGKQRELVA (SEQ ID NO: 681), FR3 contains the amino acid sequence RFTISRDNAKNTVYLQMNSLLPEDTAVYYCNA (SEQ ID NO: 736), and FR4 contains the amino acid sequenceWGQGTLVTVSS (SEQ ID NO: 761); u) FR1 contains the amino acid sequenceQVQLVESGGGLVQPGGSLRLSCAASGSIFS (SEQ ID NO: 696), FR2 contains the amino acid sequenceWYRQAPGKQRELVA (SEQ ID NO: 681), FR3 contains the amino acid sequence RFTISRDNAKNTVYLQMNSLKPEDTAVYYCNA (SEQ ID NO: 734), and FR4 contains the amino acid sequence WGQGTLVTVSS (SEQ ID NO: 761); v) FR1 contains the amino acid sequenceQVQLVESGGGLVQAGDSLRLSCAAASGRALS (SEQ ID NO: 697), FR2 contains the amino acid sequenceWYRQAPGKEREFVA (SEQ ID NO: 724), FR3 contains the amino acid sequence RFTISRDNALSTMSLRMNSLKSEDTAIYYCQG (SEQ ID NO: 737), and FR4 contains the amino acid sequenceWGQGTQVTVSS (SEQ ID NO: 542); w) FR1 contains the amino acid sequenceQVQLVESGGGSVEPGGSLRLSCATSGLILS (SEQ ID NO: 698), FR2 contains the amino acid sequenceWARQVPGKEVEWVS (SEQ ID NO: 725), FR3 contains the amino acid sequence RFTISRDNVKNTVYLQMNSLKPEDTAVYYCAA (SEQ ID NO: 738), and FR4 contains the amino acid sequence WGQGTQVTVSS (SEQ ID NO: 542); x) FR1 contains the amino acid sequenceEVQLVESGGGLAQPGGSLRLSCVASGFAFG (SEQ ID NO: 699), FR2 contains the amino acid sequenceWVRQPPGKGPEWVS (SEQ ID NO: 726), FR3 contains the amino acid sequence RFTISRDNAKNTLYLQLNSLKPEDTAVYLCAA (SEQ ID NO: 739), and FR4 contains the amino acid sequence WGQGTQVTVSS (SEQ ID NO: 542); y) FR1 contains the amino acid sequenceEVQLVESGGGLVQPGGSLRLSCSASGFPFD (SEQ ID NO: 700), FR2 contains the amino acid sequenceWVRQAPGKGLEWVS (SEQ ID NO: 727), FR3 contains the amino acid sequence RFTISRDNAKNTLYLQMSSLKPEDTGVYLCAA (SEQ ID NO: 740), and FR4 contains the amino acid sequence WGQGTQVTVSS (SEQ ID NO: 542); z) FR1 contains the amino acid sequenceQVQLVESGGGLVQPGGSLRLSCTASGRTIA (SEQ ID NO: 701), FR2 contains the amino acid sequenceWYRQTPGKEREFVA (SEQ ID NO: 728), FR3 contains the amino acid sequence RFTISRDNAKNTVYLQMNNLKPEDTAIYYCYW (SEQ ID NO: 741), and FR4 contains the amino acid sequence WGQGTQVTVSS (SEQ ID NO: 542); aa) FR1 contains the amino acid sequence QVQLVESGGRLVQAGGSLRLSCAASGRTFN (SEQ ID NO: 702), FR2 contains the amino acid sequenceWFRQAPGKEREFVA (SEQ ID NO: 729), FR3 contains the amino acid sequence RFTIFRDNAKNLAYLQLNSLKPEDTAVYSCAA (SEQ ID NO: 742), and FR4 contains the amino acid sequence WGQGTQVTVSS (SEQ ID NO: 542); ab) FR1 contains the amino acid sequenceQVQLVESGGGLVQPGGSLRLSCAASGSTFN (SEQ ID NO: 703), FR2 contains the amino acid sequenceWFRQAPGKEREFVA (SEQ ID NO: 729), FR3 contains the amino acid sequence RFTIFRDNAKNLGYLQMNSLKPEDTAVYSCAA (SEQ ID NO: 743), and FR4 contains the amino acid sequence WGQGTQVTVSS (SEQ ID NO: 542); ac) FR1 contains the amino acid sequence QVQLVESGGGLVHAGGSLRLSCAASGRTFN (SEQ ID NO: 706), FR2 contains the amino acid sequenceWFRQAPGKEREFVA (SEQ ID NO: 729), FR3 contains the amino acid sequence RFTIFRDNAKGLAYLQMDSLKPEDTAVYSCAA (SEQ ID NO: 744), and FR4 contains the amino acid sequence WGQGTQVTVSS (SEQ ID NO: 542); ad) FR1 contains the amino acid sequenceEVQLVESGGGLVHAGGSLRLSCVASGRTFN (SEQ ID NO: 704), FR2 contains the amino acid sequenceWFRQAPGKEREFVA (SEQ ID NO: 729), FR3 contains the amino acid sequence RFTIFRDNAKNLAYLQMNSLKPEDTAVYSCAA (SEQ ID NO: 745), and FR4 contains the amino acid sequence WGQGTQVTVSS (SEQ ID NO: 542); ae) FR1 contains the amino acid sequence EVQLVESGGGLVHAGGSLRLSCAASGRTFN (SEQ ID NO: 705), FR2 contains the amino acid sequenceWFRQAPGKEREFVA (SEQ ID NO: 729), FR3 contains the amino acid sequence RFTIFRDNAKNLAYLQMNSLKPEDTAVYSCAA (SEQ ID NO: 745), and FR4 contains the amino acid sequence WGQGTQVTVSS (SEQ ID NO: 542); af) FR1 contains the amino acid sequenceQVQLVESGGGLVHAGGSLRLSCAASGRTFN (SEQ ID NO: 706), FR2 contains the amino acid sequenceWFRQAPGKEREFVA (SEQ ID NO: 729), FR3 contains the amino acid sequence RFTIFRDNAKNLAYLQMNSLKPEDTAVYSCAA (SEQ ID NO: 745), and FR4 contains the amino acid sequence WGQGTQVTVSS (SEQ ID NO: 542); ag) FR1 contains the amino acid sequenceQVQLQESGGGLVQAGETLGLSCVHSGRAFS (SEQ ID NO: 707), FR2 contains the amino acid sequenceWFRQAPGKEREFVA (SEQ ID NO: 729), FR3 contains the amino acid sequence RFTISRVNADNTVSLQMNSLKPEDTAVYFCAA (SEQ ID NO: 746), and FR4 contains the amino acid sequence WGQGTQVTVSS (SEQ ID NO: 542 ); ah) FR1 contains the amino acid sequenceQVQLVESGGGLVQAGESLRLSCVASGRALS (SEQ ID NO: 708), FR2 contains the amino acid sequenceWFRQAPGKEREFVA (SEQ ID NO: 729), FR3 contains the amino acid sequence RFTISRVNAENTVSVSLQMNSLKPDDTAVYFCAA (SEQ ID NO: 747), and FR4 contains the amino acid sequence WGQGTQVTVSS (SEQ ID NO: 542); ai) FR1 contains the amino acid sequenceQVQLVESGGGKVQPGGSLRLSCAASGFTFS (SEQ ID NO: 709), FR2 contains the amino acid sequenceWVRQAPGKGLEWVS (SEQ ID NO: 727), FR3 contains the amino acid sequence RFTISRDNAKNTVYLQMNSLKPEDTAVYYCAK (SEQ ID NO: 748), and FR4 contains the amino acid sequence WGQGTLVTVSS (SEQ ID NO: 761); aj) FR1 contains the amino acid sequenceQVQLVESGGGLVQPGGSLRLSCAASGFLFS (SEQ ID NO: 710), FR2 contains the amino acid sequenceWVRQAPGKGLEWVS (SEQ ID NO: 727), FR3 contains the amino acid sequence RFTISRDNAKNTLYLQMDSLTPGDTAVYYCAV (SEQ ID NO: 749), and FR4 contains the amino acid sequence RGQGTQVTVSS (SEQ ID NO: 762); ak) FR1 contains the amino acid sequenceEVQLVESGGGLVQPGGSLRLSCAASGFTFS (SEQ ID NO: 711), FR2 contains the amino acid sequenceWVRQAPGKGLEWVS (SEQ ID NO: 727), FR3 contains the amino acid sequence RFTISRDNAKNTVYLQMNSLKPEDTAVYYCAA (SEQ ID NO: 750), and FR4 contains the amino acid sequence WGQGTQVTVSS (SEQ ID NO: 542 ); al) FR1 contains the amino acid sequenceQVQLVESGGGLVQAGGSLRLSCAAASHTFD (SEQ ID NO: 780), FR2 contains the amino acid sequenceWFRQAPGKEREFVA (SEQ ID NO: 729), FR3 contains the amino acid sequence RFTISRDNVKNRVYLQMNSLKPEDTAVYYCAA (SEQ ID NO: 751), and FR4 contains the amino acid sequence WGQGTQVTVSS (SEQ ID NO:542 ); am) FR1 contains the amino acid sequenceQVQLVESGGGLVQAGGSLRLSCAAASLTFD (SEQ ID NO: 715), FR2 contains the amino acid sequenceWFRQAPGKEREFVA (SEQ ID NO: 729), FR3 contains the amino acid sequence RFTISRDNVKNTVYLQMNSLKPEDTAVYYCAA (SEQ ID NO: 738), and FR4 contains the amino acid sequence WGQGTQVTVSS (SEQ ID NO: 542 ); an) FR1 contains the amino acid sequenceQVQLVESGGGLVQAGGSLRLSCVASGRTFS (SEQ ID NO: 716), FR2 contains the amino acid sequenceWYRQAPGKEREFVA (SEQ ID NO: 724), FR3 contains the amino acid sequence RFTISRDSAKNTVYLQMNSLKPEDTAIYYCNA (SEQ ID NO: 752), and FR4 contains the amino acid sequence WGQGTQVTVSS (SEQ ID NO: 542 ); ao) FR1 contains the amino acid sequenceQLQLVESGGGLVRAGGSLRLSCVLSGRTFS (SEQ ID NO: 712), FR2 contains the amino acid sequenceWFRQAPGKEREFVS (SEQ ID NO: 730), FR3 contains the amino acid sequence RFTISRDNAKNTVYLQMNSLKPEDAAVYYCAA (SEQ ID NO: 753), and FR4 contains the amino acid sequence WGPGTQVTVSS (SEQ ID NO: 763); ap) FR1 contains the amino acid sequenceQLQLVESGGGLVRAGGSLRLSCVLSGRTFS (SEQ ID NO: 712), FR2 contains the amino acid sequenceWFRQAPGKEREFVS (SEQ ID NO: 730), FR3 contains the amino acid sequence RFTISRDNAKNTVYLQMNSLKPEDTAVYYCAA (SEQ ID NO: 750), and FR4 contains the amino acid sequence WGPGTQVTVSS (SEQ ID NO: 763); aq) FR1 contains the amino acid sequenceQVQLVESGGGLVQPGGSLRLSCVLSGRTFS (SEQ ID NO: 717), FR2 contains the amino acid sequenceWFRQAPGKEREFVS (SEQ ID NO: 730), FR3 contains the amino acid sequence RFTISRDNAKNTVYLQMNSLKPEDTAVYYCAA (SEQ ID NO: 750), and FR4 contains the amino acid sequence WGPGTQVTVSS (SEQ ID NO: 763); ar) FR1 contains the amino acid sequenceQVQLVESGGGLVQAGGSLRLSCAASGRTFS (SEQ ID NO: 714), FR2 contains the amino acid sequenceWFRQAPGKERQFVA (SEQ ID NO: 731), FR3 contains the amino acid sequence RFTISRDNAKNTVYLQMDSLKPEDTAVYYCAP (SEQ ID NO: 754), and FR4 contains the amino acid sequence WGQGTQVTVSS (SEQ ID NO: 542 ); as) FR1 contains the amino acid sequence QVQLVESGGGLVQTGGSLRLSCAASGRTFS (SEQ ID NO: 713), FR2 contains the amino acid sequenceWFRQAPGKEREFVA (SEQ ID NO: 729), FR3 contains the amino acid sequence RFTISRDNAKNTVDLQMNSLKPEDTAVYYCTP (SEQ ID NO: 755), and FR4 contains the amino acid sequence WGQGTQVTVSS (SEQ ID NO: 542); at) FR1 contains the amino acid sequenceQVQLVESGGGLVQAGGSLRLSCAASGRTFS (SEQ ID NO: 714), FR2 contains the amino acid sequenceWFRQAPGKEREFVA (SEQ ID NO: 729), FR3 contains the amino acid sequence RFTISRDNAKNTVYLQMNSLKPEDTAVYYCAP (SEQ ID NO: 756 ), and FR4 contains the amino acid sequenceWGQGTQVTVSS (SEQ ID NO: 542); au) FR1 contains the amino acid sequenceQVQLVESGGGLVQAGGSLRLSCAASGRTFS (SEQ ID NO: 714), FR2 contains the amino acid sequence WFRQAPGKEREFVA (SEQ ID NO: 729), FR3 contains the amino acid sequence RFTISRDNAKNTVYLQMNSLKPEDTAVYYCAP (SEQ ID NO: 756 ), and FR4 contains the amino acid sequenceWGQGTQVTVSS (SEQ ID NO: 542); av) FR1 contains the amino acid sequenceQVQLVESGGGLVQAGGSLRLSCAASGRTFS (SEQ ID NO: 714), FR2 contains the amino acid sequenceWFRQAPGKEREFVA (SEQ ID NO: 729), FR3 contains the amino acid sequence RFTISRDNAKNTVYLQMNSLKPEDTAVYYCAA (SEQ ID NO: 750), and FR4 contains the amino acid sequence WGQGTQVTVSS (SEQ ID NO: 542); aw) FR1 contains the amino acid sequence QVQLVESGGGLVQAGGSLRLSCAASGRTFS (SEQ ID NO: 714), FR2 contains the amino acid sequenceWFRQAPGKEREFVA (SEQ ID NO: 729), FR3 contains the amino acid sequence RFTISRDNAKNTVYLQMNSLKPEDTAVYYCAA (SEQ ID NO: 750), and FR4 contains the amino acid sequence WGQGTQVTVSS (SEQ ID NO: 542); ax) FR1 contains the amino acid sequenceEVQLVESGGGLVQAGGSLRLSCAASGRTFR (SEQ ID NO: 718), FR2 contains the amino acid sequenceWFRQAPGKEREFVA (SEQ ID NO: 729), FR3 contains the amino acid sequence RFTISRDNAKNTVYLQMNSLKPEDTAVYYCAA (SEQ ID NO: 750), and FR4 contains the amino acid sequence WGQGTQVTVSS (SEQ ID NO: 542); ay) FR1 contains the amino acid sequenceQVQLVESGGGLVQAGGSLRLSCAASGRTFS (SEQ ID NO: 714), FR2 contains the amino acid sequenceWFRQAPGKEREFVA (SEQ ID NO: 729), FR3 contains the amino acid sequence RFTISRDNAKNTVSLQMNSLKPEDTAVYYCAA (SEQ ID NO: 757), and FR4 contains the amino acid sequence WGQGTQVTVSS (SEQ ID NO: 542); az) FR1 contains the amino acid sequence QLQLVESGGGLVQAGGSLRLSCAASGRTVS (SEQ ID NO: 719), FR2 contains the amino acid sequenceWFRQAPGKEREFVA (SEQ ID NO: 729), FR3 contains the amino acid sequence RFTISRDNAKNTVYLQMNSLKPEDTAVYYCAA (SEQ ID NO: 750), and FR4 contains the amino acid sequence WGQGTQVTVSS (SEQ ID NO: 542); ba) FR1 contains the amino acid sequenceQVQLVESGGGLVQAGGSLRLSCAASGRTFT (SEQ ID NO: 720), FR2 contains the amino acid sequenceWFRQAPGKEREFVA (SEQ ID NO: 729), FR3 contains the amino acid sequence RFTISRENAKNTVYLQMISLKPEDTAVYYCAA (SEQ ID NO: 758), and FR4 contains the amino acid sequence WGQGTQVTVSS (SEQ ID NO: 542); bb) FR1 contains the amino acid sequence EVQLVESGGGLVQAGGSLRLSCAASGRTFS (SEQ ID NO: 721), FR2 contains the amino acid sequenceWFRQAPGKEREFVS (SEQ ID NO:730), FR3 contains the amino acid sequenceRFTISRDNAKNTVYLQMISLKPEDTAVYYCAA (SEQ ID NO: 759), and FR4 contains the amino acid sequence WGQGTQVTVSS (SEQ ID NO: 542); bc) FR1 contains the amino acid sequenceQVQLVESGGGLVQAGGSLRLSCAASGRTVS (SEQ ID NO: 722), FR2 contains the amino acid sequenceWFRQAPGKEREFVA (SEQ ID NO: 729), FR3 contains the amino acid sequence RFTISRDNAKNTVYLQMISLKPEDTAVYYCAA (SEQ ID NO: 759), and FR4 contains the amino acid sequence WGQGTQVTVSS (SEQ ID NO: 542 ); or bd) FR1 contains the amino acid sequence QVQLVESGGGLVQAGGSLRLSCAASGRTVS (SEQ ID NO: 722), FR2 contains the amino acid sequenceWFRQAPGKEREFVA (SEQ ID NO: 729), FR3 contains the amino acid sequence RFTISRDNAKNTVYLQMISLKPEDTAVYYCAA (SEQ ID NO: 759), and FR4 contains the amino acid sequence WGQGTQVTVSS (SEQ ID NO: 542 ). In any aspect or embodiment of the disclosure, the VHH antibody contains an amino acid sequence having at least 85% sequence identity to an amino acid sequence selected from one or more of: EVQLVESGGGLVQPGGSLRLSCAASGFALDGYTIGWFRQAPGKEREGVACISRSDTSTKYADSV KGRFTISRDNAKRTVSLQMNSLKPEDTAVYYCAASLQSGLLSRFLLPRQYDHWGQGTQVTVSS (SEQ ID NO: 426); QLQLVESGGGLVQPGGSLRLSCVASGFALDSYTIGWFRQAPGKEREGLSCISRSTSDARYADSV KGRFTISRDNAKTTVSLLMSSLKPEDTAVYYCAASRQTGLLSTFLLPRQYDHWGQGTQVTVSS (SEQ ID NO: 427); QVQLVESGGGLVQPGGSLRLSCAASGFSLDFYSIGWFRQAPGKEREGVSCITWSGERTNYKDSV KGRFTISRDDAKATVFLQMNNLKPEDTAVYYCAADSGYPCYGSSWSSVGYDFWGQGTQVTVSS (SEQ ID NO: 428); QVQLVESGGGSVEPGGSLRLSCATSGLILSNHGMGWARQVPGKEVEWVSGSYTDGSTYYADSVK GRFTISRDNVKNTVYLQMNSLKPEDTAVYYCAARQYYRSGYVDYWGQGTQVTVSS (SEQ ID NO: 429); QVQLVESGGGKVQPGGSLRLSCAASGFTFSNYGMMWVRQAPGKGLEWVSYIDSGGGSTYYTDSV RGRFTISRDNAKNTVYLQMNSLKPEDTAVYYCAKAIGVVSGSLEVWGQGTLVTVSS (SEQ ID NO: 430); QVQLVESGGGLVQAGGSLRLSCAASGRTFTSYAMGWFRQAPGKEREFVAAISWRGVNTYYADSV KGRFTISRENAKNTVYLQMISLKPEDTAVYYCAAGPLGATMSEIGSWGQGTQVTVSS (SEQ ID NO: 431); EVQLVESGGGLVQAGGSLRLSCAASGRTFSNYAMGWFRQAPGKEREFVSAISWSGGSTYYADSV KGRFTISRDNAKNTVYLQMISLKPEDTAVYYCAAGPLGATMSEIGSWGQGTQVTVSS (SEQ ID NO: 432); QVQLVESGGGLVQAGGSLRLSCAASGRTVSSYAMGWFRQAPGKEREFVAAISWSGGGTYYADSV KGRFTISRDNAKNTVYLQMISLKPEDTAVYYCAAGPLGATMSEIGSWGQGTQVTVSS (SEQ ID NO: 433); QVQLVESGGGLVQAGGSLRLSCAASGRTVSSYAMGWFRQAPGKEREFVAAISWSGGSTYYADSV KGRFTISRDNAKNTVYLQMISLKPEDTAVYYCAAGPLGATMSEIGSWGQGTQVTVSS (SEQ ID NO: 434); EVQLVESGGGLAQPGGSLRLSCVASGFAFGSFAIDWVRQPPGKGPEWVSAINRGGDRTYYSDSV KGRFTISRDNAKNTLYLQLNSLKPEDTAVYLCAAGGRVSADGKKWEYDYWGQGTQVTVSS (SEQ ID NO: 435); EVQLVESGGGLVHAGGSLRLSCAASGRTFNTMAWFRQAPGKEREFVAAIAWNSGLTYYGDSVKG RFTIFRDNAKNLAYLQMNSLKPEDTAVYSCAARRTFRTGLINTVTAYDTWGQGTQVTVSS (SEQ ID NO: 436); EVQLVESGGGLVHAGGSLRLSCVASGRTFNTMAWFRQAPGKEREFVAAISWSGGLTYYGDSVKG RFTIFRDNAKNLAYLQMNSLKPEDTAVYSCAARRTFRTALINTITAYDTWGQGTQVTVSS (SEQ ID NO: 437); EVQLVESGGGLVQAGGSLRLSCAASGNIVDIDDMGWYRQAPGRDLVASITAGGITKYADSAKGR FTISRDNVKNTVYLQMNSLKPEDTATYYCYAVRRYYPRFDYWGQGTQVTVSS (SEQ ID NO: 438); EVQLVESGGGLVQAGGSLRLSCAASGNIVEIDDMGWYRQAPGKQRDLVATITAGGITNYASSAK GRFTISRDNVKNTVYLQMNSLKPEDTATYYCYAIRKYYPRFDYWGQGTQVTVSS (SEQ ID NO: 439); EVQLVESGGGLVQAGGSLRLSCAASGRTFRSYAMGWFRQAPGKEREFVAAISWSGGRIYYADSV KGRFTISRDNAKNTVYLQMNSLKPEDTAVYYCAADDFERTMTEVRYWGQGTQVTVSS (SEQ ID NO: 440); EVQLVESGGGLVQPGGSLRLSCAASGFTFSGYYMSWVRQAPGKGLEWVSSIYSDDSNTYYADSV KGRFTISRDNAKNTVYLQMNSLKPEDTAVYYCAASATLRGRDTRFDYWGQGTQVTVSS (SEQ ID NO: 441); EVQLVESGGGLVQPGGSLRLSCSASGFPFDDYSMDWVRQAPGKGLEWVSAINRNGGSTYYAESM KGRFTISRDNAKNTLYLQMSSLKPEDTGVYLCAAGGRVSADGKKWEYDYWGQGTQVTVSS (SEQ ID NO: 442); QLQLVESGGGLVQAGGSLRLSCAASDPIVTFNTMGWYRQAPGKQRELVARITMSGIPNYADSVK GRFTISRDNAKNTLYLQMNSLKPEDSAVYYCRAEHSGYWGQGTQVTVSS (SEQ ID NO: 443); QLQLVESGGGLVQAGGSLRLSCAASGNIVDIDDMGWYRQAPGKQRDLVATITAGGIANYADSAK GRFTISRDNAKNTVYLQMNSLKPEDTATYYCYAIRRYYPRFDYWGQGAQVTVSS (SEQ ID NO: 444); QLQLVESGGGLVQAGGSLRLSCAASGRTVSSYAMGWFRQAPGKEREFVAAISWSGGSTYYADSV KGRFTISRDNAKNTVYLQMNSLKPEDTAVYYCAADPSLSRTMDEIGSWGQGTQVTVSS (SEQ ID NO: 445); QLQLVESGGGLVQTGGSLNLSCAASGAFVSIDAMAWYRQAPGKARELVAFSSSGGITNYADSVK GRFTITRDNAKNTVYLQMNSLKPEDTAVYYCNADILQSGWYTYWGQGTQVTVSS (SEQ ID NO: 446); QLQLVESGGGLVRAGGSLRLSCVLSGRTFSSYAMGWFRQAPGKEREFVSTISLSGGSTFYSDSA KGRFTISRDNAKNTVYLQMNSLKPEDAAVYYCAARPVLISRSSTDYAYWGPGTQVTVSS (SEQ ID NO: 447); QLQLVESGGGLVRAGGSLRLSCVLSGRTFSSYAMGWFRQAPGKEREFVSTISLSGGSTFYSDSA KGRFTISRDNAKNTVYLQMNSLKPEDTAVYYCAARPVLISRSSIDYAYWGPGTQVTVSS (SEQ ID NO: 448); QVQLQESGGGLVQAGETLGLSCVHSGRAFSGHGMGWFRQAPGKEREFVAAISWSGVSTAYADSV KGRFTISRVNADNTVSLQMNSLKPEDTAVYFCAAGLYSRPTTERREYIYWGQGTQVTVSS (SEQ ID NO: 449); QVQLQESGGGLVQAGGSLRLSCAASGNSVDIDDMGWYRQAPGKQRDLVATITAGGITKYGDSAK GRFTISRDNVKNTVYLQMNSLKPEDTATYYCYAVRRYYPRFDYWGQGTQVTVSS (SEQ ID NO: 450); QVQLQESGGGLVQPGGSLRLSCAASGSIFSMNAMGWYRQAPGKQRELVATITDNDFTYYAASVK DRFTISRGNAKNTVYLQMNSLTPEDTAVYYCNADGIYSGGRYYPSSWGQGTQVTVSS (SEQ ID NO: 451); QVQLQESGGGLVQPGGSLRLSCAASGSIFSVNDMGWYRQAPGKQRELVAASYSGGSTNYADSVK GRFTISRDNAKNTVYLQMNSLLPEDTAVYYCNADLVVVTTTPPSFPMPYRFLEVWGQGTLVTVS S (SEQ ID NO: 452); QVQLVESGGGLVHAGGSLRLSCAASGRTFNTMAWFRQAPGKEREFVAAISWSGGLTYYADSVKG RFTIFRDNAKGLAYLQMDSLKPEDTAVYSCAARRTFRTALINTVTAYDTWGQGTQVTVSS (SEQ ID NO: 453); QVQLVESGGGLVHAGGSLRLSCAASGRTFNTMAWFRQAPGKEREFVAAISWSGGLTYYGDSVKG RFTIFRDNAKNLAYLQMNSLKPEDTAVYSCAARRTFRTGLIDTVTAYDTWGQGTQVTVSS (SEQ ID NO: 454); QVQLVESGGGLVQAGDSLRLSCAAASGRALSGWQMGWYRQAPGKEREFVASISMSDGSTSYQDS VKGRFTISRDNALSTMSLRMNSLKSEDTAIYYCQGRSRFGFEYWGQGTQVTVSS (SEQ ID NO: 455); QVQLVESGGGLVQAGESLRLSCVASGRALSGHGMGWFRQAPGKEREFVAAISWSGVSTAYADSV KGRFTISRVNAENTVSVSLQMNSLKPDDTAVYFCAAGLYSRPTTERRDYIYWGQGTQVTVSS (SEQ ID NO: 456); QVQLVESGGGLVQAGGSLRLSCAAASHTFDSYTMGWFRQAPGKEREFVAAVNWDNVKNYADPVK GRFTISRDNVKNRVYLQMNSLKPEDTAVYYCAAGTNLPTRGSGSWGQGTQVTVSS (SEQ ID NO: 457); QVQLVESGGGLVQAGGSLRLSCAAASLTFDSYTMGWFRQAPGKEREFVAAVNWDNVKNYADPVK GRFTISRDNVKNTVYLQMNSLKPEDTAVYYCAAGTNLPTIESGSWGQGTQVTVSS (SEQ ID NO: 458); QVQLVESGGGLVQAGGSLRLSCAASGNGVDIDDMGWYRQAPGKQRDLVASITAGGITKYADSAK GRFTISRDNVKNTVYLQMNSLKPEDTATYYCYAIRRFYPRFDYWGQGTQVTVSS (SEQ ID NO: 459); QVQLVESGGGLVQAGGSLRLSCAASGNGVDIDDMGWYRQAPGKQRDLVASITAGGITNYADSAK GRFTISRDNVKNTVYLQMNSLKPEDTATYYCYAIRRFYPRFDYWGQGTQVTVSS (SEQ ID NO: 460); QVQLVESGGGLVQAGGSLRLSCAASGNGVDIDDMGWYRQAPGKQRDLVATITAGGITKYADSAK GRFTISRDNVKNTVYLQMNSLKPEDTATYYCYAIRRFYPRFDYWGQGTQVTVSS (SEQ ID NO: 461); QVQLVESGGGLVQAGGSLRLSCAASGNGVDIDDMGWYRQAPGKQRDLVATITAGGITNYADSAK GRFTISRDNVKNTVYLQMNSLKPEDTGTYYCYAIRKFYPRFDYWGQGTQVTVSS (SEQ ID NO: 462); QVQLVESGGGLVQAGGSLRLSCAASGNIVDIDDMGWYRQAPGKQRDLVASITAGGITKYADSAK GRFTISRDNVKNTVSLQMNSLKPEDTATYYCYAVRKYYPRFDYWGQGTQVTVSS (SEQ ID NO: 463); QVQLVESGGGLVQAGGSLRLSCAASGNIVDIDDMGWYRQAPGKQRDLVASITAGRITKYADSAK GRFTISRDNVKNTVYLQMNSLKPEDTATYYCYAIRRSYPRFDYWGQGTQVTVSS (SEQ ID NO: 464); QVQLVESGGGLVQAGGSLRLSCAASGRTFSNYAMGWFRQAPGKEREFVAAINWSGGRIYYTDSV KGRFTISRDNAKNTVYLQMNSLKPEDTAVYYCAAGTNWSIPPDYWGQGTQVTVSS (SEQ ID NO: 465); QVQLVESGGGLVQAGGSLRLSCAASGRTFSSYAMGWFRQAPGKEREFVAAIRWSGGSTYYGDSV KGRFTISRDNAKNTVYLQMNSLKPEDTAVYYCAADPIGLGYEMGEYDYWGQGTQVTVSS (SEQ ID NO: 466); QVQLVESGGGLVQAGGSLRLSCAASGRTFSSYAMGWFRQAPGKEREFVAAISWSGGSIYYADSV KGRFTISRDNAKNTVSLQMNSLKPEDTAVYYCAADGTLRTPMNLIHYWGQGTQVTVSS (SEQ ID NO: 467); QVQLVESGGGLVQAGGSLRLSCAASGRTFSSYAMGWFRQAPGKEREFVAAISWSGGSTYYANSV KGRFTISRDNAKNTVYLQMNSLKPEDTAVYYCAPGEEVAGKYFRQLYDYWGQGTQVTVSS (SEQ ID NO: 468); QVQLVESGGGLVQAGGSLRLSCAASGRTFSSYAMGWFRQAPGKEREFVADISWSGGTTNYANSV KGRFTISRDNAKNTVYLQMNSLKPEDTAVYYCAPGEEVDGKYFRPLYDYWGQGTQVTVSS (SEQ ID NO: 469); QVQLVESGGGLVQAGGSLRLSCAASGRTFSTYTMGWFRQAPGKERQFVAAISSSGDSTYYTDSV KGRFTISRDNAKNTVYLQMDSLKPEDTAVYYCAPGEEVAGKYFRALYDYWGQGTQVTVSS (SEQ ID NO: 470); QVQLVESGGGLVQAGGSLRLSCAASGSIFSINAMAWYRQAPGKQRELVAVITSGGSTNYADSVK GRFTISRDNAKNTVYLQMNSLKPEDTAVYYCNADLVYYSGNPGDYGMDYWGKGTLVTVSS (SEQ ID NO: 471); QVQLVESGGGLVQAGGSLRLSCVASGRTFSINNINWYRQAPGKEREFVATTRWRGDSTYYADSV AGRFTISRDSAKNTVYLQMNSLKPEDTAIYYCNAKGGVDVWGQGTQVTVSS (SEQ ID NO: 472); QVQLVESGGGLVQPGGSLRLSCAASGFLFSLYAMAWVRQAPGKGLEWVSDISNGGVTTRYADSV KGRFTISRDNAKNTLYLQMDSLTPGDTAVYYCAVTTTGWRARGQGTQVTVSS (SEQ ID NO: 473); QVQLVESGGGLVQPGGSLRLSCAASGSIFRPNDMGWYRQAPGKQRELVAIITDGGITNYAATVK GRFTISRDNAKNTVYLQMNSLKPEDTAVYYCNLNIPYPRVSSWGQGTQVTVSS (SEQ ID NO: 474); QVQLVESGGGLVQPGGSLRLSCAASGSIFSVNDMGWYRQAPGKQRELVAAIYSGGSTNYADSVK GRFTISRDNAKNTVYLQMNSLKPEDTAVYYCNADIVVVTTTPPSFPMPYRFLEVWGQGTLVTVS S (SEQ ID NO: 475); QVQLVESGGGLVQPGGSLRLSCAASGSTFNTMAWFRQAPGKEREFVAAISWSGGLTYYGDSVKG RFTIFRDNAKNLGYLQMNSLKPEDTAVYSCAARTTFRTGLIVTVTAYDTWGQGTQVTVSS (SEQ ID NO: 476); QVQLVESGGGLVQPGGSLRLSCVLSGRTFSSYAMGWFRQAPGKEREFVSTISLSGGSTFYSGSA KGRFTISRDNAKNTVYLQMNSLKPEDTAVYYCAARPVLISRSSTDYAYWGPGTQVTVSS (SEQ ID NO: 477); QVQLVESGGGLVQTGGSLRLSCAASGRTFSSYAMGWFRQAPGKEREFVAAITWSGGSTYYANSV KGRFTISRDNAKNTVDLQMNSLKPEDTAVYYCTPGEEVAGKYFRPLYDYWGQGTQVTVSS (SEQ ID NO: 479); QVQLVESGGGLVQVGGSLRLSCSISRSIAIFNFMAWYREAEGKQRELVASITGGSRLSYIDSVK GRFTVSKDTANNTLDLQMNSLRPEDTAVYRCAASSPFAGEFWGQGTQVTVSS (SEQ ID NO: 480); QVQLVESGGRLVQAGGSLRLSCAASGRTFNTMAWFRQAPGKEREFVAAITWSGGLTYYEDSVKG RFTIFRDNAKNLAYLQLNSLKPEDTAVYSCAARSTFRTALVNTVTAYDTWGQGTQVTVSS (SEQ ID NO: 481); and QVQLVESGGGLVQPGGSLRLSCTASGRTIASTIMGWYRQTPGKEREFVAISARSGDSESYASSV KDRFTISRDNAKNTVYLQMNNLKPEDTAIYYCYWNTGAGTIWGQGTQVTVSS (SEQ ID NO: 482). In any aspect or embodiment of the disclosure, the CAR polypeptide contains the following from N-terminus to C-terminus: a cluster of differentiation 8-alpha (CD8a) signal peptide, the VHH antibody, a cluster of differentiation 8a (CD8a) hinge region domain, a CD8a transmembrane region domain, a 4-1BB domain, and a cluster of differentiation 3-zeta (CD3z) domain. In any aspect or embodiment of the disclosure, the CD8a signal peptide contains the following amino acid sequence:MALPVTALLLPLALLLHAARP (SEQ ID NO: 767). In any aspect or embodiment of the disclosure, the CAR polypeptide contains an amino acid sequence with at least about 85% identity to the following sequence: TTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGVLLLSLV ITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVKFSRSADAPAYQQGQ NQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERR RGKGHDGLYQGLSTATKDTYDALHMQALPPR (SEQ ID NO: 766). In any aspect or embodiment of the disclosure, the polynucleotide contains a nucleotide sequence selected from one or more of: GAGGTGCAATTGGTCGAGAGCGGTGGCGGGTTGGTTCAACCAGGTGGTTCTTTGCGGCTGTCAT GTGCAGCCTCTGGCTTTGCTCTGGACGGATACACAATAGGGTGGTTTCGCCAAGCTCCGGGTAA AGAGCGGGAGGGAGTGGCATGTATCAGTCGATCTGATACTTCCACGAAGTACGCAGATTCAGTT AAGGGGAGGTTTACGATTAGTCGAGATAACGCCAAAAGAACTGTCTCTCTTCAAATGAACTCTC TCAAGCCGGAGGACACGGCGGTTTATTATTGTGCCGCCTCACTTCAATCTGGACTGCTTTCCAG ATTTCTCTTGCCTCGCCAGTATGACCACTGGGGACAGGGTACTCAGGTTACTGTTAGCAGC (SEQ ID NO: 848); CAACTTCAACTCGTTGAGTCAGGAGGGGGGCTCGTCCAGCCTGGAGGTAGTCTGCGGCTCTCCT GCGTAGCTTCCGGTTTTGCACTTGACTCATATACTATTGGGTGGTTCCGGCAAGCACCAGGTAA AGAACGGGAGGGGCTTTCCTGTATATCCAGGTCAACCTCCGATGCTAGATATGCGGACTCTGTT AAAGGACGGTTCACGATATCTCGGGATAATGCGAAGACTACCGTAAGCCTGTTGATGAGCTCCC TCAAACCCGAGGACACTGCCGTCTATTATTGCGCTGCCAGTAGACAAACTGGCCTCCTCTCCAC TTTCCTTCTTCCGCGCCAGTACGATCACTGGGGCCAGGGAACGCAAGTAACTGTCTCCAGC (SEQ ID NO: 849); CAAGTTCAACTGGTTGAAAGTGGTGGCGGCTTGGTTCAGCCGGGCGGGTCCCTTCGCCTTTCAT GTGCAGCGTCAGGCTTTTCCCTTGACTTTTATTCAATCGGATGGTTCAGACAAGCCCCTGGTAA AGAAAGGGAAGGAGTCTCTTGTATAACATGGTCAGGAGAGCGAACGAATTACAAGGATAGCGTA AAAGGTCGATTCACAATAAGCAGGGACGATGCTAAGGCGACGGTTTTTTTGCAGATGAATAATC TGAAACCGGAAGATACAGCAGTCTACTACTGTGCAGCGGATTCTGGCTACCCGTGTTATGGGTC CTCCTGGTCCTCTGTAGGCTATGATTTTTGGGGCCAGGGGACGCAAGTTACAGTCTCTTCA (SEQ ID NO: 850); CAGGTGCAACTCGTTGAAAGCGGTGGAGGGAGTGTGGAACCCGGCGGGAGCCTCAGATTGAGCT GCGCCACCTCTGGGCTTATCCTCAGTAATCACGGCATGGGGTGGGCCAGACAGGTTCCCGGCAA AGAAGTTGAATGGGTTTCCGGAAGCTACACCGACGGAAGCACGTATTATGCGGATAGTGTTAAG GGCCGCTTTACCATTAGCCGGGATAATGTCAAGAATACAGTTTATCTTCAAATGAATAGTCTTA AACCCGAAGACACTGCCGTCTACTACTGTGCCGCAAGGCAATATTATCGCTCCGGCTATGTGGA CTATTGGGGGCAAGGAACCCAAGTGACGGTGTCATCT (SEQ ID NO: 851); CAGGTCCAACTGGTAGAAAGCGGCGGAGGCAAAGTGCAACCCGGAGGTTCCCTTCGGCTTTCAT GTGCCGCGAGCGGATTTACGTTTTCCAACTACGGTATGATGTGGGTGAGACAAGCTCCAGGCAA AGGGTTGGAGTGGGTTAGCTATATTGACAGCGGCGGTGGATCCACCTACTACACCGACTCTGTA CGAGGGAGGTTTACAATTAGTAGAGACAACGCTAAAAACACAGTCTACCTCCAAATGAATAGTC TCAAGCCAGAGGACACAGCCGTGTACTACTGCGCAAAAGCGATAGGTGTTGTCTCTGGCTCCTT GGAAGTATGGGGACAAGGGACGCTGGTCACAGTAAGCTCT (SEQ ID NO: 852); CAGGTTCAGCTTGTTGAAAGCGGAGGAGGACTGGTTCAGGCAGGGGGCAGCTTGCGACTCTCAT GCGCCGCCAGCGGGCGGACCTTCACAAGTTATGCTATGGGGTGGTTTAGACAAGCACCGGGAAA AGAGAGAGAATTCGTAGCAGCCATTTCATGGCGGGGCGTAAATACCTATTATGCCGATAGCGTG AAAGGAAGGTTTACCATTAGCAGAGAAAACGCAAAAAATACGGTGTACTTGCAAATGATCAGTC TGAAGCCGGAGGATACAGCGGTGTATTACTGTGCCGCAGGTCCATTGGGCGCGACCATGTCTGA GATCGGTTCTTGGGGGCAGGGGACACAAGTCACCGTGTCTTCC (SEQ ID NO: 853); GAGGTGCAGTTGGTTGAATCCGGGGGAGGGCTTGTCCAAGCTGGAGGTTCTCTCAGACTCAGTT GTGCAGCTAGTGGACGCACCTTTAGTAACTATGCTATGGGATGGTTCCGCCAGGCTCCTGGTAA AGAACGAGAGTTCGTATCAGCGATTTCTTGGTCCGGTGGGTCCACCTATTACGCGGACAGCGTC AAAGGTCGATTTACCATTTCTCGAGATAATGCGAAAAATACCGTCTATCTGCAAATGATATCTC TCAAGCCCGAGGATACTGCTGTGTACTATTGCGCGGCTGGTCCGCTCGGAGCAACAATGTCAGA AATTGGAAGTTGGGGCCAAGGGACGCAAGTTACCGTATCCTCT (SEQ ID NO: 854); CAAGTTCAATTGGTCGAAAGTGGAGGCGGCTTGGTACAAGCGGGTGGATCACTGAGACTTAGCT GCGCTGCCTCAGGTAGGACCGTGTCAAGTTATGCTATGGGCTGGTTCAGGCAGGCGCCTGGCAA GGAACGAGAATTTGTCGCCGCAATTTCATGGTCCGGCGGAGGCACTTACTATGCTGATTCCGTC AAGGGCCGGTTTACTATCAGCCGGGATAACGCAAAAAACACGGTGTACCTGCAAATGATTTCCC TGAAGCCCGAAGATACAGCAGTGTATTATTGTGCGGCGGGACCGCTTGGTGCGACGATGAGTGA GATCGGGAGCTGGGGACAGGGCACACAAGTAACGGTGTCCAGC (SEQ ID NO: 855); CAAGTCCAACTTGTTGAATCTGGGGGTGGGCTCGTGCAAGCTGGGGGGAGTCTTCGGTTGTCAT GCGCCGCGTCAGGACGCACTGTATCAAGCTACGCCATGGGATGGTTTAGGCAGGCACCTGGTAA GGAGCGGGAGTTCGTCGCGGCGATTTCCTGGTCAGGTGGAAGCACGTACTACGCAGACTCAGTG AAAGGTAGATTCACGATCTCACGGGATAATGCCAAAAATACCGTCTACCTCCAGATGATCTCTC TTAAACCTGAAGATACAGCCGTGTACTATTGCGCCGCTGGGCCACTCGGTGCTACGATGAGTGA AATTGGGAGTTGGGGCCAGGGCACGCAGGTCACTGTTTCAAGC (SEQ ID NO: 856); GAAGTTCAGTTGGTAGAATCTGGCGGTGGCCTGGCTCAACCTGGGGGATCACTCAGACTCAGTT GTGTAGCGTCCGGCTTTGCCTTCGGCTCCTTCGCTATAGATTGGGTGCGACAACCGCCCGGAAA GGGACCTGAATGGGTATCTGCGATCAACCGGGGAGGGGATCGCACATACTATAGTGATAGCGTA AAGGGTCGATTTACAATCTCCCGCGATAACGCCAAGAATACACTCTATCTGCAATTGAACAGTC TTAAACCGGAGGACACGGCGGTTTATCTGTGTGCTGCTGGAGGGCGCGTGTCTGCTGATGGAAA AAAGTGGGAGTACGACTATTGGGGTCAGGGCACGCAAGTGACCGTATCTTCC (SEQ ID NO: 857); GAGGTGCAACTTGTCGAGAGCGGAGGAGGTCTTGTTCATGCGGGAGGTTCTCTGCGCCTGAGCT GCGCCGCGAGCGGACGGACATTCAATACCATGGCTTGGTTCCGGCAGGCGCCTGGCAAGGAGAG AGAATTCGTAGCCGCCATAGCATGGAATTCAGGTCTTACCTACTATGGGGACAGTGTAAAGGGG CGCTTCACCATCTTTCGAGACAATGCGAAGAATCTGGCCTACCTCCAGATGAACTCCTTGAAAC CTGAGGATACTGCGGTCTATTCCTGCGCTGCACGACGGACGTTCCGCACCGGACTGATCAACAC TGTCACCGCGTATGATACATGGGGTCAGGGGACACAAGTCACCGTCTCATCA (SEQ ID NO: 858); GAAGTACAACTTGTCGAGAGCGGCGGCGGGCTCGTACATGCTGGCGGCTCATTGCGCCTTAGCT GCGTAGCAAGCGGGAGGACTTTTAACACTATGGCCTGGTTTAGACAAGCTCCTGGTAAAGAAAG AGAATTTGTCGCGGCAATTTCCTGGAGCGGAGGGCTCACGTACTACGGGGATAGCGTTAAGGGG CGATTCACGATATTCAGAGACAACGCTAAAAACCTGGCCTACCTTCAAATGAATAGCTTGAAAC CAGAAGACACTGCCGTATATTCATGTGCAGCCCGCCGGACGTTCCGGACAGCCCTCATCAACAC TATCACAGCCTATGATACCTGGGGTCAAGGAACTCAAGTGACTGTCAGCTCC (SEQ ID NO: 859); GAAGTTCAACTCGTCGAGTCAGGTGGTGGCCTTGTCCAAGCCGGGGGAAGCCTCCGATTGTCTT GCGCTGCAAGTGGGAATATTGTTGATATAGACGACATGGGATGGTACCGGCAGGCACCTGGACG CGACTTGGTCGCTTCTATAACGGCTGGCGGGATTACAAAGTACGCTGATTCAGCGAAGGGCAGG TTCACTATCTCCCGCGATAACGTTAAAAACACCGTGTATCTGCAAATGAACAGTCTTAAACCTG AAGATACGGCGACGTACTACTGTTATGCAGTGAGACGGTACTACCCTCGATTTGATTATTGGGG CCAGGGCACACAAGTGACAGTGTCCAGT (SEQ ID NO: 860); GAGGTTCAACTTGTGGAAAGTGGCGGGGGGCTCGTGCAAGCGGGTGGGAGCCTCCGGCTGTCTT GCGCAGCCAGCGGGAACATCGTTGAAATCGACGACATGGGGTGGTATAGACAAGCACCAGGAAA ACAGCGGGACCTTGTTGCCACAATTACAGCTGGAGGCATTACGAATTATGCATCTTCAGCTAAA GGGAGGTTTACGATCTCCCGAGATAACGTAAAGAACACAGTCTATTTGCAAATGAACTCCCTGA AACCGGAGGATACCGCAACGTACTACTGCTATGCCATACGAAAGTATTACCCACGATTCGATTA TTGGGGTCAAGGCACTCAGGTGACCGTGTCAAGT (SEQ ID NO: 861); GAGGTTCAACTCGTTGAAAGTGGAGGAGGGCTCGTCCAGGCGGGCGGGAGTCTGAGGCTTTCTT GCGCCGCGAGCGGTAGAACTTTCCGATCCTATGCTATGGGCTGGTTCAGACAGGCTCCCGGAAA AGAGAGAGAATTTGTGGCGGCCATATCTTGGTCCGGTGGGCGGATATACTATGCAGACAGCGTC AAGGGGAGATTCACGATAAGCCGAGATAATGCAAAGAATACGGTATACCTGCAGATGAACTCCC TTAAACCCGAGGACACCGCAGTATATTATTGTGCCGCTGATGATTTTGAGAGGACCATGACGGA AGTACGGTATTGGGGGCAGGGCACTCAAGTCACCGTGTCTTCA (SEQ ID NO: 862); GAGGTGCAACTGGTTGAGAGTGGCGGGGGTCTTGTCCAGCCAGGGGGATCACTTAGGCTGTCAT GTGCGGCTAGCGGCTTTACCTTCAGCGGGTATTACATGAGTTGGGTCCGCCAGGCTCCAGGAAA GGGACTTGAGTGGGTAAGTAGTATATATAGCGATGATTCAAACACTTATTATGCGGATTCAGTT AAGGGTAGATTTACGATTAGCAGAGATAATGCAAAGAACACTGTCTATCTCCAAATGAACAGCC TTAAACCAGAGGACACTGCAGTTTACTATTGTGCAGCAAGCGCGACACTTAGAGGCCGCGATAC CAGGTTCGATTACTGGGGCCAGGGAACACAAGTCACTGTCAGCTCC (SEQ ID NO: 863); GAGGTTCAACTCGTCGAATCCGGAGGGGGATTGGTGCAACCCGGCGGATCACTTAGGCTTTCCT GTAGTGCATCTGGCTTCCCTTTCGACGATTACAGTATGGACTGGGTCAGGCAGGCACCGGGGAA AGGCTTGGAATGGGTGAGTGCCATCAACAGGAACGGGGGATCAACGTATTACGCCGAGTCCATG AAGGGGAGGTTCACGATCAGCCGGGATAATGCCAAAAACACGCTGTATCTCCAGATGTCCAGTC TTAAACCAGAAGATACCGGGGTCTATCTCTGTGCTGCGGGGGGCAGGGTGTCCGCAGATGGTAA GAAATGGGAATATGATTATTGGGGTCAGGGGACCCAAGTTACGGTTTCTAGC (SEQ ID NO: 864); CAACTCCAGCTGGTCGAGTCTGGAGGTGGTTTGGTCCAGGCTGGGGGGAGCCTTCGCCTGTCAT GCGCTGCGAGTGACCCCATCGTTACCTTCAACACTATGGGATGGTATAGACAAGCGCCTGGCAA GCAGAGAGAACTTGTTGCGAGAATTACCATGTCTGGCATTCCCAACTACGCGGATTCCGTAAAA GGGCGGTTTACCATATCCCGAGATAACGCGAAAAATACGCTGTATCTTCAAATGAACTCTTTGA AGCCCGAGGATAGTGCCGTTTACTATTGTCGAGCTGAGCATTCTGGCTATTGGGGGCAGGGAAC TCAGGTTACTGTAAGCAGC (SEQ ID NO: 865); CAACTCCAACTTGTTGAGTCTGGGGGCGGCTTGGTTCAAGCTGGTGGCTCCTTGCGACTCTCTT GCGCCGCTAGCGGGAACATTGTTGATATAGACGACATGGGATGGTATCGCCAGGCACCGGGAAA ACAGCGCGATCTGGTCGCCACCATCACGGCGGGTGGGATTGCCAACTATGCCGATTCAGCGAAA GGGAGGTTTACGATAAGCCGCGACAACGCTAAGAACACAGTGTACCTGCAAATGAACTCTCTCA AACCAGAGGACACTGCAACATATTACTGTTACGCAATCCGGCGGTACTACCCTAGATTCGATTA TTGGGGGCAAGGAGCCCAAGTTACAGTATCCTCC (SEQ ID NO: 866); CAGCTTCAGCTTGTGGAAAGCGGAGGGGGCCTGGTGCAAGCAGGTGGCAGTCTTCGACTCTCAT GTGCGGCGTCAGGACGGACTGTCAGTTCATACGCCATGGGCTGGTTCAGGCAGGCACCGGGCAA AGAAAGGGAGTTTGTCGCGGCCATTAGTTGGTCTGGGGGGAGCACTTACTATGCCGATAGTGTT AAGGGTAGATTTACTATTAGTCGCGATAACGCTAAGAACACCGTTTATTTGCAGATGAACTCAC TTAAACCAGAGGATACAGCAGTGTACTATTGCGCTGCCGACCCCAGCCTGAGTCGCACCATGGA CGAGATAGGCTCCTGGGGTCAAGGAACGCAGGTCACGGTTTCCTCT (SEQ ID NO: 867); CAACTCCAACTTGTGGAATCAGGAGGGGGTCTCGTACAGACAGGAGGATCACTCAACTTGAGTT GTGCCGCCTCTGGAGCTTTTGTGTCTATAGATGCCATGGCGTGGTATCGACAGGCTCCCGGCAA GGCTCGGGAGCTTGTCGCCTTTTCAAGCAGCGGTGGGATAACAAATTATGCGGACAGTGTCAAG GGCCGATTTACCATTACTAGGGATAACGCGAAAAATACTGTTTATCTCCAAATGAATTCCCTTA AACCAGAGGATACGGCTGTGTACTATTGCAACGCAGACATCTTGCAATCAGGTTGGTACACGTA CTGGGGACAAGGAACTCAGGTGACAGTGTCTAGC (SEQ ID NO: 868); CAGTTGCAACTTGTGGAGAGCGGTGGAGGCCTGGTTCGGGCAGGAGGTAGTCTCCGGTTGTCTT GTGTATTGTCAGGGAGGACATTTTCCAGTTACGCGATGGGATGGTTCAGGCAGGCTCCTGGGAA AGAACGAGAATTCGTTTCAACTATTTCTCTGTCCGGCGGATCAACCTTCTATAGCGATTCCGCC AAGGGTCGCTTTACCATAAGTCGGGACAACGCCAAAAACACCGTTTATCTGCAAATGAATAGTC TGAAGCCAGAGGACGCGGCGGTGTACTACTGTGCTGCACGGCCCGTGTTGATTAGTCGCAGTTC CACGGACTACGCTTATTGGGGGCCTGGAACCCAGGTGACCGTCAGCTCT (SEQ ID NO: 869); CAGCTTCAGCTCGTTGAATCTGGGGGAGGCCTGGTTCGCGCTGGAGGCAGCCTTCGCCTCTCCT GCGTGCTTTCAGGACGAACTTTTTCAAGCTATGCGATGGGTTGGTTTAGGCAGGCGCCTGGAAA AGAGCGGGAATTTGTCAGTACGATAAGCCTTAGCGGGGGTAGTACATTTTACTCAGATAGCGCG AAAGGCCGATTTACTATATCCCGAGATAATGCGAAAAATACGGTCTATTTGCAGATGAATAGTC TGAAACCAGAGGATACTGCCGTCTATTACTGCGCTGCGAGGCCCGTACTTATTTCCCGGAGCTC CATAGACTATGCTTACTGGGGTCCGGGCACACAGGTAACGGTCTCCAGT (SEQ ID NO: 870); CAGGTCCAACTTCAGGAAAGCGGTGGGGGTTTGGTACAGGCAGGAGAAACGCTGGGACTTAGTT GCGTACACAGTGGACGCGCGTTCTCAGGCCATGGTATGGGGTGGTTTCGCCAGGCCCCTGGAAA AGAAAGGGAGTTTGTGGCGGCTATAAGTTGGTCAGGCGTCTCAACTGCCTATGCCGACTCTGTA AAAGGTCGATTCACCATCTCTAGAGTGAACGCTGACAACACGGTGTCACTTCAAATGAATAGTC TGAAACCCGAGGACACAGCCGTTTACTTCTGCGCGGCGGGCCTCTACTCTCGACCAACCACTGA ACGCAGGGAATACATATACTGGGGTCAGGGAACTCAGGTAACAGTTAGCAGC (SEQ ID NO: CAAGTACAGCTGCAAGAGAGTGGGGGCGGGCTCGTCCAAGCCGGGGGATCTTTGCGGCTCAGTT GCGCGGCCTCTGGTAATTCCGTTGACATTGACGACATGGGATGGTACCGACAGGCTCCTGGCAA GCAACGAGATTTGGTCGCGACTATCACCGCAGGAGGCATCACCAAGTATGGTGACTCTGCGAAA GGCAGGTTCACAATAAGCAGAGATAACGTGAAGAATACCGTGTACTTGCAGATGAATAGCCTGA AGCCTGAGGACACCGCAACCTACTACTGTTATGCCGTCCGGCGCTATTACCCACGCTTCGACTA TTGGGGCCAGGGTACGCAAGTAACAGTAAGTAGT (SEQ ID NO: 872); CAGGTTCAGTTGCAAGAAAGCGGGGGAGGCCTCGTTCAGCCGGGTGGCTCATTGAGGTTGTCAT GCGCCGCTTCAGGTTCTATATTCTCTATGAACGCGATGGGATGGTATAGACAAGCCCCCGGCAA ACAACGCGAACTTGTGGCGACTATTACAGATAATGACTTTACTTACTATGCAGCCTCCGTGAAA GATCGGTTTACAATTTCTCGGGGGAACGCCAAGAACACTGTGTATCTTCAGATGAACAGTCTGA CGCCTGAAGATACGGCGGTCTACTATTGCAATGCGGATGGCATCTACTCCGGTGGAAGATATTA CCCATCTTCATGGGGACAGGGTACACAAGTCACAGTAAGCAGC (SEQ ID NO: 873); CAGGTACAGCTTCAGGAATCTGGCGGTGGCCTGGTCCAGCCAGGAGGAAGCCTGAGATTGAGCT GTGCGGCATCCGGCAGCATTTTTTCTGTAAATGATATGGGCTGGTACAGACAGGCTCCAGGGAA GCAACGCGAATTGGTGGCGGCCTCATACTCTGGTGGGTCAACGAATTATGCCGATAGTGTTAAG GGACGGTTTACGATTAGCAGGGATAATGCAAAAAACACTGTGTATTTGCAAATGAATTCTCTTC TCCCCGAAGATACAGCTGTGTATTATTGTAATGCCGATTTGGTCGTAGTTACGACTACGCCGCC TAGTTTCCCCATGCCGTACCGATTCCTTGAGGTGTGGGGTCAGGGTACGCTGGTTACCGTCAGC AGC (SEQ ID NO: 874); CAAGTACAACTTGTAGAATCTGGAGGGGGTCTCGTACACGCGGGCGGTTCTCTCCGCCTTTCTT GCGCTGCCAGTGGAAGGACATTCAACACGATGGCATGGTTCCGCCAAGCACCAGGAAAAGAGCG AGAATTTGTCGCGGCTATATCATGGTCCGGAGGTCTCACTTATTACGCGGACTCCGTGAAGGGG CGATTCACCATTTTTCGGGACAATGCGAAGGGTCTGGCCTACCTCCAAATGGATTCATTGAAGC CAGAAGATACGGCAGTGTACTCATGCGCCGCGAGAAGGACCTTCAGAACAGCGCTGATTAACAC TGTAACGGCTTACGACACCTGGGGCCAGGGAACTCAGGTCACTGTCTCAAGT (SEQ ID NO: 875); CAAGTTCAACTGGTTGAATCCGGGGGCGGGCTGGTGCATGCGGGCGGTTCTCTTCGACTCTCTT GCGCCGCCTCAGGTAGAACCTTCAATACGATGGCTTGGTTTCGGCAAGCACCGGGTAAGGAGCG GGAGTTCGTGGCGGCAATTAGCTGGTCAGGTGGACTGACCTATTACGGAGATTCTGTGAAGGGC CGCTTCACTATATTCCGGGACAATGCGAAGAATCTGGCGTATCTTCAAATGAACTCACTGAAGC CCGAGGACACTGCTGTGTACTCCTGCGCTGCTCGAAGGACTTTCAGGACGGGACTTATAGATAC GGTTACAGCGTACGATACTTGGGGGCAGGGAACCCAGGTTACGGTTTCTAGC (SEQ ID NO: 876); CAGGTCCAGCTTGTGGAATCCGGCGGCGGGTTGGTGCAAGCCGGTGATAGCCTGCGCCTTTCTT GCGCGGCTGCTAGTGGGCGCGCTTTGAGCGGCTGGCAAATGGGTTGGTATCGGCAGGCGCCGGG GAAGGAAAGAGAGTTTGTTGCATCCATTTCCATGTCCGATGGGAGTACTAGCTACCAAGATTCT GTCAAGGGGAGATTTACGATCAGCCGCGACAATGCACTTAGTACAATGTCTTTGAGAATGAACA GTCTTAAATCCGAGGACACTGCTATTTACTACTGCCAGGGGCGGTCTAGGTTCGGGTTTGAGTA TTGGGGTCAAGGCACTCAAGTCACAGTCTCTAGT (SEQ ID NO: 877); CAGGTACAACTCGTAGAAAGCGGTGGGGGCCTTGTTCAGGCAGGGGAGAGCCTCCGGTTGTCTT GCGTCGCTAGCGGTCGAGCCTTGTCAGGACACGGTATGGGGTGGTTCCGACAAGCGCCAGGGAA GGAAAGAGAGTTCGTAGCTGCTATCAGTTGGAGTGGGGTGTCAACTGCTTACGCAGACTCCGTA AAAGGTCGCTTCACGATCAGTAGGGTTAATGCGGAAAACACAGTGTCTGTATCCTTGCAGATGA ACTCACTGAAGCCAGATGATACAGCAGTCTATTTCTGCGCCGCTGGGTTGTATTCCCGCCCGAC AACGGAGCGACGCGACTACATATACTGGGGACAGGGAACACAGGTTACCGTGAGCAGC (SEQ ID NO: 878); CAGGTGCAACTGGTAGAAAGTGGCGGGGGCCTGGTACAAGCGGGAGGCAGCTTGCGGCTCTCTT GCGCGGCGGCGTCCCACACGTTCGATTCTTATACGATGGGTTGGTTCCGACAGGCTCCGGGAAA AGAAAGGGAGTTCGTGGCTGCTGTGAATTGGGATAATGTGAAGAACTACGCAGATCCGGTTAAA GGGCGGTTCACAATCTCTCGAGACAATGTGAAAAACCGCGTGTATTTGCAGATGAATAGCTTGA AACCCGAAGATACGGCAGTCTACTATTGTGCGGCAGGTACCAATCTGCCGACGAGAGGAAGCGG ATCTTGGGGGCAGGGTACACAAGTTACTGTCTCAAGT (SEQ ID NO: 879); CAAGTCCAACTCGTCGAGTCAGGAGGTGGGCTCGTTCAGGCAGGCGGGAGCCTGAGGTTGAGTT GTGCCGCCGCAAGTCTTACCTTTGATTCATATACTATGGGATGGTTTAGACAGGCGCCAGGTAA AGAAAGAGAGTTCGTAGCAGCAGTTAACTGGGACAACGTAAAGAATTATGCAGATCCAGTAAAG GGTCGCTTTACCATCTCAAGAGATAATGTCAAAAATACGGTGTACCTCCAAATGAACAGTCTGA AGCCTGAGGATACAGCCGTATACTATTGCGCCGCCGGGACCAACCTCCCCACTATAGAGTCAGG GAGTTGGGGGCAGGGCACTCAAGTAACTGTGAGTAGT (SEQ ID NO: 880); CAAGTACAACTTGTTGAGAGCGGGGGAGGATTGGTGCAGGCCGGAGGTTCCCTCCGGCTGTCCT GCGCTGCGTCAGGAAATGGGGTAGATATAGACGACATGGGTTGGTACAGACAGGCACCCGGCAA ACAAAGGGACCTGGTAGCATCTATTACTGCTGGAGGAATTACTAAATACGCCGATTCTGCAAAA GGACGGTTTACGATCAGTCGGGACAACGTAAAGAACACTGTTTACCTCCAGATGAATTCCCTGA AGCCGGAGGACACAGCGACTTACTATTGTTACGCTATCAGACGATTCTACCCTCGCTTCGACTA CTGGGGCCAGGGTACGCAGGTTACGGTTTCATCT (SEQ ID NO: 881); CAGGTACAGCTCGTCGAATCCGGGGGAGGCTTGGTCCAGGCGGGCGGAAGTCTTAGATTGTCTT GTGCCGCATCTGGGAACGGCGTTGATATTGACGATATGGGGTGGTATCGACAGGCGCCCGGTAA GCAGCGCGATCTGGTTGCCAGCATCACGGCAGGAGGAATCACTAATTATGCGGATAGTGCCAAA GGAAGGTTTACCATCTCTCGGGACAACGTCAAAAATACAGTATATCTTCAGATGAACTCCCTTA AACCAGAGGATACTGCGACCTATTATTGCTACGCAATACGCCGGTTTTACCCTCGGTTTGACTA CTGGGGTCAAGGGACGCAGGTGACAGTATCATCA (SEQ ID NO: 882); CAGGTTCAACTGGTCGAGTCCGGTGGAGGCTTGGTGCAAGCGGGTGGTAGTCTGCGGCTGAGCT GCGCTGCTAGTGGTAACGGTGTCGACATCGACGACATGGGATGGTACAGACAGGCACCAGGGAA GCAGAGGGACCTTGTTGCTACAATCACAGCCGGCGGGATAACCAAATACGCAGATTCTGCAAAG GGTCGGTTTACAATTTCACGAGATAATGTAAAGAATACCGTCTATTTGCAGATGAACAGCCTTA AACCCGAAGATACTGCCACATATTATTGTTACGCCATAAGGCGATTCTATCCCCGCTTCGACTA TTGGGGTCAGGGGACTCAAGTTACTGTTAGCTCC (SEQ ID NO: 883); CAGGTGCAACTCGTTGAAAGCGGGGGAGGACTCGTGCAAGCGGGAGGATCACTCCGACTGAGTT GTGCTGCTTCAGGGAATGGCGTTGATATAGACGACATGGGTTGGTATCGACAGGCACCCGGAAA GCAACGGGATTTGGTCGCGACTATTACAGCGGGGGGTATTACTAACTATGCGGATAGCGCCAAG GGGCGATTCACTATCTCACGCGATAACGTGAAAAACACCGTATATCTTCAGATGAACAGTTTGA AACCAGAAGACACCGGTACATACTATTGTTACGCTATCAGAAAATTTTACCCCAGATTTGATTA CTGGGGGCAGGGAACGCAGGTTACGGTCAGTAGC (SEQ ID NO: 884); CAGGTCCAGCTGGTTGAAAGCGGTGGGGGGCTGGTCCAAGCCGGCGGTTCTCTTAGACTTAGCT GCGCCGCGTCTGGTAACATTGTTGACATCGACGACATGGGGTGGTATAGGCAGGCTCCAGGTAA ACAACGAGATTTGGTTGCCTCAATCACAGCGGGGGGTATAACCAAATATGCAGATTCAGCTAAG GGACGATTCACCATTAGCCGAGACAATGTAAAGAACACTGTTAGTTTGCAGATGAACTCACTGA AACCTGAAGATACGGCGACATATTATTGTTATGCAGTTAGAAAGTATTACCCCAGATTTGACTA TTGGGGCCAAGGCACTCAAGTGACCGTATCCTCT (SEQ ID NO: 885); CAGGTCCAGTTGGTGGAGAGCGGCGGTGGGTTGGTTCAGGCGGGAGGGTCTCTCAGGCTGAGCT GTGCTGCAAGTGGGAATATCGTCGACATCGACGATATGGGTTGGTACCGCCAAGCACCTGGGAA GCAACGAGATTTGGTTGCATCTATAACCGCAGGCAGAATAACCAAATATGCTGATAGCGCGAAA GGAAGGTTTACAATATCTAGGGATAATGTTAAAAATACCGTTTATCTCCAGATGAACTCACTGA AGCCAGAAGATACCGCGACTTATTACTGTTACGCAATAAGGCGGTCATACCCAAGGTTCGACTA CTGGGGACAGGGGACACAGGTCACAGTGTCAAGC (SEQ ID NO: 886); CAGGTACAACTTGTCGAATCAGGTGGAGGACTCGTGCAGGCTGGGGGGTCCCTGCGCTTGAGTT GCGCCGCTAGTGGTAGGACATTTTCCAATTACGCCATGGGTTGGTTTAGACAAGCTCCTGGGAA GGAGCGCGAATTCGTGGCTGCAATTAACTGGTCCGGCGGACGCATTTACTATACAGACTCCGTG AAAGGTCGATTTACAATCAGTAGAGACAACGCCAAGAATACGGTTTATCTTCAGATGAACAGTC TTAAACCGGAAGATACTGCCGTGTACTATTGCGCTGCGGGGACGAATTGGTCAATACCACCTGA TTACTGGGGTCAGGGGACGCAGGTAACCGTGAGCTCC (SEQ ID NO: 887); CAAGTACAGCTCGTGGAGTCAGGTGGTGGACTCGTTCAGGCGGGTGGTTCCCTTAGGTTGTCCT GTGCTGCGTCAGGTCGCACGTTCAGCTCCTATGCTATGGGCTGGTTCAGGCAGGCACCGGGGAA GGAGCGAGAATTTGTAGCGGCAATACGATGGAGTGGAGGCTCTACTTATTACGGAGATAGTGTT AAAGGGAGGTTCACTATTTCTAGAGATAATGCGAAAAACACCGTGTATCTCCAAATGAACAGCC TCAAACCTGAAGATACGGCAGTCTACTACTGTGCGGCTGACCCCATTGGCCTCGGATACGAAAT GGGAGAGTATGATTACTGGGGTCAAGGTACGCAGGTTACTGTATCAAGT (SEQ ID NO: 888); CAGGTACAGCTTGTCGAAAGCGGGGGCGGTCTGGTTCAGGCCGGTGGAAGTTTGAGGCTCAGTT GTGCAGCGAGCGGGAGAACCTTCTCCAGTTACGCGATGGGGTGGTTCCGACAGGCGCCAGGGAA GGAGAGAGAATTCGTGGCAGCAATCTCATGGTCCGGCGGAAGCATTTATTATGCGGACTCTGTA AAGGGGCGATTTACAATATCCCGAGACAACGCGAAGAACACAGTATCCCTCCAAATGAATAGCC TGAAGCCTGAAGACACGGCTGTGTACTATTGTGCCGCAGACGGAACGCTCCGCACGCCCATGAA CCTTATTCATTATTGGGGGCAGGGAACCCAAGTGACTGTATCTTCT (SEQ ID NO: 889); CAAGTCCAACTGGTAGAGAGTGGCGGTGGGCTCGTCCAAGCCGGGGGCTCTCTCAGGTTGTCCT GTGCCGCGTCCGGCAGGACCTTCTCAAGTTATGCGATGGGATGGTTCCGACAGGCACCAGGAAA AGAGAGGGAGTTTGTCGCAGCTATTTCATGGTCTGGCGGTAGCACGTATTATGCCAATAGCGTG AAAGGGCGGTTCACGATTAGTCGGGACAATGCGAAAAACACCGTTTATCTGCAAATGAATTCCC TGAAGCCTGAGGACACCGCTGTGTACTACTGCGCTCCTGGCGAAGAAGTAGCAGGCAAGTATTT CCGCCAACTCTATGACTACTGGGGGCAGGGCACACAAGTTACAGTGAGTTCC (SEQ ID NO: 890); CAAGTTCAACTTGTTGAGTCCGGGGGTGGCCTCGTCCAAGCAGGAGGGTCCCTCCGGCTGTCAT GCGCGGCTAGCGGTCGGACATTTAGCAGTTATGCGATGGGGTGGTTCCGGCAAGCACCAGGTAA GGAAAGGGAGTTTGTGGCAGACATTTCATGGAGTGGAGGTACGACAAATTATGCAAACAGCGTT AAGGGGCGCTTTACGATTTCCCGAGACAATGCAAAAAACACAGTATATCTGCAGATGAACTCAC TCAAGCCGGAAGATACGGCGGTTTACTACTGTGCGCCTGGAGAAGAAGTGGACGGCAAATATTT CCGCCCTCTCTATGATTACTGGGGGCAGGGAACTCAGGTAACCGTAAGCAGT (SEQ ID NO: 891); CAGGTACAACTGGTGGAATCAGGTGGGGGGTTGGTCCAGGCTGGAGGATCATTGCGACTCAGTT GCGCCGCATCAGGGCGAACTTTTTCTACCTATACGATGGGATGGTTTCGGCAAGCCCCCGGTAA AGAACGACAGTTTGTCGCAGCCATTAGTTCCTCAGGAGACTCAACCTACTACACTGATTCCGTG AAAGGCCGGTTTACCATTTCCAGAGATAATGCCAAGAACACTGTTTATCTGCAGATGGACAGCC TGAAGCCCGAGGACACAGCGGTGTATTACTGCGCACCGGGTGAAGAAGTAGCTGGAAAATACTT CCGCGCACTGTATGATTACTGGGGCCAGGGCACTCAAGTTACCGTCTCTAGT (SEQ ID NO: 892); CAAGTCCAGCTTGTAGAAAGCGGTGGCGGTCTCGTTCAAGCCGGTGGAAGCCTCCGGCTTTCAT GTGCGGCATCAGGTTCAATTTTCTCCATTAACGCGATGGCATGGTATAGGCAAGCCCCTGGTAA GCAGCGCGAGCTCGTGGCTGTTATCACATCAGGAGGGAGTACTAACTACGCGGATTCTGTTAAA GGAAGATTTACCATTTCCCGCGATAATGCTAAGAATACAGTCTACCTCCAAATGAACTCCCTGA AGCCTGAAGACACTGCCGTGTATTATTGCAATGCTGATCTGGTCTACTACTCAGGCAATCCTGG AGACTATGGTATGGACTACTGGGGAAAGGGGACATTGGTGACTGTCAGTAGT (SEQ ID NO: 893); CAGGTTCAGTTGGTAGAATCCGGCGGTGGATTGGTGCAGGCTGGAGGGTCCTTGAGACTTTCCT GTGTTGCGAGCGGGAGGACGTTTTCAATCAATAACATTAACTGGTATAGACAGGCCCCTGGCAA GGAGCGAGAGTTCGTTGCCACTACCAGATGGCGGGGAGACAGCACTTACTACGCTGACTCTGTG GCCGGTCGATTTACCATATCAAGAGACTCAGCTAAAAATACCGTGTACCTCCAAATGAACTCAC TGAAACCAGAGGATACTGCTATATACTATTGCAATGCTAAGGGCGGCGTTGATGTCTGGGGTCA AGGAACCCAGGTAACGGTTTCCAGT (SEQ ID NO: 894); CAGGTACAGCTTGTTGAGTCCGGCGGGGGTCTCGTACAGCCGGGCGGCTCCTTGCGCCTCAGTT GTGCGGCGAGTGGATTCTTGTTCTCACTCTACGCTATGGCATGGGTCCGGCAAGCCCCAGGCAA AGGTCTGGAGTGGGTAAGTGATATAAGCAACGGAGGTGTTACCACAAGATACGCGGATTCAGTA AAAGGCCGGTTTACAATTTCACGAGATAATGCGAAAAATACGTTGTATCTTCAAATGGATAGTC TGACGCCGGGGGATACTGCGGTCTATTACTGTGCTGTTACAACCACGGGCTGGCGGGCAAGAGG CCAAGGGACCCAAGTGACTGTCTCCTCC (SEQ ID NO: 895); CAGGTCCAACTTGTTGAATCAGGCGGAGGACTCGTTCAGCCTGGAGGCAGCCTGAGGCTTTCTT GCGCCGCTTCAGGAAGCATATTCAGACCAAACGACATGGGCTGGTACCGACAGGCGCCCGGTAA ACAAAGGGAACTCGTGGCAATCATAACGGACGGGGGTATCACAAATTACGCTGCAACGGTAAAG GGGAGGTTTACGATTAGTCGAGACAATGCCAAAAATACAGTGTACCTTCAAATGAACAGCCTCA AACCGGAGGACACGGCGGTTTATTATTGCAACCTTAATATCCCGTACCCTCGCGTTTCCTCATG GGGCCAGGGAACGCAGGTCACAGTCTCATCT (SEQ ID NO: 896); CAGGTGCAGCTCGTCGAGTCTGGGGGAGGCCTTGTCCAGCCTGGTGGCTCCCTTCGCCTGAGTT GTGCAGCATCTGGGAGTACATTTAACACCATGGCCTGGTTCCGGCAAGCGCCGGGAAAGGAGCG CGAATTCGTGGCGGCCATATCATGGAGCGGCGGATTGACCTATTATGGTGATTCCGTCAAGGGA AGATTCACCATATTCAGGGATAACGCGAAGAATTTGGGCTATCTCCAGATGAATTCCCTTAAAC CGGAAGATACTGCGGTATATAGTTGCGCCGCGAGGACAACTTTCCGAACCGGTTTGATCGTAAC CGTAACAGCCTATGATACATGGGGTCAAGGTACACAAGTGACAGTCAGTTCC (SEQ ID NO: 897); CAGGTGCAGTTGGTAGAGTCCGGAGGAGGTCTCGTGCAGCCCGGAGGTTCACTCAGACTTTCAT GTGTGTTGAGTGGGCGGACGTTTTCTAGTTATGCAATGGGATGGTTCCGGCAAGCGCCGGGCAA AGAAAGAGAGTTCGTGAGTACAATCTCCTTGTCCGGGGGAAGCACATTTTACTCAGGGAGTGCG AAAGGGCGGTTCACGATAAGTAGAGATAACGCCAAAAACACCGTTTATCTCCAGATGAACTCCT TGAAGCCTGAAGACACTGCGGTGTACTACTGCGCTGCACGACCTGTTCTTATTAGCCGGAGCTC AACAGACTACGCCTATTGGGGTCCGGGAACTCAAGTTACAGTTAGCTCA (SEQ ID NO: 898); CAGGTTCAACTCGTTGAGTCCGGCGGCGGCCTTGTCCAACCTGGTGGGAGTTTGCGGTTGTCCT GTGTACTTAGCGGCAGAACCTTTAGCTCATACGCGATGGGATGGTTTCGCCAAGCGCCGGGTAA AGAGCGAGAGTTCGTATCAACTATCAGCTTGTCTGGCGGATCAACGTTCTATAGCGGTTCTGCC AAAGGACGGTTCACCATTTCAAGAGACAATGCGAAAAACACTGTATATCTGCAGATGAATAGTC TCAAACCTGAGGACACTGCCGTCTACTATTGTGCTGCTCGGCCAGTTTTGATAAGCCGAAGTAG CACCGATTATGCCTACTGGGGACCTGGTACTCAGGTGACCGTTTCCAGT (SEQ ID NO: 899); CAGGTGCAACTCGTAGAAAGCGGGGGTGGGTTGGTTCAAACCGGTGGCTCATTGCGATTGTCCT GCGCGGCATCTGGAAGAACGTTTAGTTCTTATGCGATGGGTTGGTTTAGGCAGGCTCCTGGAAA GGAACGGGAATTTGTCGCCGCAATCACCTGGTCAGGTGGATCCACCTATTACGCAAACAGTGTA AAGGGGCGCTTTACAATCTCTCGGGACAACGCTAAAAATACAGTGGATTTGCAAATGAACAGTC TCAAGCCCGAGGACACAGCAGTCTATTATTGCACTCCTGGAGAAGAAGTAGCCGGTAAGTATTT TAGACCTCTGTATGATTATTGGGGGCAAGGGACGCAAGTTACCGTTTCATCA (SEQ ID NO: 900); CAGGTTCAGTTGGTTGAATCTGGAGGTGGTCTCGTACAGGTCGGCGGGTCATTGCGGCTGTCCT GCTCTATTAGCAGGAGCATTGCAATTTTTAATTTTATGGCCTGGTATAGGGAGGCCGAAGGGAA GCAGCGGGAACTCGTCGCCTCCATCACTGGCGGGAGTCGACTGTCATATATTGATAGTGTTAAG GGACGCTTCACGGTCAGTAAGGACACAGCTAACAATACACTCGATCTCCAAATGAACTCCCTGC GACCAGAGGACACCGCCGTGTATCGATGCGCGGCGTCTAGTCCGTTTGCTGGTGAGTTCTGGGG CCAAGGGACCCAGGTAACTGTGTCTTCA (SEQ ID NO: 901); CAGGTGCAGCTGGTGGAATCAGGGGGACGCTTGGTTCAAGCAGGGGGTAGCCTTAGGTTGTCTT GTGCGGCAAGTGGGCGGACGTTTAATACAATGGCCTGGTTTCGACAGGCACCTGGAAAGGAAAG GGAATTTGTAGCTGCCATCACCTGGTCCGGGGGGTTGACATACTACGAGGATAGCGTAAAAGGG AGGTTTACAATTTTTCGAGACAACGCAAAAAATTTGGCATACCTTCAGCTCAACTCATTGAAAC CCGAGGATACAGCTGTATATTCTTGTGCCGCCCGATCAACTTTTAGGACTGCCCTGGTTAATAC TGTTACGGCGTATGACACTTGGGGACAAGGCACCCAAGTGACGGTAAGCTCA (SEQ ID NO: 902); CAGGTGCAACTGGTTGAGTCCGGCGGTGGCTTGGTACAGCCCGGCGGCAGTCTCCGACTTAGTT GTACGGCGTCAGGTCGCACAATTGCGAGCACGATTATGGGCTGGTACAGACAAACGCCCGGCAA AGAACGGGAATTTGTCGCTATCAGCGCTAGGAGCGGCGATTCCGAATCCTATGCAAGTTCAGTG AAGGATAGGTTTACCATCAGTCGCGATAATGCGAAAAATACCGTCTACCTCCAGATGAACAATT TGAAACCTGAGGACACTGCTATATATTACTGCTACTGGAATACGGGAGCAGGAACCATCTGGGG GCAGGGAACACAAGTGACTGTCTCTTCC (SEQ ID NO: 903); and CAAGTTCAATTGGTAGAGTCCGGTGGAGGACTGGTCCAACCGGGAGGGTCTTTGCGGTTGTCAT GCGCCGCCTCTGGCAGCATTTTTTCTGTGAATGATATGGGTTGGTATCGACAAGCGCCTGGTAA GCAACGGGAACTCGTAGCCGCGATATATTCCGGTGGCTCTACAAATTACGCGGATAGTGTAAAA GGCCGGTTTACCATCTCCCGAGATAATGCTAAGAATACCGTCTATCTTCAAATGAACAGCTTGA AGCCCGAGGACACAGCAGTGTATTATTGCAACGCCGACATTGTAGTGGTCACGACTACCCCTCC GAGTTTCCCTATGCCCTATCGGTTCTTGGAGGTATGGGGTCAGGGAACGCTTGTTACTGTAAGT TCT (SEQ ID NO: 961). In any aspect or embodiment of the disclosure, the lipid nanoparticle is conjugated to the VHH antibody. In any aspect or embodiment of the disclosure, the VHH antibody is covalently bound to a polyethylene glycol (PEG) molecule of the lipid nanoparticle. In any aspect or embodiment of the disclosure, the VHH antibody is covalently bound to a PEG portion of a PEG-modified lipid of the lipid nanoparticle. In any aspect or embodiment of the disclosure, the lipid nanoparticle contains a polynucleotide encoding a chimeric antigen receptor. In any or embodiment of the disclosure, the chimeric antigen receptor contains an antigen binding domain capable of binding a marker associated with a neoplasia. In any aspect or embodiment of the disclosure, the lipid nanoparticle further contains a base editor system. The base editor system contains a base editor, or a polynucleotide encoding the base editor, and a guide RNA, or a polynucleotide encoding the guide RNA. The guide RNA directs the base editor to deaminate a nucleobase in a target polynucleotide. In any aspect or embodiment of the disclosure, the carrier or excipient is a pharmaceutical carrier or excipient. In any aspect or embodiment of the disclosure, the disease is a neoplasia. In any aspect or embodiment of the disclosure, the neoplasia is a B cell lymphoma or a T cell lymphoma. In any aspect or embodiment of the disclosure, the T cell lymphoma is a B-cell acute lymphoblastic leukemia. In any aspect or embodiment of the disclosure, the method is not a process for modifying the germline identity of human beings. Definitions Unless defined otherwise, all technical and scientific terms used herein have the meaning commonly understood by a person skilled in the art to which this disclosure belongs. The following references provide one of skill with a general definition of many of the terms used in this disclosure: Singleton et al., Dictionary of Microbiology and Molecular Biology (2nd ed. 1994); The Cambridge Dictionary of Science and Technology (Walker ed., 1988); The Glossary of Genetics, 5th Ed., R. Rieger et al. (eds.), Springer Verlag (1991); and Hale & Marham, The Harper Collins Dictionary of Biology (1991). As used herein, the following terms have the meanings ascribed to them below, unless specified otherwise. By “4-1BB (4-1BB) polypeptide” is meant a polypeptide having at least about 85% amino acid sequence identity to the following amino acid sequence, or a fragment thereof having immunomodulatory activity: KRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCEL (SEQ ID NO: 764. By “4-1BB (4-1BB) polynucleotide” is meant a polynucleotide encoding a 4-1BB polypeptide, as well as the introns, exons, 3′ untranslated regions, 5′ untranslated regions, and regulatory sequences associated with its expression, or fragments thereof. In embodiments, a 4- 1BB polynucleotide is the genomic sequence, cDNA, mRNA, or gene associated with and / or required for 4-1BB expression. An exemplary 4-1BB nucleic acid sequence is provided below. AAGCGGGGCCGGAAGAAGCTGCTGTACATCTTCAAGCAGCCCTTCATGCGCCCCGTGCAGACCA CCCAGGAGGAGGACGGCTGCAGCTGCAGGTTCCCCGAGGAGGAGGAGGGGGGCTGCGAGCTG (SEQ ID NO: 765. By “adenine” or “ 9H-Purin-6-amine” is meant a purine nucleobase with the molecular formula C5H5N5, having the structure , and corresponding to CAS No.73- . By “adenosine” or “ 4-Amino-1-[(2R,3R,4S,5R)-3,4-dihydroxy-5- (hydroxymethyl)oxolan-2-yl]pyrimidin-2(1H)-one” is meant an adenine molecule attached to a ribose sugar via a glycosidic bond, having the structure corresponding to CAS No.65-46-3. Its molecular formula is C10H13N5O4. By “adenosine deaminase” or “adenine deaminase” is meant a polypeptide or fragment thereof capable of catalyzing the hydrolytic deamination of adenine or adenosine. In some embodiments, the deaminase or deaminase domain is an adenosine deaminase catalyzing the hydrolytic deamination of adenosine to inosine or deoxy adenosine to deoxyinosine. In some embodiments, the adenosine deaminase catalyzes the hydrolytic deamination of adenine or adenosine in deoxyribonucleic acid (DNA). The adenosine deaminases (e.g., engineered adenosine deaminases, evolved adenosine deaminases) provided herein may be from any organism (e.g., eukaryotic, prokaryotic), including but not limited to algae, bacteria, fungi, plants, invertebrates (e.g., insects), and vertebrates (e.g., amphibians, mammals). In some embodiments, the adenosine deaminase is an adenosine deaminase variant with one or more alterations and is capable of deaminating both adenine and cytosine in a target polynucleotide (e.g., DNA, RNA) and may be referred to as a “dual deaminase”. Non-limiting examples of dual deaminases include those described in PCT / US22 / 22050. In some embodiments, the target polynucleotide is single or double stranded. In some embodiments, the adenosine deaminase variant is capable of deaminating both adenine and cytosine in DNA. In some embodiments, the adenosine deaminase variant is capable of deaminating both adenine and cytosine in single- stranded DNA. In some embodiments, the adenosine deaminase variant is capable of deaminating both adenine and cytosine in RNA. In embodiments, the adenosine deaminase variant is selected from those described in PCT / US2020 / 018192, PCT / US2020 / 049975, PCT / US2017 / 045381, and PCT / US2020 / 028568, the full contents of which are each incorporated herein by reference in their entireties for all purposes. By “adenosine deaminase activity” is meant catalyzing the deamination of adenine or adenosine to guanine in a polynucleotide. By “Adenosine Base Editor (ABE)” is meant a base editor comprising an adenosine deaminase. By “Adenosine Base Editor (ABE) polynucleotide” is meant a polynucleotide encoding an ABE. By “Adenosine Base Editor 8 (ABE8) polypeptide” or “ABE8” is meant a base editor as defined herein comprising an adenosine deaminase or adenosine deaminase variant comprising one or more of the alterations listed in Table 4, one of the combinations of alterations listed in Table 4, or an alteration at one or more of the amino acid positions listed in Table 4, such alterations are relative to the following reference sequence: MSEVEFSHEYWMRHALTLAKRARDEREVPVGAVLVLNNRVIGEGWNRAIGLHDPTAHAEIMALR QGGLVMQNYRLIDATLYVTFEPCVMCAGAMIHSRIGRVVFGVRNAKTGAAGSLMDVLHYPGMNH RVEITEGILADECAALLCYFFRMPRQVFNAQKKAQSSTD (SEQ ID NO: 1), or a corresponding position in another adenosine deaminase. In embodiments, ABE8 comprises alterations at amino acids 82 and / or 166 of SEQ ID NO: 1. In some embodiments, ABE8 comprises further alterations, as described herein, relative to the reference sequence. By “Adenosine Base Editor 8 (ABE8) polynucleotide” is meant a polynucleotide encoding an ABE8 polypeptide. “Administering” is referred to herein as providing one or more compositions described herein to a patient or a subject. By way of example and without limitation, composition administration (e.g., injection) can be performed by intravenous (i.v.) injection, sub-cutaneous (s.c.) injection, intradermal (i.d.) injection, intraperitoneal (i.p.) injection, or intramuscular (i.m.) injection. One or more such routes can be employed. Parenteral administration can be, for example, by bolus injection or by gradual perfusion over time. In some embodiments, parenteral administration includes infusing or injecting intravascularly, intravenously, intramuscularly, intraarterially, intrathecally, intratumorally, intradermally, intraperitoneally, transtracheally, subcutaneously, subcuticularly, intraarticularly, subcapsularly, subarachnoidly and intrasternally. Alternatively, or concurrently, administration can be by the oral route. By “agent” is meant any small molecule chemical compound, antibody, nucleic acid molecule, or polypeptide, or fragments thereof. “Allogeneic,” as used herein, refers to cells that are genetically dissimilar and immunologically incompatible. In embodiments, allogeneic cells are administered to a genetically dissimilar and immunologically incompatible subject. In some embodiments, the allogeneic cells comprise modifications improving their persistence in the subject allogeneic to the cells. By “alteration” is meant a change in the level, structure, or activity of an analyte, gene or polypeptide as detected by standard art known methods, such as those described herein. As used herein, an alteration includes a change (e.g., increase or reduction) in expression levels. In embodiments, the increase or reduction in expression levels is by 10%, 25%, 40%, 50% or greater. In some embodiments, an alteration (e.g., in structure) includes an insertion, deletion, or substitution of a nucleobase or amino acid (e.g., by genetic engineering). By “ameliorate” is meant reduce, suppress, attenuate, diminish, arrest, or stabilize the development or progression of a disease. By “analog” is meant a molecule that is not identical but has analogous functional or structural features. For example, a polypeptide analog retains the biological activity of a corresponding naturally-occurring polypeptide, while having certain biochemical modifications that enhance the analog’s function relative to a naturally occurring polypeptide. Such biochemical modifications could increase the analog’s protease resistance, membrane permeability, or half-life, without altering, for example, ligand binding. An analog may include an unnatural amino acid. By “anionic lipid” is meant a lipid species that carries a net negative charge at a selected pH. As used herein, the term "antibody" or “antigen-binding domain” refers to an immunoglobulin molecule, a single-domain antibody (sdAb), or a fragment thereof that specifically binds to, or is immunologically reactive with, a particular antigen. Non-limiting examples of antibodies or antigen-binding domains include VHH antibodies, polyclonal, monoclonal, genetically engineered and otherwise modified forms of antibodies, including but not limited to chimeric antibodies, humanized antibodies, heteroconjugate antibodies (e.g., bi- tri- and quad-specific antibodies, diabodies, triabodies, and tetrabodies), and antigen-binding fragments of antibodies, including e.g., Fab', F(ab')2, Fab, Fv, rlgG, and scFv fragments, as well as engineered antibodies, which include CrossMabs (e.g., CrossMabFabs, CrossMabCH1-CLand CrossMabVH-VLformats), or fragments thereof. Moreover, unless otherwise indicated, the term "monoclonal antibody" (mAb) is meant to include both intact molecules, as well as antibody fragments (such as, for example, Fab and F(ab')2 fragments) that are capable of specifically binding to a target protein. Fab and F(ab')2fragments lack the Fc fragment of an intact antibody, clear more rapidly from the circulation of the animal, and may have less non-specific tissue binding than an intact antibody (see Wahl et al., J. Nucl. Med.24:316, 1983; incorporated herein by reference). Antibody structure is well known in the art. Briefly, the variable (V) regions or domains of antibody heavy (H) and light (L) chains contain Complementarity-Determining Regions (CDRs), which bind to specific antigens or immunogens (e.g., protein antigens or immunogens). CDRs are situated within framework (FR) sequences of the V regions of the heavy (VH) and light chains (VL) of an antibody. CDRs are the most variable parts of antibodies and are critical components in the diversity of antigen specificities of antibodies produced by B lymphocytes. In general, three CDRs (CDR1, CDR2 and CDR3) are arranged consecutively in a V domain of an antibody. Because a VHH, such as a camelid VHH, is essentially a single chain antibody polypeptide, it contains three CDRs that bind to an antigen or target protein such as CD19 in the context of four framework (FR) regions, as follows: FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4. Because most of the sequence variability associated with immunoglobulins and antigen binding is found in the CDRs, these regions are sometimes referred to as hypervariable regions. Typically, CDR1, CDR2 and CDR3 of VHHs contribute to and / or do not interfere with antigen binding. The CDRs of a number of anti-CD19 VHHs described herein are shown, for example, in Tables 1A and 1B. By “antigen” is meant an agent to which an antibody or other polypeptide capture molecule specifically binds. In an embodiment, the antigen is a tumor antigen. Exemplary antigens include small molecules, carbohydrates, proteins, and polynucleotides. By “base editor (BE),” or “nucleobase editor polypeptide (NBE)” is meant an agent that binds a polynucleotide and has nucleobase modifying activity. In various embodiments, the base editor comprises a nucleobase modifying polypeptide (e.g., a deaminase) and a polynucleotide programmable nucleotide binding domain (e.g., Cas9 or Cpf1). Representative nucleic acid and protein sequences of base editors include those sequences having about or at least about 85% sequence identity to any base editor sequence provided in the sequence listing, such as those corresponding to SEQ ID NOs: 2-11. By “BE4 cytidine deaminase (BE4) polypeptide,” is meant a base editor comprising a nucleic acid programmable DNA binding protein (napDNAbp) domain, a cytidine deaminase domain, and two uracil glycosylase inhibitor domains (UGIs). In embodiments, the napDNAbp is a Cas9n (D10A) polypeptide. Non-limiting examples of cytidine deaminase domains include rAPOBEC, ppAPOBEC, RrA3F, AmAPOBEC1, and SsAPOBEC3B. By “BE4 cytidine deaminase (BE4) polynucleotide,” is meant a polynucleotide encoding a BE4 polypeptide. By “base editing activity” is meant acting to chemically alter a base within a polynucleotide. In one embodiment, a first base is converted to a second base. In one embodiment, the base editing activity is cytidine deaminase activity, e.g., converting target C•G to T•A. In another embodiment, the base editing activity is adenosine or adenine deaminase activity, e.g., converting A•T to G•C. The term “base editor system” refers to an intermolecular complex for editing a nucleobase of a target nucleotide sequence. In various embodiments, the base editor (BE) system comprises (1) a polynucleotide programmable nucleotide binding domain, a deaminase domain (e.g., cytidine deaminase or adenosine deaminase) for deaminating nucleobases in the target nucleotide sequence; and (2) one or more guide polynucleotides (e.g., guide RNA) in conjunction with the polynucleotide programmable nucleotide binding domain. In various embodiments, the base editor (BE) system comprises a nucleobase editor domain selected from an adenosine deaminase or a cytidine deaminase, and a domain having nucleic acid sequence specific binding activity. In some embodiments, the base editor system comprises (1) a base editor (BE) comprising a polynucleotide programmable DNA binding domain and a deaminase domain for deaminating one or more nucleobases in a target nucleotide sequence; and (2) one or more guide RNAs in conjunction with the polynucleotide programmable DNA binding domain. In some embodiments, the polynucleotide programmable nucleotide binding domain is a polynucleotide programmable DNA binding domain. In some embodiments, the base editor is a cytidine base editor (CBE). In some embodiments, the base editor is an adenine or adenosine base editor (ABE). In some embodiments, the base editor is an adenine or adenosine base editor (ABE) or a cytidine or cytosine base editor (CBE). In some embodiments, the base editor system (e.g., a base editor system comprising a cytidine deaminase) comprises a uracil glycosylase inhibitor or other agent or peptide (e.g., a uracil stabilizing protein such as provided in WO2022015969, the disclosure of which is incorporated herein by reference in its entirety for all purposes) that inhibits the inosine base excision repair system. A “camelid VHH framework region (FR)” refers to the structural FR portions or components of a camelid VHH antibody or binding molecule, namely, FR1, FR2, FR4 and FR4, that positionally and structurally support the three CDR components, namely, CDR1, CDR2 and CDR3 of a VHH polypeptide, as described above. Similar to the FRs in conventional antibody polypeptides, the respective FR regions (FR1, FR2, FR3 and FR4) of the anti-CD19 VHH polypeptides described herein are highly similar in sequence not only among different CD19 binding VHHs but also among camelid VHH polypeptides that bind to other antigens, e.g., unrelated VHH polypeptides. (See, e.g., L.S. Mitchell and L.J. Colwell, 2018, Proteins, 86(7): 697-706 and A.M. Vattekatte et al., March, 2020, PeerJ., 6(8):e8408. DOI: 10.7717 / peerj.8408). Accordingly, the FR regions FR1, FR2, FR3 and FR4 of different VHHs do not vary significantly in sequence. By way of example, the below FR sequences of the VHH in the above-mentioned publication of Mitchell and Colwell are similar to the FR sequences of other VHHs, including the anti-CD19 VHH polypeptides described herein. FR1 (SEQ ID NO:539): FR1 (continued):

[0002] FR3 (SEQ ID NO: 541): FR3 (continued): FR4 (SEQ ID NO: 542): It will be appreciated that the amino acid position numbers of the VHH FRs shown above are approximate and may vary to some degree in length or amino acid sequence depending on VHH length and on the start and termination amino acid positions of the VHH CDRs. Thus, substantial similarities exist among the structural FRs of camelid VHHs, independent of antigen binding specificity. The term “Cas9” or “Cas9 domain” refers to an RNA guided nuclease comprising a Cas9 protein, or a fragment thereof (e.g., a protein comprising an active, inactive, or partially active DNA cleavage domain of Cas9, and / or the gRNA binding domain of Cas9). A Cas9 nuclease is also referred to sometimes as a casnl nuclease or a CRISPR (clustered regularly interspaced short palindromic repeat) associated nuclease. As used herein, the term “complementarity determining region (CDR)” refers to noncontiguous antigen-binding sites within an antibody. In various embodiments, amino acids in a CDR are identified using sequence or structure based methods. These particular regions have been described by Kabat et al., J. Biol. Chem.252:6609-6616, 1977 and Kabat, et al., Sequences of Proteins of Immunological Interest, Fifth Edition, U.S. Department of Health and Human Services, NIH Publication No.91-3242, 1991; by Chothia et al., (J. Mol. Biol.196:901-917, 1987), and by MacCallum et al., (J. Mol. Biol.262:732-745, 1996) where the definitions include overlapping or subsets of amino acid residues when compared against each other. In certain embodiments, a CDR is defined by Kabat based on sequence comparisons. In various embodiments, a CDR is defined using a numbering scheme selected from Chothia, Martin (Enhanced Chothia or AbM), Kabat, Honnegeer (AHo), Contact, and IMGT. By “chimeric antigen receptor” or “CAR” is meant a synthetic or engineered receptor comprising an extracellular antigen binding domain joined to one or more intracellular signaling domains where the CAR confers specificity for an antigen bound by the extracellular antigen binding domain onto an immune effector cell (e.g., a T-cell, an NK cell, or a macrophage). In embodiments, the CAR is a SUPRA CAR, an anti-tag CAR, a TCR-CAR, or a TCR-like CAR (see, e.g., Guedan, et al. “Engineering and Design of Chimeric Antigen Receptors,” Methods and Clinical Development, 12:145-156 (2019); Poorebrahim, et al., “TCR-like CARs and TCR- CARs targeting neoepitopes: an emerging potential,” Cancer Gene Therapy, 28:581-589 (2021); and Minutolo, et al. “The Emergence of Universal Immune Receptor T Cell Therapy for Cancer,” Front Oncol., 9:176 (2019), the disclosures of which are incorporated herein by reference in their entireties for all purposes). In various embodiments, a CAR comprise a VHH of the disclosure, a CD8a hinge region domain, a CD8a transmembrane region domain, a 4-1BB costimulatory domain, and a CD3z domain. In some instances, the CAR comprises in order from N-terminus to C-terminus the following elements: a VHH of the disclosure, a CD8a hinge region domain, a CD8a transmembrane region domain, 4-1BB domain, and a CD3z domain. The CAR may comprise a VHH domain of the disclosure, or a fragment thereof capable of binding a CD19 polypeptide fused to an amino acid sequence with at least about 85% identity to the following amino acid sequence, or a fragment thereof with immunomodulatory activity: TTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGVLLLSLV ITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVKFSRSADAPAYQQGQ NQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERR RGKGHDGLYQGLSTATKDTYDALHMQALPPR (SEQ ID NO: 766). In various embodiments, a CAR of the disclosure further comprises a CD8a signal peptide fused to the N-terminus of the CAR. In various embodiments, the CAR contains an amino acid sequence having about or at least about 85%, 90%, 95%, 96%, 97%, 98%, 99% or more amino acid sequence identity with a sequence listed in Table 10, or a fragment thereof having immunomodulatory activity. In various embodiments, a polynucleotide sequence encoding the CAR shares about or at least about 85%, 90%, 95%, 96%, 97%, 98%, 99% or more amino acid sequence identity with a sequence listed in Table 11, or a fragment thereof. By “chimeric antigen receptor (CAR) T cell” or “CAR-T cell” is meant a T cell expressing a CAR that has antigen specificity determined by the antibody-derived targeting domain of the CAR. As used herein, “CAR-T cells” include T cells, regulatory T cells (TREG), macrophages, or NK cells. As used herein, “CAR-T cells” include cells engineered to express a CAR or a T cell receptor (TCR, sometimes referred to as TCR-CARs or TCR-like CARs). Methods of making CARs (e.g., for treatment of cancer) are publicly available (see, e.g., Park et al., Trends Biotechnol., 29:550-557, 2011; Grupp et al., N Engl J Med., 368:1509-1518, 2013; Han et al., J. Hematol Oncol.6:47, 2013; Haso et al., (2013) Blood, 121, 1165-1174; Mohseni, et al., (2020) Front. Immunol., 11, art.1608, doi: 10.3389 / fimmu.2020.01608; Eggenhuizen, et al. Int. J. Mol. Sci. (2020), 21:7015, doi: 10.3390 / ijms21197015; Poorebrahim, et al., Cancer Gene Ther 28, 581–589 (2021), doi.org / 10.1038 / s41417-021-00307-7, PCT Pubs. WO2012 / 079000, WO2013 / 059593; and U.S. Pub.2012 / 0213783, the disclosure of each of which is incorporated herein by reference herein in its entirety). By “cluster of differentiation 8-alpha (CD8a or CD8α) signal peptide” is meant a polypeptide having at least about 85% amino acid sequence identity to the following amino acid sequence, or a fragment thereof functional as a signal peptide: MALPVTALLLPLALLLHAARP (SEQ ID NO: 767). By “cluster of differentiation 8-alpha (CD3a or CD3α) signal peptide polynucleotide” is meant a polynucleotide encoding a CD8a signal peptide polypeptide, as well as the introns, exons, 3′ untranslated regions, 5′ untranslated regions, and regulatory sequences associated with its expression, or fragments thereof. In embodiments, a CD8a signal peptide polynucleotide is the genomic sequence, cDNA, mRNA, or gene associated with and / or required for CD8a signal peptide expression. An exemplary CD8a signal peptide nucleic acid sequence is provided below. ATGGCCCTGCCCGTTACCGCCCTACTCCTGCCCCTGGCCCTCCTGCTCCACGCCGCCAGGCCC (SEQ ID NO: 768). By “cluster of differentiation 3-zeta (CD3z or CD3ζ) polypeptide” is meant a polypeptide having at least about 85% amino acid sequence identity to the following amino acid sequence, or a fragment thereof having immunomodulatory activity: RVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQK DKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR (SEQ ID NO: 769). By “cluster of differentiation 3-zeta (CD3z or CD3ζ) polynucleotide” is meant a polynucleotide encoding a CD3z polypeptide, as well as the introns, exons, 3′ untranslated regions, 5′ untranslated regions, and regulatory sequences associated with its expression, or fragments thereof. In embodiments, a CD3z polynucleotide is the genomic sequence, cDNA, mRNA, or gene associated with and / or required for CD3z expression. An exemplary CD3z nucleic acid sequence is provided below. CGGGTGAAGTTCAGCAGGAGCGCCGACGCCCCTGCTTACCAGCAGGGCCAGAATCAGCTGTACA ACGAGCTGAATCTGGGCCGGAGGGAGGAGTACGACGTGCTGGACAAGCGGAGGGGCAGGGACCC CGAGATGGGCGGCAAGCCCAGGCGGAAGAACCCCCAGGAGGGGCTGTACAACGAGCTGCAGAAG GACAAGATGGCCGAGGCCTACTCCGAGATCGGCATGAAGGGCGAGAGGCGGAGAGGCAAGGGCC ATGACGGCCTGTACCAGGGCCTGTCCACCGCCACCAAGGACACCTACGACGCCCTGCACATGCA GGCCCTGCCCCCCCGC (SEQ ID NO: 770). By “cluster of differentiation 8a (CD8a) hinge region polypeptide” is meant a polypeptide having at least about 85% amino acid sequence identity to the following amino acid sequence, or a fragment thereof functional as a hinge in a chimeric antigen receptor protein: TTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACD (SEQ ID NO: 771). By “cluster of differentiation 8a (CD8a) hinge region polynucleotide” is meant a polynucleotide encoding a CD8a hinge region polypeptide, as well as the introns, exons, 3′ untranslated regions, 5′ untranslated regions, and regulatory sequences associated with its expression, or fragments thereof. In embodiments, a CD8a hinge region polynucleotide is the genomic sequence, cDNA, mRNA, or gene associated with and / or required for CD8a hinge region expression. An exemplary CD8a hinge region nucleic acid sequence is provided below. ACCACCACCCCTGCCCCCAGGCCCCCCACCCCCGCCCCCACCATCGCCAGCCAGCCCCTGTCCC TGCGGCCCGAGGCCTGCCGGCCCGCCGCCGGCGGCGCCGTGCACACCCGGGGCCTGGACTTCGC CTGCGAC (SEQ ID NO: 772). By “cluster of differentiation 8a (CD8a) transmembrane region polypeptide” is meant a polypeptide having at least about 85% amino acid sequence identity to the following amino acid sequence, or a fragment thereof functional in anchoring a protein to which the CD8a transmembrane region polypeptide is fused to a membrane of a cell: IYIWAPLAGTCGVLLLSLVITLYC (SEQ ID NO: 773). By “cluster of differentiation 8a (CD8a) transmembrane region polynucleotide” is meant a polynucleotide encoding a CD8a transmembrane region polypeptide, as well as the introns, exons, 3′ untranslated regions, 5′ untranslated regions, and regulatory sequences associated with its expression, or fragments thereof. In embodiments, a CD8a transmembrane region polynucleotide is the genomic sequence, cDNA, mRNA, or gene associated with and / or required for CD8a transmembrane region expression. An exemplary CD8a transmembrane region nucleic acid sequence is provided below. ATCTACATCTGGGCCCCCCTGGCCGGAACCTGCGGCGTGCTGCTGCTGTCCCTGGTGATCACCC TGTACTGC (SEQ ID NO: 774). By “cluster of differentiation 19 (CD19) polypeptide” is meant a protein having at least about 85% amino acid sequence identity to Genbank Accession No. AAB60697.1, which is reproduced below, or a fragment thereof having immunomodulatory activity. >AAB60697.1 CD19 [Homo sapiens] MPPPRLLFFLLFLTPMEVRPEEPLVVKVEGEGDNAVLQCLKGTSDGPTQQLTWSRESPLKPFLK LSLGLPGLGIHMRPLASWLFIFNVSQQMGGFYLCQPGPPSEKAWQPGWTVNVEGSGELFRWNVS DLGGLGCGLKNRSSEGPSSPSGKLMSPKLYVWAKDRPEIWEGEPPCVPPRDSLNQSLSQDLTMA PGSTLWLSCGVPPDSVSRGPLSWTHVHPKGPKSLLSLELKDDRPARDMWVMETGLLLPRATAQD AGKYYCHRGNLTMSFHLEITARPVLWHWLLRTGGWKVSAVTLAYLIFCLCSLVGILHLQRALVL RRKRKRMTDPTRRFFKVTPPPGSGPQNQYGNVLSLPTPTSGLGRAQRWAAGLGGTAPSYGNPSS DVQADGALGSRSPPGVGPEEEEGEGYEEPDSEEDSEFYENDSNLGQDQLSQDGSGYENPEDEPL GPEDEDSFSNAESYENEDEELTQPVARTMDFLSPHGSAWDPSREATSLGSQSYEDMRGILYAAP QLRSIRGQPGPNHEEDADSYENMDNPDGPDPAWGGGGRMGTWSTR (SEQ ID NO: 775). By “cluster of differentiation 19 (CD19) polynucleotide” is meant a polynucleotide encoding a CD19 polypeptide, as well as the introns, exons, 3′ untranslated regions, 5′ untranslated regions, and regulatory sequences associated with its expression, or fragments thereof. In embodiments, a CD19 polynucleotide is the genomic sequence, cDNA, mRNA, or gene associated with and / or required for CD19 expression. An exemplary CD19 nucleic acid sequence is provided below (GenBank Accession No.: AH005421.2:331-421,665-931,1230- 1433,1554-1829,2057-2167,2769-2817,3128-3216,3591-3704,3896-4000,4174-4242,4343- 4399,4488-4544,4813-4905,5231-5322). >AH005421.2:331-421,665-931,1230-1433,1554-1829,2057-2167,2769-2817,3128-3216,3591- 3704,3896-4000,4174-4242,4343-4399,4488-4544,4813-4905,5231-5322 Homo sapiens CD19 (CD19) gene, complete cds ATGCCACCTCCTCGCCTCCTCTTCTTCCTCCTCTTCCTCACCCCCATGGAAGTCAGGCCCGAGG AACCTCTAGTGGTGAAGGTGGAAGGTGAGGGAGATAACGCTGTGCTGCAGTGCCTCAAGGGGAC CTCAGATGGCCCCACTCAGCAGCTGACCTGGTCTCGGGAGTCCCCGCTTAAACCCTTCTTAAAA CTCAGCCTGGGGCTGCCAGGCCTGGGAATCCACATGAGGCCCCTGGCATCCTGGCTTTTCATCT TCAACGTCTCTCAACAGATGGGGGGCTTCTACCTGTGCCAGCCGGGGCCCCCCTCTGAGAAGGC CTGGCAGCCTGGCTGGACAGTCAATGTGGAGGGCAGCGGGGAGCTGTTCCGGTGGAATGTTTCG GACCTAGGTGGCCTGGGCTGTGGCCTGAAGAACAGGTCCTCAGAGGGCCCCAGCTCCCCTTCCG GGAAGCTCATGAGCCCCAAGCTGTATGTGTGGGCCAAAGACCGCCCTGAGATCTGGGAGGGAGA GCCTCCGTGTGTCCCACCGAGGGACAGCCTGAACCAGAGCCTCAGCCAGGACCTCACCATGGCC CCTGGCTCCACACTCTGGCTGTCCTGTGGGGTACCCCCTGACTCTGTGTCCAGGGGCCCCCTCT CCTGGACCCATGTGCACCCCAAGGGGCCTAAGTCATTGCTGAGCCTAGAGCTGAAGGACGATCG CCCGGCCAGAGATATGTGGGTAATGGAGACGGGTCTGTTGTTGCCCCGGGCCACAGCTCAAGAC GCTGGAAAGTATTATTGTCACCGTGGCAACCTGACCATGTCATTCCACCTGGAGATCACTGCTC GGCCAGTACTATGGCACTGGCTGCTGAGGACTGGTGGCTGGAAGGTCTCAGCTGTGACTTTGGC TTATCTGATCTTCTGCCTGTGTTCCCTTGTGGGCATTCTTCATCTTCAAAGAGCCCTGGTCCTG AGGAGGAAAAGAAAGCGAATGACTGACCCCACCAGGAGATTCTTCAAAGTGACGCCTCCCCCAG GAAGCGGGCCCCAGAACCAGTACGGGAACGTGCTGTCTCTCCCCACACCCACCTCAGGCCTCGG ACGCGCCCAGCGTTGGGCCGCAGGCCTGGGGGGCACTGCCCCGTCTTATGGAAACCCGAGCAGC GACGTCCAGGCGGATGGAGCCTTGGGGTCCCGGAGCCCGCCGGGAGTGGGCCCAGAAGAAGAGG AAGGGGAGGGCTATGAGGAACCTGACAGTGAGGAGGACTCCGAGTTCTATGAGAACGACTCCAA CCTTGGGCAGGACCAGCTCTCCCAGGATGGCAGCGGCTACGAGAACCCTGAGGATGAGCCCCTG GGTCCTGAGGATGAAGACTCCTTCTCCAACGCTGAGTCTTATGAGAACGAGGATGAAGAGCTGA CCCAGCCGGTCGCCAGGACAATGGACTTCCTGAGCCCTCATGGGTCAGCCTGGGACCCCAGCCG GGAAGCAACCTCCCTGGGGTCCCAGTCCTATGAGGATATGAGAGGAATCCTGTATGCAGCCCCC CAGCTCCGCTCCATTCGGGGCCAGCCTGGACCCAATCATGAGGAAGATGCAGACTCTTATGAGA ACATGGATAATCCCGATGGGCCAGACCCAGCCTGGGGAGGAGGGGGCCGCATGGGCACCTGGAG CACCAGGTGA (SEQ ID NO: 672). An exemplary CD19 gene sequence is provided at ENSEMBL Accession No. ENSG00000177455. The term “conservative amino acid substitution” or “conservative mutation” refers to the replacement of one amino acid by another amino acid with a common property. A functional way to define common properties between individual amino acids is to analyze the normalized frequencies of amino acid changes between corresponding proteins of homologous organisms (Schulz, G. E. and Schirmer, R. H., Principles of Protein Structure, Springer-Verlag, New York (1979)). According to such analyses, groups of amino acids can be defined where amino acids within a group exchange preferentially with each other, and therefore resemble each other most in their impact on the overall protein structure (Schulz, G. E. and Schirmer, R. H., supra). Non- limiting examples of conservative mutations include amino acid substitutions of amino acids, for example, lysine for arginine and vice versa such that a positive charge can be maintained; glutamic acid for aspartic acid and vice versa such that a negative charge can be maintained; serine for threonine such that a free –OH can be maintained; and glutamine for asparagine such that a free –NH2 can be maintained. Amino acids generally can be grouped into classes according to the following common side- chain properties: (1) hydrophobic: Norleucine, Met, Ala, Val, Leu, He; (2) neutral hydrophilic: Cys, Ser, Thr, Asn, Gin; (3) acidic: Asp, Glu; (4) basic: His, Lys, Arg; (5) residues that influence chain orientation: Gly, Pro; (6) aromatic: Trp, Tyr, Phe. In some embodiments, conservative substitutions can involve the exchange of a member of one of these classes for another member of the same class. In some embodiments, non- conservative amino acid substitutions can involve exchanging a member of one of these classes for another class. The term “coding sequence” or “protein coding sequence” as used interchangeably herein refers to a segment of a polynucleotide that codes for a protein. Coding sequences can also be referred to as open reading frames. The region or sequence is bounded nearer the 5′ end by a start codon and nearer the 3′ end with a stop codon. By “complex” is meant a combination of two or more molecules whose interaction relies on inter-molecular forces. Non-limiting examples of inter-molecular forces include covalent and non-covalent interactions. Non-limiting examples of non-covalent interactions include hydrogen bonding, ionic bonding, halogen bonding, hydrophobic bonding, van der Waals interactions (e.g., dipole-dipole interactions, dipole-induced dipole interactions, and London dispersion forces), and π-effects. In an embodiment, a complex comprises polypeptides, polynucleotides, or a combination of one or more polypeptides and one or more polynucleotides. In one embodiment, a complex comprises one or more polypeptides that associate to form a base editor (e.g., base editor comprising a nucleic acid programmable DNA binding protein, such as Cas9, and a deaminase) and a polynucleotide (e.g., a guide RNA). In an embodiment, the complex is held together by hydrogen bonds. It should be appreciated that one or more components of a base editor (e.g., a deaminase, or a nucleic acid programmable DNA binding protein) may associate covalently or non-covalently. As one example, a base editor may include a deaminase covalently linked to a nucleic acid programmable DNA binding protein (e.g., by a peptide bond). Alternatively, a base editor may include a deaminase and a nucleic acid programmable DNA binding protein that associate noncovalently (e.g., where one or more components of the base editor are supplied in trans and associate directly or via another molecule such as a protein or nucleic acid). In an embodiment, one or more components of the complex are held together by hydrogen bonds. By “cytosine” or “4-Aminopyrimidin-2(1H)-one” is meant a purine nucleobase with the molecular formula C4H5N3O, having the structure , and corresponding to CAS No.71-30-7. By “cytidine” is meant a cytosine molecule attached to a ribose sugar via a glycosidic bond, having the structure , and corresponding to CAS No.65-46-3. Its molecular formula is C9H13N3O5. By “Cytidine Base Editor (CBE)” is meant a base editor comprising a cytidine deaminase. By “Cytidine Base Editor (CBE) polynucleotide” is meant a polynucleotide encoding a CBE. By “cytidine deaminase” or “cytosine deaminase” is meant a polypeptide or fragment thereof capable of deaminating cytidine or cytosine. In embodiments, the cytidine or cytosine is present in a polynucleotide. In one embodiment, the cytidine deaminase converts cytosine to uracil or 5-methylcytosine to thymine. The terms “cytidine deaminase” and “cytosine deaminase” are used interchangeably throughout the application. Petromyzon marinus cytosine deaminase 1 (PmCDA1) (SEQ ID NO: 13-14), Activation-induced cytidine deaminase (AICDA) (SEQ ID NOs: 15-21), and APOBEC (SEQ ID NOs: 12-61) are exemplary cytidine deaminases. Further exemplary cytidine deaminase (CDA) sequences are provided in the Sequence Listing as SEQ ID NOs: 62-66 and SEQ ID NOs: 67-189. Non-limiting examples of cytidine deaminases include those described in PCT / US20 / 16288, PCT / US2018 / 021878, 180802-021804 / PCT, PCT / US2018 / 048969, and PCT / US2016 / 058344. By “cytosine deaminase activity” is meant catalyzing the deamination of cytosine or cytidine. In one embodiment, a polypeptide having cytosine deaminase activity converts an amino group to a carbonyl group. In an embodiment, a cytosine deaminase converts cytosine to uracil (i.e., C to U) or 5-methylcytosine to thymine (i.e., 5mC to T). In some embodiments, a cytosine deaminase as provided herein has increased cytosine deaminase activity (e.g., at least 10-fold, 20-fold, 30-fold, 40-fold, 50-fold, 60-fold, 70-fold, 80-fold, 90-fold, 100-fold or more) relative to a reference cytosine deaminase. The term “deaminase” or “deaminase domain,” as used herein, refers to a protein or fragment thereof that catalyzes a deamination reaction. “Detect” refers to identifying the presence, absence or amount of the analyte to be detected. In one embodiment, a sequence alteration in a polynucleotide or polypeptide is detected. In another embodiment, the presence of indels is detected. By “detectable label” is meant a composition that when linked to a molecule of interest renders the latter detectable, via spectroscopic, photochemical, biochemical, immunochemical, or chemical means. For example, useful labels include radioactive isotopes, magnetic beads, metallic beads, colloidal particles, fluorescent dyes, electron-dense reagents, enzymes (for example, as commonly used in an enzyme linked immunosorbent assay (ELISA)), biotin, digoxigenin, or haptens. By “disease” is meant any condition or disorder that damages or interferes with the normal function of a cell, tissue, or organ. In some embodiments, the disease is a cancer (e.g., a hematological cancer or a solid tumor). In some instances, the disease is a disease that can be treated using the modified allogeneic T cells of the disclosure. In one embodiment, the disease is a neoplasia or cancer. In some instances, the disease is a malignancy. In some cases, the disease is a dysplasia, or a non-malignant or benign neoplasia. In some embodiments, the disease is a hematological cancer. By “hematological cancer” is meant a malignancy of immune system cells. In some embodiments, the hematological cancer is leukemia, myeloma, and / or lymphoma. Lymphomas and Leukemias are examples of “liquid cancers” or cancers present in the blood and are derived from the transformation of either a hematopoietic precursor in the bone marrow or a mature hematopoietic cell in the blood. Leukemias can be lymphoid or myeloid, and acute or chronic. In the case of myelomas, the transformed cell is a fully differentiated plasma cell that may be present as a dispersed collection of malignant cells or as a solid mass in the bone marrow. In the case of lymphomas, a transformed lymphocyte in a secondary lymphoid tissue generates a solid mass. Lymphomas are classified either Hodgkin lymphoma (HL) or non- Hodgkin lymphoma (NHL). In some cases, the disease or disorder is an autoimmune disorder, such as arthritis (e.g., rheumatoid arthritis) or systemic lupus erythematosus (SLE). In some embodiments, the disease is a B-cell lymphoma or a T-cell lymphoma (e.g., B-cell acute lymphoblastic leukemia (B-ALL), Non-Hodgkin’s Lymphoma (NHL), B-cell chronic lymphocytic leukemia (B-CLL), or T-cell acute lymphoblastic leukemia (T-ALL)). By “dual editing activity” or “dual deaminase activity” is meant having adenosine deaminase and cytidine deaminase activity. In one embodiment, a base editor having dual editing activity has both A→G and C→T activity, wherein the two activities are approximately equal or are within about 10% or 20% of each other. In another embodiment, a dual editor has A→G activity that no more than about 10% or 20% greater than C→T activity. In another embodiment, a dual editor has A→G activity that is no more than about 10% or 20% less than C→T activity. In some embodiments, the adenosine deaminase variant has predominantly cytosine deaminase activity, and little, if any, adenosine deaminase activity. In some embodiments, the adenosine deaminase variant has cytosine deaminase activity, and no significant or no detectable adenosine deaminase activity. By “effective amount” is meant the amount of an agent or active compound, that is required to ameliorate the symptoms of a disease relative to an untreated patient or an individual without disease, i.e., a healthy individual, or is the amount of the agent or active compound sufficient to elicit a desired biological response. The effective amount of active compound(s) used to practice the embodiments of the present disclosure for therapeutic treatment of a disease varies depending upon the manner of administration, the age, body weight, and general health of the subject. Ultimately, the attending physician or veterinarian will decide the appropriate amount and dosage regimen. Such amount is referred to as an “effective” amount. In one embodiment, an effective amount is the amount of a base editor of the disclosure sufficient to introduce an alteration in a gene of interest in a cell (e.g., a cell in vitro or in vivo). In one embodiment, an effective amount is the amount of a base editor required to achieve a therapeutic effect. Such therapeutic effect need not be sufficient to alter a pathogenic gene in all cells of a subject, tissue or organ, but only to alter the pathogenic gene in about 1%, 5%, 10%, 25%, 50%, 75% or more of the cells present in a subject, tissue or organ. In one embodiment, an effective amount is sufficient to ameliorate one or more symptoms of a disease. An “epitope tag” refers to a peptide or amino acid sequence (e.g., an epitope) that is fused, linked, or coupled to a protein, such as a recombinant protein produced by recombinant techniques, and that can be specifically bound by an antibody, e.g., an anti-tag monoclonal antibody or binding molecule that is directed to or generated against the tag peptide or amino acid sequence. In an embodiment, the protein to which an epitope tag is fused, linked, or coupled is an antibody or VHH protein, e.g., a recombinantly produced antibody or VHH protein. In an embodiment, the VHH is an anti-CD19 VHH antibody. Other molecules may serve as protein, amino acid sequence, or polynucleotide tags that are fused, linked, or coupled to a protein, such as a recombinant protein produced by recombinant techniques, e.g., an anti-CD19 VHH antibody described herein. In an embodiment, the tag can be specifically bound by an antibody, e.g., an anti-tag monoclonal antibody or binding molecule that is directed to or generated against the tag peptide or amino acid sequence. Examples of tags include, without limitation, FLAG tags (peptide sequenceDYKDDDDK (SEQ ID NO: 776) recognized by an anti-FLAG antibody), polyHistidine (His) tags (5-10 histidine residues (HHHHHH (SEQ ID NO: 777)) bound by a nickel or cobalt chelate), E-tag, a peptide comprising amino acid sequenceGAPVPYPDPLEPR (SEQ ID NO: 778) recognized by an antibody; an immunoglobulin Fc region or portion thereof, e.g., having effector or modulator function (Fc tag). By “fragment” is meant a portion of a polypeptide or nucleic acid molecule. This portion contains, at least about 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, or 90% of the entire length of the reference nucleic acid molecule or polypeptide. A fragment may contain 10, 20, 30, 40, 50, 60, 70, 80, 90, or 100, 200, 300, 400, 500, 600, 700, 800, 900, or 1000 nucleotides or amino acids. In some embodiments, the fragment is a functional fragment. A "framework (FR) region" or "FR region" includes amino acid residues that are adjacent to the CDRs in VH, and VL regions, and in VHHs. For example, FR region residues may be present in VHHs as described herein, camelid antibodies (VHHs), human antibodies, rodent- derived antibodies (e.g., murine and rat antibodies), humanized antibodies, primatized antibodies, chimeric antibodies, antibody fragments (e.g., Fab fragments), VHHs, single-chain antibody fragments (e.g., scFv fragments), antibody domains, and bispecific antibodies, among others. By “guide polynucleotide” is meant a polynucleotide or polynucleotide complex which is specific for a target sequence and can form a complex with a polynucleotide programmable nucleotide binding domain protein (e.g., Cas9 or Cpf1). In an embodiment, the guide polynucleotide is a guide RNA (gRNA). gRNAs can exist as a complex of two or more RNAs, or as a single RNA molecule. A guide polynucleotide typically contains a “spacer,” which may be about 20 base pairs in length. Shorter or longer spacers may also be used in guide polynucleotides, e.g., 15-, 16-, 17-, 18-, 19-, 21-, 22-, 23-, 24-, or 25-nucleotides in length. In some embodiments, a target sequence is in a gene or on a chromosome, for example, and is complementary to a space. In some embodiments, a degree of complementarity or identity between a spacer sequence and its corresponding target sequence may be about or at least 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100%. The term "humanized" antibodies refers to forms of non-human (e.g., murine) antibodies, camelid-derived single domain antibody (sdAb) binding molecules, which are comprised of the heavy chain variable (VH) region of heavy-chain-only antibodies (Abs) or VHHs. Humanized antibodies include chimeric immunoglobulins, immunoglobulin chains or fragments thereof (such as Fv, Fab, Fab', F(ab')2or other target-binding subdomains of antibodies) which contain minimal sequences derived from non-human immunoglobulin. In general, a humanized antibody or VHH may comprise substantially all of at least one variable domain (or two variable domains in the case of non-VHH antibodies), in which all or substantially all of the CDR regions correspond to those of a non-human immunoglobulin. All or substantially all of the FR regions of a humanized antibody may also be derived from a human immunoglobulin sequence. In the case of non-VHH antibodies, a VHH or a humanized antibody can also comprise at least a portion of an immunoglobulin constant region (Fc), which may be that of a human immunoglobulin consensus sequence. Techniques and protocols for humanizing antibodies (as well as VHHs) are known and practiced in the art, as described, for examples, in Riechmann et al., Nature, 332:323-7, 1988; Kasmiri et al., Methods, 36(1):25-34, 2005; U.S. Patent Nos. 5,530,101; 5,585,089; 5,693,761; 5,693,762; and U.S. Patent No.6,180,370 to Queen et al; EP239400; WO 1991 / 09967; U.S. Patent No.5,225,539; EP592106; and EP519596, the contents of which are incorporated herein by reference. Humanized antibodies or VHHs are molecularly engineered to contain even more human-like immunoglobulin domains, and incorporate only the CDRs of the VHH or animal-derived monoclonal antibody by carefully examining the sequence of the hyper-variable loops of the V regions of the monoclonal antibody or VHH, and fitting them to the structure of the human antibody chains. This process is routinely and commonly carried out by one having skill in the art. See, e.g., U.S. Patent No.6,187,287, the contents of which are incorporated by reference herein. “Graft versus host disease” (GVHD) refers to a pathological condition where transplanted cells of a donor generate an immune response against cells of the host. By “heterologous,” or “exogenous” is meant a polynucleotide or polypeptide that 1) has been experimentally incorporated into a polynucleotide or polypeptide sequence to which the polynucleotide or polypeptide is not normally found in nature; and / or 2) has been experimentally placed into a cell that does not normally comprise the polynucleotide or polypeptide. In some embodiments, “heterologous” means that a polynucleotide or polypeptide has been experimentally placed into a non-native context. In some embodiments, a heterologous polynucleotide or polypeptide is derived from a first species or host organism and is incorporated into a polynucleotide or polypeptide derived from a second species or host organism. In some embodiments, the first species or host organism is different from the second species or host organism. In some embodiments the heterologous polynucleotide is DNA. In some embodiments the heterologous polynucleotide is RNA. “Host versus graft disease” (HVGD) or “host-versus-graft rejection” refers to a pathological condition where the immune system of a host generates an immune response against transplanted cells of an allogeneic donor. “Hybridization” means hydrogen bonding, which may be Watson-Crick, Hoogsteen or reversed Hoogsteen hydrogen bonding, between complementary nucleobases. For example, adenine and thymine are complementary nucleobases that pair through the formation of hydrogen bonds. By “immune cell” is meant a cell of the immune system capable of generating an immune response. Exemplary immune cells include, but are not limited to, T cells, NK cells, B cells, macrophages, hematopoietic stem cells, or precursors thereof. In embodiments, an immune cell is allogeneic to a subject to whom the cell is to be administered. In embodiments, an immune cell is from a donor and is allogeneic to a subject to which the immune cell will be administered after being modified according to the methods provided herein. The aspects and embodiments of the disclosure features methods for preparing modified allogeneic immune cells with improved characteristics (e.g., increased persistence in a subject) as well as the cells produced by these methods. By “immune effector cell” is meant a lymphocyte, once activated, capable of effecting an immune response upon a target cell. In some embodiments, immune effector cells are effector T cells. In some embodiments, the effector T cell is a naïve CD8+T cell, a cytotoxic T cell, a natural killer T (NKT) cell, a natural killer (NK) cell, or a regulatory T (Treg) cell. In some embodiments, immune effector cells are effector NK cells. In some embodiments, the effector T cells are thymocytes, immature T lymphocytes, mature T lymphocytes, resting T lymphocytes, or activated T lymphocytes. In some embodiments the immune effector cell is a CD4+CD8+T cell or a CD4- CD8- T cell. In some embodiments the immune effector cell is a T helper cell. In some embodiments the T helper cell is a T helper 1 (Th1), a T helper 2 (Th2) cell, or a helper T cell expressing CD4 (CD4+ T cell). By “immunomodulatory activity” is meant increasing, decreasing, or sustaining an immune response. By “increases” is meant a positive alteration of at least 10%, 25%, 50%, 75%, or 100%, or about 1.5 fold, about 2 fold, about 3-fold, about 4-fold, about 5-fold, about 6-fold, about 7- fold, about 8-fold, about 9-fold, about 10-fold, about 15-fold, about 20-fold, about 25-fold, about 30-fold, about 35-fold, about 40-fold, about 45-fold, about 50-fold, or about 100-fold. The terms “inhibitor of base repair,” “base repair inhibitor,” “IBR” or their grammatical equivalents refer to a protein that is capable in inhibiting the activity of a nucleic acid repair enzyme, for example a base excision repair enzyme. The terms “isolated,” “purified,” or “biologically pure” refer to material that is free to varying degrees from components which normally accompany it as found in its native state. “Isolate” denotes a degree of separation from original source or surroundings. “Purify” denotes a degree of separation that is higher than isolation. A “purified” or “biologically pure” protein is sufficiently free of other materials such that any impurities do not materially affect the biological properties of the protein or cause other adverse consequences. That is, a nucleic acid or peptide of this disclosure is purified if it is substantially free of cellular material, viral material, or culture medium when produced by recombinant DNA techniques, or chemical precursors or other chemicals when chemically synthesized. Purity and homogeneity are typically determined using analytical chemistry techniques, for example, polyacrylamide gel electrophoresis or high performance liquid chromatography. The term “purified” can denote that a nucleic acid or protein gives rise to essentially one band in an electrophoretic gel. For a protein that can be subjected to modifications, for example, phosphorylation or glycosylation, different modifications may give rise to different isolated proteins, which can be separately purified. By “isolated polynucleotide” is meant a nucleic acid molecule that is free of the genes which, in the naturally-occurring genome of the organism from which the nucleic acid molecule of the disclosure is derived, flank the gene. The term therefore includes, for example, a recombinant DNA that is incorporated into a vector; into an autonomously replicating plasmid or virus; or into the genomic DNA of a prokaryote or eukaryote; or that exists as a separate molecule (for example, a cDNA or a genomic or cDNA fragment produced by PCR or restriction endonuclease digestion) independent of other sequences. In addition, the term includes an RNA molecule that is transcribed from a DNA molecule, as well as a recombinant DNA that is part of a hybrid gene encoding additional polypeptide sequence. By an “isolated polypeptide” is meant a polypeptide of the disclosure that has been separated from components that naturally accompany it. Typically, the polypeptide is isolated when it is at least 60%, by weight, free from the proteins and naturally-occurring organic molecules with which it is naturally associated. In some embodiments, the preparation is at least 75%, at least 90%, or at least 99%, by weight, a polypeptide of the disclosure. An isolated polypeptide of the disclosure may be obtained, for example, by extraction from a natural source, by expression of a recombinant nucleic acid encoding such a polypeptide; or by chemically synthesizing the protein. Purity can be measured by any appropriate method, for example, column chromatography, polyacrylamide gel electrophoresis, or by HPLC analysis. The term “kill switch” refers to a polypeptide capable of mediating the killing of a cell when the polypeptide is specifically bound by an agent. In some cases, the agent is a small molecule or monoclonal antibody. In some cases, the agent is Ritixumab. In various embodiments, the kill switch is selected from RQR1, RQR2, RQR8, RQR1G4S, RQR2G4S, RR, G4SRR, G4SRRG4S, G4SRRG4SCD8, G4SRRG4SCD28, G4SRRCD28, and QG4S. In various embodiments, the kill switch is fused to a chimeric antigen receptor. In some embodiments, a kill switch is expressed on the surface of a cell and is not fused to a chimeric antigen receptor. The term “linker”, as used herein, refers to a molecule that links two moieties. In one embodiment, the term “linker” refers to a covalent linker (e.g., covalent bond) or a non-covalent linker. By “marker” is meant any agent or clinical parameter having an alteration that is associated with a disease or disorder. In embodiments, the agent is a polypeptide or polynucleotide and the alteration is in expression, level, structure, or activity. In embodiments, the disease or disorder is a neoplasia, such as a hematologic cancer (e.g., B-cell acute lymphoblastic leukemia (B-ALL), Non-Hodgkin’s Lymphoma (NHL), B-cell chronic lymphocytic leukemia (B-CLL), or T-cell acute lymphoblastic leukemia (T-ALL)). Non-limiting examples of markers include B2M, CD2, CD5, CD19, CD45, CIITA, HLA-DR, IFNg, PD1, and TCRαβ. The term “mRNA” refers to a polynucleotide and comprises an open reading frame that can be translated into a polypeptide. An mRNA molecule may serve as a substrate for translation by a ribosome and amino-acylated tRNAs. An mRNA molecule may comprise a phosphate- sugar backbone including ribose residues or analogs thereof, e.g., 2’-methoxy ribose residues. In some embodiments, the sugars of an mRNA phosphate-sugar backbone contain or contain only ribose residues, 2’-methoxy ribose residues, or a combination thereof. The term “mutation,” as used herein, refers to a substitution of a residue within a sequence, e.g., a nucleic acid or amino acid sequence, with another residue, or a deletion or insertion of one or more residues within a sequence. Mutations are typically described herein by identifying the original residue followed by the position of the residue within the sequence and by the identity of the newly substituted residue. Various methods for making the amino acid substitutions (mutations) provided herein are well known in the art, and are provided by, for example, Green and Sambrook, Molecular Cloning: A Laboratory Manual (4thed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. (2012)). "Neoplasia" refers to cells or tissues exhibiting abnormal growth or proliferation. The term neoplasia encompasses cancer, liquid, and solid tumors. In some embodiments, the neoplasia is a solid tumor. In other embodiments, the neoplasia is a liquid tumor. In some embodiments, the neoplasia is a hematological cancer. In some embodiments, the hematological cancer is leukemia, myeloma, and / or lymphoma. In some embodiments, the hematological cancer is a B cell cancer. In some embodiments, the B cell cancer is a lymphoma or a leukemia. In some cases, the leukemia comprises a pre-leukemia. In some cases, the leukemia is an acute leukemia. Acute leukemias include, for example, an acute myeloid leukemia (AML). Acute leukemias also include, for example, an acute lymphoid leukemia or an acute lymphocytic leukemia (ALL); ALL includes B-lineage ALL; T-lineage ALL; and T-cell acute lymphocytic leukemia (T-ALL). By “helper lipid” is meant any neutral, zwitterionic, or anionic lipid. The terms “nucleic acid” and “nucleic acid molecule,” as used herein, refer to a compound comprising a nucleobase and an acidic moiety, e.g., a nucleoside, a nucleotide, or a polymer of nucleotides. Typically, polymeric nucleic acids, e.g., nucleic acid molecules comprising three or more nucleotides are linear molecules, in which adjacent nucleotides are linked to each other via a phosphodiester linkage. In some embodiments, “nucleic acid” refers to individual nucleic acid residues (e.g., nucleotides and / or nucleosides). In some embodiments, “nucleic acid” refers to an oligonucleotide chain comprising three or more individual nucleotide residues. As used herein, the terms “oligonucleotide” and “polynucleotide” can be used interchangeably to refer to a polymer of nucleotides (e.g., a string of at least three nucleotides). In some embodiments, “nucleic acid” encompasses RNA as well as single and / or double- stranded DNA. Nucleic acids may be naturally occurring, for example, in the context of a genome, a transcript, an mRNA, tRNA, rRNA, siRNA, snRNA, a plasmid, cosmid, chromosome, chromatid, or other naturally occurring nucleic acid molecule. On the other hand, a nucleic acid molecule may be a non-naturally occurring molecule, e.g., a recombinant DNA or RNA, an artificial chromosome, an engineered genome, or fragment thereof, or a synthetic DNA, RNA, DNA / RNA hybrid, or including non-naturally occurring nucleotides or nucleosides. Furthermore, the terms “nucleic acid,” “DNA,” “RNA,” and / or similar terms include nucleic acid analogs, e.g., analogs having other than a phosphodiester backbone. Nucleic acids can be purified from natural sources, produced using recombinant expression systems and optionally purified, chemically synthesized, etc. Where appropriate, e.g., in the case of chemically synthesized molecules, nucleic acids comprise nucleoside analogs such as analogs having chemically modified bases or sugars, and backbone modifications. A nucleic acid sequence is presented in the 5′ to 3′ direction unless otherwise indicated. In some embodiments, a nucleic acid is or comprises natural nucleosides (e.g. adenosine, thymidine, guanosine, cytidine, uridine, deoxyadenosine, deoxythymidine, deoxyguanosine, and deoxycytidine); nucleoside analogs (e.g., 2-aminoadenosine, 2-thiothymidine, inosine, pyrrolo-pyrimidine, 3-methyl adenosine, 5- methylcytidine, 2-aminoadenosine, C5-bromouridine, C5-fluorouridine, C5-iodouridine, C5- propynyl-uridine, C5-propynyl-cytidine, C5-methylcytidine, 2-aminoadenosine, 7- deazaadenosine, 7-deazaguanosine, 8-oxoadenosine, 8-oxoguanosine, O(6)-methylguanine, and 2-thiocytidine); chemically modified bases; biologically modified bases (e.g., methylated bases); intercalated bases; modified sugars (e.g., 2′-fluororibose, ribose, 2′-deoxyribose, arabinose, and hexose); and / or modified phosphate groups (e.g., phosphorothioates and 5′-N-phosphoramidite linkages). The term “nuclear localization sequence,” “nuclear localization signal,” or “NLS” refers to an amino acid sequence that promotes import of a protein into the cell nucleus. Nuclear localization sequences are known in the art and described, for example, in Plank et al., International PCT application, PCT / EP2000 / 011690, filed November 23, 2000, published as WO / 2001 / 038547 on May 31, 2001, the contents of which are incorporated herein by reference for their disclosure of exemplary nuclear localization sequences. In other embodiments, the NLS is an optimized NLS described, for example, by Koblan et al., Nature Biotech.2018 doi:10.1038 / nbt.4172. In some embodiments, an NLS comprises the amino acid sequence KRTADGSEFESPKKKRKV (SEQ ID NO: 190),KRPAATKKAGQAKKKK (SEQ ID NO: 191), KKTELQTTNAENKTKKL (SEQ ID NO: 192),KRGINDRNFWRGENGRKTR (SEQ ID NO: 193), RKSGKIAAIVVKRPRK (SEQ ID NO: 194),PKKKRKV (SEQ ID NO: 195), MDSLLMNRRKFLYQFKNVRWAKGRRETYLC (SEQ ID NO: 196), PKKKRKVEGADKRTADGSEFESPKKKRKV (SEQ ID NO: 328), or RKSGKIAAIVVKRPRKPKKKRKV (SEQ ID NO: 329). The term “nucleobase,” “nitrogenous base,” or “base,” used interchangeably herein, refers to a nitrogen-containing biological compound that forms a nucleoside, which in turn is a component of a nucleotide. The ability of nucleobases to form base pairs and to stack one upon another leads directly to long-chain helical structures such as ribonucleic acid (RNA) and deoxyribonucleic acid (DNA). Five nucleobases – adenine (A), cytosine (C), guanine (G), thymine (T), and uracil (U) – are called primary or canonical. Adenine and guanine are derived from purine, and cytosine, uracil, and thymine are derived from pyrimidine. DNA and RNA can also contain other (non-primary) bases that are modified. Non-limiting exemplary modified nucleobases can include hypoxanthine, xanthine, 7-methylguanine, 5,6-dihydrouracil, 5- methylcytosine (m5C), and 5-hydromethylcytosine. Hypoxanthine and xanthine can be created through mutagen presence, both of them through deamination (replacement of the amine group with a carbonyl group). Hypoxanthine can be modified from adenine. Xanthine can be modified from guanine. Uracil can result from deamination of cytosine. A “nucleoside” consists of a nucleobase and a five carbon sugar (either ribose or deoxyribose). Examples of a nucleoside include adenosine, guanosine, uridine, cytidine, 5-methyluridine (m5U), deoxyadenosine, deoxyguanosine, thymidine, deoxyuridine, and deoxycytidine. Examples of a nucleoside with a modified nucleobase includes inosine (I), xanthosine (X), 7-methylguanosine (m7G), dihydrouridine (D), 5-methylcytidine (m5C), and pseudouridine (Ψ). A “nucleotide” consists of a nucleobase, a five carbon sugar (either ribose or deoxyribose), and at least one phosphate group. Non-limiting examples of modified nucleobases and / or chemical modifications that a modified nucleobase may include are the following: pseudo-uridine, 5-Methyl-cytosine, 2′-O- methyl-3′-phosphonoacetate, 2′-O-methyl thioPACE (MSP), 2′-O-methyl-PACE (MP), 2′-fluoro RNA (2′-F-RNA), constrained ethyl (S-cEt), 2′-O-methyl (‘M’), 2′-O-methyl-3′- phosphorothioate (‘MS’), 2′-O-methyl-3′-thiophosphonoacetate (‘MSP’), 5-methoxyuridine, phosphorothioate, and N1-Methylpseudouridine. The term “nucleic acid programmable DNA binding protein” or “napDNAbp” may be used interchangeably with “polynucleotide programmable nucleotide binding domain” to refer to a protein that associates with a nucleic acid (e.g., DNA or RNA), such as a guide nucleic acid or guide polynucleotide (e.g., gRNA), that guides the napDNAbp to a specific nucleic acid sequence. In some embodiments, the polynucleotide programmable nucleotide binding domain is a polynucleotide programmable DNA binding domain. In some embodiments, the polynucleotide programmable nucleotide binding domain is a polynucleotide programmable RNA binding domain. In some embodiments, the polynucleotide programmable nucleotide binding domain is a Cas9 protein. A Cas9 protein can associate with a guide RNA that guides the Cas9 protein to a specific DNA sequence that is complementary to the guide RNA. In some embodiments, the napDNAbp is a Cas9 domain, for example a nuclease active Cas9, a Cas9 nickase (nCas9), or a nuclease inactive Cas9 (dCas9). Non-limiting examples of nucleic acid programmable DNA binding proteins include, Cas9 (e.g., dCas9 and nCas9), Cas12a / Cpfl, Cas12b / C2cl, Cas12c / C2c3, Cas12d / CasY, Cas12e / CasX, Cas12g, Cas12h, Cas12i, and Cas12j / CasΦ (Cas12j / Casphi). Non-limiting examples of Cas enzymes include Cas1, Cas1B, Cas2, Cas3, Cas4, Cas5, Cas5d, Cas5t, Cas5h, Cas5a, Cas6, Cas7, Cas8, Cas8a, Cas8b, Cas8c, Cas9 (also known as Csn1 or Csx12), Cas10, Cas10d, Cas12a / Cpfl, Cas12b / C2cl, Cas12c / C2c3, Cas12d / CasY, Cas12e / CasX, Cas12g, Cas12h, Cas12i, Cas12j / CasΦ, Cpf1, Csy1 , Csy2, Csy3, Csy4, Cse1, Cse2, Cse3, Cse4, Cse5e, Csc1, Csc2, Csa5, Csn1, Csn2, Csm1, Csm2, Csm3, Csm4, Csm5, Csm6, Cmr1, Cmr3, Cmr4, Cmr5, Cmr6, Csb1, Csb2, Csb3, Csx17, Csx14, Csx10, Csx16, CsaX, Csx3, Csx1, Csx1S, Csx11, Csf1, Csf2, CsO, Csf4, Csd1, Csd2, Cst1, Cst2, Csh1, Csh2, Csa1, Csa2, Csa3, Csa4, Csa5, Type II Cas effector proteins, Type V Cas effector proteins, Type VI Cas effector proteins, CARF, DinG, homologues thereof, or modified or engineered versions thereof. Other nucleic acid programmable DNA binding proteins are also within the scope of this disclosure, although they may not be specifically listed in this disclosure. See, e.g., Makarova et al. “Classification and Nomenclature of CRISPR-Cas Systems: Where from Here?” CRISPR J.2018 Oct;1:325-336. doi: 10.1089 / crispr.2018.0033; Yan et al., “Functionally diverse type V CRISPR-Cas systems” Science.2019 Jan 4;363(6422):88-91. doi: 10.1126 / science.aav7271, the entire contents of each are hereby incorporated by reference. Exemplary nucleic acid programmable DNA binding proteins and nucleic acid sequences encoding nucleic acid programmable DNA binding proteins are provided in the Sequence Listing as SEQ ID NOs: 197-231, 232-245, 254-257, 260, and 378. In some embodiments, the napDNAbp is a (CRISPR-associated system) Cas9 endonuclease, for example, Cas9 (Csnl) from Streptococcus pyogenes (e.g., SEQ ID NO: 197), Cas9 from Neisseria meningitidis (NmeCas9; SEQ ID NO: 208), Nme2Cas9 (SEQ ID NO: 209), Streptococcus constellatus (ScoCas9), or derivatives thereof (e.g., a sequence with at least about 85% sequence identity to a Cas9, such as Nme2Cas9 or spCas9). The terms “nucleobase editing domain” or “nucleobase editing protein,” as used herein, refers to a protein or enzyme that can catalyze a nucleobase modification in RNA or DNA, such as cytosine (or cytidine) to uracil (or uridine) or thymine (or thymidine), and adenine (or adenosine) to hypoxanthine (or inosine) deaminations, as well as non-templated nucleotide additions and insertions. In some embodiments, the nucleobase editing domain is a deaminase domain (e.g., an adenine deaminase or an adenosine deaminase; or a cytidine deaminase or a cytosine deaminase). As used herein, “obtaining” as in “obtaining an agent” includes synthesizing, purchasing, or otherwise acquiring the agent. By "operably linked" is meant the connection between regulatory elements and one or more polynucleotides (genes) or a coding region. That is, gene expression is typically placed under the control of certain regulatory elements, including constitutive or inducible promoters, tissue-specific regulatory elements, and enhancers. A polynucleotide (gene or genes) or coding region is said to be "operably linked to" or "operatively linked to" or "operably associated with" the regulatory elements, meaning that the polynucleotide (gene or genes) or coding region is controlled or influenced by the regulatory elements. The one or more polynucleotides may be separated by spacers or linkers. The term “PEG lipid” or “PEG-modified lipid” refers to polyethylene glycol (PEG)- modified lipids. By “subject” or “patient” is meant a mammal, including, but not limited to, a human or non-human mammal. In embodiments, the mammal is a bovine, equine, canine, ovine, rabbit, rodent, nonhuman primate, or feline. In an embodiment, “patient” refers to a mammalian subject with a higher than average likelihood of developing a disease or a disorder. Exemplary patients can be humans, non-human primates, cats, dogs, pigs, cattle, cats, horses, camels, llamas, goats, sheep, rodents (e.g., mice, rabbits, rats, or guinea pigs) and other mammalians that can benefit from the therapies disclosed herein. Exemplary human patients can be male and / or female. “Patient in need thereof” or “subject in need thereof” is referred to herein as a patient diagnosed with, at risk or having, predetermined to have, or suspected of having a disease or disorder. By “persistence” in the context of an allogeneic transplant is meant the continued survival of a donor cell in a host organism. In some embodiments, allogeneic cell(s) comprising one or more of the edits described herein (e.g., a base edit in a CD19, CD3e, CD3g, B2M, and / or CIITA gene, or regulatory element(s) thereof; or knockdown of a CD19, TCRαβ, B2M, and / or CIITA polypeptide) persist in a subject allogeneic to the cells at higher levels over time post- infusion than corresponding unedited allogeneic control cells. In embodiments, the percentage of edited cells (e.g., T cells, NK cells, or lymphocytes) persisting in a subject at a given time point (e.g., 7 days, 14 days, 1 month, 3 months, 6 months, 9 months, or greater than 1, 2, or 3 years is at least about 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 60%, 70%, 80%, 90%, 95%, 99%, or 100% greater than the level of unedited control cells at the same time point. A cell(s) modified by methods of the present disclosure are more persistent than a reference unmodified cell(s). The terms “protein”, “peptide”, “polypeptide”, and their grammatical equivalents are used interchangeably herein, and refer to a polymer of amino acid residues linked together by peptide (amide) bonds. A protein, peptide, or polypeptide can be naturally occurring, recombinant, or synthetic, or any combination thereof. The term “fusion protein” as used herein refers to a hybrid polypeptide which comprises protein domains from at least two different proteins. The term “recombinant” as used herein in the context of proteins or nucleic acids refers to proteins or nucleic acids that do not occur in nature but are the product of human engineering. For example, in some embodiments, a recombinant protein or nucleic acid molecule comprises an amino acid or nucleotide sequence that comprises at least one, at least two, at least three, at least four, at least five, at least six, or at least seven mutations as compared to any naturally occurring sequence. By “reduces” is meant a negative alteration of at least 10%, 25%, 50%, 75%, or 100%. By “reference” is meant a standard or control condition. In one embodiment, the reference is a wild-type or healthy cell. In other embodiments and without limitation, a reference is an untreated cell or subject that is not subjected to a test condition, or is subjected to placebo or normal saline, medium, buffer, and / or a control vector that does not harbor a polynucleotide of interest. In some cases, the reference is an unedited or wild type cell (e.g., a T cell). In some cases, a reference is a healthy subject, such as a subject not having a neoplasia. In some embodiments, the reference is a subject not treated according to a method provided herein or not administered a composition provided herein (e.g., a composition comprising a CD19-binding polypeptide of the disclosure). The reference can be a cell that does not express one or more of the polypeptides described herein. The reference can be a subject before administration of a composition provided herein or treated according to a method provided herein and / or the subject before a change in a treatment (e.g., an alteration in dose or agent administered to the subject). The terms “RNA-programmable nuclease,” and “RNA-guided nuclease” refer to a nuclease that forms a complex with (e.g., binds or associates with) one or more RNA(s) that is not a target for cleavage. In some embodiments, an RNA-programmable nuclease, when in a complex with an RNA, may be referred to as a nuclease-RNA complex. Typically, the bound RNA(s) is referred to as a guide RNA (gRNA). By "specifically binds" is meant to recognize and bind a polypeptide of the disclosure but not substantially recognize and bind other molecules in a sample. A VHH domain or fragment thereof that specifically binds to an antigen will bind to the antigen with a KDof less than 100 nM. For example, a VHH domain or fragment thereof that specifically binds to an antigen will bind to the antigen with a KDof up to 100 nM (e.g., between 1 pM and 100 nM). A VHH domain or fragment thereof that does not exhibit specific binding to a particular antigen or epitope thereof will exhibit a KDof greater than 100 nM (e.g., greater than 500 nm, 1 uM, 100 uM, 500 uM, or 1 mM) for that particular antigen or epitope thereof. A variety of immunoassay formats may be used to select a VHH domain or fragment thereof that specifically immunoreactive with a particular protein or carbohydrate. For example, solid-phase ELISA immunoassays are routinely used to select VHH domains or fragments thereof specifically immunoreactive with a protein or carbohydrate. See, Harlow & Lane, Antibodies, A Laboratory Manual, Cold Spring Harbor Press, New York (1988) and Harlow & Lane, Using Antibodies, A Laboratory Manual, Cold Spring Harbor Press, New York (1999), for a description of immunoassay formats and conditions that can be used to determine specific immunoreactivity. By “substantially identical” is meant a polypeptide or nucleic acid molecule exhibiting at least 50% identity to a reference amino acid sequence. In one embodiment, a reference sequence is a wild-type amino acid or nucleic acid sequence. In another embodiment, a reference sequence is any one of the amino acid or nucleic acid sequences described herein. In one embodiment, such a sequence is at least about 60%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, 99.9%, or even 99.99% identical at the amino acid level or nucleic acid level to the sequence used for comparison. Nucleic acid molecules useful in the methods of the disclosure include any nucleic acid molecule that encodes a polypeptide of the disclosure or a functional fragment thereof. Such nucleic acid molecules need not be 100% identical with an endogenous nucleic acid sequence but will typically exhibit substantial identity. Polynucleotides having “substantial identity” to an endogenous sequence are typically capable of hybridizing with at least one strand of a double- stranded nucleic acid molecule. Nucleic acid molecules useful in the methods of the disclosure include any nucleic acid molecule that encodes a polypeptide of the disclosure or a functional fragment thereof. Such nucleic acid molecules need not be 100% identical with an endogenous nucleic acid sequence but will typically exhibit substantial identity. Polynucleotides having “substantial identity” to an endogenous sequence are typically capable of hybridizing with at least one strand of a double-stranded nucleic acid molecule. By “hybridize” is meant pair to form a double-stranded molecule between complementary polynucleotide sequences (e.g., a gene described herein), or portions thereof, under various conditions of stringency. (See, e.g., Wahl, G. M. and S. L. Berger (1987) Methods Enzymol.152:399; Kimmel, A. R. (1987) Methods Enzymol.152:507). By “specifically binds” or “selectively binds” is meant a polypeptide (e.g., antibody) that recognizes and binds a molecule (e.g., polypeptide, antigen, ligand), but that does not substantially recognize or bind to other molecules in a sample, for example, a biological sample. For example, two molecules (e.g., an antibody and its ligand) that specifically bind to each other form a complex that is relatively stable under physiologic conditions. Specific binding is characterized by a high affinity and a low to moderate capacity, as distinguished from nonspecific binding which usually has a low affinity with a moderate to high capacity. The term “targeting molecules” refers to molecules that bind to target cells of interest. In some embodiments, a targeting molecule is an anti-CD19 VHH antibody of the disclosure, or a CD19-binding fragment thereof. In some embodiments, a targeting molecule is an antibody or antigen-binding fragment thereof. In some embodiments, the targeting molecule is a ligand, receptor and / or antibody / antibody fragment. In some cases, a targeting molecule bind specifically to a target cell. A targeting molecule is considered to bind to a target cell if it binds to a cell surface marker (e.g., antigen, ligand, receptor) of the target cell. In some embodiments, targeting molecules bind specifically to particular target cells—that is, they bind to cell surface markers that are present only on the particular target cells. Thus, a targeting molecule is considered to bind specifically to a T cell if it binds a cell surface marker that is expressed only on T cells. In some embodiments, a targeting molecule is an anti-CD19 VHH antibody of the disclosure, or a CD19-binding fragment thereof. The term “Targeting particles” or “targeted particles” refers to particles that comprise on their surface targeting molecules that bind to cell surface markers on target cells of interest. In some embodiments, the target cells are lymphocytes (e.g., T cells). A targeting particle is considered to comprise a targeting molecule on its surface if the targeting molecule is associated with or interacts with (e.g., is covalently or non-covalently conjugated to / bound to) the surface of the targeting particle. The term “target site” refers to a nucleotide sequence or nucleobase of interest within a nucleic acid molecule that is modified. In embodiments, the modification is deamination of a base. The deaminase can be a cytidine or an adenine deaminase. The fusion protein or base editing complex comprising a deaminase may comprise a dCas9-adenosine deaminase fusion protein, a Cas12b-adenosine deaminase fusion, or a base editor disclosed herein. As used herein, the terms “treat,” treating,” “treatment,” and the like refer to reducing or ameliorating a disorder and / or symptoms associated therewith or obtaining a desired pharmacologic and / or physiologic effect. It will be appreciated that, although not precluded, treating a disorder or condition does not require that the disorder, condition or symptoms associated therewith be completely eliminated. In some embodiments, the effect is therapeutic, i.e., without limitation, the effect partially or completely reduces, diminishes, abrogates, abates, alleviates, reduces the intensity of, or cures a disease and / or adverse symptom attributable to the disease. In some embodiments, the effect is preventative, i.e., the effect protects or prevents an occurrence or reoccurrence of a disease or condition. To this end, the presently disclosed methods comprise administering a therapeutically effective amount of a composition as described herein. By “uracil glycosylase inhibitor” or “UGI” is meant an agent that inhibits the uracil- excision repair system. Base editors comprising a cytidine deaminase convert cytosine to uracil, which is then converted to thymine through DNA replication or repair. In various embodiments, a uracil DNA glycosylase (UGI) prevent base excision repair which changes the U back to a C. In some instances, contacting a cell and / or polynucleotide with a UGI and a base editor prevents base excision repair which changes the U back to a C. An exemplary UGI comprises an amino acid sequence as follows: >splP14739IUNGI_BPPB2 Uracil-DNA glycosylase inhibitor MTNLSDIIEKETGKQLVIQESILMLPEEVEEVIGNKPESDILVHTAYDESTDENVMLLTSDAPE YKPWALVIQDSNGENKIKML (SEQ ID NO: 231). In some embodiments, the agent inhibiting the uracil-excision repair system is a uracil stabilizing protein (USP). See, e.g., WO 2022015969 A1, incorporated herein by reference. As used herein, the term "vector" refers to a means of introducing a nucleic acid molecule into a cell, resulting in a transformed cell. Vectors include plasmids, transposons, phages, viruses, liposomes, lipid nanoparticles, and episomes. Ranges provided herein are understood to be shorthand for all of the values within the range. For example, a range of 1 to 50 is understood to include any number, combination of numbers, or sub-range from the group consisting 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50. By “VHH domain” is meant an antigen binding domain of a heavy chain only antibody or an antigen binding fragment thereof. A “VHH binding molecule” or “VHH antibody,” or simply “VHH,” as referred to herein is, in general, a single domain immunoglobulin molecule (antibody). A VHH (or VHH antibody) corresponds to the heavy chain of a VHH antibody having a single variable domain (or single variable region), e.g., a camelid-derived single variable H (VH) domain antibody. A VHH typically has a molecular weight (MW) of about 12-15 kDa. VHH antibodies lack light chains. These heavy-chain antibody molecules contain a single variable domain (VHH) and, typically, two constant domains (CH2and CH3). See, e.g., Methods in Molecular Biology, “Single Domain Antibodies – Methods and Protocols,” Eds. D. Saerens and S. Muyldermans, Humana Press (Springer), 2012. A cloned (recombinantly produced) and isolated VHH domain is a stable polypeptide harboring the antigen-binding capacity of the original heavy-chain antibody. See, e.g., U.S. Patent No.5,840,526 and U.S. Patent No.6,015,695, each of which is incorporated by reference herein in its entirety. VHHs are efficiently expressed in E. coli, coupled to detection markers, such as a fluorescent marker, or conjugated with enzymes. The small size of VHHs permits their binding to epitopes (antigenic determinants in antigen proteins), e.g., “hidden epitopes” that are not accessible to whole antibodies of much larger size. As a therapeutic, a VHH is capable of efficient penetration and rapid clearance. Its single domain nature allows a VHH to be expressed in a cell without a requirement for supramolecular assembly, as is needed for whole antibodies which are typically tetrameric (two heavy chains and two light chains, having a MW of about 150 kDa). VHHs are also exhibit stability over time and have a longer half-life versus non-VHH antibody molecules, which comprise disulfide bonds that are susceptible to chemical reduction or enzymatic cleavage. Similar to immunoglobulins, VHHs may be modified post-translationally, e.g., to add chemical linkers, detectable moieties, such as fluorescent dyes, enzymes, substrates, chemiluminescent moieties, etc., or specific binding moieties, such as streptavidin, avidin, or biotin, etc., for use in the compositions and methods described herein. The recitation of a listing of chemical groups in any definition of a variable herein includes definitions of that variable as any single group or combination of listed groups. The recitation of an embodiment for a variable or aspect herein includes that embodiment as any single embodiment or in combination with any other embodiments or portions thereof. All terms are intended to be understood as they would be understood by a person skilled in the art. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the disclosure pertains In this application, the use of the singular includes the plural unless specifically stated otherwise. It must be noted that, as used in the specification, the singular forms “a,” “an” and “the” include plural referents unless the context clearly dictates otherwise. In this application, the use of “or” means “and / or” unless stated otherwise. Furthermore, use of the term “including” as well as other forms, such as “include”, “includes,” and “included,” is not limiting. As used in this specification and claim(s), the words “comprising” (and any form of comprising, such as “comprise” and “comprises”), “having” (and any form of having, such as “have” and “has”), “including” (and any form of including, such as “includes” and “include”) or “containing” (and any form of containing, such as “contains” and “contain”) are inclusive or open-ended. This wording indicates that specific elements, features, components, and / or method steps are present, but does not exclude the presence of other additional, unrecited elements, features, components, and / or method steps. Any embodiments specified as “comprising” a particular component(s) or element(s) are also contemplated as “consisting of” or “consisting essentially of” the particular component(s) or element(s) in some embodiments. It is contemplated that any embodiment discussed in this specification can be implemented with respect to any method or composition of the present disclosure, and vice versa. Furthermore, compositions of the present disclosure can be used to achieve methods of the present disclosure. The term “about” or “approximately” means within an acceptable error range for the particular value as determined by one of ordinary skill in the art, which will depend in part on how the value is measured or determined, i.e., the limitations of the measurement system. Reference in the specification to “some embodiments,” “an embodiment,” “one embodiment” or “other embodiments” means that a particular feature, structure, or characteristic described in connection with the embodiments is included in at least some embodiments, but not necessarily all embodiments, of the present disclosures. BRIEF DESCRIPTION OF THE DRAWINGS FIGs.1A to 1C provide schematic diagrams providing a description of an Octet™ assay. FIG.1A provides an image showing the construction of dimeric polypeptides prepared to evaluate anti-CD19 VHH antibodies. The anti-CD19 VHH antibodies were expressed recombinantly as human IgG1 Fc (hFc tag) fusions that were then used to evaluate binding of the anti-CD19 VHH antibodies to CD19 using Biolayer Interferometry (BLI) using an Octet™ Instrument. FIG.1B provides a schematic diagram providing a description of the different stages of the Octet™ assay and the measurements taken at each stage of the Octet™ assay. FIG.1C provides schematic diagrams providing a description of an assay for avidity binding where the antigen (i.e., CD19) is immobilized to a biosensor and of monovalent binding in which the anti- CD19 VHH antibody is immobilized to a biosensor. Anti-Human Capture (AHC) Biosensors were used to immobilize the anti-CD19 VHH antibodies in the assay for monovalent binding. Immobilized Streptavidin (SA) Biosensors were used to immobilize CD19 in the assay for avid binding. FIG.2 provides a series of plots providing data gathered using the avid binding assay described in FIGs.1A-1C. In the plots of FIG.2, the y-axis represents response in terms of nanometer (nm) shift in interference pattern and is directly proportional to the number of molecules bound to the surface of the biosensor. In the plots of FIG.2, the x-axis represents time elapsed in seconds (s) where the following timepoints are labeled: 0, 100, 200, 300, 400, and 500 seconds; or 0, 100, 200, 300, 400, 500, and 600 seconds. In the plots of FIG.2, the zero timepoint indicates the time at which the biosensor was contacted with analyte (i.e., the beginning of the “Measure kon” stage of FIG.1B), and the vertical dotted line represents the point at which analyte was removed (i.e., the beginning of the “Measure koff” stage of FIG.1B). The numbers used to label each plot of FIG.2 correspond to the VHH #’s of Tables 1A to 1D. The plots labeled “FMC63” and “Blank” correspond to positive and negative control samples, respectively. FMC63 is an IgG2a mouse monoclonal antibody known to be capable of binding a CD19 polypeptide (see, e.g., Zola, et al. Immunol Cell Biol.69:411-22 (1991), the disclosure of which is incorporated herein in its entirety for all purposes). FIG.3 provides a series of plots providing data gathered using the monovalent binding assay described in FIGs.1A-1C. In the plots of FIG.3, the y-axis represents response in terms of nanometer (nm) shift in interference pattern and is directly proportional to the number of molecules bound to the surface of the biosensor. In the plots of FIG.3, the x-axis represents time elapsed in seconds (s) where the following timepoints are labeled: 0, 100, 200, 300, 400, 500, and 600 seconds. In the plots of FIG.3, the zero timepoint indicates the time at which the biosensor was contacted with analyte (i.e., the beginning of the “Measure kon” stage of FIG.1B), and the vertical dotted line represents the point at which analyte was removed (i.e., the beginning of the “Measure koff” stage of FIG.1B). The numbers used to label each plot of FIG.3 correspond to the VHH #’s of Tables 1A to 1D. The plots labeled “FMC63” and “Blank” correspond to positive and negative control samples, respectively. FIGs.4A and 4B provide schematic diagrams describing the domain structure of an anti- CD19 chimeric antigen receptor (19CAR) of the disclosure (FIG.4A) and a lentiviral construct (LV construct) used to introduce polynucleotides encoding the 19CAR to a cell (FIG.4B). In FIG.4B, the term “EGFR” indicates “epidermal growth factor receptor,” the term “MND” indicates a synthetic retroviral-derived MND promoter, and the black rectangle between the 19CAR and EGFR polypeptides indicates a self-cleaving peptide. In FIG.4A, an anti-CD19 VHH domain (αCD19 VHH binder) of the disclosure is fused to a CD8a hinge region domain, a CD8a transmembrane domain, a 4-1BB intracellular domain, and a CD3z intracellular domain. In FIG.4B, EGFR was co-expressed with the 19CAR to facilitate identification of LV- transduced cells using flow cytometry. FIG.5 provides flow cytometry scatter plots showing that T cells transduced with the lentiviral constructs of FIG.4B encoding the CAR polypeptides of FIG.4A containing anti- CD19 VHH domains corresponding to BTxCM Identifiers 537, 538, and 539 of Tables 1A to 1D, as indicated above the plots, expressed on the surface of the T cells. Detection of EGFR on the surface of the cells confirmed successful lentiviral transduction of the cells. In FIG.5, “VHH” indicates the 19CAR polypeptide. In FIG.5, the term “APC” indicates the fluorophore allophycocyanin (APC) and the term BV421 indicates the fluorophore Brilliant Violet™ 421 dye having an emission wavelength of 421 nm. The numbers in each quadrant of the plots of FIG.5 indicate the percent of total cells counted falling within the corresponding quadrant. FIG.6 provides a bar graph showing levels of surface expression of CAR polypeptides in cells transduced with the lentiviral constructs of FIG.4B encoding the CAR polypeptides of FIG.4A containing anti-CD19 VHH domains corresponding to the BTxCM identifiers of Tables 1A to 1D indicated along the x-axis. Cells expressing chimeric antigen receptors containing an FMC63 antigen binding domain were used as a positive control. In FIG.6, the term “UTD” indicates cells untransduced cells that did not express any chimeric antigen receptor polypeptide. FIG.7 provides bar graphs showing levels of expression of the cytokine interferon gamma (IFNγ) in T cells expressing the chimeric antigen receptors (CARs) of FIG.4A containing the antigen binding domains indicated along the x-axis and challenged with NALM6 CD19+ cells. The cells were transduced with lentiviruses containing the lentiviral constructs of FIG.4B. Expression levels of IFNγ was measured in cell cultures using an Ella Automated Immunoassay System. In FIG.7, FMC63 indicates the FMC63 antigen binding domain, “UTD” indicates untransduced cells that do not express any CAR, and “TUMOR” indicates a cell culture containing only NALM6 CD19+ cells and no CAR-expressing T cells. NALM6 cells are a B cell precursor leukemia cell line that surface-expresses CD19+. The numbers along the x-axis of FIG.7 correspond to the BTxCM identifiers of Tables 1A to 1D. In FIG.7, the vertical numbers indicate the IFNγ concentration corresponding to each bar. FIGs.8A and 8B provide plots showing that that T cells transduced with the lentiviral constructs of FIG.4B encoding the CAR polypeptides of FIG.4A containing anti-CD19 VHH domains corresponding to BTxCM Identifiers 537, 538, and 539 of Tables 1A to 1D were effective in killing NALM6 CD19+ cells. The NALM6 cells expressed green fluorescent protein. The y-axis of each figure represents green calibrated units (GCUs). CAR19 T cell-mediated killing of the NALM6 cells was measured at effector (CAR19 T cells) to target (NALM6 cells) ratios of 0.25:1 (FIG.8A) and 0.06:1 (FIG.8B). Killing of the NALM6 cells in the co-cultures was measured using a cytotoxicity assay carried out using an IncuCyte® Live-Cell Analysis System. DETAILED DESCRIPTION The present disclosure features polypeptides capable of binding a cluster of differentiation 19 (CD19) antigen and polynucleotides encoding said CD19-binding polypeptides, compositions comprising the same, and methods for use thereof. The disclosure also features lipid nanoparticles comprising the CD19-binding polypeptides and methods for use thereof for delivery of a polynucleotide (e.g., a polynucleotide encoding a chimeric antigen receptor) to a T cell in vivo. The aspects and embodiments of the disclosure are based, at least in part, on the discovery detailed in the Examples provided herein of new VHH antibodies capable of binding to a CD19 antigen. VHH ANTIBODIES In various aspects, the disclosure provides VHH antibodies, also known as “single- domain antibodies (sdAbs),” capable of binding a CD19 antigen, as well as polypeptides containing VHH domains or polynucleotides encoding the same. In embodiments, the CD19 bound by the VHH antibodies is associated with a disease or disorder, such as a neoplasia. In embodiments, the VHH binds an antigen associated with a target cell. In embodiments, the target cell is a neoplastic cell. VHH domains are derived from sdAbs. Single-domain antibodies are antibody-derived therapeutic proteins that contain the unique structural and functional properties of naturally- occurring heavy-chain antibodies. These heavy-chain antibodies contain a single variable domain (VHH) and two constant domains (CH2 and CH3). Importantly, a cloned and isolated VHH domain is a stable polypeptide harboring the full antigen-binding capacity of the original heavy- chain antibody. Single-domain antibodies have a high homology with the VH domains of human antibodies and can be further humanized without any loss of activity. Importantly, Single- domain antibodies have a low immunogenic potential, which has been confirmed in primate studies with sdAb lead compounds. Single-domain antibodies combine the advantages of conventional antibodies with important features of small molecule drugs. Like conventional antibodies, sdAbs show high target specificity, high affinity for their target, and low inherent toxicity. However, like small molecule drugs they can inhibit enzymes and readily access receptor clefts. Furthermore, sdAbs are stable, can be administered by means other than injection (see, e.g., WO2004041867A2, which is herein incorporated by reference in its entirety) and are easy to manufacture. Other advantages of sdAbs include recognizing uncommon or hidden epitopes as a result of their small size, binding into cavities or active sites of protein targets with high affinity and selectivity due to their unique 3-dimensional, drug format flexibility, tailoring of half-life and ease and speed of drug discovery. Single-domain antibodies are encoded by single genes and are efficiently produced in almost all prokaryotic and eukaryotic hosts, e.g., E. coli (see, e.g., U.S. Pat. No.6,765,087, which is herein incorporated by reference in its entirety), molds (for example Aspergillus or Trichoderma) and yeast (for example Saccharomyces, Kluyveromyces, Hansenula, or Pichia) (see, e.g., U.S. Pat. No.6,838,254, which is herein incorporated by reference in its entirety). VHHs, such as the anti-CD19 VHHs described herein, have a number of advantages over conventional antibodies and recombinant antibody domains, including (i) they are small monomeric proteins (14 kDa) that express and fold efficiently in recombinant hosts; (ii) they are more stable to extremes of pH and temperature compared with conventional antibodies; (iii) they typically bind conformational epitopes; and (iv) they are amenable to designed multimerization which often leads to higher potencies; and (v) they offer more therapeutic versatility, such as multispecificity, thus supporting their beneficial utility in treating diseases caused by or associated with CD19. The amino acid sequences of representative anti-CD19 VHH antibodies described herein are provided in Table 1A below. Representative polynucleotide sequences encoding the anti- CD19 VHH polypeptide sequences listed in Table 1A are provided in Table 1D below. Representative embodiments of the binding regions of the anti- CD19 VHHs include CDRs (CDR1, CDR2 and CDR3) as set forth in the sequences of representative anti-CD19 VHHs are presented in Tables 1A and 1B below. The CDR binding regions are positioned within framework (FR) regions (see Table 1C) of the VHH polypeptide (see Table 1A), which do not vary substantially in sequence between discrete anti-CD19 VHHs and which provide a “structural scaffold” for the CDRs, which bind to CD19. By way of non-limiting example, the binding of CDRs within FRs to a target protein (antigen), e.g., CD19, may be via conformational binding or interaction, electrostatic binding interaction, hydrogen bonding, Van der Waals forces, or hydrophobic bonding, or combinations thereof, as would be appreciated by those having skill in the art. Table 1A. Anti-CD19 VHH antibody amino acid sequences. Embodiments of complementarity determining regions (CDRs) calculated using the Kabat numbering scheme are underlined in each sequence, where the CDRs, from N-terminus to C-terminus, are CDR1, CDR2, and CDR3. The non-underlined portions of each sequence correspond, in order from N-terminus to C-terminus, FR1, FR2, FR3, and FR4.

[0003] Table 1B. Anti-CD19 VHH antibody complementarity determining region (CDR) amino acid sequences, where the CDRs were calculated using Chothia, AbM, Kabat, Contact, and IMGT numbering schemes, as indicated.

[0004] Table 1C. Anti-CD19 VHH antibody framework region (FR) amino acid sequences.

[0005] Table 1D. Anti-CD19 VHH antibody polynucleotide sequences. In various embodiments, the FR1 of a VHH antibody of the disclosure contains the following amino acid sequence: X1X2QLX3ESGGX4X5X6X7X8GX9X10LX11LSCAX12X13X14X15X16X17X18X19(SEQ ID NO: 781, where X1is E or Q; X2is L or V; X3is V or Q; X4is G or R; X5is K, L, or S; X6is A or V; X7is E, H, Q, or R; X8is A, P, T, or V; X9is D, E, or G; X10is S or T; X11is G, N, or R; X12is A or null; X13is A, H, I, L, or T; X14is A or S; X15is D, G, R, or S; X16is A, F, H, L, N, P, R, or S; X17is A, F, G, I, L, P, S, or T; X18is A, F, I, L, or V; and X19is A, D, E, G, I, N, R, S, or T. In various embodiments, the FR2 of a VHH antibody of the disclosure contains the following amino acid sequence: WX20RX21X22X23GX24X25X26X27X28X29X30, where X20is A, F, V, or Y; X21is E or Q; X22is A, P, T, or V; X23is E or P; X24is K or null; X25is A, E, G, null, or Q; X26is L, P, R, or V; X27is D, E, or Q; X28is F, G, L, or W; X29is L or V; and X30is A or S. In various embodiments, the FR3 of a VHH antibody of the disclosure contains the following amino acid sequence: RFTX31X32X33X34X35X36X37X38X39X40X41X42X43LX44X45X46X47LX48X49X50DX51X52X53YX54CX55X56(SEQ ID NO: 782), where X31is I or V; X32is F, S, or T; X33is K or R; X34is D, E, G, or V; X35is D, N, S, or T; X36is A or V; X37is D, E, K, L, or N; X38is A, G, N, R, S, or T; X39is L, R, or T; X40is A, G, L, M, or V; X41is null or S; X42is null or V; X43is D, F, S, or Y; X44is Q or R; X45is L or M; X46is D, I, N, or S; X47is N or S; X48is K, L, R, or T; X49is P or S; X50is D, E, or G; X51is A, S, or T; X52is A or G; X53is I, T, or V; X54is F, L, R, S, or Y; X55is A, N, Q, R, T, or Y; and X56is A, G, K, L, P, V, or W. In various embodiments, the FR4 of a VHH antibody of the disclosure contains the following amino acid sequence: X57GX58GX59X60VTVSS (SEQ ID NO: 783), where X57is R or W; X58is K, P, or Q; X59is A or T; and X60is L or Q. The CDRs of the anti-CD19 VHH polypeptides described herein may vary in amino acid sequence length. It will be appreciated by one skilled in the art that number of amino acids that constitute a CDR is not necessarily precise. In some cases, an amino acid residue, or 2 or 3 amino acid residues, at one end or both ends of a given CDR may be considered as part of the CDR or as part of the neighboring FR region. The CDR regions of representative anti-CD19 VHH antibody polypeptides described herein are presented in Tables 1A and 1B. The anti- CD19 VHH antibodies described herein demonstrate the CDR diversity that is selected during affinity maturation of CD19 binding polypeptides in the same animal. Despite such CDR diversity, the CD19 binding VHHs generated as described herein show detectable binding to CD19. The anti-CD19 VHH polypeptides demonstrate significant binding to the CD19 antigen, despite some variation among the CDR sequences in the context of their framework regions. In view of the representative anti-CD19 VHH amino acid sequences listed in Tables 1A- 1C, it will be appreciated by one skilled in the art that individual VHH polypeptides, (e.g., of from about 105 to about 140 amino acids in length and comprising 3 CDRs and 4 FR regions), which comprise at least about or equal to 85%, or 88%, or greater identity in amino acid sequence bind to CD19 antigen. In an embodiment, at least about or equal to 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% amino acid sequence identity is tolerated among the anti-CD19 VHHs without adversely affecting or eliminating binding of the VHH polypeptides to the CD19 antigen. In an embodiment, such amino acid sequence variation among the anti-CD19 VHH polypeptides is tolerated in the CDRs of the VHH polypeptides without adversely affecting binding of the VHHs to CD19. In a particular embodiment, the amino acid sequence variations between or among anti-CD19 VHHs encompass one or more conservative amino acid substitutions or changes in a VHH amino acid sequence. In an embodiment, the one or more conservative amino acid substitutions or changes in a VHH amino acid sequence occur in one or more CDR sequences of the VHH, in one or more FR sequences of the VHH, or in CDR and FR sequences of the VHH. The three CDRs of the anti-CD19 VHH polypeptides are arranged or positioned in the context of four FR regions as follows: FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4, in which FR1 to FR4 refer to the framework regions 1-4, respectively, and in which CDR1 to CDR3 refer to the complementarity determining regions 1-3, respectively. An alignment of anti-CD19 VHHs, all of which specifically bind to CD19 protein antigen, demonstrates the extensive similarities among the sequences of each of the FRs (FR1, FR2, FR3 and FR4) found in the different CD19- binding VHH polypeptides. Similar to the FRs in conventional antibody polypeptides, the respective FRs (FR1, FR2, FR3 and FR4) of the anti-CD19 VHH polypeptides described herein are highly similar in sequence among different CD19-binding VHHs that were generated. Accordingly, provided are anti-CD19 VHH polypeptides comprising CDR1-3, in the structural context of FR1-4, that bind to CD19 protein, or to suitable fragments of the CD19 protein, as well as polypeptides that comprise or consist essentially of one or more of the anti-CD19 VHHs and / or CD19 binding fragments thereof (e.g., a chimeric antigen receptor (CAR) polypeptide). In addition, the FRs of the CD19-binding VHHs described herein are highly or essentially similar in sequence to the FRs of VHHs produced in camelid animals, such as alpacas, camels, llamas, and the like. As they provide structural and conformational support for the CDRs of VHH polypeptides, the FRs and the FR1, FR2, FR3 and FR4 regions among camelid VHH polypeptides generally share significant sequence identity. See, e.g., A.M. Vattekatte et al., March, 2020, PeerJ., 6(8):e8408. DOI: 10.7717 / peerj.8408 and L.S. Mitchell and L.J. Colwell, 2018, Proteins, 86(7): 697-706). Table 1C presents the amino acid sequences of the four framework regions, i.e., FR1, FR2, FR3 and FR4, respectively, of representative anti-CD19 VHH polypeptides described herein. In embodiments, in cases in which a FR (or CDR) amino acid residue in a VHH polypeptide may be one of several alternative amino acid residues, the alternative amino acid residues will frequently share similar characteristics or properties, e.g., hydrophobicity, polarity, and / or charge. A conservative replacement (also called a conservative substitution) is an amino acid replacement or substitution in a polypeptide or region thereof that changes a given amino acid residue to a different amino acid residue with similar biochemical properties, such as charge, hydrophobicity, and / or size. By way of non-limiting example, the below Table 2 presents amino acids and their 1-letter codes categorized into six main classes based on their structure and the general chemical characteristics of their side chains (R groups). Table 2. Classes of amino acids based on structural and chemical characteristics of their side chains. In embodiments, an amino acid within an FR or CDR of a VHH antibody of the disclosure is substituted with another amino acid from the same class indicated in Table 2. In an embodiment, amino acid sequence substitutions or changes in an anti-CD19 VHH polypeptide relative to another anti-CD19 VHH polypeptide comprise conservative amino acid substitutions or changes such that a given amino acid residue is substituted with or replaced by a different amino acid residue with similar biochemical properties, such as charge, hydrophobicity, and / or size. In an embodiment, sequence variation between or among anti-CD19 VHH polypeptides results from one or more conservative amino acid changes and account for the percent sequence variation, e.g., 85%, 86%, 87%, 88%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence variation. In some embodiments, the VHHs as described herein are humanized using methods and techniques practiced by those having skill in the art. (See, e.g., U.S. Patent Nos.8,975,382 and 10,550,174, the contents of which are incorporated by reference herein). The anti-CD19 VHH antibodies described herein have widespread application (e.g., as antigen binding domains of chimeric antigen receptor polypeptides). In embodiments, the disclosure provides polynucleotides that encode operably linked modular components that constitute the described anti-CD19 VHHs. In embodiments, the anti-CD19 VHHs are recombinantly produced. In embodiments, the anti-CD19 VHHs encompass the proteins (polypeptides) encoded by the polynucleotides. In embodiments, the polynucleotide is DNA, cDNA, RNA, mRNA, or the like. In an embodiment, the anti-CD19 VHHs may be humanized or codon-optimized using methods practiced by those having skill in the art. Suitable methods of producing or isolating antibody fragments having the requisite binding specificity and affinity for binding to an epitope tag include for example, methods which select recombinant antibody from a library or by PCR (e.g., U.S. Patent No.5,455,030 and U.S. Patent No.7,745,587 each of which is incorporated by reference herein in its entirety). Functional fragments of antibodies, including fragments of chimeric, humanized, primatized, veneered, or single chain antibodies, can also be produced. Functional fragments or portions of the foregoing antibodies include those which are reactive with the CD19 protein. For example, antibody fragments capable of binding to CD19 or a portion thereof, include, but not limited to, scFvs, Fabs, VHHs, Fv, Fab, Fab' and F(ab')2. Such fragments can be produced by enzymatic cleavage or by recombinant techniques. For instance, papain or pepsin cleavage are used generate Fab or F(ab')2antibody fragments, respectively. Antibody fragments are produced in a variety of truncated forms using antibody-encoding genes in which one or more stop codons has been introduced upstream of the natural stop site. For example, a chimeric gene encoding a F(ab')2 heavy chain peptide portion can be designed to include DNA sequences encoding the CH1peptide domain and hinge region of an immunoglobulin heavy chain. LIPID NANOPARTICLES Lipid nanoparticles are spherical vesicles made of ionizable lipids, which are positively charged at low pH (enabling RNA complexation) and neutral at physiological pH (reducing potential toxic effects, as compared with positively charged lipids, such as liposomes) (see Nature Reviews Materials 6:99 (2021)). Owing to their size and properties, lipid nanoparticles are taken up by cells via endocytosis, and the ionizability of the lipids at low pH (likely) enables endosomal escape, which allows release of polypeptides or polynucleotides contained within the lipid nanoparticle to be released into the cytoplasm. In addition, lipid nanoparticles may contain a helper lipid to promote cell binding, cholesterol to fill the gaps between the lipids, and / or a polyethylene glycol (PEG) to reduce opsonization by serum proteins and reticuloendothelial clearance. The relative amounts of ionizable lipid, helper lipid, cholesterol and PEG substantially affect the efficacy of lipid nanoparticles, and need to be optimized for a given application and administration route. Moreover, lipid type, size and surface charge impact the behavior of lipid nanoparticles in vivo. Lipid nanoparticles may be used for the delivery of a polynucleotide to a cell. It can be advantageous to conjugate a lipid nanoparticle to an antigen-binding polypeptide (e.g., the CD19-binding polypeptides provided herein) where the antigen-binding polypeptide binds an antigen on a target cell so as to target the lipid nanoparticle to the garget cell. For example, given that B cells express CD19 on their surface, lipid nanoparticles conjugated to the CD19-binding polypeptides of the disclosure may be used for targeted delivery of a polynucleotide contained within the lipid nanoparticle to a B cell in a subject. Methods are available to the skilled practitioner for conjugating a lipid nanoparticle to an antigen-binding polypeptide (see, e.g., Yaozhong, et al. “Nanobody™-based delivery systems for diagnosis and targeted tumor therapy,” Front Immunol 8:1442 (2017)). Lipid nanoparticles include any one or more lipids. In some embodiments, the lipid nanoparticles (LNPs) include one or more cationic / ionizable, PEGylated, structural, or other lipids, such as phospholipids. In some embodiments, an LNP comprises a cationic lipid, a helper lipid, and a PEG-modified lipid. In some embodiments, an LNP comprises a cationic lipid, a helper lipid, a PEG-modified lipid, and sterol. Cationic lipids include both permanently charged and ionizable lipids. The ionizable lipids, for example, comprise ionizable lipids including a central amine moiety and at least one biodegradable group. The lipids described herein may be advantageously used in lipid nanoparticles and lipid nanoparticle formulations for the delivery of a therapeutic and / or prophylactic agent, such as a nucleic acid molecule, to a mammalian cell, tissue, or organ. Suitable LNPs include, for example, lipids familiar to a skilled practitioner or any novel inventive lipids that are generated in the future. Exemplary lipids are described, for example, in the following PCT patent application publications: WO 2015 / 095340, WO 2020 / 150320, WO 2020 / 219876, WO 2021 / 021634, WO 2021 / 113365, WO 2022 / 060871, WO 2017 / 075531, and WO 2021 / 141969, and the PCT Application No.: PCT / US2021 / 64339; the contents of each of which are incorporated herein by reference in their entirety for all purposes. Helper lipids In some embodiments, an LNP comprises one or more helper lipids. Helper lipids include, but are not limited to, distearoylphosphatidylcholine (DSPC), dioleoylphosphatidylcholine (DOPC), dipalmitoylphosphatidylcholine (DPPC), dioleoylphosphatidylglycerol (DOPG), dipalmitoylphosphatidylglycerol (DPPG), dioleoylphosphatidylethanolamine (DOPE), palmitoyloleoylphosphatidylcholine (POPC), palmitoyloleoyl-phosphatidylethanolamine (POPE), dioleoyl-phosphatidylethanolamine 4- (N- maleimidomethyl)-cyclohexane-l-carboxylate (DOPE-mal), dipalmitoyl phosphatidyl ethanolamine (DPPE), dimyristoylphosphoethanolamine (DMPE), distearoyl-phosphatidyl- ethanolamine (DSPE), 16-O-monomethyl PE, 16-O-dimethyl PE, 18-1-trans PE, l-stearoyl-2- oleoyl-phosphatidyethanolamine (SOPE), or a mixture thereof. PEG-modified Lipids In some embodiments, an LNP comprises one or more PEG lipids. PEG lipids include PEG-modified phosphatidylethanolamine and phosphatidic acid, PEG-ceramide conjugates (e.g., PEG- CerC14 or PEG-CerC20), PEG-modified dialkylamines and PEG-modified 1,2- diacyloxypropan-3-amines. Such lipids are also referred to as PEGylated lipids. In some embodiments, a PEG lipid can be PEG-c-DOMG, PEG-DMG, PEG-DLPE, PEG-DMPE, PEG- DPPC, or a PEG-DSPE lipid. In some embodiments, the PEG lipid includes, but are not limited to, 1,2- dimyristoyl-sn- glycerol methoxypoly ethylene glycol (PEG-DMG), 1,2-distearoyl-sn-glycero- 3- phosphoethanolamine-N-[amino(polyethylene glycol)] (PEG-DSPE), PEG-disteryl glycerol (PEG-DSG), PEG-dipalmetoleyl, PEG-dioleyl, PEG-distearyl, PEG-diacylglycamide (PEG- DAG), PEG-dipalmitoyl phosphatidylethanolamine (PEG-DPPE), or PEG-1, 2- dimyristyloxlpropy 1-3 -amine (PEG-c-DMA). In some embodiments, the PEG lipid is selected from the group consisting of a PEG- modified phosphatidylethanolamine, a PEG-modified phosphatidic acid, a PEG- modified ceramide, a PEG-modified dialkylamine, a PEG-modified diacylglycerol, a PEG- modified dialkylglycerol, and mixtures thereof. In some embodiments, the lipid moiety of the PEG lipids includes those having lengths of from about C14to about C22, e.g., from about C14to about C16. In some embodiments, a PEG moiety, for example an mPEG-NEb, has a size of about 1000, 2000, 5000, 10,000, 15,000 or 20,000 Daltons. In some embodiments, the PEG lipid is PEG2k- DMG. In some embodiments, the lipid nanoparticles described herein may comprise a PEG lipid which is a non-diffusible PEG. Non-limiting examples of non-diffusible PEGs include PEG-DSG and PEG-DSPE. PEG lipids are known in the art, such as those described in U.S. Patent No.8158601 and International Publ. No. WO 2015 / 130584 A2, the disclosures of which are incorporated herein by reference in their entirety for all purposes. In general, some of the other lipid components (e.g., PEG lipids) of various formulae, described herein may be synthesized as described International Patent Application No. PCT / US2016 / 000129, filed December 10, 2016, entitled “Compositions and Methods for Delivery of Therapeutic Agents,” the disclosure of which is incorporated herein by reference in its entirety for all purposes. The lipid component of a lipid nanoparticle or lipid nanoparticle formulation may include one or more molecules comprising polyethylene glycol, such as PEG or PEG- modified lipids. Such species may be alternately referred to as PEGylated lipids. A PEG lipid is a lipid modified with polyethylene glycol. A PEG lipid may be selected from the non-limiting group including PEG-modified phosphatidylethanolamines, PEG-modified phosphatidic acids, PEG-modified ceramides, PEG-modified dialkylamines, PEG-modified diacylglycerols, PEG-modified dialkylglycerols, and mixtures thereof. In some embodiments, a PEG lipid may be PEG-c- DOMG, PEG-DMG, PEG-DLPE, PEG-DMPE, PEG-DPPC, or a PEG-DSPE lipid. Sterols In some embodiments, an LNP comprises one or more sterol-based lipids. In some embodiments, a sterol is a cholesterol, or a variant or derivative thereof. In some embodiments, a cholesterol is modified. In some embodiments, a cholesterol is an oxidized cholesterol. Exemplary sterols that are considered for use in the disclosed lipid nanoparticles include but are not limited to 25-hydroxycholesterol (25-OH), 20α-hydroxycholesterol (20α-OH), 27- hydroxycholesterol, 6-keto-5α-hydroxycholesterol, 7-ketocholesterol, 7β-hydroxycholesterol, 7α-hydroxycholesterol, 7β-25-dihydroxycholesterol, beta-sitosterol, stigmasterol, brassicasterol, campesterol, or combinations thereof. In some embodiments, a side-chain oxidized cholesterol can enhance cargo delivery relative to other cholesterol variants. In some embodiments, a cholesterol is an unmodified cholesterol. Other examples of suitable cholesterol-based lipids include, for example, DC-Choi (N,N-dimethyl-N-ethylcarboxamidocholesterol), l,4-bis(3-N- oleylamino- propyl)piperazine (Gao, et al. Biochem. Biophys. Res. Comm.179, 280 (1991); Wolf et al. BioTechniques 23, 139 (1997); U.S. Pat. No.5,744,335, the disclosures of which are incorporated herein by reference in their entireties for all purposes), or ICE. Targeting Molecules In some embodiments, an LNP comprises one or more targeting molecules. It should be understood that a targeting particle of the present disclosure may comprise at least one (e.g., two or more) targeting molecules that are the same as each other (e.g., targeting ligands) or different from each other (e.g., targeting ligands and targeting antibodies). In some embodiments, a targeting molecule is an anti-CD19 VHH antibody of the disclosure, or a CD19-binding fragment thereof. Targeting Particles Compositions and methods of the disclosure involve targeting particles (also referred to as targeted particles). In various embodiments, a targeted particle is an LNPs (e.g., are capable of transporting molecules) of the disclosure, optionally with active agent encapsulated in or bound to (e.g., covalently or non-covalently conjugated to) the particle surface. Examples of particles of the present disclosure include, without limitation, liposomes and polymeric particles. In various embodiments, a targeted particle of the disclosure (e.g., an LNP) contains an anti-CD19 VHH antibody of the disclosure. In some cases, the anti-CD19 VHH antibody is covalently linked to a PEG molecule of an LNP. In some cases the anti-CD19 VHH antibody is covalently linked to a PEG portion of a PEG-modified lipid of an LNP of the disclosure. Non-limiting examples of cells that may be targeted by targeted particles of the disclosure include cells that express a CD19 polypeptide or a fragment thereof on their surface. In some cases, the cells targeted by the targeted particles of the disclosure are neoplastic cells (e.g., cells of a neoplasia, such as a B cell lymphoma or T cell lymphoma). The targeted cells may be B-cell acute lymphoblastic leukemia (B-ALL) cells, Non-Hodgkin’s Lymphoma (NHL) cells, or B-cell chronic lymphocytic leukemia (B-CLL) cells. In some embodiments, a targeted particle of the disclosure contains an anti-CD19 VHH antibody or CD19-binding fragment thereof conjugated to a surface thereof. Particle Conjugation In some embodiments, particles comprise antibodies or antibody fragments on their surface (e.g., an anti-CD19 VHH antibody of the disclosure, or an antigen-binding fragment thereof). In some embodiments, the antibodies may be designed to bind to target cells without triggering their elimination by complement or other antibody effector mechanisms. This may be achieved either by using antibody fragments or antibodies with mutations that abrogate Fc receptor binding or other effector mechanisms. In various embodiments, conjugating a VHH antibody of the disclosure to a molecule or particle involves introducing one or more cysteine amino acid residues to the VHH antibody and subsequently conjugating the one or more cysteines to a thiol-reactive compound (e.g., Maleimide, which is commonly used in bioconjugation reactions, as described, e.g., in Ravasco, et al., Chemistry Europe, 25:43-59 (2019) doi: 10.1002 / chem.201803174, the disclosure of which is incorporated herein by reference in its entirety for all purposes). In various embodiments, the particle is a lipid nanoparticle. In some cases, the VHH antibody is conjugated to a molecule (e.g., a PEG molecule) forming part of a lipid nanoparticle. These antibody and non-antibody based ligands may be conjugated (or attached or bound, as the terms are used interchangeably herein) to the particle surface covalently or non-covalently. The particles may be synthesized or modified post-synthesis to comprise one or more reactive groups on their exterior surface that can be used to conjugate the antibody and non-antibody based ligands. These particle reactive groups include without limitation thiol-reactive maleimide head groups, haloacetyl (e.g., iodoacetyl) groups, imidoester groups, N-hydroxysuccinimide esters, pyridyl disulfide groups, and the like. As an example, particles may be synthesized to include maleimide conjugated phospholipids such as, without limitation, DSPE-MaL-PEG2000. It will be understood that when surface modified in this manner, the particles are intended for use with ligands having complementary reactive groups (i.e., reactive groups that react with those of the particles). Methods for conjugating ligands or receptors such as antibodies to particle surfaces are described by Kwong et al. Cancer Research, 2013, 73:1547-1558, the entire contents of which are incorporated by reference herein for all purposes. Other exemplary methods of conjugation can include a reversible conjugation, such that the delivery vehicle can be disassociated from the targeting domain upon exposure to certain conditions or chemical agents. In another embodiment, the conjugation is an irreversible conjugation, such that under normal conditions the delivery vehicle does not dissociate from the targeting domain. In some embodiments, the conjugation comprises a covalent bond between an activated polymer conjugated lipid and the targeting domain. An activated polymer conjugated lipid is a molecule comprising a lipid portion and a polymer portion that has been activated via functionalization of a polymer conjugated lipid with a first coupling group. In one embodiment, the activated polymer conjugated lipid comprises a first coupling group capable of reacting with a second coupling group. In one embodiment, the activated polymer conjugated lipid is an activated pegylated lipid. In one embodiment, the first coupling group is bound to the lipid portion of the pegylated lipid. In another embodiment, the first coupling group is bound to the polyethylene glycol portion of the pegylated lipid. In one embodiment, the second functional group is covalently attached to the targeting domain. The first coupling group and second coupling group can be any functional groups known to those of skill in the art to react together form a covalent bond, for example under mild reaction conditions or physiological conditions. In some embodiments, the first coupling group or second coupling group are selected from the group consisting of maleimides, N-hydroxysuccinimide (NHS) esters, carbodiimides, hydrazide, pentafluorophenyl (PFP) esters, phosphines, hydroxymethyl phosphines, psoralen, imidoesters, pyridyl disulfide, isocyanates, vinyl sulfones, alpha-haloacetyls, aryl azides, acyl azides, alkyl azides, diazirines, benzophenone, epoxides, carbonates, anhydrides, sulfonyl chlorides, cyclooctyne, aldehydes, and sulfhydryl groups. In some embodiments, the first coupling group or second coupling group is selected from the group consisting of free amines (—NH2), free sulfhydryl groups (—SH), free hydroxide groups (— OH), carboxylates, hydrazides, and alkoxyamines. In some embodiments, the first coupling group is a functional group that is reactive toward sulfhydryl groups, such as maleimide, pyridyl disulfide, or a haloacetyl. In one embodiment, the first coupling group is a maleimide. In one embodiment, the second coupling group is a sulfhydryl group. The sulfhydryl group can be installed on the targeting domain using any method known to those of skill in the art. In one embodiment, the sulfhydryl group is present on a free cysteine residue. In one embodiment, the sulfhydryl group is revealed via reduction of a disulfide on the targeting domain, such as through reaction with 2-mercaptoethylamine. In one embodiment, the sulfhydryl group is installed via a chemical reaction, such as the reaction between a free amine and 2- iminothilane or N-succinimidyl S-acetylthioacetate (SATA). In some embodiments, the polymer conjugated lipid and targeting domain are functionalized with groups used in “click” chemistry. Bioorthogonal “click” chemistry comprises the reaction between a functional group with a 1,3-dipole, such as an azide, a nitrile oxide, a nitrone, an isocyanide, and the link, with an alkene or an alkyne dipolarophiles. Exemplary dipolarophiles include any strained cycloalkenes and cycloalkynes known to those of skill in the art, including, but not limited to, cyclooctynes, dibenzocyclooctynes, monofluorinated cyclcooctynes, difluorinated cyclooctynes, and biarylazacyclooctynone. Cargo In some embodiments, a particle or LNP composition of the disclosure may contain a cargo, such as one or more nucleic acids (e.g., a polynucleotide encoding a chimeric antigen receptor, an mRNA molecule encoding a base editor of the disclosure, and / or a guide RNA molecule). In some embodiments, the cargo is or comprises one or more biologically active agents, such as an mRNA, guide RNA (gRNA), nucleic acid, RNA-guided DNA-binding agent, expression vector, template nucleic acid, antibody (e.g. , monoclonal, chimeric, humanized, sdAb, and fragments thereof, etc.), cholesterol, hormone, peptide, protein, chemotherapeutic and other types of antineoplastic agent, low molecular weight drug, vitamin, co-factor, nucleoside, nucleotide, oligonucleotide, enzymatic nucleic acid, antisense nucleic acid, triplex forming oligonucleotide, antisense DNA or RNA composition, chimeric DNA:RNA composition, allozyme, aptamer, ribozyme, decoys and analogs thereof, plasmid and other types of vectors, and small nucleic acid molecule, RNAi agent, short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA), short hairpin RNA (shRNA) and self-replicating RNA (e.g., an RNA molecule encoding a replicase enzyme activity and capable of directing its own replication or amplification in vivo) molecules, peptide nucleic acid (PNA), a locked nucleic acid ribonucleotide (LNA), morpholino nucleotide, threose nucleic acid (TNA), glycol nucleic acid (GNA), sisiRNA (small internally segmented interfering RNA), and iRNA (asymmetrical interfering RNA). The above list of biologically active agents is exemplary only, and is not intended to be limiting. Such compounds may be purified or partially purified, and may be naturally occurring or synthetic, and may be chemically modified. Cargo delivered via an LNP composition may be an RNA, such as an mRNA molecule encoding a protein of interest. For example, in some embodiments, an mRNA for expressing a protein such as green fluorescent protein (GFP), an RNA-guided DNA-binding agent, or a Cas nuclease is described herein. LNP compositions that include a Cas nuclease mRNA, for example a Class 2 Cas nuclease mRNA that allows for expression in a cell of a Class 2 Cas nuclease such as a Cas9 or Cpfl protein are provided. Further, cargo may contain one or more guide RNAs or nucleic acids encoding guide RNAs. A template nucleic acid, e.g., for repair or recombination, may also be included in the composition or a template nucleic acid may be used in the methods described herein. In some embodiments, cargo comprises an mRNA that encodes a Streptococcus pyogenes Cas9, optionally and an S. pyogenes gRNA. In some embodiments, cargo comprises an mRNA that encodes a Neisseria meningitidis Cas9, optionally and an nme gRNA. In some embodiments, the disclosed compositions, preparations, nanoparticles, and / or nanomaterials contain an mRNA encoding an RNA-guided DNA-binding agent, such as a Cas nuclease, and / or a base editor of the disclosure. In particular embodiments, the disclosed compositions, preparations, nanoparticles, and / or nanomaterials comprise an mRNA encoding a Class 2 Cas nuclease, such as S. pyogenes Cas9. In some embodiments, cargo for an LNP composition includes at least one guide RNA containing a spacer sequence that mediates directing of a napDNAbp to a target DNA. gRNA may guide a Cas nuclease, Class 2 Cas nuclease, and / or base editor to a target sequence on a target nucleic acid molecule. Certain embodiments of the disclosure also provide nucleic acids, e.g., expression cassettes, encoding a gRNA described herein. Certain embodiments of the present disclosure also provide delivery of a base editor (e.g., an adenine base editors (“ABEs”), a cytidine base editor (“CBE”) or a cytidine adenine base editor (“CABE”)) using the LNPs compositions, preparations, nanoparticles, and / or nanomaterials described herein. Base editors and methods of their use are described herein and in, e.g., U.S. Patents No.10,113,163, 10,167,457 and 9,840,699, and U.S. Patent Publication No. 2021 / 0130805, the contents of each of which are hereby incorporated by reference in their entireties for all purposes. EDITING OF TARGET GENES To edit a polynucleotide in a cell, cells within or collected from a subject are contacted with one or more guide RNAs and a nucleobase editor polypeptide comprising a nucleic acid programmable DNA binding protein (napDNAbp) and a cytidine deaminase or adenosine deaminase or comprising one or more deaminases with cytidine deaminase and / or adenosine deaminase activity (e.g., a “dual deaminase” which has cytidine and adenosine deaminase activity). Editing a polynucleotide in a cell may involve administering to a subject a lipid nanoparticle of the disclosure, where the lipid nanoparticle contains as a cargo a base editor system (e.g., an mRNA molecule encoding a base editor of the disclosure and a gRNA molecule). In some embodiments, cells to be edited are contacted with at least one nucleic acid, wherein the at least one nucleic acid encodes one or more guide RNAs and a nucleobase editor polypeptide comprising a nucleic acid programmable DNA binding protein (napDNAbp) and a cytidine deaminase. In some embodiments, the gRNA comprises nucleotide analogs. In some instances, the gRNA is added directly to a cell. These nucleotide analogs can inhibit degradation of the gRNA from cellular processes. NUCLEOBASE EDITORS Useful in the methods and compositions described herein are nucleobase editors that edit, modify or alter a target nucleotide sequence of a polynucleotide. Nucleobase editors described herein typically include a polynucleotide programmable nucleotide binding domain and a nucleobase editing domain (e.g., adenosine deaminase, cytidine deaminase, or a dual deaminase). A polynucleotide programmable nucleotide binding domain, when in conjunction with a bound guide polynucleotide (e.g., gRNA), can specifically bind to a target polynucleotide sequence and thereby localize the base editor to the target nucleic acid sequence desired to be edited. Polynucleotide Programmable Nucleotide Binding Domain Polynucleotide programmable nucleotide binding domains bind polynucleotides (e.g., RNA, DNA). A polynucleotide programmable nucleotide binding domain of a base editor can itself comprise one or more domains (e.g., one or more nuclease domains). In some embodiments, the nuclease domain of a polynucleotide programmable nucleotide binding domain comprises an endonuclease or an exonuclease. Disclosed herein are base editors comprising a polynucleotide programmable nucleotide binding domain comprising all or a portion (e.g., a functional portion) of a CRISPR protein (i.e., a base editor comprising as a domain all or a portion (e.g., a functional portion) of a CRISPR protein (e.g., a Cas protein), also referred to as a “CRISPR protein-derived domain” of the base editor). A CRISPR protein-derived domain incorporated into a base editor can be modified compared to a wild-type or natural version of the CRISPR protein. A CRISPR protein-derived domain may comprise one or more mutations, insertions, deletions, rearrangements and / or recombinations relative to a wild-type or natural version of the CRISPR protein. Cas proteins that can be used herein include class 1 and class 2. Non-limiting examples of Cas proteins include Cas1, Cas1B, Cas2, Cas3, Cas4, Cas5, Cas5d, Cas5t, Cas5h, Cas5a, Cas6, Cas7, Cas8, Cas9 (also known as Csn1 or Csx12), Cas10, Csy1 , Csy2, Csy3, Csy4, Cse1, Cse2, Cse3, Cse4, Cse5e, Csc1, Csc2, Csa5, Csn1, Csn2, Csm1, Csm2, Csm3, Csm4, Csm5, Csm6, Cmr1, Cmr3, Cmr4, Cmr5, Cmr6, Csb1, Csb2, Csb3, Csx17, Csx14, Csx10, Csx16, CsaX, Csx3, Csx1, Csx1S, Csf1, Csf2, CsO, Csf4, Csd1, Csd2, Cst1, Cst2, Csh1, Csh2, Csa1, Csa2, Csa3, Csa4, Csa5, Cas12a / Cpf1, Cas12b / C2c1 (e.g., SEQ ID NO: 232), Cas12c / C2c3, Cas12d / CasY, Cas12e / CasX, Cas12g, Cas12h, Cas12i, and Cas12j / CasΦ, CARF, DinG, homologues thereof, or modified versions thereof. A CRISPR enzyme can direct cleavage of one or both strands at a target sequence, such as within a target sequence and / or within a complement of a target sequence. For example, a CRISPR enzyme can direct cleavage of one or both strands within about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 50, 100, 200, 500, or more base pairs from the first or last nucleotide of a target sequence. In some embodiments, the napDNAbp is a circular permutant (e.g., SEQ ID NO: 238). In some embodiments, the polynucleotide programmable nucleotide binding domain comprises a nickase domain. Herein the term “nickase” refers to a polynucleotide programmable nucleotide binding domain comprising a nuclease domain that is capable of cleaving only one strand of the two strands in a duplexed nucleic acid molecule (e.g., DNA). For example, where a polynucleotide programmable nucleotide binding domain comprises a nickase domain derived from Cas9, the Cas9-derived nickase domain can include a D10A mutation and a histidine at position 840. In another example, a Cas9-derived nickase domain comprises an H840A mutation, while the amino acid residue at position 10 remains a D. Also provided herein are base editors comprising a polynucleotide programmable nucleotide binding domain which is catalytically dead (i.e., incapable of cleaving a target polynucleotide sequence). For example, in the case of a base editor comprising a Cas9 domain, the Cas9 may comprise both a D10A mutation and an H840A mutation. In further embodiments, a catalytically dead polynucleotide programmable nucleotide binding domain comprises a point mutation (e.g., D10A or H840A) as well as a deletion of all or a portion (e.g., a functional portion) of a nuclease domain. dCas9 domains are known in the art and described, for example, in Qi et al., “Repurposing CRISPR as an RNA-guided platform for sequence-specific control of gene expression.” Cell.2013; 152(5):1173-83, the entire contents of which are incorporated herein by reference. The term “protospacer adjacent motif (PAM)” or PAM-like motif refers to a 2-6 base pair DNA sequence immediately following the DNA sequence targeted by a nucleic acid programmable DNA binding protein. In some embodiments, the PAM can be a 5′ PAM (i.e., located upstream of the 5′ end of the protospacer). In other embodiments, the PAM can be a 3′ PAM (i.e., located downstream of the 5′ end of the protospacer). The PAM sequence can be any PAM sequence known in the art. Suitable PAM sequences in...

Claims

CLAIMS What is claimed:

1. A VHH antibody or an antigen binding fragment thereof that specifically binds to a cluster of differentiation 19 (CD19) polypeptide, wherein the VHH antibody comprises three Complementarity Determining Regions (CDRs): CDR1, CDR2 and CDR3, that are structurally positioned between four camelid VHH framework (FR) regions (FR1-FR4) as follows: FR1- CDR1-FR2-CDR2-FR3-CDR3-FR4; wherein a) CDR1 is selected from the group consisting of:FYSIG (SEQ ID NO: 543),GYTIG (SEQ ID NO: 544),SYTIG (SEQ ID NO: 545),FNFMA (SEQ ID NO: 546),FNTMG (SEQ ID NO: 547),IDDMG (SEQ ID NO: 548),IDAMA (SEQ ID NO: 549),MNAMG (SEQ ID NO: 550), INAMA (SEQ ID NO: 551),PNDMG (SEQ ID NO: 552),VNDMG (SEQ ID NO: 553),GWQMG (SEQ ID NO: 554),NHGMG (SEQ ID NO: 594),SFAID (SEQ ID NO: 595),DYSMD (SEQ ID NO: 596),STIMG (SEQ ID NO: 597),TMA,GHGMG (SEQ ID NO: 598),NYGMM (SEQ ID NO: 599),LYAMA (SEQ ID NO: 600),GYYMS (SEQ ID NO: 601),SYTMG (SEQ ID NO: 602), INNIN (SEQ ID NO: 603),SYAMG (SEQ ID NO: 604),TYTMG (SEQ ID NO: 605), andNYAMG (SEQ ID NO: 643); b) CDR2 is selected from the group consisting of:CITWSGERTNYKDSVKG (SEQ ID NO: 555),CISRSDTSTKYADSVKG (SEQ ID NO: 556),CISRSTSDARYADSVKG (SEQ ID NO: 557),SITGGSRLSYIDSVKG (SEQ ID NO: 558),RITMSGIPNYADSVKG (SEQ ID NO: 559), TITAGGIANYADSAKG (SEQ ID NO: 560),SITAGGITKYADSAKG (SEQ ID NO: 561), TITAGGITNYASSAKG (SEQ ID NO: 562),TITAGGITKYGDSAKG (SEQ ID NO: 563), SITAGRITKYADSAKG (SEQ ID NO: 564),TITAGGITNYADSAKG (SEQ ID NO: 565), TITAGGITKYADSAKG (SEQ ID NO: 566),SITAGGITNYADSAKG (SEQ ID NO: 567), FSSSGGITNYADSVKG (SEQ ID NO: 568),TITDNDFTYYAASVKD (SEQ ID NO: 569), VITSGGSTNYADSVKG (SEQ ID NO: 570),IITDGGITNYAATVKG (SEQ ID NO: 571), ASYSGGSTNYADSVKG (SEQ ID NO: 572),AIYSGGSTNYADSVKG (SEQ ID NO: 573), SISMSDGSTSYQDSVKG (SEQ ID NO: 574),GSYTDGSTYYADSVKG (SEQ ID NO: 606), AINRGGDRTYYSDSVKG (SEQ ID NO: 607),AINRNGGSTYYAESMKG (SEQ ID NO: 608), ISARSGDSESYASSVKD (SEQ ID NO: 609),AITWSGGLTYYEDSVKG (SEQ ID NO: 610), AISWSGGLTYYGDSVKG (SEQ ID NO: 611),AISWSGGLTYYADSVKG (SEQ ID NO: 612), AIAWNSGLTYYGDSVKG (SEQ ID NO: 613),AISWSGVSTAYADSVKG (SEQ ID NO: 614), YIDSGGGSTYYTDSVRG (SEQ ID NO: 615),DISNGGVTTRYADSVKG (SEQ ID NO: 616),SIYSDDSNTYYADSVKG (SEQ ID NO: 617),AVNWDNVKNYADPVKG (SEQ ID NO: 618), TTRWRGDSTYYADSVAG (SEQ ID NO: 619),TISLSGGSTFYSDSAKG (SEQ ID NO: 620), TISLSGGSTFYSGSAKG (SEQ ID NO: 621),AISSSGDSTYYTDSVKG (SEQ ID NO:622), AITWSGGSTYYANSVKG (SEQ ID NO: 644),AISWSGGSTYYANSVKG (SEQ ID NO: 645), DISWSGGTTNYANSVKG (SEQ ID NO: 646),AINWSGGRIYYTDSVKG (SEQ ID NO: 647), AIRWSGGSTYYGDSVKG (SEQ ID NO: 648),AISWSGGRIYYADSVKG (SEQ ID NO: 649), AISWSGGSIYYADSVKG (SEQ ID NO: 650),AISWSGGSTYYADSVKG (SEQ ID NO: 651), AISWRGVNTYYADSVKG (SEQ ID NO: 652), and AISWSGGGTYYADSVKG (SEQ ID NO: 653); and c) CDR3 is selected from the group consisting of:DSGYPCYGSSWSSVGYDF (SEQ ID NO: 575),SLQSGLLSRFLLPRQYDH (SEQ ID NO: 576),SRQTGLLSTFLLPRQYDH (SEQ ID NO: 577),SSPFAGEF (SEQ ID NO: 578),EHSGY (SEQ ID NO: 579),IRRYYPRFDY (SEQ ID NO: 580),VRRYYPRFDY (SEQ ID NO: 581),IRKYYPRFDY (SEQ ID NO: 582),VRKYYPRFDY (SEQ ID NO: 583),IRRSYPRFDY (SEQ ID NO: 584),IRKFYPRFDY (SEQ ID NO: 585), IRRFYPRFDY (SEQ ID NO: 586),DILQSGWYTY (SEQ ID NO: 587),DGIYSGGRYYPSS (SEQ ID NO: 588),DLVYYSGNPGDYGMDY (SEQ ID NO: 589),NIPYPRVSS (SEQ ID NO: 590), DLVVVTTTPPSFPMPYRFLEV (SEQ ID NO: 591),DIVVVTTTPPSFPMPYRFLEV (SEQ ID NO: 592),RSRFGFEY (SEQ ID NO: 779),RQYYRSGYVDY (SEQ ID NO: 623), GGRVSADGKKWEYDY (SEQ ID NO: 624),NTGAGTI (SEQ ID NO: 625), RSTFRTALVNTVTAYDT (SEQ ID NO: 626),RTTFRTGLIVTVTAYDT (SEQ ID NO: 627), RRTFRTALINTVTAYDT (SEQ ID NO:628),RRTFRTALINTITAYDT (SEQ ID NO: 629), RRTFRTGLINTVTAYDT (SEQ ID NO: 630),RRTFRTGLIDTVTAYDT (SEQ ID NO: 631), GLYSRPTTERREYIY (SEQ ID NO: 632), GLYSRPTTERRDYIY (SEQ ID NO: 633), AIGVVSGSLEV (SEQ ID NO: 634),TTTGWRA (SEQ ID NO: 635),SATLRGRDTRFDY (SEQ ID NO: 636),GTNLPTRGSGS (SEQ ID NO: 637),GTNLPTIESGS (SEQ ID NO: 638), KGGVDV (SEQ ID NO: 639),RPVLISRSSTDYAY (SEQ ID NO: 640),RPVLISRSSIDYAY (SEQ ID NO: 641),GEEVAGKYFRALYDY (SEQ ID NO: 642), GEEVAGKYFRPLYDY (SEQ ID NO: 654),GEEVAGKYFRQLYDY (SEQ ID NO: 655),GEEVDGKYFRPLYDY (SEQ ID NO: 656), GTNWSIPPDY (SEQ ID NO: 657),DPIGLGYEMGEYDY (SEQ ID NO: 658),DDFERTMTEVRY (SEQ ID NO: 659),DGTLRTPMNLIHY (SEQ ID NO: 660),DPSLSRTMDEIGS (SEQ ID NO: 661), and GPLGATMSEIGS (SEQ ID NO: 662).

2. The method of claim 1, wherein:a) CDR1 comprises the amino acid sequence FYSIG (SEQ ID NO: 543), CDR2 comprises the amino acid sequence CITWSGERTNYKDSVKG (SEQ ID NO: 555), and CDR3 comprises the amino acid sequence DSGYPCYGSSWSSVGYDF (SEQ ID NO: 575); b) CDR1 comprises the amino acid sequence GYTIG (SEQ ID NO: 544), CDR2 comprises the amino acid sequence CISRSDTSTKYADSVKG (SEQ ID NO: 556), and CDR3 comprises the amino acid sequence SLQSGLLSRFLLPRQYDH (SEQ ID NO: 576); c) CDR1 comprises the amino acid sequence SYTIG (SEQ ID NO: 545), CDR2 comprises the amino acid sequence CISRSTSDARYADSVKG (SEQ ID NO: 557), and CDR3 comprises the amino acid sequence SRQTGLLSTFLLPRQYDH (SEQ ID NO: 577); d) CDR1 comprises the amino acid sequence FNFMA (SEQ ID NO: 546), CDR2 comprises the amino acid sequence SITGGSRLSYIDSVKG (SEQ ID NO: 558), and CDR3 comprises the amino acid sequence SSPFAGEF (SEQ ID NO: 578); e) CDR1 comprises the amino acid sequence FNTMG (SEQ ID NO: 547), CDR2 comprises the amino acid sequenceRITMSGIPNYADSVKG (SEQ ID NO: 559), and CDR3 comprises the amino acid sequenceEHSGY (SEQ ID NO: 579); f) CDR1 comprises the amino acid sequenceIDDMG (SEQ ID NO: 548), CDR2 comprises the amino acid sequenceTITAGGIANYADSAKG (SEQ ID NO: 560), and CDR3 comprises the amino acid sequenceIRRYYPRFDY (SEQ ID NO: 580); g) CDR1 comprises the amino acid sequence IDDMG (SEQ ID NO: 548), CDR2 comprises the amino acid sequenceSITAGGITKYADSAKG (SEQ ID NO: 561), and CDR3 comprises the amino acid sequenceVRRYYPRFDY (SEQ ID NO: 581); h) CDR1 comprises the amino acid sequence IDDMG (SEQ ID NO: 548), CDR2 comprises the amino acid sequenceTITAGGITNYASSAKG (SEQ ID NO: 562), and CDR3 comprises the amino acid sequenceIRKYYPRFDY (SEQ ID NO: 582); i) CDR1 comprises the amino acid sequence IDDMG (SEQ ID NO: 548), CDR2 comprises the amino acid sequenceSITAGGITKYADSAKG (SEQ ID NO: 561), and CDR3 comprises the amino acid sequenceVRKYYPRFDY (SEQ ID NO: 583); j) CDR1 comprises the amino acid sequence IDDMG (SEQ ID NO: 548), CDR2 comprises the amino acid sequenceTITAGGITKYGDSAKG (SEQ ID NO: 563), and CDR3 comprises the amino acid sequenceVRRYYPRFDY (SEQ ID NO: 581); k) CDR1 comprises the amino acid sequence IDDMG (SEQ ID NO: 548), CDR2 comprises the amino acid sequenceSITAGRITKYADSAKG (SEQ ID NO: 564), and CDR3 comprises the amino acid sequence IRRSYPRFDY (SEQ ID NO: 584);l) CDR1 comprises the amino acid sequence IDDMG (SEQ ID NO: 548), CDR2 comprises the amino acid sequenceTITAGGITNYADSAKG (SEQ ID NO: 565), and CDR3 comprises the amino acid sequenceIRKFYPRFDY (SEQ ID NO: 585); m) CDR1 comprises the amino acid sequence IDDMG (SEQ ID NO: 548), CDR2 comprises the amino acid sequenceTITAGGITKYADSAKG (SEQ ID NO: 566), and CDR3 comprises the amino acid sequenceIRRFYPRFDY (SEQ ID NO: 586); n) CDR1 comprises the amino acid sequence IDDMG (SEQ ID NO: 548), CDR2 comprises the amino acid sequenceSITAGGITKYADSAKG (SEQ ID NO: 561), and CDR3 comprises the amino acid sequenceIRRFYPRFDY (SEQ ID NO: 586); o) CDR1 comprises the amino acid sequence IDDMG (SEQ ID NO: 548), CDR2 comprises the amino acid sequenceSITAGGITNYADSAKG (SEQ ID NO: 567), and CDR3 comprises the amino acid sequenceIRRFYPRFDY (SEQ ID NO: 586); p) CDR1 comprises the amino acid sequence IDAMA (SEQ ID NO: 549), CDR2 comprises the amino acid sequenceFSSSGGITNYADSVKG (SEQ ID NO: 568), and CDR3 comprises the amino acid sequenceDILQSGWYTY (SEQ ID NO: 587); q) CDR1 comprises the amino acid sequence MNAMG (SEQ ID NO: 550), CDR2 comprises the amino acid sequenceTITDNDFTYYAASVKD (SEQ ID NO: 569), and CDR3 comprises the amino acid sequenceDGIYSGGRYYPSS (SEQ ID NO: 588); r) CDR1 comprises the amino acid sequenceINAMA (SEQ ID NO: 551), CDR2 comprises the amino acid sequenceVITSGGSTNYADSVKG (SEQ ID NO: 570), and CDR3 comprises the amino acid sequenceDLVYYSGNPGDYGMDY (SEQ ID NO: 589); s) CDR1 comprises the amino acid sequencePNDMG (SEQ ID NO: 552), CDR2 comprises the amino acid sequenceIITDGGITNYAATVKG (SEQ ID NO: 571), and CDR3 comprises the amino acid sequenceNIPYPRVSS (SEQ ID NO: 590); t) CDR1 comprises the amino acid sequence VNDMG (SEQ ID NO: 553), CDR2 comprises the amino acid sequenceASYSGGSTNYADSVKG (SEQ ID NO: 572), and CDR3 comprises the amino acid sequenceDLVVVTTTPPSFPMPYRFLEV (SEQ ID NO: 591); u) CDR1 comprises the amino acid sequence VNDMG (SEQ ID NO: 553), CDR2 comprises the amino acid sequenceAIYSGGSTNYADSVKG (SEQ ID NO: 573), and CDR3 comprises the amino acid sequenceDIVVVTTTPPSFPMPYRFLEV (SEQ ID NO: 592); v) CDR1 comprises the amino acid sequence GWQMG (SEQ ID NO: 554), CDR2 comprises the amino acid sequenceSISMSDGSTSYQDSVKG (SEQ ID NO: 574), and CDR3 comprises the amino acid sequenceRSRFGFEY (SEQ ID NO: 779);w) CDR1 comprises the amino acid sequenceNHGMG (SEQ ID NO: 594), CDR2 comprises the amino acid sequenceGSYTDGSTYYADSVKG (SEQ ID NO: 606), and CDR3 comprises the amino acid sequenceRQYYRSGYVDY (SEQ ID NO: 623); x) CDR1 comprises the amino acid sequence SFAID (SEQ ID NO: 595), CDR2 comprises the amino acid sequenceAINRGGDRTYYSDSVKG (SEQ ID NO: 607), and CDR3 comprises the amino acid sequenceGGRVSADGKKWEYDY (SEQ ID NO: 624); y) CDR1 comprises the amino acid sequenceDYSMD (SEQ ID NO: 596), CDR2 comprises the amino acid sequenceAINRNGGSTYYAESMKG (SEQ ID NO: 608), and CDR3 comprises the amino acid sequenceGGRVSADGKKWEYDY (SEQ ID NO: 624); z) CDR1 comprises the amino acid sequence STIMG (SEQ ID NO: 597), CDR2 comprises the amino acid sequenceISARSGDSESYASSVKD (SEQ ID NO: 609), and CDR3 comprises the amino acid sequenceNTGAGTI (SEQ ID NO: 625); aa) CDR1 comprises the amino acid sequence TMA CDR2 comprises the amino acid sequenceAITWSGGLTYYEDSVKG (SEQ ID NO: 610), and CDR3 comprises the amino acid sequenceRSTFRTALVNTVTAYDT (SEQ ID NO: 626); ab) CDR1 comprises the amino acid sequenceTMA CDR2 comprises the amino acid sequenceAISWSGGLTYYGDSVKG (SEQ ID NO: 611), and CDR3 comprises the amino acid sequenceRTTFRTGLIVTVTAYDT (SEQ ID NO: 627); ac) CDR1 comprises the amino acid sequence TMA CDR2 comprises the amino acid sequenceAISWSGGLTYYADSVKG (SEQ ID NO: 612), and CDR3 comprises the amino acid sequenceRRTFRTALINTVTAYDT (SEQ ID NO: 628); ad) CDR1 comprises the amino acid sequenceTMA CDR2 comprises the amino acid sequenceAISWSGGLTYYGDSVKG (SEQ ID NO: 611), and CDR3 comprises the amino acid sequenceRRTFRTALINTITAYDT (SEQ ID NO: 629); ae) CDR1 comprises the amino acid sequence TMA CDR2 comprises the amino acid sequenceAIAWNSGLTYYGDSVKG (SEQ ID NO: 613), and CDR3 comprises the amino acid sequenceRRTFRTGLINTVTAYDT (SEQ ID NO: 630); af) CDR1 comprises the amino acid sequence TMA CDR2 comprises the amino acid sequenceAISWSGGLTYYGDSVKG (SEQ ID NO: 611), and CDR3 comprises the amino acid sequenceRRTFRTGLIDTVTAYDT (SEQ ID NO: 631); ag) CDR1 comprises the amino acid sequenceGHGMG (SEQ ID NO: 598), CDR2 comprises the amino acid sequence AISWSGVSTAYADSVKG (SEQ ID NO: 614), and CDR3 comprises the amino acid sequence GLYSRPTTERREYIY (SEQ ID NO: 632);ah) CDR1 comprises the amino acid sequenceGHGMG (SEQ ID NO: 598), CDR2 comprises the amino acid sequence AISWSGVSTAYADSVKG (SEQ ID NO: 614), and CDR3 comprises the amino acid sequence GLYSRPTTERRDYIY (SEQ ID NO: 633); ai) CDR1 comprises the amino acid sequenceNYGMM (SEQ ID NO: 599), CDR2 comprises the amino acid sequenceYIDSGGGSTYYTDSVRG (SEQ ID NO: 615), and CDR3 comprises the amino acid sequenceAIGVVSGSLEV (SEQ ID NO: 634); aj) CDR1 comprises the amino acid sequenceLYAMA (SEQ ID NO: 600), CDR2 comprises the amino acid sequenceDISNGGVTTRYADSVKG (SEQ ID NO: 616), and CDR3 comprises the amino acid sequenceTTTGWRA (SEQ ID NO: 635); ak) CDR1 comprises the amino acid sequenceGYYMS (SEQ ID NO: 601), CDR2 comprises the amino acid sequenceSIYSDDSNTYYADSVKG (SEQ ID NO: 617), and CDR3 comprises the amino acid sequenceSATLRGRDTRFDY (SEQ ID NO: 636); al) CDR1 comprises the amino acid sequenceSYTMG (SEQ ID NO: 602), CDR2 comprises the amino acid sequenceAVNWDNVKNYADPVKG (SEQ ID NO: 618), and CDR3 comprises the amino acid sequenceGTNLPTRGSGS (SEQ ID NO: 637); am) CDR1 comprises the amino acid sequence SYTMG (SEQ ID NO: 602), CDR2 comprises the amino acid sequenceAVNWDNVKNYADPVKG (SEQ ID NO: 618), and CDR3 comprises the amino acid sequenceGTNLPTIESGS (SEQ ID NO: 638); an) CDR1 comprises the amino acid sequenceINNIN (SEQ ID NO: 603), CDR2 comprises the amino acid sequenceTTRWRGDSTYYADSVAG (SEQ ID NO:619), and CDR3 comprises the amino acid sequenceKGGVDV (SEQ ID NO: 639); ao) CDR1 comprises the amino acid sequenceSYAMG (SEQ ID NO: 604), CDR2 comprises the amino acid sequenceTISLSGGSTFYSDSAKG (SEQ ID NO: 620), and CDR3 comprises the amino acid sequenceRPVLISRSSTDYAY (SEQ ID NO: 640); ap) CDR1 comprises the amino acid sequenceSYAMG (SEQ ID NO: 604), CDR2 comprises the amino acid sequenceTISLSGGSTFYSDSAKG (SEQ ID NO: 620), and CDR3 comprises the amino acid sequenceRPVLISRSSIDYAY (SEQ ID NO: 641); aq) CDR1 comprises the amino acid sequenceSYAMG (SEQ ID NO: 604), CDR2 comprises the amino acid sequenceTISLSGGSTFYSGSAKG (SEQ ID NO:621), and CDR3 comprises the amino acid sequenceRPVLISRSSTDYAY (SEQ ID NO: 640); ar) CDR1 comprises the amino acid sequence TYTMG (SEQ ID NO: 605), CDR2 comprises the amino acid sequenceAISSSGDSTYYTDSVKG (SEQ ID NO: 622), and CDR3 comprises the amino acid sequenceGEEVAGKYFRALYDY (SEQ ID NO: 642);as) CDR1 comprises the amino acid sequence SYAMG (SEQ ID NO: 604), CDR2 comprises the amino acid sequenceAITWSGGSTYYANSVKG (SEQ ID NO: 644), and CDR3 comprises the amino acid sequenceGEEVAGKYFRPLYDY (SEQ ID NO: 654); at) CDR1 comprises the amino acid sequenceSYAMG (SEQ ID NO: 604), CDR2 comprises the amino acid sequenceAISWSGGSTYYANSVKG (SEQ ID NO: 645), and CDR3 comprises the amino acid sequenceGEEVAGKYFRQLYDY (SEQ ID NO: 655); au) CDR1 comprises the amino acid sequenceSYAMG (SEQ ID NO: 604), CDR2 comprises the amino acid sequenceDISWSGGTTNYANSVKG (SEQ ID NO: 646), and CDR3 comprises the amino acid sequenceGEEVDGKYFRPLYDY (SEQ ID NO: 656); av) CDR1 comprises the amino acid sequenceNYAMG (SEQ ID NO: 643), CDR2 comprises the amino acid sequenceAINWSGGRIYYTDSVKG (SEQ ID NO: 647), and CDR3 comprises the amino acid sequenceGTNWSIPPDY (SEQ ID NO: 657); aw) CDR1 comprises the amino acid sequenceSYAMG (SEQ ID NO: 604), CDR2 comprises the amino acid sequenceAIRWSGGSTYYGDSVKG (SEQ ID NO: 648), and CDR3 comprises the amino acid sequenceDPIGLGYEMGEYDY (SEQ ID NO: 658); ax) CDR1 comprises the amino acid sequenceSYAMG (SEQ ID NO: 604), CDR2 comprises the amino acid sequenceAISWSGGRIYYADSVKG (SEQ ID NO: 649), and CDR3 comprises the amino acid sequenceDDFERTMTEVRY (SEQ ID NO: 659); ay) CDR1 comprises the amino acid sequenceSYAMG (SEQ ID NO: 604), CDR2 comprises the amino acid sequenceAISWSGGSIYYADSVKG (SEQ ID NO: 650), and CDR3 comprises the amino acid sequenceDGTLRTPMNLIHY (SEQ ID NO: 660); az) CDR1 comprises the amino acid sequence SYAMG (SEQ ID NO: 604), CDR2 comprises the amino acid sequenceAISWSGGSTYYADSVKG (SEQ ID NO: 651), and CDR3 comprises the amino acid sequenceDPSLSRTMDEIGS (SEQ ID NO: 661); ba) CDR1 comprises the amino acid sequence SYAMG (SEQ ID NO: 604), CDR2 comprises the amino acid sequenceAISWRGVNTYYADSVKG (SEQ ID NO: 652), and CDR3 comprises the amino acid sequenceGPLGATMSEIGS (SEQ ID NO: 662); bb) CDR1 comprises the amino acid sequence NYAMG (SEQ ID NO: 643), CDR2 comprises the amino acid sequenceAISWSGGSTYYADSVKG (SEQ ID NO: 651), and CDR3 comprises the amino acid sequenceGPLGATMSEIGS (SEQ ID NO: 662); bc) CDR1 comprises the amino acid sequence SYAMG (SEQ ID NO: 604), CDR2 comprises the amino acid sequenceAISWSGGGTYYADSVKG (SEQ ID NO: 653), and CDR3 comprises the amino acid sequenceGPLGATMSEIGS (SEQ ID NO: 662); orbd) CDR1 comprises the amino acid sequence SYAMG (SEQ ID NO: 604), CDR2 comprises the amino acid sequenceAISWSGGSTYYADSVKG (SEQ ID NO: 651), and CDR3 comprises the amino acid sequenceGPLGATMSEIGS (SEQ ID NO: 662).

3. The VHH antibody of claim 1, wherein: a) FR1 comprises the following amino acid sequence: X1X2QLX3ESGGX4X5X6X7X8GX9X10LX11LSCAX12X13X14X15X16X17X18X19(SEQ ID NO: 781), wherein X1is E or Q; X2is L or V; X3is V or Q; X4is G or R; X5is K, L, or S; X6is A or V; X7is E, H, Q, or R; X8is A, P, T, or V; X9is D, E, or G; X10is S or T; X11is G, N, or R; X12is A or null; X13is A, H, I, L, or T; X14is A or S; X15is D, G, R, or S; X15is A, F, H, L, N, P, R, or S; X17is A, F, G, I, L, P, S, or T; X18is A, F, I, L, or V; and X19is A, D, E, G, I, N, R, S, or T; b) FR2 comprises the amino acid sequence: WX20RX21X22X23GX24X25X26X27X28X29X30, wherein X20is A, F, V, or Y; X21is E or Q; X22is A, P, T, or V; X23is E or P; X24is K or null;X25is A, E, G, null, or Q; X26is L, P, R, or V; X27is D, E, or Q; X28is F, G, L, or W; X29is L or V; and X30is A or S; c) FR3 comprises the amino acid sequence: RFTX31X32X33X34X35X36X37X38X39X40X41X42X43LX44X45X46X47LX48X49X50DX51X52X53YX54CX55X56(SEQ ID NO: 782), wherein X31is I or V; X32is F, S, or T; X33is K or R; X34is D, E, G, or V; X35is D, N, S, or T; X36is A or V; X37is D, E, K, L, or N; X38is A, G, N, R, S, or T; X39is L, R, or T; X40is A, G, L, M, or V; X41is null or S; X42is null or V; X43is D, F, S, or Y; X44is Q or R; X45is L or M; X46is D, I, N, or S; X47is N or S; X48is K, L, R, or T; X49is P or S; X50is D, E, or G; X51is A, S, or T; X52is A or G; X53is I, T, or V; X54is F, L, R, S, or Y; X55is A, N, Q, R, T, or Y; andX56is A, G, K, L, P, V, or W; and / or d) FR4 comprises the amino acid sequence: X57GX58GX59X60VTVSS (SEQ ID NO: 783), wherein X57is R or W; X58is K, P, or Q; X59is A or T; and X60is L or Q.

4. The VHH antibody of claim 1, wherein: a) FR1 comprises an amino acid sequence selected from the group consisting of: QVQLVESGGGLVQPGGSLRLSCAASGFSLD (SEQ ID NO: 663), EVQLVESGGGLVQPGGSLRLSCAASGFALD (SEQ ID NO: 664), QLQLVESGGGLVQPGGSLRLSCVASGFALD (SEQ ID NO: 665), QVQLVESGGGLVQVGGSLRLSCSISRSIAI (SEQ ID NO:673 ), QLQLVESGGGLVQAGGSLRLSCAASDPIVT (SEQ ID NO: 674 ), QLQLVESGGGLVQAGGSLRLSCAASGNIVD (SEQ ID NO: 675 ), EVQLVESGGGLVQAGGSLRLSCAASGNIVD (SEQ ID NO: 676), EVQLVESGGGLVQAGGSLRLSCAASGNIVE (SEQ ID NO: 677), QVQLVESGGGLVQAGGSLRLSCAASGNIVD (SEQ ID NO: 678 ), QVQLQESGGGLVQAGGSLRLSCAASGNSVD (SEQ ID NO:679 ), QVQLVESGGGLVQAGGSLRLSCAASGNGVD (SEQ ID NO: 691), QLQLVESGGGLVQTGGSLNLSCAASGAFVS (SEQ ID NO: 692), QVQLQESGGGLVQPGGSLRLSCAASGSIFS (SEQ ID NO: 693), QVQLVESGGGLVQAGGSLRLSCAASGSIFS (SEQ ID NO: 694), QVQLVESGGGLVQPGGSLRLSCAASGSIFR (SEQ ID NO: 695), QVQLVESGGGLVQPGGSLRLSCAASGSIFS (SEQ ID NO: 696), QVQLVESGGGLVQAGDSLRLSCAAASGRALS (SEQ ID NO: 697), QVQLVESGGGSVEPGGSLRLSCATSGLILS (SEQ ID NO: 698), EVQLVESGGGLAQPGGSLRLSCVASGFAFG (SEQ ID NO: 699), EVQLVESGGGLVQPGGSLRLSCSASGFPFD (SEQ ID NO: 700), QVQLVESGGGLVQPGGSLRLSCTASGRTIA (SEQ ID NO: 701), QVQLVESGGRLVQAGGSLRLSCAASGRTFN (SEQ ID NO: 702), QVQLVESGGGLVQPGGSLRLSCAASGSTFN (SEQ ID NO: 703),QVQLVESGGGLVHAGGSLRLSCAASGRTFN (SEQ ID NO: 706), EVQLVESGGGLVHAGGSLRLSCVASGRTFN (SEQ ID NO: 704), EVQLVESGGGLVHAGGSLRLSCAASGRTFN (SEQ ID NO: 705), QVQLQESGGGLVQAGETLGLSCVHSGRAFS (SEQ ID NO: 707), QVQLVESGGGLVQAGESLRLSCVASGRALS (SEQ ID NO: 708), QVQLVESGGGKVQPGGSLRLSCAASGFTFS (SEQ ID NO: 709), QVQLVESGGGLVQPGGSLRLSCAASGFLFS (SEQ ID NO: 710), EVQLVESGGGLVQPGGSLRLSCAASGFTFS (SEQ ID NO: 711), QVQLVESGGGLVQAGGSLRLSCAAASHTFD (SEQ ID NO: 780), QVQLVESGGGLVQAGGSLRLSCAAASLTFD (SEQ ID NO: 715), QVQLVESGGGLVQAGGSLRLSCVASGRTFS (SEQ ID NO: 716), QLQLVESGGGLVRAGGSLRLSCVLSGRTFS (SEQ ID NO: 712), QVQLVESGGGLVQPGGSLRLSCVLSGRTFS (SEQ ID NO: 717), QVQLVESGGGLVQAGGSLRLSCAASGRTFS (SEQ ID NO: 714), QVQLVESGGGLVQTGGSLRLSCAASGRTFS (SEQ ID NO: 713), EVQLVESGGGLVQAGGSLRLSCAASGRTFR (SEQ ID NO: 718), QLQLVESGGGLVQAGGSLRLSCAASGRTVS (SEQ ID NO: 719), QVQLVESGGGLVQAGGSLRLSCAASGRTFT (SEQ ID NO: 720), EVQLVESGGGLVQAGGSLRLSCAASGRTFS (SEQ ID NO: 721), and QVQLVESGGGLVQAGGSLRLSCAASGRTVS (SEQ ID NO: 722); b) FR2 comprises an amino acid sequence selected from the group consisting of: WFRQAPGKEREGVS (SEQ ID NO: 666),WFRQAPGKEREGVA (SEQ ID NO: 667), WFRQAPGKEREGLS (SEQ ID NO: 668),WYREAEGKQRELVA (SEQ ID NO: 680), WYRQAPGKQRELVA (SEQ ID NO: 681),WYRQAPGKQRDLVA (SEQ ID NO: 682), WYRQAPGRDLVA (SEQ ID NO: 683),WYRQAPGKARELVA (SEQ ID NO: 723), WYRQAPGKEREFVA (SEQ ID NO: 724),WARQVPGKEVEWVS (SEQ ID NO: 725), WVRQPPGKGPEWVS (SEQ ID NO: 726),WVRQAPGKGLEWVS (SEQ ID NO: 727), WYRQTPGKEREFVA (SEQ ID NO: 728),WFRQAPGKEREFVA (SEQ ID NO: 729), WFRQAPGKEREFVS (SEQ ID NO: 730), andWFRQAPGKERQFVA (SEQ ID NO: 731); c) FR3 comprises an amino acid sequence selected from the group consisting of: RFTISRDDAKATVFLQMNNLKPEDTAVYYCAA (SEQ ID NO: 669), RFTISRDNAKRTVSLQMNSLKPEDTAVYYCAA (SEQ ID NO: 670), RFTISRDNAKTTVSLLMSSLKPEDTAVYYCAA (SEQ ID NO: 671),RFTVSKDTANNTLDLQMNSLRPEDTAVYRCAA (SEQ ID NO: 684), RFTISRDNAKNTLYLQMNSLKPEDSAVYYCRA (SEQ ID NO: 685), RFTISRDNAKNTVYLQMNSLKPEDTATYYCYA (SEQ ID NO: 686), RFTISRDNVKNTVYLQMNSLKPEDTATYYCYA (SEQ ID NO: 687), RFTISRDNVKNTVSLQMNSLKPEDTATYYCYA (SEQ ID NO: 688), RFTISRDNVKNTVYLQMNSLKPEDTGTYYCYA (SEQ ID NO: 689), RFTITRDNAKNTVYLQMNSLKPEDTAVYYCNA (SEQ ID NO: 732), RFTISRGNAKNTVYLQMNSLTPEDTAVYYCNA (SEQ ID NO: 733), RFTISRDNAKNTVYLQMNSLKPEDTAVYYCNA (SEQ ID NO: 734), RFTISRDNAKNTVYLQMNSLKPEDTAVYYCNL (SEQ ID NO: 735), RFTISRDNAKNTVYLQMNSLLPEDTAVYYCNA (SEQ ID NO: 736), RFTISRDNALSTMSLRMNSLKSEDTAIYYCQG (SEQ ID NO: 737), RFTISRDNVKNTVYLQMNSLKPEDTAVYYCAA (SEQ ID NO: 738), RFTISRDNAKNTLYLQLNSLKPEDTAVYLCAA (SEQ ID NO: 739), RFTISRDNAKNTLYLQMSSLKPEDTGVYLCAA (SEQ ID NO: 740), RFTISRDNAKNTVYLQMNNLKPEDTAIYYCYW (SEQ ID NO: 741), RFTIFRDNAKNLAYLQLNSLKPEDTAVYSCAA (SEQ ID NO: 742), RFTIFRDNAKNLGYLQMNSLKPEDTAVYSCAA (SEQ ID NO: 743), RFTIFRDNAKGLAYLQMDSLKPEDTAVYSCAA (SEQ ID NO: 744), RFTIFRDNAKNLAYLQMNSLKPEDTAVYSCAA (SEQ ID NO: 745), RFTISRVNADNTVSLQMNSLKPEDTAVYFCAA (SEQ ID NO: 746), RFTISRVNAENTVSVSLQMNSLKPDDTAVYFCAA (SEQ ID NO: 747), RFTISRDNAKNTVYLQMNSLKPEDTAVYYCAK (SEQ ID NO: 748), RFTISRDNAKNTLYLQMDSLTPGDTAVYYCAV (SEQ ID NO: 749), RFTISRDNAKNTVYLQMNSLKPEDTAVYYCAA (SEQ ID NO: 750), RFTISRDNVKNRVYLQMNSLKPEDTAVYYCAA (SEQ ID NO: 751), RFTISRDSAKNTVYLQMNSLKPEDTAIYYCNA (SEQ ID NO: 752), RFTISRDNAKNTVYLQMNSLKPEDAAVYYCAA (SEQ ID NO: 753), RFTISRDNAKNTVYLQMDSLKPEDTAVYYCAP (SEQ ID NO: 754), RFTISRDNAKNTVDLQMNSLKPEDTAVYYCTP (SEQ ID NO: 755), RFTISRDNAKNTVYLQMNSLKPEDTAVYYCAP (SEQ ID NO: 756 ), RFTISRDNAKNTVSLQMNSLKPEDTAVYYCAA (SEQ ID NO: 757),RFTISRENAKNTVYLQMISLKPEDTAVYYCAA (SEQ ID NO: 758), and RFTISRDNAKNTVYLQMISLKPEDTAVYYCAA (SEQ ID NO: 759); and / or d) FR4 comprises an amino acid sequence selected from the group consisting of: WGQGTQVTVSS (SEQ ID NO: 542), WGQGAQVTVSS (SEQ ID NO: 690), WGKGTLVTVSS (SEQ ID NO: 760), WGQGTLVTVSS (SEQ ID NO: 761), RGQGTQVTVSS (SEQ ID NO: 762), and WGPGTQVTVSS (SEQ ID NO: 763).

5. The VHH antibody of claim 1, wherein: a) FR1 comprises the amino acid sequence QVQLVESGGGLVQPGGSLRLSCAASGFSLD (SEQ ID NO: 663), FR2 comprises the amino acid sequenceWFRQAPGKEREGVS (SEQ ID NO: 666), FR3 comprises the amino acid sequence RFTISRDDAKATVFLQMNNLKPEDTAVYYCAA (SEQ ID NO: 669), and FR4 comprises the amino acid sequence WGQGTQVTVSS (SEQ ID NO: 542); b) FR1 comprises the amino acid sequence EVQLVESGGGLVQPGGSLRLSCAASGFALD (SEQ ID NO: 664), FR2 comprises the amino acid sequenceWFRQAPGKEREGVA (SEQ ID NO: 667), FR3 comprises the amino acid sequence RFTISRDNAKRTVSLQMNSLKPEDTAVYYCAA (SEQ ID NO: 670), and FR4 comprises the amino acid sequence WGQGTQVTVSS (SEQ ID NO: 542); c) FR1 comprises the amino acid sequence QLQLVESGGGLVQPGGSLRLSCVASGFALD (SEQ ID NO: 665), FR2 comprises the amino acid sequenceWFRQAPGKEREGLS (SEQ ID NO: 668), FR3 comprises the amino acid sequence RFTISRDNAKTTVSLLMSSLKPEDTAVYYCAA (SEQ ID NO: 671), and FR4 comprises the amino acid sequence WGQGTQVTVSS (SEQ ID NO: 542); d) FR1 comprises the amino acid sequenceQVQLVESGGGLVQVGGSLRLSCSISRSIAI (SEQ ID NO: 673), FR2 comprises the amino acid sequenceWYREAEGKQRELVA (SEQ ID NO: 680), FR3 comprises the amino acid sequence RFTVSKDTANNTLDLQMNSLRPEDTAVYRCAA (SEQ ID NO: 684), and FR4 comprises the amino acid sequence WGQGTQVTVSS (SEQ ID NO: 542); e) FR1 comprises the amino acid sequenceQLQLVESGGGLVQAGGSLRLSCAASDPIVT (SEQ ID NO: 674), FR2 comprises the amino acid sequenceWYRQAPGKQRELVA (SEQ ID NO: 681), FR3 comprises the amino acid sequence RFTISRDNAKNTLYLQMNSLKPEDSAVYYCRA (SEQ ID NO: 685), and FR4 comprises the amino acid sequence WGQGTQVTVSS (SEQ ID NO: 542);f) FR1 comprises the amino acid sequence QLQLVESGGGLVQAGGSLRLSCAASGNIVD (SEQ ID NO: 675), FR2 comprises the amino acid sequenceWYRQAPGKQRDLVA (SEQ ID NO: 682), FR3 comprises the amino acid sequence RFTISRDNAKNTVYLQMNSLKPEDTATYYCYA (SEQ ID NO: 686), and FR4 comprises the amino acid sequence WGQGAQVTVSS (SEQ ID NO: 690); g) FR1 comprises the amino acid sequence EVQLVESGGGLVQAGGSLRLSCAASGNIVD (SEQ ID NO: 676), FR2 comprises the amino acid sequenceWYRQAPGRDLVA (SEQ ID NO: 683), FR3 comprises the amino acid sequence RFTISRDNVKNTVYLQMNSLKPEDTATYYCYA (SEQ ID NO: 687), and FR4 comprises the amino acid sequence WGQGTQVTVSS (SEQ ID NO: 542); h) FR1 comprises the amino acid sequence EVQLVESGGGLVQAGGSLRLSCAASGNIVE (SEQ ID NO: 677 ), FR2 comprises the amino acid sequence WYRQAPGKQRDLVA (SEQ ID NO: 682), FR3 comprises the amino acid sequence RFTISRDNVKNTVYLQMNSLKPEDTATYYCYA (SEQ ID NO: 687), and FR4 comprises the amino acid sequence WGQGTQVTVSS (SEQ ID NO: 542); i) FR1 comprises the amino acid sequenceQVQLVESGGGLVQAGGSLRLSCAASGNIVD (SEQ ID NO: 678 ), FR2 comprises the amino acid sequence WYRQAPGKQRDLVA (SEQ ID NO: 682), FR3 comprises the amino acid sequence RFTISRDNVKNTVSLQMNSLKPEDTATYYCYA (SEQ ID NO: 688), and FR4 comprises the amino acid sequence WGQGTQVTVSS (SEQ ID NO: 542); j) FR1 comprises the amino acid sequenceQVQLQESGGGLVQAGGSLRLSCAASGNSVD (SEQ ID NO: 679 ), FR2 comprises the amino acid sequence WYRQAPGKQRDLVA (SEQ ID NO: 682), FR3 comprises the amino acid sequence RFTISRDNVKNTVYLQMNSLKPEDTATYYCYA (SEQ ID NO: 687), and FR4 comprises the amino acid sequence WGQGTQVTVSS (SEQ ID NO: 542); k) FR1 comprises the amino acid sequence QVQLVESGGGLVQAGGSLRLSCAASGNIVD (SEQ ID NO: 678 ), FR2 comprises the amino acid sequence WYRQAPGKQRDLVA (SEQ ID NO: 682), FR3 comprises the amino acid sequence RFTISRDNVKNTVYLQMNSLKPEDTATYYCYA (SEQ ID NO: 687), and FR4 comprises the amino acid sequence WGQGTQVTVSS (SEQ ID NO: 542); l) FR1 comprises the amino acid sequenceQVQLVESGGGLVQAGGSLRLSCAASGNGVD (SEQ ID NO: 780), FR2 comprises the amino acid sequenceWYRQAPGKQRDLVA (SEQ ID NO: 682), FR3 comprises the amino acid sequence RFTISRDNVKNTVYLQMNSLKPEDTGTYYCYA(SEQ ID NO: 689), and FR4 comprises the amino acid sequence WGQGTQVTVSS (SEQ ID NO: 542); m) FR1 comprises the amino acid sequenceQVQLVESGGGLVQAGGSLRLSCAASGNGVD (SEQ ID NO: 780), FR2 comprises the amino acid sequenceWYRQAPGKQRDLVA (SEQ ID NO: 682), FR3 comprises the amino acid sequence RFTISRDNVKNTVYLQMNSLKPEDTATYYCYA (SEQ ID NO: 687), and FR4 comprises the amino acid sequence WGQGTQVTVSS (SEQ ID NO: 542); n) FR1 comprises the amino acid sequence QVQLVESGGGLVQAGGSLRLSCAASGNGVD (SEQ ID NO: 780), FR2 comprises the amino acid sequenceWYRQAPGKQRDLVA (SEQ ID NO: 682), FR3 comprises the amino acid sequence RFTISRDNVKNTVYLQMNSLKPEDTATYYCYA (SEQ ID NO: 687), and FR4 comprises the amino acid sequence WGQGTQVTVSS (SEQ ID NO: 542); o) FR1 comprises the amino acid sequence QVQLVESGGGLVQAGGSLRLSCAASGNGVD (SEQ ID NO: 780), FR2 comprises the amino acid sequenceWYRQAPGKQRDLVA (SEQ ID NO: 682), FR3 comprises the amino acid sequence RFTISRDNVKNTVYLQMNSLKPEDTATYYCYA (SEQ ID NO: 687), and FR4 comprises the amino acid sequence WGQGTQVTVSS (SEQ ID NO: 542); p) FR1 comprises the amino acid sequence QLQLVESGGGLVQTGGSLNLSCAASGAFVS (SEQ ID NO: 692), FR2 comprises the amino acid sequenceWYRQAPGKARELVA (SEQ ID NO: 723), FR3 comprises the amino acid sequence RFTITRDNAKNTVYLQMNSLKPEDTAVYYCNA (SEQ ID NO: 732), and FR4 comprises the amino acid sequence WGQGTQVTVSS (SEQ ID NO: 542); q) FR1 comprises the amino acid sequence QVQLQESGGGLVQPGGSLRLSCAASGSIFS (SEQ ID NO: 693), FR2 comprises the amino acid sequenceWYRQAPGKQRELVA (SEQ ID NO: 681), FR3 comprises the amino acid sequence RFTISRGNAKNTVYLQMNSLTPEDTAVYYCNA (SEQ ID NO: 733), and FR4 comprises the amino acid sequence WGQGTQVTVSS (SEQ ID NO: 542); r) FR1 comprises the amino acid sequence QVQLVESGGGLVQAGGSLRLSCAASGSIFS (SEQ ID NO: 694), FR2 comprises the amino acid sequenceWYRQAPGKQRELVA (SEQ ID NO: 681), FR3 comprises the amino acid sequence RFTISRDNAKNTVYLQMNSLKPEDTAVYYCNA (SEQ ID NO: 734), and FR4 comprises the amino acid sequence WGKGTLVTVSS (SEQ ID NO: 760);s) FR1 comprises the amino acid sequence QVQLVESGGGLVQPGGSLRLSCAASGSIFR (SEQ ID NO: 695), FR2 comprises the amino acid sequenceWYRQAPGKQRELVA (SEQ ID NO: 681), FR3 comprises the amino acid sequence RFTISRDNAKNTVYLQMNSLKPEDTAVYYCNL (SEQ ID NO: 735), and FR4 comprises the amino acid sequence WGQGTQVTVSS (SEQ ID NO: 542); t) FR1 comprises the amino acid sequenceQVQLQESGGGLVQPGGSLRLSCAASGSIFS (SEQ ID NO: 693), FR2 comprises the amino acid sequenceWYRQAPGKQRELVA (SEQ ID NO: 681), FR3 comprises the amino acid sequence RFTISRDNAKNTVYLQMNSLLPEDTAVYYCNA (SEQ ID NO: 736), and FR4 comprises the amino acid sequence WGQGTLVTVSS (SEQ ID NO: 761); u) FR1 comprises the amino acid sequence QVQLVESGGGLVQPGGSLRLSCAASGSIFS (SEQ ID NO: 696), FR2 comprises the amino acid sequenceWYRQAPGKQRELVA (SEQ ID NO: 681), FR3 comprises the amino acid sequence RFTISRDNAKNTVYLQMNSLKPEDTAVYYCNA (SEQ ID NO: 734), and FR4 comprises the amino acid sequence WGQGTLVTVSS (SEQ ID NO: 761); v) FR1 comprises the amino acid sequence QVQLVESGGGLVQAGDSLRLSCAAASGRALS (SEQ ID NO: 697), FR2 comprises the amino acid sequence WYRQAPGKEREFVA (SEQ ID NO: 724), FR3 comprises the amino acid sequence RFTISRDNALSTMSLRMNSLKSEDTAIYYCQG (SEQ ID NO: 737), and FR4 comprises the amino acid sequence WGQGTQVTVSS (SEQ ID NO: 542); w) FR1 comprises the amino acid sequence QVQLVESGGGSVEPGGSLRLSCATSGLILS (SEQ ID NO: 698), FR2 comprises the amino acid sequenceWARQVPGKEVEWVS (SEQ ID NO: 725), FR3 comprises the amino acid sequence RFTISRDNVKNTVYLQMNSLKPEDTAVYYCAA (SEQ ID NO: 738), and FR4 comprises the amino acid sequence WGQGTQVTVSS (SEQ ID NO: 542); x) FR1 comprises the amino acid sequence EVQLVESGGGLAQPGGSLRLSCVASGFAFG (SEQ ID NO: 699), FR2 comprises the amino acid sequenceWVRQPPGKGPEWVS (SEQ ID NO: 726), FR3 comprises the amino acid sequence RFTISRDNAKNTLYLQLNSLKPEDTAVYLCAA (SEQ ID NO: 739), and FR4 comprises the amino acid sequence WGQGTQVTVSS (SEQ ID NO: 542); y) FR1 comprises the amino acid sequence EVQLVESGGGLVQPGGSLRLSCSASGFPFD (SEQ ID NO: 700), FR2 comprises the amino acid sequenceWVRQAPGKGLEWVS (SEQ ID NO: 727), FR3 comprises the amino acid sequence RFTISRDNAKNTLYLQMSSLKPEDTGVYLCAA(SEQ ID NO: 740), and FR4 comprises the amino acid sequence WGQGTQVTVSS (SEQ ID NO: 542); z) FR1 comprises the amino acid sequence QVQLVESGGGLVQPGGSLRLSCTASGRTIA (SEQ ID NO: 701), FR2 comprises the amino acid sequenceWYRQTPGKEREFVA (SEQ ID NO: 728), FR3 comprises the amino acid sequence RFTISRDNAKNTVYLQMNNLKPEDTAIYYCYW (SEQ ID NO: 741), and FR4 comprises the amino acid sequence WGQGTQVTVSS (SEQ ID NO: 542); aa) FR1 comprises the amino acid sequence QVQLVESGGRLVQAGGSLRLSCAASGRTFN (SEQ ID NO: 702), FR2 comprises the amino acid sequenceWFRQAPGKEREFVA (SEQ ID NO: 729), FR3 comprises the amino acid sequence RFTIFRDNAKNLAYLQLNSLKPEDTAVYSCAA (SEQ ID NO: 742), and FR4 comprises the amino acid sequence WGQGTQVTVSS (SEQ ID NO: 542); ab) FR1 comprises the amino acid sequence QVQLVESGGGLVQPGGSLRLSCAASGSTFN (SEQ ID NO: 703), FR2 comprises the amino acid sequenceWFRQAPGKEREFVA (SEQ ID NO: 729), FR3 comprises the amino acid sequence RFTIFRDNAKNLGYLQMNSLKPEDTAVYSCAA (SEQ ID NO: 743), and FR4 comprises the amino acid sequence WGQGTQVTVSS (SEQ ID NO: 542); ac) FR1 comprises the amino acid sequence QVQLVESGGGLVHAGGSLRLSCAASGRTFN (SEQ ID NO: 706), FR2 comprises the amino acid sequenceWFRQAPGKEREFVA (SEQ ID NO: 729), FR3 comprises the amino acid sequence RFTIFRDNAKGLAYLQMDSLKPEDTAVYSCAA (SEQ ID NO: 744), and FR4 comprises the amino acid sequence WGQGTQVTVSS (SEQ ID NO: 542); ad) FR1 comprises the amino acid sequence EVQLVESGGGLVHAGGSLRLSCVASGRTFN (SEQ ID NO: 704), FR2 comprises the amino acid sequenceWFRQAPGKEREFVA (SEQ ID NO: 729), FR3 comprises the amino acid sequence RFTIFRDNAKNLAYLQMNSLKPEDTAVYSCAA (SEQ ID NO: 745), and FR4 comprises the amino acid sequence WGQGTQVTVSS (SEQ ID NO: 542); ae) FR1 comprises the amino acid sequence EVQLVESGGGLVHAGGSLRLSCAASGRTFN (SEQ ID NO: 705), FR2 comprises the amino acid sequenceWFRQAPGKEREFVA (SEQ ID NO: 729), FR3 comprises the amino acid sequence RFTIFRDNAKNLAYLQMNSLKPEDTAVYSCAA (SEQ ID NO: 745), and FR4 comprises the amino acid sequence WGQGTQVTVSS (SEQ ID NO: 542);af) FR1 comprises the amino acid sequenceQVQLVESGGGLVHAGGSLRLSCAASGRTFN (SEQ ID NO: 706), FR2 comprises the amino acid sequenceWFRQAPGKEREFVA (SEQ ID NO: 729), FR3 comprises the amino acid sequence RFTIFRDNAKNLAYLQMNSLKPEDTAVYSCAA (SEQ ID NO: 745), and FR4 comprises the amino acid sequence WGQGTQVTVSS (SEQ ID NO: 542); ag) FR1 comprises the amino acid sequence QVQLQESGGGLVQAGETLGLSCVHSGRAFS (SEQ ID NO: 707), FR2 comprises the amino acid sequenceWFRQAPGKEREFVA (SEQ ID NO: 729), FR3 comprises the amino acid sequence RFTISRVNADNTVSLQMNSLKPEDTAVYFCAA (SEQ ID NO: 746), and FR4 comprises the amino acid sequence WGQGTQVTVSS (SEQ ID NO: 542 ); ah) FR1 comprises the amino acid sequence QVQLVESGGGLVQAGESLRLSCVASGRALS (SEQ ID NO: 708), FR2 comprises the amino acid sequenceWFRQAPGKEREFVA (SEQ ID NO: 729), FR3 comprises the amino acid sequence RFTISRVNAENTVSVSLQMNSLKPDDTAVYFCAA (SEQ ID NO: 747), and FR4 comprises the amino acid sequence WGQGTQVTVSS (SEQ ID NO: 542); ai) FR1 comprises the amino acid sequenceQVQLVESGGGKVQPGGSLRLSCAASGFTFS (SEQ ID NO: 709), FR2 comprises the amino acid sequenceWVRQAPGKGLEWVS (SEQ ID NO: 727), FR3 comprises the amino acid sequence RFTISRDNAKNTVYLQMNSLKPEDTAVYYCAK (SEQ ID NO: 748), and FR4 comprises the amino acid sequence WGQGTLVTVSS (SEQ ID NO: 761); aj) FR1 comprises the amino acid sequenceQVQLVESGGGLVQPGGSLRLSCAASGFLFS (SEQ ID NO: 710), FR2 comprises the amino acid sequenceWVRQAPGKGLEWVS (SEQ ID NO: 727), FR3 comprises the amino acid sequence RFTISRDNAKNTLYLQMDSLTPGDTAVYYCAV (SEQ ID NO: 749), and FR4 comprises the amino acid sequence RGQGTQVTVSS (SEQ ID NO: 762); ak) FR1 comprises the amino acid sequenceEVQLVESGGGLVQPGGSLRLSCAASGFTFS (SEQ ID NO: 711), FR2 comprises the amino acid sequenceWVRQAPGKGLEWVS (SEQ ID NO: 727), FR3 comprises the amino acid sequence RFTISRDNAKNTVYLQMNSLKPEDTAVYYCAA (SEQ ID NO: 750), and FR4 comprises the amino acid sequence WGQGTQVTVSS (SEQ ID NO: 542 ); al) FR1 comprises the amino acid sequence QVQLVESGGGLVQAGGSLRLSCAAASHTFD (SEQ ID NO: 780), FR2 comprises the amino acid sequenceWFRQAPGKEREFVA (SEQ ID NO: 729), FR3 comprises the amino acid sequence RFTISRDNVKNRVYLQMNSLKPEDTAVYYCAA(SEQ ID NO: 751), and FR4 comprises the amino acid sequence WGQGTQVTVSS (SEQ ID NO:542 ); am) FR1 comprises the amino acid sequence QVQLVESGGGLVQAGGSLRLSCAAASLTFD (SEQ ID NO: 715), FR2 comprises the amino acid sequenceWFRQAPGKEREFVA (SEQ ID NO: 729), FR3 comprises the amino acid sequence RFTISRDNVKNTVYLQMNSLKPEDTAVYYCAA (SEQ ID NO: 738), and FR4 comprises the amino acid sequence WGQGTQVTVSS (SEQ ID NO: 542 ); an) FR1 comprises the amino acid sequenceQVQLVESGGGLVQAGGSLRLSCVASGRTFS (SEQ ID NO: 716), FR2 comprises the amino acid sequenceWYRQAPGKEREFVA (SEQ ID NO: 724), FR3 comprises the amino acid sequence RFTISRDSAKNTVYLQMNSLKPEDTAIYYCNA (SEQ ID NO: 752), and FR4 comprises the amino acid sequence WGQGTQVTVSS (SEQ ID NO: 542 ); ao) FR1 comprises the amino acid sequenceQLQLVESGGGLVRAGGSLRLSCVLSGRTFS (SEQ ID NO: 712), FR2 comprises the amino acid sequenceWFRQAPGKEREFVS (SEQ ID NO: 730), FR3 comprises the amino acid sequence RFTISRDNAKNTVYLQMNSLKPEDAAVYYCAA (SEQ ID NO: 753), and FR4 comprises the amino acid sequence WGPGTQVTVSS (SEQ ID NO: 763); ap) FR1 comprises the amino acid sequenceQLQLVESGGGLVRAGGSLRLSCVLSGRTFS (SEQ ID NO: 712), FR2 comprises the amino acid sequenceWFRQAPGKEREFVS (SEQ ID NO: 730), FR3 comprises the amino acid sequence RFTISRDNAKNTVYLQMNSLKPEDTAVYYCAA (SEQ ID NO: 750), and FR4 comprises the amino acid sequence WGPGTQVTVSS (SEQ ID NO: 763); aq) FR1 comprises the amino acid sequenceQVQLVESGGGLVQPGGSLRLSCVLSGRTFS (SEQ ID NO: 717), FR2 comprises the amino acid sequenceWFRQAPGKEREFVS (SEQ ID NO: 730), FR3 comprises the amino acid sequence RFTISRDNAKNTVYLQMNSLKPEDTAVYYCAA (SEQ ID NO: 750), and FR4 comprises the amino acid sequence WGPGTQVTVSS (SEQ ID NO: 763); ar) FR1 comprises the amino acid sequenceQVQLVESGGGLVQAGGSLRLSCAASGRTFS (SEQ ID NO: 714), FR2 comprises the amino acid sequenceWFRQAPGKERQFVA (SEQ ID NO: 731), FR3 comprises the amino acid sequence RFTISRDNAKNTVYLQMDSLKPEDTAVYYCAP (SEQ ID NO: 754), and FR4 comprises the amino acid sequence WGQGTQVTVSS (SEQ ID NO: 542 );as) FR1 comprises the amino acid sequence QVQLVESGGGLVQTGGSLRLSCAASGRTFS (SEQ ID NO: 713), FR2 comprises the amino acid sequenceWFRQAPGKEREFVA (SEQ ID NO: 729), FR3 comprises the amino acid sequence RFTISRDNAKNTVDLQMNSLKPEDTAVYYCTP (SEQ ID NO: 755), and FR4 comprises the amino acid sequence WGQGTQVTVSS (SEQ ID NO: 542); at) FR1 comprises the amino acid sequenceQVQLVESGGGLVQAGGSLRLSCAASGRTFS (SEQ ID NO: 714), FR2 comprises the amino acid sequenceWFRQAPGKEREFVA (SEQ ID NO: 729), FR3 comprises the amino acid sequence RFTISRDNAKNTVYLQMNSLKPEDTAVYYCAP (SEQ ID NO: 756 ), and FR4 comprises the amino acid sequence WGQGTQVTVSS (SEQ ID NO: 542); au) FR1 comprises the amino acid sequence QVQLVESGGGLVQAGGSLRLSCAASGRTFS (SEQ ID NO: 714), FR2 comprises the amino acid sequence WFRQAPGKEREFVA (SEQ ID NO: 729), FR3 comprises the amino acid sequence RFTISRDNAKNTVYLQMNSLKPEDTAVYYCAP (SEQ ID NO: 756 ), and FR4 comprises the amino acid sequence WGQGTQVTVSS (SEQ ID NO: 542); av) FR1 comprises the amino acid sequence QVQLVESGGGLVQAGGSLRLSCAASGRTFS (SEQ ID NO: 714), FR2 comprises the amino acid sequenceWFRQAPGKEREFVA (SEQ ID NO: 729), FR3 comprises the amino acid sequence RFTISRDNAKNTVYLQMNSLKPEDTAVYYCAA (SEQ ID NO: 750), and FR4 comprises the amino acid sequence WGQGTQVTVSS (SEQ ID NO: 542); aw) FR1 comprises the amino acid sequence QVQLVESGGGLVQAGGSLRLSCAASGRTFS (SEQ ID NO: 714), FR2 comprises the amino acid sequenceWFRQAPGKEREFVA (SEQ ID NO: 729), FR3 comprises the amino acid sequence RFTISRDNAKNTVYLQMNSLKPEDTAVYYCAA (SEQ ID NO: 750), and FR4 comprises the amino acid sequence WGQGTQVTVSS (SEQ ID NO: 542); ax) FR1 comprises the amino acid sequenceEVQLVESGGGLVQAGGSLRLSCAASGRTFR (SEQ ID NO: 718), FR2 comprises the amino acid sequenceWFRQAPGKEREFVA (SEQ ID NO: 729), FR3 comprises the amino acid sequence RFTISRDNAKNTVYLQMNSLKPEDTAVYYCAA (SEQ ID NO: 750), and FR4 comprises the amino acid sequence WGQGTQVTVSS (SEQ ID NO: 542); ay) FR1 comprises the amino acid sequenceQVQLVESGGGLVQAGGSLRLSCAASGRTFS (SEQ ID NO: 714), FR2 comprises the amino acid sequenceWFRQAPGKEREFVA (SEQ ID NO: 729), FR3 comprises the amino acid sequence RFTISRDNAKNTVSLQMNSLKPEDTAVYYCAA(SEQ ID NO: 757), and FR4 comprises the amino acid sequence WGQGTQVTVSS (SEQ ID NO: 542); az) FR1 comprises the amino acid sequence QLQLVESGGGLVQAGGSLRLSCAASGRTVS (SEQ ID NO: 719), FR2 comprises the amino acid sequenceWFRQAPGKEREFVA (SEQ ID NO: 729), FR3 comprises the amino acid sequence RFTISRDNAKNTVYLQMNSLKPEDTAVYYCAA (SEQ ID NO: 750), and FR4 comprises the amino acid sequence WGQGTQVTVSS (SEQ ID NO: 542); ba) FR1 comprises the amino acid sequence QVQLVESGGGLVQAGGSLRLSCAASGRTFT (SEQ ID NO: 720), FR2 comprises the amino acid sequenceWFRQAPGKEREFVA (SEQ ID NO: 729), FR3 comprises the amino acid sequence RFTISRENAKNTVYLQMISLKPEDTAVYYCAA (SEQ ID NO: 758), and FR4 comprises the amino acid sequence WGQGTQVTVSS (SEQ ID NO: 542); bb) FR1 comprises the amino acid sequenceEVQLVESGGGLVQAGGSLRLSCAASGRTFS (SEQ ID NO: 721), FR2 comprises the amino acid sequenceWFRQAPGKEREFVS (SEQ ID NO:730), FR3 comprises the amino acid sequence RFTISRDNAKNTVYLQMISLKPEDTAVYYCAA (SEQ ID NO: 759), and FR4 comprises the amino acid sequence WGQGTQVTVSS (SEQ ID NO: 542); bc) FR1 comprises the amino acid sequenceQVQLVESGGGLVQAGGSLRLSCAASGRTVS (SEQ ID NO: 722), FR2 comprises the amino acid sequenceWFRQAPGKEREFVA (SEQ ID NO: 729), FR3 comprises the amino acid sequence RFTISRDNAKNTVYLQMISLKPEDTAVYYCAA (SEQ ID NO: 759), and FR4 comprises the amino acid sequence WGQGTQVTVSS (SEQ ID NO: 542 ); or bd) FR1 comprises the amino acid sequenceQVQLVESGGGLVQAGGSLRLSCAASGRTVS (SEQ ID NO: 722), FR2 comprises the amino acid sequenceWFRQAPGKEREFVA (SEQ ID NO: 729), FR3 comprises the amino acid sequence RFTISRDNAKNTVYLQMISLKPEDTAVYYCAA (SEQ ID NO: 759), and FR4 comprises the amino acid sequence WGQGTQVTVSS (SEQ ID NO: 542 ).

6. The VHH antibody of claim 1, wherein the VHH antibody comprises an amino acid sequence having at least 85% sequence identity to an amino acid sequence selected from the group consisting of: EVQLVESGGGLVQPGGSLRLSCAASGFALDGYTIGWFRQAPGKEREGVACISRSDTSTKYADSV KGRFTISRDNAKRTVSLQMNSLKPEDTAVYYCAASLQSGLLSRFLLPRQYDHWGQGTQVTVSS(SEQ ID NO: 426); QLQLVESGGGLVQPGGSLRLSCVASGFALDSYTIGWFRQAPGKEREGLSCISRSTSDARYADSV KGRFTISRDNAKTTVSLLMSSLKPEDTAVYYCAASRQTGLLSTFLLPRQYDHWGQGTQVTVSS (SEQ ID NO: 427); QVQLVESGGGLVQPGGSLRLSCAASGFSLDFYSIGWFRQAPGKEREGVSCITWSGERTNYKDSV KGRFTISRDDAKATVFLQMNNLKPEDTAVYYCAADSGYPCYGSSWSSVGYDFWGQGTQVTVSS (SEQ ID NO: 428); QVQLVESGGGSVEPGGSLRLSCATSGLILSNHGMGWARQVPGKEVEWVSGSYTDGSTYYADSVK GRFTISRDNVKNTVYLQMNSLKPEDTAVYYCAARQYYRSGYVDYWGQGTQVTVSS (SEQ ID NO: 429); QVQLVESGGGKVQPGGSLRLSCAASGFTFSNYGMMWVRQAPGKGLEWVSYIDSGGGSTYYTDSV RGRFTISRDNAKNTVYLQMNSLKPEDTAVYYCAKAIGVVSGSLEVWGQGTLVTVSS (SEQ ID NO: 430); QVQLVESGGGLVQAGGSLRLSCAASGRTFTSYAMGWFRQAPGKEREFVAAISWRGVNTYYADSV KGRFTISRENAKNTVYLQMISLKPEDTAVYYCAAGPLGATMSEIGSWGQGTQVTVSS (SEQ ID NO: 431); EVQLVESGGGLVQAGGSLRLSCAASGRTFSNYAMGWFRQAPGKEREFVSAISWSGGSTYYADSV KGRFTISRDNAKNTVYLQMISLKPEDTAVYYCAAGPLGATMSEIGSWGQGTQVTVSS (SEQ ID NO: 432); QVQLVESGGGLVQAGGSLRLSCAASGRTVSSYAMGWFRQAPGKEREFVAAISWSGGGTYYADSV KGRFTISRDNAKNTVYLQMISLKPEDTAVYYCAAGPLGATMSEIGSWGQGTQVTVSS (SEQ ID NO: 433); QVQLVESGGGLVQAGGSLRLSCAASGRTVSSYAMGWFRQAPGKEREFVAAISWSGGSTYYADSV KGRFTISRDNAKNTVYLQMISLKPEDTAVYYCAAGPLGATMSEIGSWGQGTQVTVSS (SEQ ID NO: 434); EVQLVESGGGLAQPGGSLRLSCVASGFAFGSFAIDWVRQPPGKGPEWVSAINRGGDRTYYSDSV KGRFTISRDNAKNTLYLQLNSLKPEDTAVYLCAAGGRVSADGKKWEYDYWGQGTQVTVSS (SEQ ID NO: 435); EVQLVESGGGLVHAGGSLRLSCAASGRTFNTMAWFRQAPGKEREFVAAIAWNSGLTYYGDSVKG RFTIFRDNAKNLAYLQMNSLKPEDTAVYSCAARRTFRTGLINTVTAYDTWGQGTQVTVSS (SEQ ID NO: 436); EVQLVESGGGLVHAGGSLRLSCVASGRTFNTMAWFRQAPGKEREFVAAISWSGGLTYYGDSVKG RFTIFRDNAKNLAYLQMNSLKPEDTAVYSCAARRTFRTALINTITAYDTWGQGTQVTVSS (SEQ ID NO: 437);EVQLVESGGGLVQAGGSLRLSCAASGNIVDIDDMGWYRQAPGRDLVASITAGGITKYADSAKGR FTISRDNVKNTVYLQMNSLKPEDTATYYCYAVRRYYPRFDYWGQGTQVTVSS (SEQ ID NO: 438); EVQLVESGGGLVQAGGSLRLSCAASGNIVEIDDMGWYRQAPGKQRDLVATITAGGITNYASSAK GRFTISRDNVKNTVYLQMNSLKPEDTATYYCYAIRKYYPRFDYWGQGTQVTVSS (SEQ ID NO: 439); EVQLVESGGGLVQAGGSLRLSCAASGRTFRSYAMGWFRQAPGKEREFVAAISWSGGRIYYADSV KGRFTISRDNAKNTVYLQMNSLKPEDTAVYYCAADDFERTMTEVRYWGQGTQVTVSS (SEQ ID NO: 440); EVQLVESGGGLVQPGGSLRLSCAASGFTFSGYYMSWVRQAPGKGLEWVSSIYSDDSNTYYADSV KGRFTISRDNAKNTVYLQMNSLKPEDTAVYYCAASATLRGRDTRFDYWGQGTQVTVSS (SEQ ID NO: 441); EVQLVESGGGLVQPGGSLRLSCSASGFPFDDYSMDWVRQAPGKGLEWVSAINRNGGSTYYAESM KGRFTISRDNAKNTLYLQMSSLKPEDTGVYLCAAGGRVSADGKKWEYDYWGQGTQVTVSS (SEQ ID NO: 442); QLQLVESGGGLVQAGGSLRLSCAASDPIVTFNTMGWYRQAPGKQRELVARITMSGIPNYADSVK GRFTISRDNAKNTLYLQMNSLKPEDSAVYYCRAEHSGYWGQGTQVTVSS (SEQ ID NO: 443); QLQLVESGGGLVQAGGSLRLSCAASGNIVDIDDMGWYRQAPGKQRDLVATITAGGIANYADSAK GRFTISRDNAKNTVYLQMNSLKPEDTATYYCYAIRRYYPRFDYWGQGAQVTVSS (SEQ ID NO: 444); QLQLVESGGGLVQAGGSLRLSCAASGRTVSSYAMGWFRQAPGKEREFVAAISWSGGSTYYADSV KGRFTISRDNAKNTVYLQMNSLKPEDTAVYYCAADPSLSRTMDEIGSWGQGTQVTVSS (SEQ ID NO: 445); QLQLVESGGGLVQTGGSLNLSCAASGAFVSIDAMAWYRQAPGKARELVAFSSSGGITNYADSVK GRFTITRDNAKNTVYLQMNSLKPEDTAVYYCNADILQSGWYTYWGQGTQVTVSS (SEQ ID NO: 446); QLQLVESGGGLVRAGGSLRLSCVLSGRTFSSYAMGWFRQAPGKEREFVSTISLSGGSTFYSDSA KGRFTISRDNAKNTVYLQMNSLKPEDAAVYYCAARPVLISRSSTDYAYWGPGTQVTVSS (SEQ ID NO: 447); QLQLVESGGGLVRAGGSLRLSCVLSGRTFSSYAMGWFRQAPGKEREFVSTISLSGGSTFYSDSA KGRFTISRDNAKNTVYLQMNSLKPEDTAVYYCAARPVLISRSSIDYAYWGPGTQVTVSS (SEQ ID NO: 448); QVQLQESGGGLVQAGETLGLSCVHSGRAFSGHGMGWFRQAPGKEREFVAAISWSGVSTAYADSV KGRFTISRVNADNTVSLQMNSLKPEDTAVYFCAAGLYSRPTTERREYIYWGQGTQVTVSS (SEQID NO: 449); QVQLQESGGGLVQAGGSLRLSCAASGNSVDIDDMGWYRQAPGKQRDLVATITAGGITKYGDSAK GRFTISRDNVKNTVYLQMNSLKPEDTATYYCYAVRRYYPRFDYWGQGTQVTVSS (SEQ ID NO: 450); QVQLQESGGGLVQPGGSLRLSCAASGSIFSMNAMGWYRQAPGKQRELVATITDNDFTYYAASVK DRFTISRGNAKNTVYLQMNSLTPEDTAVYYCNADGIYSGGRYYPSSWGQGTQVTVSS (SEQ ID NO: 451); QVQLQESGGGLVQPGGSLRLSCAASGSIFSVNDMGWYRQAPGKQRELVAASYSGGSTNYADSVK GRFTISRDNAKNTVYLQMNSLLPEDTAVYYCNADLVVVTTTPPSFPMPYRFLEVWGQGTLVTVS S (SEQ ID NO: 452); QVQLVESGGGLVHAGGSLRLSCAASGRTFNTMAWFRQAPGKEREFVAAISWSGGLTYYADSVKG RFTIFRDNAKGLAYLQMDSLKPEDTAVYSCAARRTFRTALINTVTAYDTWGQGTQVTVSS (SEQ ID NO: 453); QVQLVESGGGLVHAGGSLRLSCAASGRTFNTMAWFRQAPGKEREFVAAISWSGGLTYYGDSVKG RFTIFRDNAKNLAYLQMNSLKPEDTAVYSCAARRTFRTGLIDTVTAYDTWGQGTQVTVSS (SEQ ID NO: 454); QVQLVESGGGLVQAGDSLRLSCAAASGRALSGWQMGWYRQAPGKEREFVASISMSDGSTSYQDS VKGRFTISRDNALSTMSLRMNSLKSEDTAIYYCQGRSRFGFEYWGQGTQVTVSS (SEQ ID NO: 455); QVQLVESGGGLVQAGESLRLSCVASGRALSGHGMGWFRQAPGKEREFVAAISWSGVSTAYADSV KGRFTISRVNAENTVSVSLQMNSLKPDDTAVYFCAAGLYSRPTTERRDYIYWGQGTQVTVSS (SEQ ID NO: 456); QVQLVESGGGLVQAGGSLRLSCAAASHTFDSYTMGWFRQAPGKEREFVAAVNWDNVKNYADPVK GRFTISRDNVKNRVYLQMNSLKPEDTAVYYCAAGTNLPTRGSGSWGQGTQVTVSS (SEQ ID NO: 457); QVQLVESGGGLVQAGGSLRLSCAAASLTFDSYTMGWFRQAPGKEREFVAAVNWDNVKNYADPVK GRFTISRDNVKNTVYLQMNSLKPEDTAVYYCAAGTNLPTIESGSWGQGTQVTVSS (SEQ ID NO: 458); QVQLVESGGGLVQAGGSLRLSCAASGNGVDIDDMGWYRQAPGKQRDLVASITAGGITKYADSAK GRFTISRDNVKNTVYLQMNSLKPEDTATYYCYAIRRFYPRFDYWGQGTQVTVSS (SEQ ID NO: 459); QVQLVESGGGLVQAGGSLRLSCAASGNGVDIDDMGWYRQAPGKQRDLVASITAGGITNYADSAK GRFTISRDNVKNTVYLQMNSLKPEDTATYYCYAIRRFYPRFDYWGQGTQVTVSS (SEQ ID NO: 460);QVQLVESGGGLVQAGGSLRLSCAASGNGVDIDDMGWYRQAPGKQRDLVATITAGGITKYADSAK GRFTISRDNVKNTVYLQMNSLKPEDTATYYCYAIRRFYPRFDYWGQGTQVTVSS (SEQ ID NO: 461); QVQLVESGGGLVQAGGSLRLSCAASGNGVDIDDMGWYRQAPGKQRDLVATITAGGITNYADSAK GRFTISRDNVKNTVYLQMNSLKPEDTGTYYCYAIRKFYPRFDYWGQGTQVTVSS (SEQ ID NO: 462); QVQLVESGGGLVQAGGSLRLSCAASGNIVDIDDMGWYRQAPGKQRDLVASITAGGITKYADSAK GRFTISRDNVKNTVSLQMNSLKPEDTATYYCYAVRKYYPRFDYWGQGTQVTVSS (SEQ ID NO: 463); QVQLVESGGGLVQAGGSLRLSCAASGNIVDIDDMGWYRQAPGKQRDLVASITAGRITKYADSAK GRFTISRDNVKNTVYLQMNSLKPEDTATYYCYAIRRSYPRFDYWGQGTQVTVSS (SEQ ID NO: 464); QVQLVESGGGLVQAGGSLRLSCAASGRTFSNYAMGWFRQAPGKEREFVAAINWSGGRIYYTDSV KGRFTISRDNAKNTVYLQMNSLKPEDTAVYYCAAGTNWSIPPDYWGQGTQVTVSS (SEQ ID NO: 465); QVQLVESGGGLVQAGGSLRLSCAASGRTFSSYAMGWFRQAPGKEREFVAAIRWSGGSTYYGDSV KGRFTISRDNAKNTVYLQMNSLKPEDTAVYYCAADPIGLGYEMGEYDYWGQGTQVTVSS (SEQ ID NO: 466); QVQLVESGGGLVQAGGSLRLSCAASGRTFSSYAMGWFRQAPGKEREFVAAISWSGGSIYYADSV KGRFTISRDNAKNTVSLQMNSLKPEDTAVYYCAADGTLRTPMNLIHYWGQGTQVTVSS (SEQ ID NO: 467); QVQLVESGGGLVQAGGSLRLSCAASGRTFSSYAMGWFRQAPGKEREFVAAISWSGGSTYYANSV KGRFTISRDNAKNTVYLQMNSLKPEDTAVYYCAPGEEVAGKYFRQLYDYWGQGTQVTVSS (SEQ ID NO: 468); QVQLVESGGGLVQAGGSLRLSCAASGRTFSSYAMGWFRQAPGKEREFVADISWSGGTTNYANSV KGRFTISRDNAKNTVYLQMNSLKPEDTAVYYCAPGEEVDGKYFRPLYDYWGQGTQVTVSS (SEQ ID NO: 469); QVQLVESGGGLVQAGGSLRLSCAASGRTFSTYTMGWFRQAPGKERQFVAAISSSGDSTYYTDSV KGRFTISRDNAKNTVYLQMDSLKPEDTAVYYCAPGEEVAGKYFRALYDYWGQGTQVTVSS (SEQ ID NO: 470); QVQLVESGGGLVQAGGSLRLSCAASGSIFSINAMAWYRQAPGKQRELVAVITSGGSTNYADSVK GRFTISRDNAKNTVYLQMNSLKPEDTAVYYCNADLVYYSGNPGDYGMDYWGKGTLVTVSS (SEQ ID NO: 471); QVQLVESGGGLVQAGGSLRLSCVASGRTFSINNINWYRQAPGKEREFVATTRWRGDSTYYADSVAGRFTISRDSAKNTVYLQMNSLKPEDTAIYYCNAKGGVDVWGQGTQVTVSS (SEQ ID NO: 472); QVQLVESGGGLVQPGGSLRLSCAASGFLFSLYAMAWVRQAPGKGLEWVSDISNGGVTTRYADSV KGRFTISRDNAKNTLYLQMDSLTPGDTAVYYCAVTTTGWRARGQGTQVTVSS (SEQ ID NO: 473); QVQLVESGGGLVQPGGSLRLSCAASGSIFRPNDMGWYRQAPGKQRELVAIITDGGITNYAATVK GRFTISRDNAKNTVYLQMNSLKPEDTAVYYCNLNIPYPRVSSWGQGTQVTVSS (SEQ ID NO: 474); QVQLVESGGGLVQPGGSLRLSCAASGSIFSVNDMGWYRQAPGKQRELVAAIYSGGSTNYADSVK GRFTISRDNAKNTVYLQMNSLKPEDTAVYYCNADIVVVTTTPPSFPMPYRFLEVWGQGTLVTVS S (SEQ ID NO: 475); QVQLVESGGGLVQPGGSLRLSCAASGSTFNTMAWFRQAPGKEREFVAAISWSGGLTYYGDSVKG RFTIFRDNAKNLGYLQMNSLKPEDTAVYSCAARTTFRTGLIVTVTAYDTWGQGTQVTVSS (SEQ ID NO: 476); QVQLVESGGGLVQPGGSLRLSCVLSGRTFSSYAMGWFRQAPGKEREFVSTISLSGGSTFYSGSA KGRFTISRDNAKNTVYLQMNSLKPEDTAVYYCAARPVLISRSSTDYAYWGPGTQVTVSS (SEQ ID NO: 477); QVQLVESGGGLVQTGGSLRLSCAASGRTFSSYAMGWFRQAPGKEREFVAAITWSGGSTYYANSV KGRFTISRDNAKNTVDLQMNSLKPEDTAVYYCTPGEEVAGKYFRPLYDYWGQGTQVTVSS (SEQ ID NO: 479); QVQLVESGGGLVQVGGSLRLSCSISRSIAIFNFMAWYREAEGKQRELVASITGGSRLSYIDSVK GRFTVSKDTANNTLDLQMNSLRPEDTAVYRCAASSPFAGEFWGQGTQVTVSS (SEQ ID NO: 480); QVQLVESGGRLVQAGGSLRLSCAASGRTFNTMAWFRQAPGKEREFVAAITWSGGLTYYEDSVKG RFTIFRDNAKNLAYLQLNSLKPEDTAVYSCAARSTFRTALVNTVTAYDTWGQGTQVTVSS (SEQ ID NO: 481); and QVQLVESGGGLVQPGGSLRLSCTASGRTIASTIMGWYRQTPGKEREFVAISARSGDSESYASSV KDRFTISRDNAKNTVYLQMNNLKPEDTAIYYCYWNTGAGTIWGQGTQVTVSS (SEQ ID NO: 482).

7. A chimeric antigen receptor (CAR) polypeptide comprising the VHH antibody of any one of claims 1-6, or an antigen-binding fragment thereof.

8. The CAR polypeptide of claim 7, wherein the CAR polypeptide comprises the following from N-terminus to C-terminus: a cluster of differentiation 8-alpha (CD8a) signal peptide, theVHH antibody, a cluster of differentiation 8a (CD8a) hinge region domain, a CD8a transmembrane region domain, a 4-1BB domain, and a cluster of differentiation 3-zeta (CD3z) domain.

9. The CAR polypeptide of claim 8, wherein the CD8a signal peptide comprises the following amino acid sequence:MALPVTALLLPLALLLHAARP (SEQ ID NO: 767).

10. The CAR polypeptide of claim 8, wherein the CAR polypeptide comprises an amino acid sequence with at least about 85% identity to the following sequence: TTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGVLLLSLV ITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVKFSRSADAPAYQQGQ NQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERR RGKGHDGLYQGLSTATKDTYDALHMQALPPR (SEQ ID NO: 766).

11. An immunoconjugate comprising the VHH antibody of any one of claims 1-6.

12. A polynucleotide encoding the VHH antibody of any one of claims 1-6 or the CAR of any one of claims 7-10.

13. The polynucleotide of claim 12, wherein the polynucleotide comprises a nucleotide sequence selected from the group consisting of: GAGGTGCAATTGGTCGAGAGCGGTGGCGGGTTGGTTCAACCAGGTGGTTCTTTGCGGCTGTCAT GTGCAGCCTCTGGCTTTGCTCTGGACGGATACACAATAGGGTGGTTTCGCCAAGCTCCGGGTAA AGAGCGGGAGGGAGTGGCATGTATCAGTCGATCTGATACTTCCACGAAGTACGCAGATTCAGTT AAGGGGAGGTTTACGATTAGTCGAGATAACGCCAAAAGAACTGTCTCTCTTCAAATGAACTCTC TCAAGCCGGAGGACACGGCGGTTTATTATTGTGCCGCCTCACTTCAATCTGGACTGCTTTCCAG ATTTCTCTTGCCTCGCCAGTATGACCACTGGGGACAGGGTACTCAGGTTACTGTTAGCAGC (SEQ ID NO: 848); CAACTTCAACTCGTTGAGTCAGGAGGGGGGCTCGTCCAGCCTGGAGGTAGTCTGCGGCTCTCCT GCGTAGCTTCCGGTTTTGCACTTGACTCATATACTATTGGGTGGTTCCGGCAAGCACCAGGTAA AGAACGGGAGGGGCTTTCCTGTATATCCAGGTCAACCTCCGATGCTAGATATGCGGACTCTGTT AAAGGACGGTTCACGATATCTCGGGATAATGCGAAGACTACCGTAAGCCTGTTGATGAGCTCCC TCAAACCCGAGGACACTGCCGTCTATTATTGCGCTGCCAGTAGACAAACTGGCCTCCTCTCCAC TTTCCTTCTTCCGCGCCAGTACGATCACTGGGGCCAGGGAACGCAAGTAACTGTCTCCAGC(SEQ ID NO: 849); CAAGTTCAACTGGTTGAAAGTGGTGGCGGCTTGGTTCAGCCGGGCGGGTCCCTTCGCCTTTCAT GTGCAGCGTCAGGCTTTTCCCTTGACTTTTATTCAATCGGATGGTTCAGACAAGCCCCTGGTAA AGAAAGGGAAGGAGTCTCTTGTATAACATGGTCAGGAGAGCGAACGAATTACAAGGATAGCGTA AAAGGTCGATTCACAATAAGCAGGGACGATGCTAAGGCGACGGTTTTTTTGCAGATGAATAATC TGAAACCGGAAGATACAGCAGTCTACTACTGTGCAGCGGATTCTGGCTACCCGTGTTATGGGTC CTCCTGGTCCTCTGTAGGCTATGATTTTTGGGGCCAGGGGACGCAAGTTACAGTCTCTTCA (SEQ ID NO: 850); CAGGTGCAACTCGTTGAAAGCGGTGGAGGGAGTGTGGAACCCGGCGGGAGCCTCAGATTGAGCT GCGCCACCTCTGGGCTTATCCTCAGTAATCACGGCATGGGGTGGGCCAGACAGGTTCCCGGCAA AGAAGTTGAATGGGTTTCCGGAAGCTACACCGACGGAAGCACGTATTATGCGGATAGTGTTAAG GGCCGCTTTACCATTAGCCGGGATAATGTCAAGAATACAGTTTATCTTCAAATGAATAGTCTTA AACCCGAAGACACTGCCGTCTACTACTGTGCCGCAAGGCAATATTATCGCTCCGGCTATGTGGA CTATTGGGGGCAAGGAACCCAAGTGACGGTGTCATCT (SEQ ID NO: 851); CAGGTCCAACTGGTAGAAAGCGGCGGAGGCAAAGTGCAACCCGGAGGTTCCCTTCGGCTTTCAT GTGCCGCGAGCGGATTTACGTTTTCCAACTACGGTATGATGTGGGTGAGACAAGCTCCAGGCAA AGGGTTGGAGTGGGTTAGCTATATTGACAGCGGCGGTGGATCCACCTACTACACCGACTCTGTA CGAGGGAGGTTTACAATTAGTAGAGACAACGCTAAAAACACAGTCTACCTCCAAATGAATAGTC TCAAGCCAGAGGACACAGCCGTGTACTACTGCGCAAAAGCGATAGGTGTTGTCTCTGGCTCCTT GGAAGTATGGGGACAAGGGACGCTGGTCACAGTAAGCTCT (SEQ ID NO: 852); CAGGTTCAGCTTGTTGAAAGCGGAGGAGGACTGGTTCAGGCAGGGGGCAGCTTGCGACTCTCAT GCGCCGCCAGCGGGCGGACCTTCACAAGTTATGCTATGGGGTGGTTTAGACAAGCACCGGGAAA AGAGAGAGAATTCGTAGCAGCCATTTCATGGCGGGGCGTAAATACCTATTATGCCGATAGCGTG AAAGGAAGGTTTACCATTAGCAGAGAAAACGCAAAAAATACGGTGTACTTGCAAATGATCAGTC TGAAGCCGGAGGATACAGCGGTGTATTACTGTGCCGCAGGTCCATTGGGCGCGACCATGTCTGA GATCGGTTCTTGGGGGCAGGGGACACAAGTCACCGTGTCTTCC (SEQ ID NO: 853); GAGGTGCAGTTGGTTGAATCCGGGGGAGGGCTTGTCCAAGCTGGAGGTTCTCTCAGACTCAGTT GTGCAGCTAGTGGACGCACCTTTAGTAACTATGCTATGGGATGGTTCCGCCAGGCTCCTGGTAA AGAACGAGAGTTCGTATCAGCGATTTCTTGGTCCGGTGGGTCCACCTATTACGCGGACAGCGTC AAAGGTCGATTTACCATTTCTCGAGATAATGCGAAAAATACCGTCTATCTGCAAATGATATCTC TCAAGCCCGAGGATACTGCTGTGTACTATTGCGCGGCTGGTCCGCTCGGAGCAACAATGTCAGA AATTGGAAGTTGGGGCCAAGGGACGCAAGTTACCGTATCCTCT (SEQ ID NO: 854); CAAGTTCAATTGGTCGAAAGTGGAGGCGGCTTGGTACAAGCGGGTGGATCACTGAGACTTAGCT GCGCTGCCTCAGGTAGGACCGTGTCAAGTTATGCTATGGGCTGGTTCAGGCAGGCGCCTGGCAAGGAACGAGAATTTGTCGCCGCAATTTCATGGTCCGGCGGAGGCACTTACTATGCTGATTCCGTC AAGGGCCGGTTTACTATCAGCCGGGATAACGCAAAAAACACGGTGTACCTGCAAATGATTTCCC TGAAGCCCGAAGATACAGCAGTGTATTATTGTGCGGCGGGACCGCTTGGTGCGACGATGAGTGA GATCGGGAGCTGGGGACAGGGCACACAAGTAACGGTGTCCAGC (SEQ ID NO: 855); CAAGTCCAACTTGTTGAATCTGGGGGTGGGCTCGTGCAAGCTGGGGGGAGTCTTCGGTTGTCAT GCGCCGCGTCAGGACGCACTGTATCAAGCTACGCCATGGGATGGTTTAGGCAGGCACCTGGTAA GGAGCGGGAGTTCGTCGCGGCGATTTCCTGGTCAGGTGGAAGCACGTACTACGCAGACTCAGTG AAAGGTAGATTCACGATCTCACGGGATAATGCCAAAAATACCGTCTACCTCCAGATGATCTCTC TTAAACCTGAAGATACAGCCGTGTACTATTGCGCCGCTGGGCCACTCGGTGCTACGATGAGTGA AATTGGGAGTTGGGGCCAGGGCACGCAGGTCACTGTTTCAAGC (SEQ ID NO: 856); GAAGTTCAGTTGGTAGAATCTGGCGGTGGCCTGGCTCAACCTGGGGGATCACTCAGACTCAGTT GTGTAGCGTCCGGCTTTGCCTTCGGCTCCTTCGCTATAGATTGGGTGCGACAACCGCCCGGAAA GGGACCTGAATGGGTATCTGCGATCAACCGGGGAGGGGATCGCACATACTATAGTGATAGCGTA AAGGGTCGATTTACAATCTCCCGCGATAACGCCAAGAATACACTCTATCTGCAATTGAACAGTC TTAAACCGGAGGACACGGCGGTTTATCTGTGTGCTGCTGGAGGGCGCGTGTCTGCTGATGGAAA AAAGTGGGAGTACGACTATTGGGGTCAGGGCACGCAAGTGACCGTATCTTCC (SEQ ID NO: 857); GAGGTGCAACTTGTCGAGAGCGGAGGAGGTCTTGTTCATGCGGGAGGTTCTCTGCGCCTGAGCT GCGCCGCGAGCGGACGGACATTCAATACCATGGCTTGGTTCCGGCAGGCGCCTGGCAAGGAGAG AGAATTCGTAGCCGCCATAGCATGGAATTCAGGTCTTACCTACTATGGGGACAGTGTAAAGGGG CGCTTCACCATCTTTCGAGACAATGCGAAGAATCTGGCCTACCTCCAGATGAACTCCTTGAAAC CTGAGGATACTGCGGTCTATTCCTGCGCTGCACGACGGACGTTCCGCACCGGACTGATCAACAC TGTCACCGCGTATGATACATGGGGTCAGGGGACACAAGTCACCGTCTCATCA (SEQ ID NO: 858); GAAGTACAACTTGTCGAGAGCGGCGGCGGGCTCGTACATGCTGGCGGCTCATTGCGCCTTAGCT GCGTAGCAAGCGGGAGGACTTTTAACACTATGGCCTGGTTTAGACAAGCTCCTGGTAAAGAAAG AGAATTTGTCGCGGCAATTTCCTGGAGCGGAGGGCTCACGTACTACGGGGATAGCGTTAAGGGG CGATTCACGATATTCAGAGACAACGCTAAAAACCTGGCCTACCTTCAAATGAATAGCTTGAAAC CAGAAGACACTGCCGTATATTCATGTGCAGCCCGCCGGACGTTCCGGACAGCCCTCATCAACAC TATCACAGCCTATGATACCTGGGGTCAAGGAACTCAAGTGACTGTCAGCTCC (SEQ ID NO: 859); GAAGTTCAACTCGTCGAGTCAGGTGGTGGCCTTGTCCAAGCCGGGGGAAGCCTCCGATTGTCTT GCGCTGCAAGTGGGAATATTGTTGATATAGACGACATGGGATGGTACCGGCAGGCACCTGGACG CGACTTGGTCGCTTCTATAACGGCTGGCGGGATTACAAAGTACGCTGATTCAGCGAAGGGCAGGTTCACTATCTCCCGCGATAACGTTAAAAACACCGTGTATCTGCAAATGAACAGTCTTAAACCTG AAGATACGGCGACGTACTACTGTTATGCAGTGAGACGGTACTACCCTCGATTTGATTATTGGGG CCAGGGCACACAAGTGACAGTGTCCAGT (SEQ ID NO: 860); GAGGTTCAACTTGTGGAAAGTGGCGGGGGGCTCGTGCAAGCGGGTGGGAGCCTCCGGCTGTCTT GCGCAGCCAGCGGGAACATCGTTGAAATCGACGACATGGGGTGGTATAGACAAGCACCAGGAAA ACAGCGGGACCTTGTTGCCACAATTACAGCTGGAGGCATTACGAATTATGCATCTTCAGCTAAA GGGAGGTTTACGATCTCCCGAGATAACGTAAAGAACACAGTCTATTTGCAAATGAACTCCCTGA AACCGGAGGATACCGCAACGTACTACTGCTATGCCATACGAAAGTATTACCCACGATTCGATTA TTGGGGTCAAGGCACTCAGGTGACCGTGTCAAGT (SEQ ID NO: 861); GAGGTTCAACTCGTTGAAAGTGGAGGAGGGCTCGTCCAGGCGGGCGGGAGTCTGAGGCTTTCTT GCGCCGCGAGCGGTAGAACTTTCCGATCCTATGCTATGGGCTGGTTCAGACAGGCTCCCGGAAA AGAGAGAGAATTTGTGGCGGCCATATCTTGGTCCGGTGGGCGGATATACTATGCAGACAGCGTC AAGGGGAGATTCACGATAAGCCGAGATAATGCAAAGAATACGGTATACCTGCAGATGAACTCCC TTAAACCCGAGGACACCGCAGTATATTATTGTGCCGCTGATGATTTTGAGAGGACCATGACGGA AGTACGGTATTGGGGGCAGGGCACTCAAGTCACCGTGTCTTCA (SEQ ID NO: 862); GAGGTGCAACTGGTTGAGAGTGGCGGGGGTCTTGTCCAGCCAGGGGGATCACTTAGGCTGTCAT GTGCGGCTAGCGGCTTTACCTTCAGCGGGTATTACATGAGTTGGGTCCGCCAGGCTCCAGGAAA GGGACTTGAGTGGGTAAGTAGTATATATAGCGATGATTCAAACACTTATTATGCGGATTCAGTT AAGGGTAGATTTACGATTAGCAGAGATAATGCAAAGAACACTGTCTATCTCCAAATGAACAGCC TTAAACCAGAGGACACTGCAGTTTACTATTGTGCAGCAAGCGCGACACTTAGAGGCCGCGATAC CAGGTTCGATTACTGGGGCCAGGGAACACAAGTCACTGTCAGCTCC (SEQ ID NO: 863); GAGGTTCAACTCGTCGAATCCGGAGGGGGATTGGTGCAACCCGGCGGATCACTTAGGCTTTCCT GTAGTGCATCTGGCTTCCCTTTCGACGATTACAGTATGGACTGGGTCAGGCAGGCACCGGGGAA AGGCTTGGAATGGGTGAGTGCCATCAACAGGAACGGGGGATCAACGTATTACGCCGAGTCCATG AAGGGGAGGTTCACGATCAGCCGGGATAATGCCAAAAACACGCTGTATCTCCAGATGTCCAGTC TTAAACCAGAAGATACCGGGGTCTATCTCTGTGCTGCGGGGGGCAGGGTGTCCGCAGATGGTAA GAAATGGGAATATGATTATTGGGGTCAGGGGACCCAAGTTACGGTTTCTAGC (SEQ ID NO: 864); CAACTCCAGCTGGTCGAGTCTGGAGGTGGTTTGGTCCAGGCTGGGGGGAGCCTTCGCCTGTCAT GCGCTGCGAGTGACCCCATCGTTACCTTCAACACTATGGGATGGTATAGACAAGCGCCTGGCAA GCAGAGAGAACTTGTTGCGAGAATTACCATGTCTGGCATTCCCAACTACGCGGATTCCGTAAAA GGGCGGTTTACCATATCCCGAGATAACGCGAAAAATACGCTGTATCTTCAAATGAACTCTTTGA AGCCCGAGGATAGTGCCGTTTACTATTGTCGAGCTGAGCATTCTGGCTATTGGGGGCAGGGAAC TCAGGTTACTGTAAGCAGC (SEQ ID NO: 865);CAACTCCAACTTGTTGAGTCTGGGGGCGGCTTGGTTCAAGCTGGTGGCTCCTTGCGACTCTCTT GCGCCGCTAGCGGGAACATTGTTGATATAGACGACATGGGATGGTATCGCCAGGCACCGGGAAA ACAGCGCGATCTGGTCGCCACCATCACGGCGGGTGGGATTGCCAACTATGCCGATTCAGCGAAA GGGAGGTTTACGATAAGCCGCGACAACGCTAAGAACACAGTGTACCTGCAAATGAACTCTCTCA AACCAGAGGACACTGCAACATATTACTGTTACGCAATCCGGCGGTACTACCCTAGATTCGATTA TTGGGGGCAAGGAGCCCAAGTTACAGTATCCTCC (SEQ ID NO: 866); CAGCTTCAGCTTGTGGAAAGCGGAGGGGGCCTGGTGCAAGCAGGTGGCAGTCTTCGACTCTCAT GTGCGGCGTCAGGACGGACTGTCAGTTCATACGCCATGGGCTGGTTCAGGCAGGCACCGGGCAA AGAAAGGGAGTTTGTCGCGGCCATTAGTTGGTCTGGGGGGAGCACTTACTATGCCGATAGTGTT AAGGGTAGATTTACTATTAGTCGCGATAACGCTAAGAACACCGTTTATTTGCAGATGAACTCAC TTAAACCAGAGGATACAGCAGTGTACTATTGCGCTGCCGACCCCAGCCTGAGTCGCACCATGGA CGAGATAGGCTCCTGGGGTCAAGGAACGCAGGTCACGGTTTCCTCT (SEQ ID NO: 867); CAACTCCAACTTGTGGAATCAGGAGGGGGTCTCGTACAGACAGGAGGATCACTCAACTTGAGTT GTGCCGCCTCTGGAGCTTTTGTGTCTATAGATGCCATGGCGTGGTATCGACAGGCTCCCGGCAA GGCTCGGGAGCTTGTCGCCTTTTCAAGCAGCGGTGGGATAACAAATTATGCGGACAGTGTCAAG GGCCGATTTACCATTACTAGGGATAACGCGAAAAATACTGTTTATCTCCAAATGAATTCCCTTA AACCAGAGGATACGGCTGTGTACTATTGCAACGCAGACATCTTGCAATCAGGTTGGTACACGTA CTGGGGACAAGGAACTCAGGTGACAGTGTCTAGC (SEQ ID NO: 868); CAGTTGCAACTTGTGGAGAGCGGTGGAGGCCTGGTTCGGGCAGGAGGTAGTCTCCGGTTGTCTT GTGTATTGTCAGGGAGGACATTTTCCAGTTACGCGATGGGATGGTTCAGGCAGGCTCCTGGGAA AGAACGAGAATTCGTTTCAACTATTTCTCTGTCCGGCGGATCAACCTTCTATAGCGATTCCGCC AAGGGTCGCTTTACCATAAGTCGGGACAACGCCAAAAACACCGTTTATCTGCAAATGAATAGTC TGAAGCCAGAGGACGCGGCGGTGTACTACTGTGCTGCACGGCCCGTGTTGATTAGTCGCAGTTC CACGGACTACGCTTATTGGGGGCCTGGAACCCAGGTGACCGTCAGCTCT (SEQ ID NO: 869); CAGCTTCAGCTCGTTGAATCTGGGGGAGGCCTGGTTCGCGCTGGAGGCAGCCTTCGCCTCTCCT GCGTGCTTTCAGGACGAACTTTTTCAAGCTATGCGATGGGTTGGTTTAGGCAGGCGCCTGGAAA AGAGCGGGAATTTGTCAGTACGATAAGCCTTAGCGGGGGTAGTACATTTTACTCAGATAGCGCG AAAGGCCGATTTACTATATCCCGAGATAATGCGAAAAATACGGTCTATTTGCAGATGAATAGTC TGAAACCAGAGGATACTGCCGTCTATTACTGCGCTGCGAGGCCCGTACTTATTTCCCGGAGCTC CATAGACTATGCTTACTGGGGTCCGGGCACACAGGTAACGGTCTCCAGT (SEQ ID NO: 870); CAGGTCCAACTTCAGGAAAGCGGTGGGGGTTTGGTACAGGCAGGAGAAACGCTGGGACTTAGTT GCGTACACAGTGGACGCGCGTTCTCAGGCCATGGTATGGGGTGGTTTCGCCAGGCCCCTGGAAA AGAAAGGGAGTTTGTGGCGGCTATAAGTTGGTCAGGCGTCTCAACTGCCTATGCCGACTCTGTA AAAGGTCGATTCACCATCTCTAGAGTGAACGCTGACAACACGGTGTCACTTCAAATGAATAGTCTGAAACCCGAGGACACAGCCGTTTACTTCTGCGCGGCGGGCCTCTACTCTCGACCAACCACTGA ACGCAGGGAATACATATACTGGGGTCAGGGAACTCAGGTAACAGTTAGCAGC (SEQ ID NO: 871); CAAGTACAGCTGCAAGAGAGTGGGGGCGGGCTCGTCCAAGCCGGGGGATCTTTGCGGCTCAGTT GCGCGGCCTCTGGTAATTCCGTTGACATTGACGACATGGGATGGTACCGACAGGCTCCTGGCAA GCAACGAGATTTGGTCGCGACTATCACCGCAGGAGGCATCACCAAGTATGGTGACTCTGCGAAA GGCAGGTTCACAATAAGCAGAGATAACGTGAAGAATACCGTGTACTTGCAGATGAATAGCCTGA AGCCTGAGGACACCGCAACCTACTACTGTTATGCCGTCCGGCGCTATTACCCACGCTTCGACTA TTGGGGCCAGGGTACGCAAGTAACAGTAAGTAGT (SEQ ID NO: 872); CAGGTTCAGTTGCAAGAAAGCGGGGGAGGCCTCGTTCAGCCGGGTGGCTCATTGAGGTTGTCAT GCGCCGCTTCAGGTTCTATATTCTCTATGAACGCGATGGGATGGTATAGACAAGCCCCCGGCAA ACAACGCGAACTTGTGGCGACTATTACAGATAATGACTTTACTTACTATGCAGCCTCCGTGAAA GATCGGTTTACAATTTCTCGGGGGAACGCCAAGAACACTGTGTATCTTCAGATGAACAGTCTGA CGCCTGAAGATACGGCGGTCTACTATTGCAATGCGGATGGCATCTACTCCGGTGGAAGATATTA CCCATCTTCATGGGGACAGGGTACACAAGTCACAGTAAGCAGC (SEQ ID NO: 873); CAGGTACAGCTTCAGGAATCTGGCGGTGGCCTGGTCCAGCCAGGAGGAAGCCTGAGATTGAGCT GTGCGGCATCCGGCAGCATTTTTTCTGTAAATGATATGGGCTGGTACAGACAGGCTCCAGGGAA GCAACGCGAATTGGTGGCGGCCTCATACTCTGGTGGGTCAACGAATTATGCCGATAGTGTTAAG GGACGGTTTACGATTAGCAGGGATAATGCAAAAAACACTGTGTATTTGCAAATGAATTCTCTTC TCCCCGAAGATACAGCTGTGTATTATTGTAATGCCGATTTGGTCGTAGTTACGACTACGCCGCC TAGTTTCCCCATGCCGTACCGATTCCTTGAGGTGTGGGGTCAGGGTACGCTGGTTACCGTCAGC AGC (SEQ ID NO: 874); CAAGTACAACTTGTAGAATCTGGAGGGGGTCTCGTACACGCGGGCGGTTCTCTCCGCCTTTCTT GCGCTGCCAGTGGAAGGACATTCAACACGATGGCATGGTTCCGCCAAGCACCAGGAAAAGAGCG AGAATTTGTCGCGGCTATATCATGGTCCGGAGGTCTCACTTATTACGCGGACTCCGTGAAGGGG CGATTCACCATTTTTCGGGACAATGCGAAGGGTCTGGCCTACCTCCAAATGGATTCATTGAAGC CAGAAGATACGGCAGTGTACTCATGCGCCGCGAGAAGGACCTTCAGAACAGCGCTGATTAACAC TGTAACGGCTTACGACACCTGGGGCCAGGGAACTCAGGTCACTGTCTCAAGT (SEQ ID NO: 875); CAAGTTCAACTGGTTGAATCCGGGGGCGGGCTGGTGCATGCGGGCGGTTCTCTTCGACTCTCTT GCGCCGCCTCAGGTAGAACCTTCAATACGATGGCTTGGTTTCGGCAAGCACCGGGTAAGGAGCG GGAGTTCGTGGCGGCAATTAGCTGGTCAGGTGGACTGACCTATTACGGAGATTCTGTGAAGGGC CGCTTCACTATATTCCGGGACAATGCGAAGAATCTGGCGTATCTTCAAATGAACTCACTGAAGC CCGAGGACACTGCTGTGTACTCCTGCGCTGCTCGAAGGACTTTCAGGACGGGACTTATAGATACGGTTACAGCGTACGATACTTGGGGGCAGGGAACCCAGGTTACGGTTTCTAGC (SEQ ID NO: 876); CAGGTCCAGCTTGTGGAATCCGGCGGCGGGTTGGTGCAAGCCGGTGATAGCCTGCGCCTTTCTT GCGCGGCTGCTAGTGGGCGCGCTTTGAGCGGCTGGCAAATGGGTTGGTATCGGCAGGCGCCGGG GAAGGAAAGAGAGTTTGTTGCATCCATTTCCATGTCCGATGGGAGTACTAGCTACCAAGATTCT GTCAAGGGGAGATTTACGATCAGCCGCGACAATGCACTTAGTACAATGTCTTTGAGAATGAACA GTCTTAAATCCGAGGACACTGCTATTTACTACTGCCAGGGGCGGTCTAGGTTCGGGTTTGAGTA TTGGGGTCAAGGCACTCAAGTCACAGTCTCTAGT (SEQ ID NO: 877); CAGGTACAACTCGTAGAAAGCGGTGGGGGCCTTGTTCAGGCAGGGGAGAGCCTCCGGTTGTCTT GCGTCGCTAGCGGTCGAGCCTTGTCAGGACACGGTATGGGGTGGTTCCGACAAGCGCCAGGGAA GGAAAGAGAGTTCGTAGCTGCTATCAGTTGGAGTGGGGTGTCAACTGCTTACGCAGACTCCGTA AAAGGTCGCTTCACGATCAGTAGGGTTAATGCGGAAAACACAGTGTCTGTATCCTTGCAGATGA ACTCACTGAAGCCAGATGATACAGCAGTCTATTTCTGCGCCGCTGGGTTGTATTCCCGCCCGAC AACGGAGCGACGCGACTACATATACTGGGGACAGGGAACACAGGTTACCGTGAGCAGC (SEQ ID NO: 878); CAGGTGCAACTGGTAGAAAGTGGCGGGGGCCTGGTACAAGCGGGAGGCAGCTTGCGGCTCTCTT GCGCGGCGGCGTCCCACACGTTCGATTCTTATACGATGGGTTGGTTCCGACAGGCTCCGGGAAA AGAAAGGGAGTTCGTGGCTGCTGTGAATTGGGATAATGTGAAGAACTACGCAGATCCGGTTAAA GGGCGGTTCACAATCTCTCGAGACAATGTGAAAAACCGCGTGTATTTGCAGATGAATAGCTTGA AACCCGAAGATACGGCAGTCTACTATTGTGCGGCAGGTACCAATCTGCCGACGAGAGGAAGCGG ATCTTGGGGGCAGGGTACACAAGTTACTGTCTCAAGT (SEQ ID NO: 879); CAAGTCCAACTCGTCGAGTCAGGAGGTGGGCTCGTTCAGGCAGGCGGGAGCCTGAGGTTGAGTT GTGCCGCCGCAAGTCTTACCTTTGATTCATATACTATGGGATGGTTTAGACAGGCGCCAGGTAA AGAAAGAGAGTTCGTAGCAGCAGTTAACTGGGACAACGTAAAGAATTATGCAGATCCAGTAAAG GGTCGCTTTACCATCTCAAGAGATAATGTCAAAAATACGGTGTACCTCCAAATGAACAGTCTGA AGCCTGAGGATACAGCCGTATACTATTGCGCCGCCGGGACCAACCTCCCCACTATAGAGTCAGG GAGTTGGGGGCAGGGCACTCAAGTAACTGTGAGTAGT (SEQ ID NO: 880); CAAGTACAACTTGTTGAGAGCGGGGGAGGATTGGTGCAGGCCGGAGGTTCCCTCCGGCTGTCCT GCGCTGCGTCAGGAAATGGGGTAGATATAGACGACATGGGTTGGTACAGACAGGCACCCGGCAA ACAAAGGGACCTGGTAGCATCTATTACTGCTGGAGGAATTACTAAATACGCCGATTCTGCAAAA GGACGGTTTACGATCAGTCGGGACAACGTAAAGAACACTGTTTACCTCCAGATGAATTCCCTGA AGCCGGAGGACACAGCGACTTACTATTGTTACGCTATCAGACGATTCTACCCTCGCTTCGACTA CTGGGGCCAGGGTACGCAGGTTACGGTTTCATCT (SEQ ID NO: 881); CAGGTACAGCTCGTCGAATCCGGGGGAGGCTTGGTCCAGGCGGGCGGAAGTCTTAGATTGTCTTGTGCCGCATCTGGGAACGGCGTTGATATTGACGATATGGGGTGGTATCGACAGGCGCCCGGTAA GCAGCGCGATCTGGTTGCCAGCATCACGGCAGGAGGAATCACTAATTATGCGGATAGTGCCAAA GGAAGGTTTACCATCTCTCGGGACAACGTCAAAAATACAGTATATCTTCAGATGAACTCCCTTA AACCAGAGGATACTGCGACCTATTATTGCTACGCAATACGCCGGTTTTACCCTCGGTTTGACTA CTGGGGTCAAGGGACGCAGGTGACAGTATCATCA (SEQ ID NO: 882); CAGGTTCAACTGGTCGAGTCCGGTGGAGGCTTGGTGCAAGCGGGTGGTAGTCTGCGGCTGAGCT GCGCTGCTAGTGGTAACGGTGTCGACATCGACGACATGGGATGGTACAGACAGGCACCAGGGAA GCAGAGGGACCTTGTTGCTACAATCACAGCCGGCGGGATAACCAAATACGCAGATTCTGCAAAG GGTCGGTTTACAATTTCACGAGATAATGTAAAGAATACCGTCTATTTGCAGATGAACAGCCTTA AACCCGAAGATACTGCCACATATTATTGTTACGCCATAAGGCGATTCTATCCCCGCTTCGACTA TTGGGGTCAGGGGACTCAAGTTACTGTTAGCTCC (SEQ ID NO: 883); CAGGTGCAACTCGTTGAAAGCGGGGGAGGACTCGTGCAAGCGGGAGGATCACTCCGACTGAGTT GTGCTGCTTCAGGGAATGGCGTTGATATAGACGACATGGGTTGGTATCGACAGGCACCCGGAAA GCAACGGGATTTGGTCGCGACTATTACAGCGGGGGGTATTACTAACTATGCGGATAGCGCCAAG GGGCGATTCACTATCTCACGCGATAACGTGAAAAACACCGTATATCTTCAGATGAACAGTTTGA AACCAGAAGACACCGGTACATACTATTGTTACGCTATCAGAAAATTTTACCCCAGATTTGATTA CTGGGGGCAGGGAACGCAGGTTACGGTCAGTAGC (SEQ ID NO: 884); CAGGTCCAGCTGGTTGAAAGCGGTGGGGGGCTGGTCCAAGCCGGCGGTTCTCTTAGACTTAGCT GCGCCGCGTCTGGTAACATTGTTGACATCGACGACATGGGGTGGTATAGGCAGGCTCCAGGTAA ACAACGAGATTTGGTTGCCTCAATCACAGCGGGGGGTATAACCAAATATGCAGATTCAGCTAAG GGACGATTCACCATTAGCCGAGACAATGTAAAGAACACTGTTAGTTTGCAGATGAACTCACTGA AACCTGAAGATACGGCGACATATTATTGTTATGCAGTTAGAAAGTATTACCCCAGATTTGACTA TTGGGGCCAAGGCACTCAAGTGACCGTATCCTCT (SEQ ID NO: 885); CAGGTCCAGTTGGTGGAGAGCGGCGGTGGGTTGGTTCAGGCGGGAGGGTCTCTCAGGCTGAGCT GTGCTGCAAGTGGGAATATCGTCGACATCGACGATATGGGTTGGTACCGCCAAGCACCTGGGAA GCAACGAGATTTGGTTGCATCTATAACCGCAGGCAGAATAACCAAATATGCTGATAGCGCGAAA GGAAGGTTTACAATATCTAGGGATAATGTTAAAAATACCGTTTATCTCCAGATGAACTCACTGA AGCCAGAAGATACCGCGACTTATTACTGTTACGCAATAAGGCGGTCATACCCAAGGTTCGACTA CTGGGGACAGGGGACACAGGTCACAGTGTCAAGC (SEQ ID NO: 886); CAGGTACAACTTGTCGAATCAGGTGGAGGACTCGTGCAGGCTGGGGGGTCCCTGCGCTTGAGTT GCGCCGCTAGTGGTAGGACATTTTCCAATTACGCCATGGGTTGGTTTAGACAAGCTCCTGGGAA GGAGCGCGAATTCGTGGCTGCAATTAACTGGTCCGGCGGACGCATTTACTATACAGACTCCGTG AAAGGTCGATTTACAATCAGTAGAGACAACGCCAAGAATACGGTTTATCTTCAGATGAACAGTC TTAAACCGGAAGATACTGCCGTGTACTATTGCGCTGCGGGGACGAATTGGTCAATACCACCTGATTACTGGGGTCAGGGGACGCAGGTAACCGTGAGCTCC (SEQ ID NO: 887); CAAGTACAGCTCGTGGAGTCAGGTGGTGGACTCGTTCAGGCGGGTGGTTCCCTTAGGTTGTCCT GTGCTGCGTCAGGTCGCACGTTCAGCTCCTATGCTATGGGCTGGTTCAGGCAGGCACCGGGGAA GGAGCGAGAATTTGTAGCGGCAATACGATGGAGTGGAGGCTCTACTTATTACGGAGATAGTGTT AAAGGGAGGTTCACTATTTCTAGAGATAATGCGAAAAACACCGTGTATCTCCAAATGAACAGCC TCAAACCTGAAGATACGGCAGTCTACTACTGTGCGGCTGACCCCATTGGCCTCGGATACGAAAT GGGAGAGTATGATTACTGGGGTCAAGGTACGCAGGTTACTGTATCAAGT (SEQ ID NO: 888); CAGGTACAGCTTGTCGAAAGCGGGGGCGGTCTGGTTCAGGCCGGTGGAAGTTTGAGGCTCAGTT GTGCAGCGAGCGGGAGAACCTTCTCCAGTTACGCGATGGGGTGGTTCCGACAGGCGCCAGGGAA GGAGAGAGAATTCGTGGCAGCAATCTCATGGTCCGGCGGAAGCATTTATTATGCGGACTCTGTA AAGGGGCGATTTACAATATCCCGAGACAACGCGAAGAACACAGTATCCCTCCAAATGAATAGCC TGAAGCCTGAAGACACGGCTGTGTACTATTGTGCCGCAGACGGAACGCTCCGCACGCCCATGAA CCTTATTCATTATTGGGGGCAGGGAACCCAAGTGACTGTATCTTCT (SEQ ID NO: 889); CAAGTCCAACTGGTAGAGAGTGGCGGTGGGCTCGTCCAAGCCGGGGGCTCTCTCAGGTTGTCCT GTGCCGCGTCCGGCAGGACCTTCTCAAGTTATGCGATGGGATGGTTCCGACAGGCACCAGGAAA AGAGAGGGAGTTTGTCGCAGCTATTTCATGGTCTGGCGGTAGCACGTATTATGCCAATAGCGTG AAAGGGCGGTTCACGATTAGTCGGGACAATGCGAAAAACACCGTTTATCTGCAAATGAATTCCC TGAAGCCTGAGGACACCGCTGTGTACTACTGCGCTCCTGGCGAAGAAGTAGCAGGCAAGTATTT CCGCCAACTCTATGACTACTGGGGGCAGGGCACACAAGTTACAGTGAGTTCC (SEQ ID NO: 890); CAAGTTCAACTTGTTGAGTCCGGGGGTGGCCTCGTCCAAGCAGGAGGGTCCCTCCGGCTGTCAT GCGCGGCTAGCGGTCGGACATTTAGCAGTTATGCGATGGGGTGGTTCCGGCAAGCACCAGGTAA GGAAAGGGAGTTTGTGGCAGACATTTCATGGAGTGGAGGTACGACAAATTATGCAAACAGCGTT AAGGGGCGCTTTACGATTTCCCGAGACAATGCAAAAAACACAGTATATCTGCAGATGAACTCAC TCAAGCCGGAAGATACGGCGGTTTACTACTGTGCGCCTGGAGAAGAAGTGGACGGCAAATATTT CCGCCCTCTCTATGATTACTGGGGGCAGGGAACTCAGGTAACCGTAAGCAGT (SEQ ID NO: 891); CAGGTACAACTGGTGGAATCAGGTGGGGGGTTGGTCCAGGCTGGAGGATCATTGCGACTCAGTT GCGCCGCATCAGGGCGAACTTTTTCTACCTATACGATGGGATGGTTTCGGCAAGCCCCCGGTAA AGAACGACAGTTTGTCGCAGCCATTAGTTCCTCAGGAGACTCAACCTACTACACTGATTCCGTG AAAGGCCGGTTTACCATTTCCAGAGATAATGCCAAGAACACTGTTTATCTGCAGATGGACAGCC TGAAGCCCGAGGACACAGCGGTGTATTACTGCGCACCGGGTGAAGAAGTAGCTGGAAAATACTT CCGCGCACTGTATGATTACTGGGGCCAGGGCACTCAAGTTACCGTCTCTAGT (SEQ ID NO: 892);CAAGTCCAGCTTGTAGAAAGCGGTGGCGGTCTCGTTCAAGCCGGTGGAAGCCTCCGGCTTTCAT GTGCGGCATCAGGTTCAATTTTCTCCATTAACGCGATGGCATGGTATAGGCAAGCCCCTGGTAA GCAGCGCGAGCTCGTGGCTGTTATCACATCAGGAGGGAGTACTAACTACGCGGATTCTGTTAAA GGAAGATTTACCATTTCCCGCGATAATGCTAAGAATACAGTCTACCTCCAAATGAACTCCCTGA AGCCTGAAGACACTGCCGTGTATTATTGCAATGCTGATCTGGTCTACTACTCAGGCAATCCTGG AGACTATGGTATGGACTACTGGGGAAAGGGGACATTGGTGACTGTCAGTAGT (SEQ ID NO: 893); CAGGTTCAGTTGGTAGAATCCGGCGGTGGATTGGTGCAGGCTGGAGGGTCCTTGAGACTTTCCT GTGTTGCGAGCGGGAGGACGTTTTCAATCAATAACATTAACTGGTATAGACAGGCCCCTGGCAA GGAGCGAGAGTTCGTTGCCACTACCAGATGGCGGGGAGACAGCACTTACTACGCTGACTCTGTG GCCGGTCGATTTACCATATCAAGAGACTCAGCTAAAAATACCGTGTACCTCCAAATGAACTCAC TGAAACCAGAGGATACTGCTATATACTATTGCAATGCTAAGGGCGGCGTTGATGTCTGGGGTCA AGGAACCCAGGTAACGGTTTCCAGT (SEQ ID NO: 894); CAGGTACAGCTTGTTGAGTCCGGCGGGGGTCTCGTACAGCCGGGCGGCTCCTTGCGCCTCAGTT GTGCGGCGAGTGGATTCTTGTTCTCACTCTACGCTATGGCATGGGTCCGGCAAGCCCCAGGCAA AGGTCTGGAGTGGGTAAGTGATATAAGCAACGGAGGTGTTACCACAAGATACGCGGATTCAGTA AAAGGCCGGTTTACAATTTCACGAGATAATGCGAAAAATACGTTGTATCTTCAAATGGATAGTC TGACGCCGGGGGATACTGCGGTCTATTACTGTGCTGTTACAACCACGGGCTGGCGGGCAAGAGG CCAAGGGACCCAAGTGACTGTCTCCTCC (SEQ ID NO: 895); CAGGTCCAACTTGTTGAATCAGGCGGAGGACTCGTTCAGCCTGGAGGCAGCCTGAGGCTTTCTT GCGCCGCTTCAGGAAGCATATTCAGACCAAACGACATGGGCTGGTACCGACAGGCGCCCGGTAA ACAAAGGGAACTCGTGGCAATCATAACGGACGGGGGTATCACAAATTACGCTGCAACGGTAAAG GGGAGGTTTACGATTAGTCGAGACAATGCCAAAAATACAGTGTACCTTCAAATGAACAGCCTCA AACCGGAGGACACGGCGGTTTATTATTGCAACCTTAATATCCCGTACCCTCGCGTTTCCTCATG GGGCCAGGGAACGCAGGTCACAGTCTCATCT (SEQ ID NO: 896); CAGGTGCAGCTCGTCGAGTCTGGGGGAGGCCTTGTCCAGCCTGGTGGCTCCCTTCGCCTGAGTT GTGCAGCATCTGGGAGTACATTTAACACCATGGCCTGGTTCCGGCAAGCGCCGGGAAAGGAGCG CGAATTCGTGGCGGCCATATCATGGAGCGGCGGATTGACCTATTATGGTGATTCCGTCAAGGGA AGATTCACCATATTCAGGGATAACGCGAAGAATTTGGGCTATCTCCAGATGAATTCCCTTAAAC CGGAAGATACTGCGGTATATAGTTGCGCCGCGAGGACAACTTTCCGAACCGGTTTGATCGTAAC CGTAACAGCCTATGATACATGGGGTCAAGGTACACAAGTGACAGTCAGTTCC (SEQ ID NO: 897); CAGGTGCAGTTGGTAGAGTCCGGAGGAGGTCTCGTGCAGCCCGGAGGTTCACTCAGACTTTCAT GTGTGTTGAGTGGGCGGACGTTTTCTAGTTATGCAATGGGATGGTTCCGGCAAGCGCCGGGCAAAGAAAGAGAGTTCGTGAGTACAATCTCCTTGTCCGGGGGAAGCACATTTTACTCAGGGAGTGCG AAAGGGCGGTTCACGATAAGTAGAGATAACGCCAAAAACACCGTTTATCTCCAGATGAACTCCT TGAAGCCTGAAGACACTGCGGTGTACTACTGCGCTGCACGACCTGTTCTTATTAGCCGGAGCTC AACAGACTACGCCTATTGGGGTCCGGGAACTCAAGTTACAGTTAGCTCA (SEQ ID NO: 898); CAGGTTCAACTCGTTGAGTCCGGCGGCGGCCTTGTCCAACCTGGTGGGAGTTTGCGGTTGTCCT GTGTACTTAGCGGCAGAACCTTTAGCTCATACGCGATGGGATGGTTTCGCCAAGCGCCGGGTAA AGAGCGAGAGTTCGTATCAACTATCAGCTTGTCTGGCGGATCAACGTTCTATAGCGGTTCTGCC AAAGGACGGTTCACCATTTCAAGAGACAATGCGAAAAACACTGTATATCTGCAGATGAATAGTC TCAAACCTGAGGACACTGCCGTCTACTATTGTGCTGCTCGGCCAGTTTTGATAAGCCGAAGTAG CACCGATTATGCCTACTGGGGACCTGGTACTCAGGTGACCGTTTCCAGT (SEQ ID NO: 899); CAGGTGCAACTCGTAGAAAGCGGGGGTGGGTTGGTTCAAACCGGTGGCTCATTGCGATTGTCCT GCGCGGCATCTGGAAGAACGTTTAGTTCTTATGCGATGGGTTGGTTTAGGCAGGCTCCTGGAAA GGAACGGGAATTTGTCGCCGCAATCACCTGGTCAGGTGGATCCACCTATTACGCAAACAGTGTA AAGGGGCGCTTTACAATCTCTCGGGACAACGCTAAAAATACAGTGGATTTGCAAATGAACAGTC TCAAGCCCGAGGACACAGCAGTCTATTATTGCACTCCTGGAGAAGAAGTAGCCGGTAAGTATTT TAGACCTCTGTATGATTATTGGGGGCAAGGGACGCAAGTTACCGTTTCATCA (SEQ ID NO: 900); CAGGTTCAGTTGGTTGAATCTGGAGGTGGTCTCGTACAGGTCGGCGGGTCATTGCGGCTGTCCT GCTCTATTAGCAGGAGCATTGCAATTTTTAATTTTATGGCCTGGTATAGGGAGGCCGAAGGGAA GCAGCGGGAACTCGTCGCCTCCATCACTGGCGGGAGTCGACTGTCATATATTGATAGTGTTAAG GGACGCTTCACGGTCAGTAAGGACACAGCTAACAATACACTCGATCTCCAAATGAACTCCCTGC GACCAGAGGACACCGCCGTGTATCGATGCGCGGCGTCTAGTCCGTTTGCTGGTGAGTTCTGGGG CCAAGGGACCCAGGTAACTGTGTCTTCA (SEQ ID NO: 901); CAGGTGCAGCTGGTGGAATCAGGGGGACGCTTGGTTCAAGCAGGGGGTAGCCTTAGGTTGTCTT GTGCGGCAAGTGGGCGGACGTTTAATACAATGGCCTGGTTTCGACAGGCACCTGGAAAGGAAAG GGAATTTGTAGCTGCCATCACCTGGTCCGGGGGGTTGACATACTACGAGGATAGCGTAAAAGGG AGGTTTACAATTTTTCGAGACAACGCAAAAAATTTGGCATACCTTCAGCTCAACTCATTGAAAC CCGAGGATACAGCTGTATATTCTTGTGCCGCCCGATCAACTTTTAGGACTGCCCTGGTTAATAC TGTTACGGCGTATGACACTTGGGGACAAGGCACCCAAGTGACGGTAAGCTCA (SEQ ID NO: 902); CAGGTGCAACTGGTTGAGTCCGGCGGTGGCTTGGTACAGCCCGGCGGCAGTCTCCGACTTAGTT GTACGGCGTCAGGTCGCACAATTGCGAGCACGATTATGGGCTGGTACAGACAAACGCCCGGCAA AGAACGGGAATTTGTCGCTATCAGCGCTAGGAGCGGCGATTCCGAATCCTATGCAAGTTCAGTG AAGGATAGGTTTACCATCAGTCGCGATAATGCGAAAAATACCGTCTACCTCCAGATGAACAATTTGAAACCTGAGGACACTGCTATATATTACTGCTACTGGAATACGGGAGCAGGAACCATCTGGGG GCAGGGAACACAAGTGACTGTCTCTTCC (SEQ ID NO: 903); and CAAGTTCAATTGGTAGAGTCCGGTGGAGGACTGGTCCAACCGGGAGGGTCTTTGCGGTTGTCAT GCGCCGCCTCTGGCAGCATTTTTTCTGTGAATGATATGGGTTGGTATCGACAAGCGCCTGGTAA GCAACGGGAACTCGTAGCCGCGATATATTCCGGTGGCTCTACAAATTACGCGGATAGTGTAAAA GGCCGGTTTACCATCTCCCGAGATAATGCTAAGAATACCGTCTATCTTCAAATGAACAGCTTGA AGCCCGAGGACACAGCAGTGTATTATTGCAACGCCGACATTGTAGTGGTCACGACTACCCCTCC GAGTTTCCCTATGCCCTATCGGTTCTTGGAGGTATGGGGTCAGGGAACGCTTGTTACTGTAAGT TCT (SEQ ID NO: 961).

14. A vector comprising the polynucleotide of claim 12 or claim 13.

15. A cell expressing the VHH antibody of any one of claims 1-7, the CAR of any one of claims 7-10, the polynucleotide of claim 12 or claim 13, or the vector of claim 14.

16. A lipid nanoparticle comprising the VHH antibody of any one of claims 1-6 or the polynucleotide of claim 12 or claim 13.

17. The lipid nanoparticle of claim 16, wherein the lipid nanoparticle is conjugated to the VHH antibody.

18. The lipid nanoparticle of claim 17, wherein the VHH antibody is covalently bound to a polyethylene glycol (PEG) molecule of the lipid nanoparticle.

19. The lipid nanoparticle of claim 17, wherein the VHH antibody is covalently bound to a PEG portion of a PEG-modified lipid of the lipid nanoparticle.

20. The lipid nanoparticle of claim 16, wherein the lipid nanoparticle comprises a polynucleotide encoding a chimeric antigen receptor.

21. The lipid nanoparticle of claim 16, wherein the chimeric antigen receptor comprises an antigen binding domain capable of binding a marker associated with a neoplasia.

22. The lipid nanoparticle of claim 16, wherein the lipid nanoparticle further comprises a base editor system, wherein the base editor system comprises a base editor, or a polynucleotide encoding the base editor, and a guide RNA, or a polynucleotide encoding the guide RNA, wherein the guide RNA directs the base editor to deaminate a nucleobase in a target polynucleotide.

23. A composition comprising the VHH antibody of any one of claims 1-6, the chimeric antigen receptor of any one of claims 7-10, the immunoconjugate of claim 11, the polynucleotide of claim 12 or claim 13, the vector of claim 14, the cell of claim 15, or the lipid nanoparticle of any one of claims 16-22, and a carrier or excipient.

24. The composition of claim 23, wherein the carrier or excipient is a pharmaceutical carrier or excipient.

25. A method for treating a disease in a subject in need thereof, the method comprising administering to the subject the lipid nanoparticle of claim 20 or claim 22.

26. The method of claim 25, wherein the disease is a neoplasia.

27. The method of claim 26, wherein the neoplasia is a B cell lymphoma or a T cell lymphoma.

28. The method of claim 27, wherein the T cell lymphoma is a B-cell acute lymphoblastic leukemia.

29. A chimeric antigen receptor (CAR) comprising an amino acid sequence having at least 85% sequence identity to a sequence selected from the group consisting of: MALPVTALLLPLALLLHAARPEVQLVESGGGLVQPGGSLRLSCAASGFALDGYTIGWFRQAPGK EREGVACISRSDTSTKYADSVKGRFTISRDNAKRTVSLQMNSLKPEDTAVYYCAASLQSGLLSR FLLPRQYDHWGQGTQVTVSSTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFAC DIYIWAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGG CELRVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNE LQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR (SEQ ID NO: 785); MALPVTALLLPLALLLHAARPQLQLVESGGGLVQPGGSLRLSCVASGFALDSYTIGWFRQAPGKEREGLSCISRSTSDARYADSVKGRFTISRDNAKTTVSLLMSSLKPEDTAVYYCAASRQTGLLST FLLPRQYDHWGQGTQVTVSSTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFAC DIYIWAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGG CELRVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNE LQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR (SEQ ID NO: 786); MALPVTALLLPLALLLHAARPQVQLVESGGGLVQPGGSLRLSCAASGFSLDFYSIGWFRQAPGK EREGVSCITWSGERTNYKDSVKGRFTISRDDAKATVFLQMNNLKPEDTAVYYCAADSGYPCYGS SWSSVGYDFWGQGTQVTVSSTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFAC DIYIWAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGG CELRVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNE LQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR (SEQ ID NO: 787); MALPVTALLLPLALLLHAARPQVQLVESGGGSVEPGGSLRLSCATSGLILSNHGMGWARQVPGK EVEWVSGSYTDGSTYYADSVKGRFTISRDNVKNTVYLQMNSLKPEDTAVYYCAARQYYRSGYVD YWGQGTQVTVSSTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPL AGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVKFS RSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAE AYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR (SEQ ID NO: 788); MALPVTALLLPLALLLHAARPQVQLVESGGGKVQPGGSLRLSCAASGFTFSNYGMMWVRQAPGK GLEWVSYIDSGGGSTYYTDSVRGRFTISRDNAKNTVYLQMNSLKPEDTAVYYCAKAIGVVSGSL EVWGQGTLVTVSSTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAP LAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVKF SRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMA EAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR (SEQ ID NO: 789); MALPVTALLLPLALLLHAARPQVQLVESGGGLVQAGGSLRLSCAASGRTFTSYAMGWFRQAPGK EREFVAAISWRGVNTYYADSVKGRFTISRENAKNTVYLQMISLKPEDTAVYYCAAGPLGATMSE IGSWGQGTQVTVSSTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWA PLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVK FSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKM AEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR (SEQ ID NO: 790); MALPVTALLLPLALLLHAARPEVQLVESGGGLVQAGGSLRLSCAASGRTFSNYAMGWFRQAPGK EREFVSAISWSGGSTYYADSVKGRFTISRDNAKNTVYLQMISLKPEDTAVYYCAAGPLGATMSE IGSWGQGTQVTVSSTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWA PLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVK FSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR (SEQ ID NO: 791); MALPVTALLLPLALLLHAARPQVQLVESGGGLVQAGGSLRLSCAASGRTVSSYAMGWFRQAPGK EREFVAAISWSGGGTYYADSVKGRFTISRDNAKNTVYLQMISLKPEDTAVYYCAAGPLGATMSE IGSWGQGTQVTVSSTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWA PLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVK FSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKM AEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR (SEQ ID NO: 792); MALPVTALLLPLALLLHAARPQVQLVESGGGLVQAGGSLRLSCAASGRTVSSYAMGWFRQAPGK EREFVAAISWSGGSTYYADSVKGRFTISRDNAKNTVYLQMISLKPEDTAVYYCAAGPLGATMSE IGSWGQGTQVTVSSTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWA PLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVK FSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKM AEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR (SEQ ID NO: 793); MALPVTALLLPLALLLHAARPEVQLVESGGGLAQPGGSLRLSCVASGFAFGSFAIDWVRQPPGK GPEWVSAINRGGDRTYYSDSVKGRFTISRDNAKNTLYLQLNSLKPEDTAVYLCAAGGRVSADGK KWEYDYWGQGTQVTVSSTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIY IWAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCEL RVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQK DKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR (SEQ ID NO: 794); MALPVTALLLPLALLLHAARPEVQLVESGGGLVHAGGSLRLSCAASGRTFNTMAWFRQAPGKER EFVAAIAWNSGLTYYGDSVKGRFTIFRDNAKNLAYLQMNSLKPEDTAVYSCAARRTFRTGLINT VTAYDTWGQGTQVTVSSTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIY IWAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCEL RVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQK DKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR (SEQ ID NO: 795); MALPVTALLLPLALLLHAARPEVQLVESGGGLVHAGGSLRLSCVASGRTFNTMAWFRQAPGKER EFVAAISWSGGLTYYGDSVKGRFTIFRDNAKNLAYLQMNSLKPEDTAVYSCAARRTFRTALINT ITAYDTWGQGTQVTVSSTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIY IWAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCEL RVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQK DKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR (SEQ ID NO: 796); MALPVTALLLPLALLLHAARPEVQLVESGGGLVQAGGSLRLSCAASGNIVDIDDMGWYRQAPGR DLVASITAGGITKYADSAKGRFTISRDNVKNTVYLQMNSLKPEDTATYYCYAVRRYYPRFDYWG QGTQVTVSSTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVKFSRSA DAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYS EIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR (SEQ ID NO: 797); MALPVTALLLPLALLLHAARPEVQLVESGGGLVQAGGSLRLSCAASGNIVEIDDMGWYRQAPGK QRDLVATITAGGITNYASSAKGRFTISRDNVKNTVYLQMNSLKPEDTATYYCYAIRKYYPRFDY WGQGTQVTVSSTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLA GTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVKFSR SADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEA YSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR (SEQ ID NO: 798); MALPVTALLLPLALLLHAARPEVQLVESGGGLVQAGGSLRLSCAASGRTFRSYAMGWFRQAPGK EREFVAAISWSGGRIYYADSVKGRFTISRDNAKNTVYLQMNSLKPEDTAVYYCAADDFERTMTE VRYWGQGTQVTVSSTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWA PLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVK FSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKM AEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR (SEQ ID NO: 799); MALPVTALLLPLALLLHAARPEVQLVESGGGLVQPGGSLRLSCAASGFTFSGYYMSWVRQAPGK GLEWVSSIYSDDSNTYYADSVKGRFTISRDNAKNTVYLQMNSLKPEDTAVYYCAASATLRGRDT RFDYWGQGTQVTVSSTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIW APLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRV KFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDK MAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR (SEQ ID NO: 800); MALPVTALLLPLALLLHAARPEVQLVESGGGLVQPGGSLRLSCSASGFPFDDYSMDWVRQAPGK GLEWVSAINRNGGSTYYAESMKGRFTISRDNAKNTLYLQMSSLKPEDTGVYLCAAGGRVSADGK KWEYDYWGQGTQVTVSSTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIY IWAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCEL RVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQK DKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR (SEQ ID NO: 801); MALPVTALLLPLALLLHAARPQLQLVESGGGLVQAGGSLRLSCAASDPIVTFNTMGWYRQAPGK QRELVARITMSGIPNYADSVKGRFTISRDNAKNTLYLQMNSLKPEDSAVYYCRAEHSGYWGQGT QVTVSSTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGV LLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVKFSRSADAP AYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIG MKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR (SEQ ID NO: 802); MALPVTALLLPLALLLHAARPQLQLVESGGGLVQAGGSLRLSCAASGNIVDIDDMGWYRQAPGKQRDLVATITAGGIANYADSAKGRFTISRDNAKNTVYLQMNSLKPEDTATYYCYAIRRYYPRFDY WGQGAQVTVSSTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLA GTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVKFSR SADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEA YSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR (SEQ ID NO: 803); MALPVTALLLPLALLLHAARPQLQLVESGGGLVQAGGSLRLSCAASGRTVSSYAMGWFRQAPGK EREFVAAISWSGGSTYYADSVKGRFTISRDNAKNTVYLQMNSLKPEDTAVYYCAADPSLSRTMD EIGSWGQGTQVTVSSTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIW APLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRV KFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDK MAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR (SEQ ID NO: 804); MALPVTALLLPLALLLHAARPQLQLVESGGGLVQTGGSLNLSCAASGAFVSIDAMAWYRQAPGK ARELVAFSSSGGITNYADSVKGRFTITRDNAKNTVYLQMNSLKPEDTAVYYCNADILQSGWYTY WGQGTQVTVSSTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLA GTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVKFSR SADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEA YSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR (SEQ ID NO: 805); MALPVTALLLPLALLLHAARPQLQLVESGGGLVRAGGSLRLSCVLSGRTFSSYAMGWFRQAPGK EREFVSTISLSGGSTFYSDSAKGRFTISRDNAKNTVYLQMNSLKPEDAAVYYCAARPVLISRSS TDYAYWGPGTQVTVSSTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYI WAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELR VKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKD KMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR (SEQ ID NO: 806); MALPVTALLLPLALLLHAARPQLQLVESGGGLVRAGGSLRLSCVLSGRTFSSYAMGWFRQAPGK EREFVSTISLSGGSTFYSDSAKGRFTISRDNAKNTVYLQMNSLKPEDTAVYYCAARPVLISRSS IDYAYWGPGTQVTVSSTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYI WAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELR VKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKD KMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR (SEQ ID NO: 807); MALPVTALLLPLALLLHAARPQVQLQESGGGLVQAGETLGLSCVHSGRAFSGHGMGWFRQAPGK EREFVAAISWSGVSTAYADSVKGRFTISRVNADNTVSLQMNSLKPEDTAVYFCAAGLYSRPTTE RREYIYWGQGTQVTVSSTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIY IWAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCEL RVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR (SEQ ID NO: 808); MALPVTALLLPLALLLHAARPQVQLQESGGGLVQAGGSLRLSCAASGNSVDIDDMGWYRQAPGK QRDLVATITAGGITKYGDSAKGRFTISRDNVKNTVYLQMNSLKPEDTATYYCYAVRRYYPRFDY WGQGTQVTVSSTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLA GTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVKFSR SADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEA YSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR (SEQ ID NO: 809); MALPVTALLLPLALLLHAARPQVQLQESGGGLVQPGGSLRLSCAASGSIFSMNAMGWYRQAPGK QRELVATITDNDFTYYAASVKDRFTISRGNAKNTVYLQMNSLTPEDTAVYYCNADGIYSGGRYY PSSWGQGTQVTVSSTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWA PLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVK FSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKM AEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR (SEQ ID NO: 810); MALPVTALLLPLALLLHAARPQVQLQESGGGLVQPGGSLRLSCAASGSIFSVNDMGWYRQAPGK QRELVAASYSGGSTNYADSVKGRFTISRDNAKNTVYLQMNSLLPEDTAVYYCNADLVVVTTTPP SFPMPYRFLEVWGQGTLVTVSSTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDF ACDIYIWAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEE GGCELRVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLY NELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR (SEQ ID NO: 811); MALPVTALLLPLALLLHAARPQVQLVESGGGLVHAGGSLRLSCAASGRTFNTMAWFRQAPGKER EFVAAISWSGGLTYYADSVKGRFTIFRDNAKGLAYLQMDSLKPEDTAVYSCAARRTFRTALINT VTAYDTWGQGTQVTVSSTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIY IWAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCEL RVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQK DKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR (SEQ ID NO: 812); MALPVTALLLPLALLLHAARPQVQLVESGGGLVHAGGSLRLSCAASGRTFNTMAWFRQAPGKER EFVAAISWSGGLTYYGDSVKGRFTIFRDNAKNLAYLQMNSLKPEDTAVYSCAARRTFRTGLIDT VTAYDTWGQGTQVTVSSTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIY IWAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCEL RVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQK DKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR (SEQ ID NO: 813); MALPVTALLLPLALLLHAARPQVQLVESGGGLVQAGDSLRLSCAAASGRALSGWQMGWYRQAPG KEREFVASISMSDGSTSYQDSVKGRFTISRDNALSTMSLRMNSLKSEDTAIYYCQGRSRFGFEYWGQGTQVTVSSTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLA GTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVKFSR SADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEA YSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR (SEQ ID NO: 814); MALPVTALLLPLALLLHAARPQVQLVESGGGLVQAGESLRLSCVASGRALSGHGMGWFRQAPGK EREFVAAISWSGVSTAYADSVKGRFTISRVNAENTVSVSLQMNSLKPDDTAVYFCAAGLYSRPT TERRDYIYWGQGTQVTVSSTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACD IYIWAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGC ELRVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNEL QKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR (SEQ ID NO: 815); MALPVTALLLPLALLLHAARPQVQLVESGGGLVQAGGSLRLSCAAASHTFDSYTMGWFRQAPGK EREFVAAVNWDNVKNYADPVKGRFTISRDNVKNRVYLQMNSLKPEDTAVYYCAAGTNLPTRGSG SWGQGTQVTVSSTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPL AGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVKFS RSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAE AYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR (SEQ ID NO: 816); MALPVTALLLPLALLLHAARPQVQLVESGGGLVQAGGSLRLSCAAASLTFDSYTMGWFRQAPGK EREFVAAVNWDNVKNYADPVKGRFTISRDNVKNTVYLQMNSLKPEDTAVYYCAAGTNLPTIESG SWGQGTQVTVSSTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPL AGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVKFS RSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAE AYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR (SEQ ID NO: 817); MALPVTALLLPLALLLHAARPQVQLVESGGGLVQAGGSLRLSCAASGNGVDIDDMGWYRQAPGK QRDLVASITAGGITKYADSAKGRFTISRDNVKNTVYLQMNSLKPEDTATYYCYAIRRFYPRFDY WGQGTQVTVSSTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLA GTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVKFSR SADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEA YSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR (SEQ ID NO: 818); MALPVTALLLPLALLLHAARPQVQLVESGGGLVQAGGSLRLSCAASGNGVDIDDMGWYRQAPGK QRDLVASITAGGITNYADSAKGRFTISRDNVKNTVYLQMNSLKPEDTATYYCYAIRRFYPRFDY WGQGTQVTVSSTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLA GTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVKFSR SADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEA YSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR (SEQ ID NO: 819);MALPVTALLLPLALLLHAARPQVQLVESGGGLVQAGGSLRLSCAASGNGVDIDDMGWYRQAPGK QRDLVATITAGGITKYADSAKGRFTISRDNVKNTVYLQMNSLKPEDTATYYCYAIRRFYPRFDY WGQGTQVTVSSTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLA GTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVKFSR SADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEA YSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR (SEQ ID NO: 820); MALPVTALLLPLALLLHAARPQVQLVESGGGLVQAGGSLRLSCAASGNGVDIDDMGWYRQAPGK QRDLVATITAGGITNYADSAKGRFTISRDNVKNTVYLQMNSLKPEDTGTYYCYAIRKFYPRFDY WGQGTQVTVSSTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLA GTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVKFSR SADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEA YSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR (SEQ ID NO: 821); MALPVTALLLPLALLLHAARPQVQLVESGGGLVQAGGSLRLSCAASGNIVDIDDMGWYRQAPGK QRDLVASITAGGITKYADSAKGRFTISRDNVKNTVSLQMNSLKPEDTATYYCYAVRKYYPRFDY WGQGTQVTVSSTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLA GTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVKFSR SADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEA YSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR (SEQ ID NO: 822); MALPVTALLLPLALLLHAARPQVQLVESGGGLVQAGGSLRLSCAASGNIVDIDDMGWYRQAPGK QRDLVASITAGRITKYADSAKGRFTISRDNVKNTVYLQMNSLKPEDTATYYCYAIRRSYPRFDY WGQGTQVTVSSTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLA GTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVKFSR SADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEA YSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR (SEQ ID NO: 823); MALPVTALLLPLALLLHAARPQVQLVESGGGLVQAGGSLRLSCAASGRTFSNYAMGWFRQAPGK EREFVAAINWSGGRIYYTDSVKGRFTISRDNAKNTVYLQMNSLKPEDTAVYYCAAGTNWSIPPD YWGQGTQVTVSSTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPL AGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVKFS RSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAE AYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR (SEQ ID NO: 824); MALPVTALLLPLALLLHAARPQVQLVESGGGLVQAGGSLRLSCAASGRTFSSYAMGWFRQAPGK EREFVAAIRWSGGSTYYGDSVKGRFTISRDNAKNTVYLQMNSLKPEDTAVYYCAADPIGLGYEM GEYDYWGQGTQVTVSSTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYI WAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKD KMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR (SEQ ID NO: 825); MALPVTALLLPLALLLHAARPQVQLVESGGGLVQAGGSLRLSCAASGRTFSSYAMGWFRQAPGK EREFVAAISWSGGSIYYADSVKGRFTISRDNAKNTVSLQMNSLKPEDTAVYYCAADGTLRTPMN LIHYWGQGTQVTVSSTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIW APLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRV KFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDK MAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR (SEQ ID NO: 826); MALPVTALLLPLALLLHAARPQVQLVESGGGLVQAGGSLRLSCAASGRTFSSYAMGWFRQAPGK EREFVAAISWSGGSTYYANSVKGRFTISRDNAKNTVYLQMNSLKPEDTAVYYCAPGEEVAGKYF RQLYDYWGQGTQVTVSSTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIY IWAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCEL RVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQK DKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR (SEQ ID NO: 827); MALPVTALLLPLALLLHAARPQVQLVESGGGLVQAGGSLRLSCAASGRTFSSYAMGWFRQAPGK EREFVADISWSGGTTNYANSVKGRFTISRDNAKNTVYLQMNSLKPEDTAVYYCAPGEEVDGKYF RPLYDYWGQGTQVTVSSTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIY IWAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCEL RVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQK DKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR (SEQ ID NO: 828); MALPVTALLLPLALLLHAARPQVQLVESGGGLVQAGGSLRLSCAASGRTFSTYTMGWFRQAPGK ERQFVAAISSSGDSTYYTDSVKGRFTISRDNAKNTVYLQMDSLKPEDTAVYYCAPGEEVAGKYF RALYDYWGQGTQVTVSSTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIY IWAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCEL RVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQK DKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR (SEQ ID NO: 829); MALPVTALLLPLALLLHAARPQVQLVESGGGLVQAGGSLRLSCAASGSIFSINAMAWYRQAPGK QRELVAVITSGGSTNYADSVKGRFTISRDNAKNTVYLQMNSLKPEDTAVYYCNADLVYYSGNPG DYGMDYWGKGTLVTVSSTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIY IWAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCEL RVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQK DKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR (SEQ ID NO: 830); MALPVTALLLPLALLLHAARPQVQLVESGGGLVQAGGSLRLSCVASGRTFSINNINWYRQAPGK EREFVATTRWRGDSTYYADSVAGRFTISRDSAKNTVYLQMNSLKPEDTAIYYCNAKGGVDVWGQGTQVTVSSTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTC GVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVKFSRSAD APAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSE IGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR (SEQ ID NO: 831); MALPVTALLLPLALLLHAARPQVQLVESGGGLVQPGGSLRLSCAASGFLFSLYAMAWVRQAPGK GLEWVSDISNGGVTTRYADSVKGRFTISRDNAKNTLYLQMDSLTPGDTAVYYCAVTTTGWRARG QGTQVTVSSTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGT CGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVKFSRSA DAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYS EIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR (SEQ ID NO: 832); MALPVTALLLPLALLLHAARPQVQLVESGGGLVQPGGSLRLSCAASGSIFRPNDMGWYRQAPGK QRELVAIITDGGITNYAATVKGRFTISRDNAKNTVYLQMNSLKPEDTAVYYCNLNIPYPRVSSW GQGTQVTVSSTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAG TCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVKFSRS ADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAY SEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR (SEQ ID NO: 833); MALPVTALLLPLALLLHAARPQVQLVESGGGLVQPGGSLRLSCAASGSIFSVNDMGWYRQAPGK QRELVAAIYSGGSTNYADSVKGRFTISRDNAKNTVYLQMNSLKPEDTAVYYCNADIVVVTTTPP SFPMPYRFLEVWGQGTLVTVSSTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDF ACDIYIWAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEE GGCELRVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLY NELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR (SEQ ID NO: 834); MALPVTALLLPLALLLHAARPQVQLVESGGGLVQPGGSLRLSCAASGSTFNTMAWFRQAPGKER EFVAAISWSGGLTYYGDSVKGRFTIFRDNAKNLGYLQMNSLKPEDTAVYSCAARTTFRTGLIVT VTAYDTWGQGTQVTVSSTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIY IWAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCEL RVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQK DKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR (SEQ ID NO: 842); MALPVTALLLPLALLLHAARPQVQLVESGGGLVQPGGSLRLSCVLSGRTFSSYAMGWFRQAPGK EREFVSTISLSGGSTFYSGSAKGRFTISRDNAKNTVYLQMNSLKPEDTAVYYCAARPVLISRSS TDYAYWGPGTQVTVSSTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYI WAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELR VKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR (SEQ ID NO: 843); MALPVTALLLPLALLLHAARPQVQLVESGGGLVQTGGSLRLSCAASGRTFSSYAMGWFRQAPGK EREFVAAITWSGGSTYYANSVKGRFTISRDNAKNTVDLQMNSLKPEDTAVYYCTPGEEVAGKYF RPLYDYWGQGTQVTVSSTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIY IWAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCEL RVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQK DKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR (SEQ ID NO: 844); MALPVTALLLPLALLLHAARPQVQLVESGGGLVQVGGSLRLSCSISRSIAIFNFMAWYREAEGK QRELVASITGGSRLSYIDSVKGRFTVSKDTANNTLDLQMNSLRPEDTAVYRCAASSPFAGEFWG QGTQVTVSSTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGT CGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVKFSRSA DAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYS EIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR (SEQ ID NO: 845); MALPVTALLLPLALLLHAARPQVQLVESGGRLVQAGGSLRLSCAASGRTFNTMAWFRQAPGKER EFVAAITWSGGLTYYEDSVKGRFTIFRDNAKNLAYLQLNSLKPEDTAVYSCAARSTFRTALVNT VTAYDTWGQGTQVTVSSTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIY IWAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCEL RVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQK DKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR (SEQ ID NO: 846); MALPVTALLLPLALLLHAARPQVQLVESGGGLVQPGGSLRLSCTASGRTIASTIMGWYRQTPGK EREFVAISARSGDSESYASSVKDRFTISRDNAKNTVYLQMNNLKPEDTAIYYCYWNTGAGTIWG QGTQVTVSSTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGT CGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVKFSRSA DAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYS EIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR (SEQ ID NO: 847).

30. A polynucleotide encoding the CAR of claim 29, wherein the polynucleotide comprises a sequence having at least 85% sequence identity to a sequence selected from the group consisting of: ATGGCCCTGCCCGTTACCGCCCTACTCCTGCCCCTGGCCCTCCTGCTCCACGCCGCCAGGCCCG AGGTGCAATTGGTCGAGAGCGGTGGCGGGTTGGTTCAACCAGGTGGTTCTTTGCGGCTGTCATG TGCAGCCTCTGGCTTTGCTCTGGACGGATACACAATAGGGTGGTTTCGCCAAGCTCCGGGTAAA GAGCGGGAGGGAGTGGCATGTATCAGTCGATCTGATACTTCCACGAAGTACGCAGATTCAGTTA AGGGGAGGTTTACGATTAGTCGAGATAACGCCAAAAGAACTGTCTCTCTTCAAATGAACTCTCTCAAGCCGGAGGACACGGCGGTTTATTATTGTGCCGCCTCACTTCAATCTGGACTGCTTTCCAGA TTTCTCTTGCCTCGCCAGTATGACCACTGGGGACAGGGTACTCAGGTTACTGTTAGCAGCACCA CCACCCCTGCCCCCAGGCCCCCCACCCCCGCCCCCACCATCGCCAGCCAGCCCCTGTCCCTGCG GCCCGAGGCCTGCCGGCCCGCCGCCGGCGGCGCCGTGCACACCCGGGGCCTGGACTTCGCCTGC GACATCTACATCTGGGCCCCCCTGGCCGGAACCTGCGGCGTGCTGCTGCTGTCCCTGGTGATCA CCCTGTACTGCAAGCGGGGCCGGAAGAAGCTGCTGTACATCTTCAAGCAGCCCTTCATGCGCCC CGTGCAGACCACCCAGGAGGAGGACGGCTGCAGCTGCAGGTTCCCCGAGGAGGAGGAGGGGGGC TGCGAGCTGCGGGTGAAGTTCAGCAGGAGCGCCGACGCCCCTGCTTACCAGCAGGGCCAGAATC AGCTGTACAACGAGCTGAATCTGGGCCGGAGGGAGGAGTACGACGTGCTGGACAAGCGGAGGGG CAGGGACCCCGAGATGGGCGGCAAGCCCAGGCGGAAGAACCCCCAGGAGGGGCTGTACAACGAG CTGCAGAAGGACAAGATGGCCGAGGCCTACTCCGAGATCGGCATGAAGGGCGAGAGGCGGAGAG GCAAGGGCCATGACGGCCTGTACCAGGGCCTGTCCACCGCCACCAAGGACACCTACGACGCCCT GCACATGCAGGCCCTGCCCCCCCGC (SEQ ID NO: 904); ATGGCCCTGCCCGTTACCGCCCTACTCCTGCCCCTGGCCCTCCTGCTCCACGCCGCCAGGCCCC AACTTCAACTCGTTGAGTCAGGAGGGGGGCTCGTCCAGCCTGGAGGTAGTCTGCGGCTCTCCTG CGTAGCTTCCGGTTTTGCACTTGACTCATATACTATTGGGTGGTTCCGGCAAGCACCAGGTAAA GAACGGGAGGGGCTTTCCTGTATATCCAGGTCAACCTCCGATGCTAGATATGCGGACTCTGTTA AAGGACGGTTCACGATATCTCGGGATAATGCGAAGACTACCGTAAGCCTGTTGATGAGCTCCCT CAAACCCGAGGACACTGCCGTCTATTATTGCGCTGCCAGTAGACAAACTGGCCTCCTCTCCACT TTCCTTCTTCCGCGCCAGTACGATCACTGGGGCCAGGGAACGCAAGTAACTGTCTCCAGCACCA CCACCCCTGCCCCCAGGCCCCCCACCCCCGCCCCCACCATCGCCAGCCAGCCCCTGTCCCTGCG GCCCGAGGCCTGCCGGCCCGCCGCCGGCGGCGCCGTGCACACCCGGGGCCTGGACTTCGCCTGC GACATCTACATCTGGGCCCCCCTGGCCGGAACCTGCGGCGTGCTGCTGCTGTCCCTGGTGATCA CCCTGTACTGCAAGCGGGGCCGGAAGAAGCTGCTGTACATCTTCAAGCAGCCCTTCATGCGCCC CGTGCAGACCACCCAGGAGGAGGACGGCTGCAGCTGCAGGTTCCCCGAGGAGGAGGAGGGGGGC TGCGAGCTGCGGGTGAAGTTCAGCAGGAGCGCCGACGCCCCTGCTTACCAGCAGGGCCAGAATC AGCTGTACAACGAGCTGAATCTGGGCCGGAGGGAGGAGTACGACGTGCTGGACAAGCGGAGGGG CAGGGACCCCGAGATGGGCGGCAAGCCCAGGCGGAAGAACCCCCAGGAGGGGCTGTACAACGAG CTGCAGAAGGACAAGATGGCCGAGGCCTACTCCGAGATCGGCATGAAGGGCGAGAGGCGGAGAG GCAAGGGCCATGACGGCCTGTACCAGGGCCTGTCCACCGCCACCAAGGACACCTACGACGCCCT GCACATGCAGGCCCTGCCCCCCCGC (SEQ ID NO: 905); ATGGCCCTGCCCGTTACCGCCCTACTCCTGCCCCTGGCCCTCCTGCTCCACGCCGCCAGGCCCC AAGTTCAACTGGTTGAAAGTGGTGGCGGCTTGGTTCAGCCGGGCGGGTCCCTTCGCCTTTCATG TGCAGCGTCAGGCTTTTCCCTTGACTTTTATTCAATCGGATGGTTCAGACAAGCCCCTGGTAAA GAAAGGGAAGGAGTCTCTTGTATAACATGGTCAGGAGAGCGAACGAATTACAAGGATAGCGTAAAAGGTCGATTCACAATAAGCAGGGACGATGCTAAGGCGACGGTTTTTTTGCAGATGAATAATCT GAAACCGGAAGATACAGCAGTCTACTACTGTGCAGCGGATTCTGGCTACCCGTGTTATGGGTCC TCCTGGTCCTCTGTAGGCTATGATTTTTGGGGCCAGGGGACGCAAGTTACAGTCTCTTCAACCA CCACCCCTGCCCCCAGGCCCCCCACCCCCGCCCCCACCATCGCCAGCCAGCCCCTGTCCCTGCG GCCCGAGGCCTGCCGGCCCGCCGCCGGCGGCGCCGTGCACACCCGGGGCCTGGACTTCGCCTGC GACATCTACATCTGGGCCCCCCTGGCCGGAACCTGCGGCGTGCTGCTGCTGTCCCTGGTGATCA CCCTGTACTGCAAGCGGGGCCGGAAGAAGCTGCTGTACATCTTCAAGCAGCCCTTCATGCGCCC CGTGCAGACCACCCAGGAGGAGGACGGCTGCAGCTGCAGGTTCCCCGAGGAGGAGGAGGGGGGC TGCGAGCTGCGGGTGAAGTTCAGCAGGAGCGCCGACGCCCCTGCTTACCAGCAGGGCCAGAATC AGCTGTACAACGAGCTGAATCTGGGCCGGAGGGAGGAGTACGACGTGCTGGACAAGCGGAGGGG CAGGGACCCCGAGATGGGCGGCAAGCCCAGGCGGAAGAACCCCCAGGAGGGGCTGTACAACGAG CTGCAGAAGGACAAGATGGCCGAGGCCTACTCCGAGATCGGCATGAAGGGCGAGAGGCGGAGAG GCAAGGGCCATGACGGCCTGTACCAGGGCCTGTCCACCGCCACCAAGGACACCTACGACGCCCT GCACATGCAGGCCCTGCCCCCCCGC (SEQ ID NO: 906); ATGGCCCTGCCCGTTACCGCCCTACTCCTGCCCCTGGCCCTCCTGCTCCACGCCGCCAGGCCCC AGGTGCAACTCGTTGAAAGCGGTGGAGGGAGTGTGGAACCCGGCGGGAGCCTCAGATTGAGCTG CGCCACCTCTGGGCTTATCCTCAGTAATCACGGCATGGGGTGGGCCAGACAGGTTCCCGGCAAA GAAGTTGAATGGGTTTCCGGAAGCTACACCGACGGAAGCACGTATTATGCGGATAGTGTTAAGG GCCGCTTTACCATTAGCCGGGATAATGTCAAGAATACAGTTTATCTTCAAATGAATAGTCTTAA ACCCGAAGACACTGCCGTCTACTACTGTGCCGCAAGGCAATATTATCGCTCCGGCTATGTGGAC TATTGGGGGCAAGGAACCCAAGTGACGGTGTCATCTACCACCACCCCTGCCCCCAGGCCCCCCA CCCCCGCCCCCACCATCGCCAGCCAGCCCCTGTCCCTGCGGCCCGAGGCCTGCCGGCCCGCCGC CGGCGGCGCCGTGCACACCCGGGGCCTGGACTTCGCCTGCGACATCTACATCTGGGCCCCCCTG GCCGGAACCTGCGGCGTGCTGCTGCTGTCCCTGGTGATCACCCTGTACTGCAAGCGGGGCCGGA AGAAGCTGCTGTACATCTTCAAGCAGCCCTTCATGCGCCCCGTGCAGACCACCCAGGAGGAGGA CGGCTGCAGCTGCAGGTTCCCCGAGGAGGAGGAGGGGGGCTGCGAGCTGCGGGTGAAGTTCAGC AGGAGCGCCGACGCCCCTGCTTACCAGCAGGGCCAGAATCAGCTGTACAACGAGCTGAATCTGG GCCGGAGGGAGGAGTACGACGTGCTGGACAAGCGGAGGGGCAGGGACCCCGAGATGGGCGGCAA GCCCAGGCGGAAGAACCCCCAGGAGGGGCTGTACAACGAGCTGCAGAAGGACAAGATGGCCGAG GCCTACTCCGAGATCGGCATGAAGGGCGAGAGGCGGAGAGGCAAGGGCCATGACGGCCTGTACC AGGGCCTGTCCACCGCCACCAAGGACACCTACGACGCCCTGCACATGCAGGCCCTGCCCCCCCG C (SEQ ID NO: 907); ATGGCCCTGCCCGTTACCGCCCTACTCCTGCCCCTGGCCCTCCTGCTCCACGCCGCCAGGCCCC AGGTCCAACTGGTAGAAAGCGGCGGAGGCAAAGTGCAACCCGGAGGTTCCCTTCGGCTTTCATG TGCCGCGAGCGGATTTACGTTTTCCAACTACGGTATGATGTGGGTGAGACAAGCTCCAGGCAAAGGGTTGGAGTGGGTTAGCTATATTGACAGCGGCGGTGGATCCACCTACTACACCGACTCTGTAC GAGGGAGGTTTACAATTAGTAGAGACAACGCTAAAAACACAGTCTACCTCCAAATGAATAGTCT CAAGCCAGAGGACACAGCCGTGTACTACTGCGCAAAAGCGATAGGTGTTGTCTCTGGCTCCTTG GAAGTATGGGGACAAGGGACGCTGGTCACAGTAAGCTCTACCACCACCCCTGCCCCCAGGCCCC CCACCCCCGCCCCCACCATCGCCAGCCAGCCCCTGTCCCTGCGGCCCGAGGCCTGCCGGCCCGC CGCCGGCGGCGCCGTGCACACCCGGGGCCTGGACTTCGCCTGCGACATCTACATCTGGGCCCCC CTGGCCGGAACCTGCGGCGTGCTGCTGCTGTCCCTGGTGATCACCCTGTACTGCAAGCGGGGCC GGAAGAAGCTGCTGTACATCTTCAAGCAGCCCTTCATGCGCCCCGTGCAGACCACCCAGGAGGA GGACGGCTGCAGCTGCAGGTTCCCCGAGGAGGAGGAGGGGGGCTGCGAGCTGCGGGTGAAGTTC AGCAGGAGCGCCGACGCCCCTGCTTACCAGCAGGGCCAGAATCAGCTGTACAACGAGCTGAATC TGGGCCGGAGGGAGGAGTACGACGTGCTGGACAAGCGGAGGGGCAGGGACCCCGAGATGGGCGG CAAGCCCAGGCGGAAGAACCCCCAGGAGGGGCTGTACAACGAGCTGCAGAAGGACAAGATGGCC GAGGCCTACTCCGAGATCGGCATGAAGGGCGAGAGGCGGAGAGGCAAGGGCCATGACGGCCTGT ACCAGGGCCTGTCCACCGCCACCAAGGACACCTACGACGCCCTGCACATGCAGGCCCTGCCCCC CCGC (SEQ ID NO: 908); ATGGCCCTGCCCGTTACCGCCCTACTCCTGCCCCTGGCCCTCCTGCTCCACGCCGCCAGGCCCC AGGTTCAGCTTGTTGAAAGCGGAGGAGGACTGGTTCAGGCAGGGGGCAGCTTGCGACTCTCATG CGCCGCCAGCGGGCGGACCTTCACAAGTTATGCTATGGGGTGGTTTAGACAAGCACCGGGAAAA GAGAGAGAATTCGTAGCAGCCATTTCATGGCGGGGCGTAAATACCTATTATGCCGATAGCGTGA AAGGAAGGTTTACCATTAGCAGAGAAAACGCAAAAAATACGGTGTACTTGCAAATGATCAGTCT GAAGCCGGAGGATACAGCGGTGTATTACTGTGCCGCAGGTCCATTGGGCGCGACCATGTCTGAG ATCGGTTCTTGGGGGCAGGGGACACAAGTCACCGTGTCTTCCACCACCACCCCTGCCCCCAGGC CCCCCACCCCCGCCCCCACCATCGCCAGCCAGCCCCTGTCCCTGCGGCCCGAGGCCTGCCGGCC CGCCGCCGGCGGCGCCGTGCACACCCGGGGCCTGGACTTCGCCTGCGACATCTACATCTGGGCC CCCCTGGCCGGAACCTGCGGCGTGCTGCTGCTGTCCCTGGTGATCACCCTGTACTGCAAGCGGG GCCGGAAGAAGCTGCTGTACATCTTCAAGCAGCCCTTCATGCGCCCCGTGCAGACCACCCAGGA GGAGGACGGCTGCAGCTGCAGGTTCCCCGAGGAGGAGGAGGGGGGCTGCGAGCTGCGGGTGAAG TTCAGCAGGAGCGCCGACGCCCCTGCTTACCAGCAGGGCCAGAATCAGCTGTACAACGAGCTGA ATCTGGGCCGGAGGGAGGAGTACGACGTGCTGGACAAGCGGAGGGGCAGGGACCCCGAGATGGG CGGCAAGCCCAGGCGGAAGAACCCCCAGGAGGGGCTGTACAACGAGCTGCAGAAGGACAAGATG GCCGAGGCCTACTCCGAGATCGGCATGAAGGGCGAGAGGCGGAGAGGCAAGGGCCATGACGGCC TGTACCAGGGCCTGTCCACCGCCACCAAGGACACCTACGACGCCCTGCACATGCAGGCCCTGCC CCCCCGC (SEQ ID NO: 909); ATGGCCCTGCCCGTTACCGCCCTACTCCTGCCCCTGGCCCTCCTGCTCCACGCCGCCAGGCCCG AGGTGCAGTTGGTTGAATCCGGGGGAGGGCTTGTCCAAGCTGGAGGTTCTCTCAGACTCAGTTGTGCAGCTAGTGGACGCACCTTTAGTAACTATGCTATGGGATGGTTCCGCCAGGCTCCTGGTAAA GAACGAGAGTTCGTATCAGCGATTTCTTGGTCCGGTGGGTCCACCTATTACGCGGACAGCGTCA AAGGTCGATTTACCATTTCTCGAGATAATGCGAAAAATACCGTCTATCTGCAAATGATATCTCT CAAGCCCGAGGATACTGCTGTGTACTATTGCGCGGCTGGTCCGCTCGGAGCAACAATGTCAGAA ATTGGAAGTTGGGGCCAAGGGACGCAAGTTACCGTATCCTCTACCACCACCCCTGCCCCCAGGC CCCCCACCCCCGCCCCCACCATCGCCAGCCAGCCCCTGTCCCTGCGGCCCGAGGCCTGCCGGCC CGCCGCCGGCGGCGCCGTGCACACCCGGGGCCTGGACTTCGCCTGCGACATCTACATCTGGGCC CCCCTGGCCGGAACCTGCGGCGTGCTGCTGCTGTCCCTGGTGATCACCCTGTACTGCAAGCGGG GCCGGAAGAAGCTGCTGTACATCTTCAAGCAGCCCTTCATGCGCCCCGTGCAGACCACCCAGGA GGAGGACGGCTGCAGCTGCAGGTTCCCCGAGGAGGAGGAGGGGGGCTGCGAGCTGCGGGTGAAG TTCAGCAGGAGCGCCGACGCCCCTGCTTACCAGCAGGGCCAGAATCAGCTGTACAACGAGCTGA ATCTGGGCCGGAGGGAGGAGTACGACGTGCTGGACAAGCGGAGGGGCAGGGACCCCGAGATGGG CGGCAAGCCCAGGCGGAAGAACCCCCAGGAGGGGCTGTACAACGAGCTGCAGAAGGACAAGATG GCCGAGGCCTACTCCGAGATCGGCATGAAGGGCGAGAGGCGGAGAGGCAAGGGCCATGACGGCC TGTACCAGGGCCTGTCCACCGCCACCAAGGACACCTACGACGCCCTGCACATGCAGGCCCTGCC CCCCCGC (SEQ ID NO: 910); ATGGCCCTGCCCGTTACCGCCCTACTCCTGCCCCTGGCCCTCCTGCTCCACGCCGCCAGGCCCC AAGTTCAATTGGTCGAAAGTGGAGGCGGCTTGGTACAAGCGGGTGGATCACTGAGACTTAGCTG CGCTGCCTCAGGTAGGACCGTGTCAAGTTATGCTATGGGCTGGTTCAGGCAGGCGCCTGGCAAG GAACGAGAATTTGTCGCCGCAATTTCATGGTCCGGCGGAGGCACTTACTATGCTGATTCCGTCA AGGGCCGGTTTACTATCAGCCGGGATAACGCAAAAAACACGGTGTACCTGCAAATGATTTCCCT GAAGCCCGAAGATACAGCAGTGTATTATTGTGCGGCGGGACCGCTTGGTGCGACGATGAGTGAG ATCGGGAGCTGGGGACAGGGCACACAAGTAACGGTGTCCAGCACCACCACCCCTGCCCCCAGGC CCCCCACCCCCGCCCCCACCATCGCCAGCCAGCCCCTGTCCCTGCGGCCCGAGGCCTGCCGGCC CGCCGCCGGCGGCGCCGTGCACACCCGGGGCCTGGACTTCGCCTGCGACATCTACATCTGGGCC CCCCTGGCCGGAACCTGCGGCGTGCTGCTGCTGTCCCTGGTGATCACCCTGTACTGCAAGCGGG GCCGGAAGAAGCTGCTGTACATCTTCAAGCAGCCCTTCATGCGCCCCGTGCAGACCACCCAGGA GGAGGACGGCTGCAGCTGCAGGTTCCCCGAGGAGGAGGAGGGGGGCTGCGAGCTGCGGGTGAAG TTCAGCAGGAGCGCCGACGCCCCTGCTTACCAGCAGGGCCAGAATCAGCTGTACAACGAGCTGA ATCTGGGCCGGAGGGAGGAGTACGACGTGCTGGACAAGCGGAGGGGCAGGGACCCCGAGATGGG CGGCAAGCCCAGGCGGAAGAACCCCCAGGAGGGGCTGTACAACGAGCTGCAGAAGGACAAGATG GCCGAGGCCTACTCCGAGATCGGCATGAAGGGCGAGAGGCGGAGAGGCAAGGGCCATGACGGCC TGTACCAGGGCCTGTCCACCGCCACCAAGGACACCTACGACGCCCTGCACATGCAGGCCCTGCC CCCCCGC (SEQ ID NO: 911); ATGGCCCTGCCCGTTACCGCCCTACTCCTGCCCCTGGCCCTCCTGCTCCACGCCGCCAGGCCCCAAGTCCAACTTGTTGAATCTGGGGGTGGGCTCGTGCAAGCTGGGGGGAGTCTTCGGTTGTCATG CGCCGCGTCAGGACGCACTGTATCAAGCTACGCCATGGGATGGTTTAGGCAGGCACCTGGTAAG GAGCGGGAGTTCGTCGCGGCGATTTCCTGGTCAGGTGGAAGCACGTACTACGCAGACTCAGTGA AAGGTAGATTCACGATCTCACGGGATAATGCCAAAAATACCGTCTACCTCCAGATGATCTCTCT TAAACCTGAAGATACAGCCGTGTACTATTGCGCCGCTGGGCCACTCGGTGCTACGATGAGTGAA ATTGGGAGTTGGGGCCAGGGCACGCAGGTCACTGTTTCAAGCACCACCACCCCTGCCCCCAGGC CCCCCACCCCCGCCCCCACCATCGCCAGCCAGCCCCTGTCCCTGCGGCCCGAGGCCTGCCGGCC CGCCGCCGGCGGCGCCGTGCACACCCGGGGCCTGGACTTCGCCTGCGACATCTACATCTGGGCC CCCCTGGCCGGAACCTGCGGCGTGCTGCTGCTGTCCCTGGTGATCACCCTGTACTGCAAGCGGG GCCGGAAGAAGCTGCTGTACATCTTCAAGCAGCCCTTCATGCGCCCCGTGCAGACCACCCAGGA GGAGGACGGCTGCAGCTGCAGGTTCCCCGAGGAGGAGGAGGGGGGCTGCGAGCTGCGGGTGAAG TTCAGCAGGAGCGCCGACGCCCCTGCTTACCAGCAGGGCCAGAATCAGCTGTACAACGAGCTGA ATCTGGGCCGGAGGGAGGAGTACGACGTGCTGGACAAGCGGAGGGGCAGGGACCCCGAGATGGG CGGCAAGCCCAGGCGGAAGAACCCCCAGGAGGGGCTGTACAACGAGCTGCAGAAGGACAAGATG GCCGAGGCCTACTCCGAGATCGGCATGAAGGGCGAGAGGCGGAGAGGCAAGGGCCATGACGGCC TGTACCAGGGCCTGTCCACCGCCACCAAGGACACCTACGACGCCCTGCACATGCAGGCCCTGCC CCCCCGC (SEQ ID NO: 912); ATGGCCCTGCCCGTTACCGCCCTACTCCTGCCCCTGGCCCTCCTGCTCCACGCCGCCAGGCCCG AAGTTCAGTTGGTAGAATCTGGCGGTGGCCTGGCTCAACCTGGGGGATCACTCAGACTCAGTTG TGTAGCGTCCGGCTTTGCCTTCGGCTCCTTCGCTATAGATTGGGTGCGACAACCGCCCGGAAAG GGACCTGAATGGGTATCTGCGATCAACCGGGGAGGGGATCGCACATACTATAGTGATAGCGTAA AGGGTCGATTTACAATCTCCCGCGATAACGCCAAGAATACACTCTATCTGCAATTGAACAGTCT TAAACCGGAGGACACGGCGGTTTATCTGTGTGCTGCTGGAGGGCGCGTGTCTGCTGATGGAAAA AAGTGGGAGTACGACTATTGGGGTCAGGGCACGCAAGTGACCGTATCTTCCACCACCACCCCTG CCCCCAGGCCCCCCACCCCCGCCCCCACCATCGCCAGCCAGCCCCTGTCCCTGCGGCCCGAGGC CTGCCGGCCCGCCGCCGGCGGCGCCGTGCACACCCGGGGCCTGGACTTCGCCTGCGACATCTAC ATCTGGGCCCCCCTGGCCGGAACCTGCGGCGTGCTGCTGCTGTCCCTGGTGATCACCCTGTACT GCAAGCGGGGCCGGAAGAAGCTGCTGTACATCTTCAAGCAGCCCTTCATGCGCCCCGTGCAGAC CACCCAGGAGGAGGACGGCTGCAGCTGCAGGTTCCCCGAGGAGGAGGAGGGGGGCTGCGAGCTG CGGGTGAAGTTCAGCAGGAGCGCCGACGCCCCTGCTTACCAGCAGGGCCAGAATCAGCTGTACA ACGAGCTGAATCTGGGCCGGAGGGAGGAGTACGACGTGCTGGACAAGCGGAGGGGCAGGGACCC CGAGATGGGCGGCAAGCCCAGGCGGAAGAACCCCCAGGAGGGGCTGTACAACGAGCTGCAGAAG GACAAGATGGCCGAGGCCTACTCCGAGATCGGCATGAAGGGCGAGAGGCGGAGAGGCAAGGGCC ATGACGGCCTGTACCAGGGCCTGTCCACCGCCACCAAGGACACCTACGACGCCCTGCACATGCA GGCCCTGCCCCCCCGC (SEQ ID NO: 913);ATGGCCCTGCCCGTTACCGCCCTACTCCTGCCCCTGGCCCTCCTGCTCCACGCCGCCAGGCCCG AGGTGCAACTTGTCGAGAGCGGAGGAGGTCTTGTTCATGCGGGAGGTTCTCTGCGCCTGAGCTG CGCCGCGAGCGGACGGACATTCAATACCATGGCTTGGTTCCGGCAGGCGCCTGGCAAGGAGAGA GAATTCGTAGCCGCCATAGCATGGAATTCAGGTCTTACCTACTATGGGGACAGTGTAAAGGGGC GCTTCACCATCTTTCGAGACAATGCGAAGAATCTGGCCTACCTCCAGATGAACTCCTTGAAACC TGAGGATACTGCGGTCTATTCCTGCGCTGCACGACGGACGTTCCGCACCGGACTGATCAACACT GTCACCGCGTATGATACATGGGGTCAGGGGACACAAGTCACCGTCTCATCAACCACCACCCCTG CCCCCAGGCCCCCCACCCCCGCCCCCACCATCGCCAGCCAGCCCCTGTCCCTGCGGCCCGAGGC CTGCCGGCCCGCCGCCGGCGGCGCCGTGCACACCCGGGGCCTGGACTTCGCCTGCGACATCTAC ATCTGGGCCCCCCTGGCCGGAACCTGCGGCGTGCTGCTGCTGTCCCTGGTGATCACCCTGTACT GCAAGCGGGGCCGGAAGAAGCTGCTGTACATCTTCAAGCAGCCCTTCATGCGCCCCGTGCAGAC CACCCAGGAGGAGGACGGCTGCAGCTGCAGGTTCCCCGAGGAGGAGGAGGGGGGCTGCGAGCTG CGGGTGAAGTTCAGCAGGAGCGCCGACGCCCCTGCTTACCAGCAGGGCCAGAATCAGCTGTACA ACGAGCTGAATCTGGGCCGGAGGGAGGAGTACGACGTGCTGGACAAGCGGAGGGGCAGGGACCC CGAGATGGGCGGCAAGCCCAGGCGGAAGAACCCCCAGGAGGGGCTGTACAACGAGCTGCAGAAG GACAAGATGGCCGAGGCCTACTCCGAGATCGGCATGAAGGGCGAGAGGCGGAGAGGCAAGGGCC ATGACGGCCTGTACCAGGGCCTGTCCACCGCCACCAAGGACACCTACGACGCCCTGCACATGCA GGCCCTGCCCCCCCGC (SEQ ID NO: 914); ATGGCCCTGCCCGTTACCGCCCTACTCCTGCCCCTGGCCCTCCTGCTCCACGCCGCCAGGCCCG AAGTACAACTTGTCGAGAGCGGCGGCGGGCTCGTACATGCTGGCGGCTCATTGCGCCTTAGCTG CGTAGCAAGCGGGAGGACTTTTAACACTATGGCCTGGTTTAGACAAGCTCCTGGTAAAGAAAGA GAATTTGTCGCGGCAATTTCCTGGAGCGGAGGGCTCACGTACTACGGGGATAGCGTTAAGGGGC GATTCACGATATTCAGAGACAACGCTAAAAACCTGGCCTACCTTCAAATGAATAGCTTGAAACC AGAAGACACTGCCGTATATTCATGTGCAGCCCGCCGGACGTTCCGGACAGCCCTCATCAACACT ATCACAGCCTATGATACCTGGGGTCAAGGAACTCAAGTGACTGTCAGCTCCACCACCACCCCTG CCCCCAGGCCCCCCACCCCCGCCCCCACCATCGCCAGCCAGCCCCTGTCCCTGCGGCCCGAGGC CTGCCGGCCCGCCGCCGGCGGCGCCGTGCACACCCGGGGCCTGGACTTCGCCTGCGACATCTAC ATCTGGGCCCCCCTGGCCGGAACCTGCGGCGTGCTGCTGCTGTCCCTGGTGATCACCCTGTACT GCAAGCGGGGCCGGAAGAAGCTGCTGTACATCTTCAAGCAGCCCTTCATGCGCCCCGTGCAGAC CACCCAGGAGGAGGACGGCTGCAGCTGCAGGTTCCCCGAGGAGGAGGAGGGGGGCTGCGAGCTG CGGGTGAAGTTCAGCAGGAGCGCCGACGCCCCTGCTTACCAGCAGGGCCAGAATCAGCTGTACA ACGAGCTGAATCTGGGCCGGAGGGAGGAGTACGACGTGCTGGACAAGCGGAGGGGCAGGGACCC CGAGATGGGCGGCAAGCCCAGGCGGAAGAACCCCCAGGAGGGGCTGTACAACGAGCTGCAGAAG GACAAGATGGCCGAGGCCTACTCCGAGATCGGCATGAAGGGCGAGAGGCGGAGAGGCAAGGGCC ATGACGGCCTGTACCAGGGCCTGTCCACCGCCACCAAGGACACCTACGACGCCCTGCACATGCAGGCCCTGCCCCCCCGC (SEQ ID NO: 915); ATGGCCCTGCCCGTTACCGCCCTACTCCTGCCCCTGGCCCTCCTGCTCCACGCCGCCAGGCCCG AAGTTCAACTCGTCGAGTCAGGTGGTGGCCTTGTCCAAGCCGGGGGAAGCCTCCGATTGTCTTG CGCTGCAAGTGGGAATATTGTTGATATAGACGACATGGGATGGTACCGGCAGGCACCTGGACGC GACTTGGTCGCTTCTATAACGGCTGGCGGGATTACAAAGTACGCTGATTCAGCGAAGGGCAGGT TCACTATCTCCCGCGATAACGTTAAAAACACCGTGTATCTGCAAATGAACAGTCTTAAACCTGA AGATACGGCGACGTACTACTGTTATGCAGTGAGACGGTACTACCCTCGATTTGATTATTGGGGC CAGGGCACACAAGTGACAGTGTCCAGTACCACCACCCCTGCCCCCAGGCCCCCCACCCCCGCCC CCACCATCGCCAGCCAGCCCCTGTCCCTGCGGCCCGAGGCCTGCCGGCCCGCCGCCGGCGGCGC CGTGCACACCCGGGGCCTGGACTTCGCCTGCGACATCTACATCTGGGCCCCCCTGGCCGGAACC TGCGGCGTGCTGCTGCTGTCCCTGGTGATCACCCTGTACTGCAAGCGGGGCCGGAAGAAGCTGC TGTACATCTTCAAGCAGCCCTTCATGCGCCCCGTGCAGACCACCCAGGAGGAGGACGGCTGCAG CTGCAGGTTCCCCGAGGAGGAGGAGGGGGGCTGCGAGCTGCGGGTGAAGTTCAGCAGGAGCGCC GACGCCCCTGCTTACCAGCAGGGCCAGAATCAGCTGTACAACGAGCTGAATCTGGGCCGGAGGG AGGAGTACGACGTGCTGGACAAGCGGAGGGGCAGGGACCCCGAGATGGGCGGCAAGCCCAGGCG GAAGAACCCCCAGGAGGGGCTGTACAACGAGCTGCAGAAGGACAAGATGGCCGAGGCCTACTCC GAGATCGGCATGAAGGGCGAGAGGCGGAGAGGCAAGGGCCATGACGGCCTGTACCAGGGCCTGT CCACCGCCACCAAGGACACCTACGACGCCCTGCACATGCAGGCCCTGCCCCCCCGC (SEQ ID NO: 916); ATGGCCCTGCCCGTTACCGCCCTACTCCTGCCCCTGGCCCTCCTGCTCCACGCCGCCAGGCCCG AGGTTCAACTTGTGGAAAGTGGCGGGGGGCTCGTGCAAGCGGGTGGGAGCCTCCGGCTGTCTTG CGCAGCCAGCGGGAACATCGTTGAAATCGACGACATGGGGTGGTATAGACAAGCACCAGGAAAA CAGCGGGACCTTGTTGCCACAATTACAGCTGGAGGCATTACGAATTATGCATCTTCAGCTAAAG GGAGGTTTACGATCTCCCGAGATAACGTAAAGAACACAGTCTATTTGCAAATGAACTCCCTGAA ACCGGAGGATACCGCAACGTACTACTGCTATGCCATACGAAAGTATTACCCACGATTCGATTAT TGGGGTCAAGGCACTCAGGTGACCGTGTCAAGTACCACCACCCCTGCCCCCAGGCCCCCCACCC CCGCCCCCACCATCGCCAGCCAGCCCCTGTCCCTGCGGCCCGAGGCCTGCCGGCCCGCCGCCGG CGGCGCCGTGCACACCCGGGGCCTGGACTTCGCCTGCGACATCTACATCTGGGCCCCCCTGGCC GGAACCTGCGGCGTGCTGCTGCTGTCCCTGGTGATCACCCTGTACTGCAAGCGGGGCCGGAAGA AGCTGCTGTACATCTTCAAGCAGCCCTTCATGCGCCCCGTGCAGACCACCCAGGAGGAGGACGG CTGCAGCTGCAGGTTCCCCGAGGAGGAGGAGGGGGGCTGCGAGCTGCGGGTGAAGTTCAGCAGG AGCGCCGACGCCCCTGCTTACCAGCAGGGCCAGAATCAGCTGTACAACGAGCTGAATCTGGGCC GGAGGGAGGAGTACGACGTGCTGGACAAGCGGAGGGGCAGGGACCCCGAGATGGGCGGCAAGCC CAGGCGGAAGAACCCCCAGGAGGGGCTGTACAACGAGCTGCAGAAGGACAAGATGGCCGAGGCC TACTCCGAGATCGGCATGAAGGGCGAGAGGCGGAGAGGCAAGGGCCATGACGGCCTGTACCAGGGCCTGTCCACCGCCACCAAGGACACCTACGACGCCCTGCACATGCAGGCCCTGCCCCCCCGC (SEQ ID NO: 917); ATGGCCCTGCCCGTTACCGCCCTACTCCTGCCCCTGGCCCTCCTGCTCCACGCCGCCAGGCCCG AGGTTCAACTCGTTGAAAGTGGAGGAGGGCTCGTCCAGGCGGGCGGGAGTCTGAGGCTTTCTTG CGCCGCGAGCGGTAGAACTTTCCGATCCTATGCTATGGGCTGGTTCAGACAGGCTCCCGGAAAA GAGAGAGAATTTGTGGCGGCCATATCTTGGTCCGGTGGGCGGATATACTATGCAGACAGCGTCA AGGGGAGATTCACGATAAGCCGAGATAATGCAAAGAATACGGTATACCTGCAGATGAACTCCCT TAAACCCGAGGACACCGCAGTATATTATTGTGCCGCTGATGATTTTGAGAGGACCATGACGGAA GTACGGTATTGGGGGCAGGGCACTCAAGTCACCGTGTCTTCAACCACCACCCCTGCCCCCAGGC CCCCCACCCCCGCCCCCACCATCGCCAGCCAGCCCCTGTCCCTGCGGCCCGAGGCCTGCCGGCC CGCCGCCGGCGGCGCCGTGCACACCCGGGGCCTGGACTTCGCCTGCGACATCTACATCTGGGCC CCCCTGGCCGGAACCTGCGGCGTGCTGCTGCTGTCCCTGGTGATCACCCTGTACTGCAAGCGGG GCCGGAAGAAGCTGCTGTACATCTTCAAGCAGCCCTTCATGCGCCCCGTGCAGACCACCCAGGA GGAGGACGGCTGCAGCTGCAGGTTCCCCGAGGAGGAGGAGGGGGGCTGCGAGCTGCGGGTGAAG TTCAGCAGGAGCGCCGACGCCCCTGCTTACCAGCAGGGCCAGAATCAGCTGTACAACGAGCTGA ATCTGGGCCGGAGGGAGGAGTACGACGTGCTGGACAAGCGGAGGGGCAGGGACCCCGAGATGGG CGGCAAGCCCAGGCGGAAGAACCCCCAGGAGGGGCTGTACAACGAGCTGCAGAAGGACAAGATG GCCGAGGCCTACTCCGAGATCGGCATGAAGGGCGAGAGGCGGAGAGGCAAGGGCCATGACGGCC TGTACCAGGGCCTGTCCACCGCCACCAAGGACACCTACGACGCCCTGCACATGCAGGCCCTGCC CCCCCGC (SEQ ID NO: 918); ATGGCCCTGCCCGTTACCGCCCTACTCCTGCCCCTGGCCCTCCTGCTCCACGCCGCCAGGCCCG AGGTGCAACTGGTTGAGAGTGGCGGGGGTCTTGTCCAGCCAGGGGGATCACTTAGGCTGTCATG TGCGGCTAGCGGCTTTACCTTCAGCGGGTATTACATGAGTTGGGTCCGCCAGGCTCCAGGAAAG GGACTTGAGTGGGTAAGTAGTATATATAGCGATGATTCAAACACTTATTATGCGGATTCAGTTA AGGGTAGATTTACGATTAGCAGAGATAATGCAAAGAACACTGTCTATCTCCAAATGAACAGCCT TAAACCAGAGGACACTGCAGTTTACTATTGTGCAGCAAGCGCGACACTTAGAGGCCGCGATACC AGGTTCGATTACTGGGGCCAGGGAACACAAGTCACTGTCAGCTCCACCACCACCCCTGCCCCCA GGCCCCCCACCCCCGCCCCCACCATCGCCAGCCAGCCCCTGTCCCTGCGGCCCGAGGCCTGCCG GCCCGCCGCCGGCGGCGCCGTGCACACCCGGGGCCTGGACTTCGCCTGCGACATCTACATCTGG GCCCCCCTGGCCGGAACCTGCGGCGTGCTGCTGCTGTCCCTGGTGATCACCCTGTACTGCAAGC GGGGCCGGAAGAAGCTGCTGTACATCTTCAAGCAGCCCTTCATGCGCCCCGTGCAGACCACCCA GGAGGAGGACGGCTGCAGCTGCAGGTTCCCCGAGGAGGAGGAGGGGGGCTGCGAGCTGCGGGTG AAGTTCAGCAGGAGCGCCGACGCCCCTGCTTACCAGCAGGGCCAGAATCAGCTGTACAACGAGC TGAATCTGGGCCGGAGGGAGGAGTACGACGTGCTGGACAAGCGGAGGGGCAGGGACCCCGAGAT GGGCGGCAAGCCCAGGCGGAAGAACCCCCAGGAGGGGCTGTACAACGAGCTGCAGAAGGACAAGATGGCCGAGGCCTACTCCGAGATCGGCATGAAGGGCGAGAGGCGGAGAGGCAAGGGCCATGACG GCCTGTACCAGGGCCTGTCCACCGCCACCAAGGACACCTACGACGCCCTGCACATGCAGGCCCT GCCCCCCCGC (SEQ ID NO: 919); ATGGCCCTGCCCGTTACCGCCCTACTCCTGCCCCTGGCCCTCCTGCTCCACGCCGCCAGGCCCG AGGTTCAACTCGTCGAATCCGGAGGGGGATTGGTGCAACCCGGCGGATCACTTAGGCTTTCCTG TAGTGCATCTGGCTTCCCTTTCGACGATTACAGTATGGACTGGGTCAGGCAGGCACCGGGGAAA GGCTTGGAATGGGTGAGTGCCATCAACAGGAACGGGGGATCAACGTATTACGCCGAGTCCATGA AGGGGAGGTTCACGATCAGCCGGGATAATGCCAAAAACACGCTGTATCTCCAGATGTCCAGTCT TAAACCAGAAGATACCGGGGTCTATCTCTGTGCTGCGGGGGGCAGGGTGTCCGCAGATGGTAAG AAATGGGAATATGATTATTGGGGTCAGGGGACCCAAGTTACGGTTTCTAGCACCACCACCCCTG CCCCCAGGCCCCCCACCCCCGCCCCCACCATCGCCAGCCAGCCCCTGTCCCTGCGGCCCGAGGC CTGCCGGCCCGCCGCCGGCGGCGCCGTGCACACCCGGGGCCTGGACTTCGCCTGCGACATCTAC ATCTGGGCCCCCCTGGCCGGAACCTGCGGCGTGCTGCTGCTGTCCCTGGTGATCACCCTGTACT GCAAGCGGGGCCGGAAGAAGCTGCTGTACATCTTCAAGCAGCCCTTCATGCGCCCCGTGCAGAC CACCCAGGAGGAGGACGGCTGCAGCTGCAGGTTCCCCGAGGAGGAGGAGGGGGGCTGCGAGCTG CGGGTGAAGTTCAGCAGGAGCGCCGACGCCCCTGCTTACCAGCAGGGCCAGAATCAGCTGTACA ACGAGCTGAATCTGGGCCGGAGGGAGGAGTACGACGTGCTGGACAAGCGGAGGGGCAGGGACCC CGAGATGGGCGGCAAGCCCAGGCGGAAGAACCCCCAGGAGGGGCTGTACAACGAGCTGCAGAAG GACAAGATGGCCGAGGCCTACTCCGAGATCGGCATGAAGGGCGAGAGGCGGAGAGGCAAGGGCC ATGACGGCCTGTACCAGGGCCTGTCCACCGCCACCAAGGACACCTACGACGCCCTGCACATGCA GGCCCTGCCCCCCCGC (SEQ ID NO: 920); ATGGCCCTGCCCGTTACCGCCCTACTCCTGCCCCTGGCCCTCCTGCTCCACGCCGCCAGGCCCC AACTCCAGCTGGTCGAGTCTGGAGGTGGTTTGGTCCAGGCTGGGGGGAGCCTTCGCCTGTCATG CGCTGCGAGTGACCCCATCGTTACCTTCAACACTATGGGATGGTATAGACAAGCGCCTGGCAAG CAGAGAGAACTTGTTGCGAGAATTACCATGTCTGGCATTCCCAACTACGCGGATTCCGTAAAAG GGCGGTTTACCATATCCCGAGATAACGCGAAAAATACGCTGTATCTTCAAATGAACTCTTTGAA GCCCGAGGATAGTGCCGTTTACTATTGTCGAGCTGAGCATTCTGGCTATTGGGGGCAGGGAACT CAGGTTACTGTAAGCAGCACCACCACCCCTGCCCCCAGGCCCCCCACCCCCGCCCCCACCATCG CCAGCCAGCCCCTGTCCCTGCGGCCCGAGGCCTGCCGGCCCGCCGCCGGCGGCGCCGTGCACAC CCGGGGCCTGGACTTCGCCTGCGACATCTACATCTGGGCCCCCCTGGCCGGAACCTGCGGCGTG CTGCTGCTGTCCCTGGTGATCACCCTGTACTGCAAGCGGGGCCGGAAGAAGCTGCTGTACATCT TCAAGCAGCCCTTCATGCGCCCCGTGCAGACCACCCAGGAGGAGGACGGCTGCAGCTGCAGGTT CCCCGAGGAGGAGGAGGGGGGCTGCGAGCTGCGGGTGAAGTTCAGCAGGAGCGCCGACGCCCCT GCTTACCAGCAGGGCCAGAATCAGCTGTACAACGAGCTGAATCTGGGCCGGAGGGAGGAGTACG ACGTGCTGGACAAGCGGAGGGGCAGGGACCCCGAGATGGGCGGCAAGCCCAGGCGGAAGAACCCCCAGGAGGGGCTGTACAACGAGCTGCAGAAGGACAAGATGGCCGAGGCCTACTCCGAGATCGGC ATGAAGGGCGAGAGGCGGAGAGGCAAGGGCCATGACGGCCTGTACCAGGGCCTGTCCACCGCCA CCAAGGACACCTACGACGCCCTGCACATGCAGGCCCTGCCCCCCCGC (SEQ ID NO: 921; ATGGCCCTGCCCGTTACCGCCCTACTCCTGCCCCTGGCCCTCCTGCTCCACGCCGCCAGGCCCC AACTCCAACTTGTTGAGTCTGGGGGCGGCTTGGTTCAAGCTGGTGGCTCCTTGCGACTCTCTTG CGCCGCTAGCGGGAACATTGTTGATATAGACGACATGGGATGGTATCGCCAGGCACCGGGAAAA CAGCGCGATCTGGTCGCCACCATCACGGCGGGTGGGATTGCCAACTATGCCGATTCAGCGAAAG GGAGGTTTACGATAAGCCGCGACAACGCTAAGAACACAGTGTACCTGCAAATGAACTCTCTCAA ACCAGAGGACACTGCAACATATTACTGTTACGCAATCCGGCGGTACTACCCTAGATTCGATTAT TGGGGGCAAGGAGCCCAAGTTACAGTATCCTCCACCACCACCCCTGCCCCCAGGCCCCCCACCC CCGCCCCCACCATCGCCAGCCAGCCCCTGTCCCTGCGGCCCGAGGCCTGCCGGCCCGCCGCCGG CGGCGCCGTGCACACCCGGGGCCTGGACTTCGCCTGCGACATCTACATCTGGGCCCCCCTGGCC GGAACCTGCGGCGTGCTGCTGCTGTCCCTGGTGATCACCCTGTACTGCAAGCGGGGCCGGAAGA AGCTGCTGTACATCTTCAAGCAGCCCTTCATGCGCCCCGTGCAGACCACCCAGGAGGAGGACGG CTGCAGCTGCAGGTTCCCCGAGGAGGAGGAGGGGGGCTGCGAGCTGCGGGTGAAGTTCAGCAGG AGCGCCGACGCCCCTGCTTACCAGCAGGGCCAGAATCAGCTGTACAACGAGCTGAATCTGGGCC GGAGGGAGGAGTACGACGTGCTGGACAAGCGGAGGGGCAGGGACCCCGAGATGGGCGGCAAGCC CAGGCGGAAGAACCCCCAGGAGGGGCTGTACAACGAGCTGCAGAAGGACAAGATGGCCGAGGCC TACTCCGAGATCGGCATGAAGGGCGAGAGGCGGAGAGGCAAGGGCCATGACGGCCTGTACCAGG GCCTGTCCACCGCCACCAAGGACACCTACGACGCCCTGCACATGCAGGCCCTGCCCCCCCGC (SEQ ID NO: 922); ATGGCCCTGCCCGTTACCGCCCTACTCCTGCCCCTGGCCCTCCTGCTCCACGCCGCCAGGCCCC AACTCCAACTTGTGGAATCAGGAGGGGGTCTCGTACAGACAGGAGGATCACTCAACTTGAGTTG TGCCGCCTCTGGAGCTTTTGTGTCTATAGATGCCATGGCGTGGTATCGACAGGCTCCCGGCAAG GCTCGGGAGCTTGTCGCCTTTTCAAGCAGCGGTGGGATAACAAATTATGCGGACAGTGTCAAGG GCCGATTTACCATTACTAGGGATAACGCGAAAAATACTGTTTATCTCCAAATGAATTCCCTTAA ACCAGAGGATACGGCTGTGTACTATTGCAACGCAGACATCTTGCAATCAGGTTGGTACACGTAC TGGGGACAAGGAACTCAGGTGACAGTGTCTAGCACCACCACCCCTGCCCCCAGGCCCCCCACCC CCGCCCCCACCATCGCCAGCCAGCCCCTGTCCCTGCGGCCCGAGGCCTGCCGGCCCGCCGCCGG CGGCGCCGTGCACACCCGGGGCCTGGACTTCGCCTGCGACATCTACATCTGGGCCCCCCTGGCC GGAACCTGCGGCGTGCTGCTGCTGTCCCTGGTGATCACCCTGTACTGCAAGCGGGGCCGGAAGA AGCTGCTGTACATCTTCAAGCAGCCCTTCATGCGCCCCGTGCAGACCACCCAGGAGGAGGACGG CTGCAGCTGCAGGTTCCCCGAGGAGGAGGAGGGGGGCTGCGAGCTGCGGGTGAAGTTCAGCAGG AGCGCCGACGCCCCTGCTTACCAGCAGGGCCAGAATCAGCTGTACAACGAGCTGAATCTGGGCC GGAGGGAGGAGTACGACGTGCTGGACAAGCGGAGGGGCAGGGACCCCGAGATGGGCGGCAAGCCCAGGCGGAAGAACCCCCAGGAGGGGCTGTACAACGAGCTGCAGAAGGACAAGATGGCCGAGGCC TACTCCGAGATCGGCATGAAGGGCGAGAGGCGGAGAGGCAAGGGCCATGACGGCCTGTACCAGG GCCTGTCCACCGCCACCAAGGACACCTACGACGCCCTGCACATGCAGGCCCTGCCCCCCCGC (SEQ ID NO: 9); ATGGCCCTGCCCGTTACCGCCCTACTCCTGCCCCTGGCCCTCCTGCTCCACGCCGCCAGGCCCC AGTTGCAACTTGTGGAGAGCGGTGGAGGCCTGGTTCGGGCAGGAGGTAGTCTCCGGTTGTCTTG TGTATTGTCAGGGAGGACATTTTCCAGTTACGCGATGGGATGGTTCAGGCAGGCTCCTGGGAAA GAACGAGAATTCGTTTCAACTATTTCTCTGTCCGGCGGATCAACCTTCTATAGCGATTCCGCCA AGGGTCGCTTTACCATAAGTCGGGACAACGCCAAAAACACCGTTTATCTGCAAATGAATAGTCT GAAGCCAGAGGACGCGGCGGTGTACTACTGTGCTGCACGGCCCGTGTTGATTAGTCGCAGTTCC ACGGACTACGCTTATTGGGGGCCTGGAACCCAGGTGACCGTCAGCTCTACCACCACCCCTGCCC CCAGGCCCCCCACCCCCGCCCCCACCATCGCCAGCCAGCCCCTGTCCCTGCGGCCCGAGGCCTG CCGGCCCGCCGCCGGCGGCGCCGTGCACACCCGGGGCCTGGACTTCGCCTGCGACATCTACATC TGGGCCCCCCTGGCCGGAACCTGCGGCGTGCTGCTGCTGTCCCTGGTGATCACCCTGTACTGCA AGCGGGGCCGGAAGAAGCTGCTGTACATCTTCAAGCAGCCCTTCATGCGCCCCGTGCAGACCAC CCAGGAGGAGGACGGCTGCAGCTGCAGGTTCCCCGAGGAGGAGGAGGGGGGCTGCGAGCTGCGG GTGAAGTTCAGCAGGAGCGCCGACGCCCCTGCTTACCAGCAGGGCCAGAATCAGCTGTACAACG AGCTGAATCTGGGCCGGAGGGAGGAGTACGACGTGCTGGACAAGCGGAGGGGCAGGGACCCCGA GATGGGCGGCAAGCCCAGGCGGAAGAACCCCCAGGAGGGGCTGTACAACGAGCTGCAGAAGGAC AAGATGGCCGAGGCCTACTCCGAGATCGGCATGAAGGGCGAGAGGCGGAGAGGCAAGGGCCATG ACGGCCTGTACCAGGGCCTGTCCACCGCCACCAAGGACACCTACGACGCCCTGCACATGCAGGC CCTGCCCCCCCGC (SEQ ID NO: 924); ATGGCCCTGCCCGTTACCGCCCTACTCCTGCCCCTGGCCCTCCTGCTCCACGCCGCCAGGCCCC AGCTTCAGCTCGTTGAATCTGGGGGAGGCCTGGTTCGCGCTGGAGGCAGCCTTCGCCTCTCCTG CGTGCTTTCAGGACGAACTTTTTCAAGCTATGCGATGGGTTGGTTTAGGCAGGCGCCTGGAAAA GAGCGGGAATTTGTCAGTACGATAAGCCTTAGCGGGGGTAGTACATTTTACTCAGATAGCGCGA AAGGCCGATTTACTATATCCCGAGATAATGCGAAAAATACGGTCTATTTGCAGATGAATAGTCT GAAACCAGAGGATACTGCCGTCTATTACTGCGCTGCGAGGCCCGTACTTATTTCCCGGAGCTCC ATAGACTATGCTTACTGGGGTCCGGGCACACAGGTAACGGTCTCCAGTACCACCACCCCTGCCC CCAGGCCCCCCACCCCCGCCCCCACCATCGCCAGCCAGCCCCTGTCCCTGCGGCCCGAGGCCTG CCGGCCCGCCGCCGGCGGCGCCGTGCACACCCGGGGCCTGGACTTCGCCTGCGACATCTACATC TGGGCCCCCCTGGCCGGAACCTGCGGCGTGCTGCTGCTGTCCCTGGTGATCACCCTGTACTGCA AGCGGGGCCGGAAGAAGCTGCTGTACATCTTCAAGCAGCCCTTCATGCGCCCCGTGCAGACCAC CCAGGAGGAGGACGGCTGCAGCTGCAGGTTCCCCGAGGAGGAGGAGGGGGGCTGCGAGCTGCGG GTGAAGTTCAGCAGGAGCGCCGACGCCCCTGCTTACCAGCAGGGCCAGAATCAGCTGTACAACGAGCTGAATCTGGGCCGGAGGGAGGAGTACGACGTGCTGGACAAGCGGAGGGGCAGGGACCCCGA GATGGGCGGCAAGCCCAGGCGGAAGAACCCCCAGGAGGGGCTGTACAACGAGCTGCAGAAGGAC AAGATGGCCGAGGCCTACTCCGAGATCGGCATGAAGGGCGAGAGGCGGAGAGGCAAGGGCCATG ACGGCCTGTACCAGGGCCTGTCCACCGCCACCAAGGACACCTACGACGCCCTGCACATGCAGGC CCTGCCCCCCCGC (SEQ ID NO: 925); ATGGCCCTGCCCGTTACCGCCCTACTCCTGCCCCTGGCCCTCCTGCTCCACGCCGCCAGGCCCC AGGTCCAACTTCAGGAAAGCGGTGGGGGTTTGGTACAGGCAGGAGAAACGCTGGGACTTAGTTG CGTACACAGTGGACGCGCGTTCTCAGGCCATGGTATGGGGTGGTTTCGCCAGGCCCCTGGAAAA GAAAGGGAGTTTGTGGCGGCTATAAGTTGGTCAGGCGTCTCAACTGCCTATGCCGACTCTGTAA AAGGTCGATTCACCATCTCTAGAGTGAACGCTGACAACACGGTGTCACTTCAAATGAATAGTCT GAAACCCGAGGACACAGCCGTTTACTTCTGCGCGGCGGGCCTCTACTCTCGACCAACCACTGAA CGCAGGGAATACATATACTGGGGTCAGGGAACTCAGGTAACAGTTAGCAGCACCACCACCCCTG CCCCCAGGCCCCCCACCCCCGCCCCCACCATCGCCAGCCAGCCCCTGTCCCTGCGGCCCGAGGC CTGCCGGCCCGCCGCCGGCGGCGCCGTGCACACCCGGGGCCTGGACTTCGCCTGCGACATCTAC ATCTGGGCCCCCCTGGCCGGAACCTGCGGCGTGCTGCTGCTGTCCCTGGTGATCACCCTGTACT GCAAGCGGGGCCGGAAGAAGCTGCTGTACATCTTCAAGCAGCCCTTCATGCGCCCCGTGCAGAC CACCCAGGAGGAGGACGGCTGCAGCTGCAGGTTCCCCGAGGAGGAGGAGGGGGGCTGCGAGCTG CGGGTGAAGTTCAGCAGGAGCGCCGACGCCCCTGCTTACCAGCAGGGCCAGAATCAGCTGTACA ACGAGCTGAATCTGGGCCGGAGGGAGGAGTACGACGTGCTGGACAAGCGGAGGGGCAGGGACCC CGAGATGGGCGGCAAGCCCAGGCGGAAGAACCCCCAGGAGGGGCTGTACAACGAGCTGCAGAAG GACAAGATGGCCGAGGCCTACTCCGAGATCGGCATGAAGGGCGAGAGGCGGAGAGGCAAGGGCC ATGACGGCCTGTACCAGGGCCTGTCCACCGCCACCAAGGACACCTACGACGCCCTGCACATGCA GGCCCTGCCCCCCCGC (SEQ ID NO: 926); ATGGCCCTGCCCGTTACCGCCCTACTCCTGCCCCTGGCCCTCCTGCTCCACGCCGCCAGGCCCC AAGTACAGCTGCAAGAGAGTGGGGGCGGGCTCGTCCAAGCCGGGGGATCTTTGCGGCTCAGTTG CGCGGCCTCTGGTAATTCCGTTGACATTGACGACATGGGATGGTACCGACAGGCTCCTGGCAAG CAACGAGATTTGGTCGCGACTATCACCGCAGGAGGCATCACCAAGTATGGTGACTCTGCGAAAG GCAGGTTCACAATAAGCAGAGATAACGTGAAGAATACCGTGTACTTGCAGATGAATAGCCTGAA GCCTGAGGACACCGCAACCTACTACTGTTATGCCGTCCGGCGCTATTACCCACGCTTCGACTAT TGGGGCCAGGGTACGCAAGTAACAGTAAGTAGTACCACCACCCCTGCCCCCAGGCCCCCCACCC CCGCCCCCACCATCGCCAGCCAGCCCCTGTCCCTGCGGCCCGAGGCCTGCCGGCCCGCCGCCGG CGGCGCCGTGCACACCCGGGGCCTGGACTTCGCCTGCGACATCTACATCTGGGCCCCCCTGGCC GGAACCTGCGGCGTGCTGCTGCTGTCCCTGGTGATCACCCTGTACTGCAAGCGGGGCCGGAAGA AGCTGCTGTACATCTTCAAGCAGCCCTTCATGCGCCCCGTGCAGACCACCCAGGAGGAGGACGG CTGCAGCTGCAGGTTCCCCGAGGAGGAGGAGGGGGGCTGCGAGCTGCGGGTGAAGTTCAGCAGGAGCGCCGACGCCCCTGCTTACCAGCAGGGCCAGAATCAGCTGTACAACGAGCTGAATCTGGGCC GGAGGGAGGAGTACGACGTGCTGGACAAGCGGAGGGGCAGGGACCCCGAGATGGGCGGCAAGCC CAGGCGGAAGAACCCCCAGGAGGGGCTGTACAACGAGCTGCAGAAGGACAAGATGGCCGAGGCC TACTCCGAGATCGGCATGAAGGGCGAGAGGCGGAGAGGCAAGGGCCATGACGGCCTGTACCAGG GCCTGTCCACCGCCACCAAGGACACCTACGACGCCCTGCACATGCAGGCCCTGCCCCCCCGC (SEQ ID NO: 927); ATGGCCCTGCCCGTTACCGCCCTACTCCTGCCCCTGGCCCTCCTGCTCCACGCCGCCAGGCCCC AGGTTCAGTTGCAAGAAAGCGGGGGAGGCCTCGTTCAGCCGGGTGGCTCATTGAGGTTGTCATG CGCCGCTTCAGGTTCTATATTCTCTATGAACGCGATGGGATGGTATAGACAAGCCCCCGGCAAA CAACGCGAACTTGTGGCGACTATTACAGATAATGACTTTACTTACTATGCAGCCTCCGTGAAAG ATCGGTTTACAATTTCTCGGGGGAACGCCAAGAACACTGTGTATCTTCAGATGAACAGTCTGAC GCCTGAAGATACGGCGGTCTACTATTGCAATGCGGATGGCATCTACTCCGGTGGAAGATATTAC CCATCTTCATGGGGACAGGGTACACAAGTCACAGTAAGCAGCACCACCACCCCTGCCCCCAGGC CCCCCACCCCCGCCCCCACCATCGCCAGCCAGCCCCTGTCCCTGCGGCCCGAGGCCTGCCGGCC CGCCGCCGGCGGCGCCGTGCACACCCGGGGCCTGGACTTCGCCTGCGACATCTACATCTGGGCC CCCCTGGCCGGAACCTGCGGCGTGCTGCTGCTGTCCCTGGTGATCACCCTGTACTGCAAGCGGG GCCGGAAGAAGCTGCTGTACATCTTCAAGCAGCCCTTCATGCGCCCCGTGCAGACCACCCAGGA GGAGGACGGCTGCAGCTGCAGGTTCCCCGAGGAGGAGGAGGGGGGCTGCGAGCTGCGGGTGAAG TTCAGCAGGAGCGCCGACGCCCCTGCTTACCAGCAGGGCCAGAATCAGCTGTACAACGAGCTGA ATCTGGGCCGGAGGGAGGAGTACGACGTGCTGGACAAGCGGAGGGGCAGGGACCCCGAGATGGG CGGCAAGCCCAGGCGGAAGAACCCCCAGGAGGGGCTGTACAACGAGCTGCAGAAGGACAAGATG GCCGAGGCCTACTCCGAGATCGGCATGAAGGGCGAGAGGCGGAGAGGCAAGGGCCATGACGGCC TGTACCAGGGCCTGTCCACCGCCACCAAGGACACCTACGACGCCCTGCACATGCAGGCCCTGCC CCCCCGC (SEQ ID NO: 928); ATGGCCCTGCCCGTTACCGCCCTACTCCTGCCCCTGGCCCTCCTGCTCCACGCCGCCAGGCCCC AGGTACAGCTTCAGGAATCTGGCGGTGGCCTGGTCCAGCCAGGAGGAAGCCTGAGATTGAGCTG TGCGGCATCCGGCAGCATTTTTTCTGTAAATGATATGGGCTGGTACAGACAGGCTCCAGGGAAG CAACGCGAATTGGTGGCGGCCTCATACTCTGGTGGGTCAACGAATTATGCCGATAGTGTTAAGG GACGGTTTACGATTAGCAGGGATAATGCAAAAAACACTGTGTATTTGCAAATGAATTCTCTTCT CCCCGAAGATACAGCTGTGTATTATTGTAATGCCGATTTGGTCGTAGTTACGACTACGCCGCCT AGTTTCCCCATGCCGTACCGATTCCTTGAGGTGTGGGGTCAGGGTACGCTGGTTACCGTCAGCA GCACCACCACCCCTGCCCCCAGGCCCCCCACCCCCGCCCCCACCATCGCCAGCCAGCCCCTGTC CCTGCGGCCCGAGGCCTGCCGGCCCGCCGCCGGCGGCGCCGTGCACACCCGGGGCCTGGACTTC GCCTGCGACATCTACATCTGGGCCCCCCTGGCCGGAACCTGCGGCGTGCTGCTGCTGTCCCTGG TGATCACCCTGTACTGCAAGCGGGGCCGGAAGAAGCTGCTGTACATCTTCAAGCAGCCCTTCATGCGCCCCGTGCAGACCACCCAGGAGGAGGACGGCTGCAGCTGCAGGTTCCCCGAGGAGGAGGAG GGGGGCTGCGAGCTGCGGGTGAAGTTCAGCAGGAGCGCCGACGCCCCTGCTTACCAGCAGGGCC AGAATCAGCTGTACAACGAGCTGAATCTGGGCCGGAGGGAGGAGTACGACGTGCTGGACAAGCG GAGGGGCAGGGACCCCGAGATGGGCGGCAAGCCCAGGCGGAAGAACCCCCAGGAGGGGCTGTAC AACGAGCTGCAGAAGGACAAGATGGCCGAGGCCTACTCCGAGATCGGCATGAAGGGCGAGAGGC GGAGAGGCAAGGGCCATGACGGCCTGTACCAGGGCCTGTCCACCGCCACCAAGGACACCTACGA CGCCCTGCACATGCAGGCCCTGCCCCCCCGC (SEQ ID NO: 929); ATGGCCCTGCCCGTTACCGCCCTACTCCTGCCCCTGGCCCTCCTGCTCCACGCCGCCAGGCCCC AAGTACAACTTGTAGAATCTGGAGGGGGTCTCGTACACGCGGGCGGTTCTCTCCGCCTTTCTTG CGCTGCCAGTGGAAGGACATTCAACACGATGGCATGGTTCCGCCAAGCACCAGGAAAAGAGCGA GAATTTGTCGCGGCTATATCATGGTCCGGAGGTCTCACTTATTACGCGGACTCCGTGAAGGGGC GATTCACCATTTTTCGGGACAATGCGAAGGGTCTGGCCTACCTCCAAATGGATTCATTGAAGCC AGAAGATACGGCAGTGTACTCATGCGCCGCGAGAAGGACCTTCAGAACAGCGCTGATTAACACT GTAACGGCTTACGACACCTGGGGCCAGGGAACTCAGGTCACTGTCTCAAGTACCACCACCCCTG CCCCCAGGCCCCCCACCCCCGCCCCCACCATCGCCAGCCAGCCCCTGTCCCTGCGGCCCGAGGC CTGCCGGCCCGCCGCCGGCGGCGCCGTGCACACCCGGGGCCTGGACTTCGCCTGCGACATCTAC ATCTGGGCCCCCCTGGCCGGAACCTGCGGCGTGCTGCTGCTGTCCCTGGTGATCACCCTGTACT GCAAGCGGGGCCGGAAGAAGCTGCTGTACATCTTCAAGCAGCCCTTCATGCGCCCCGTGCAGAC CACCCAGGAGGAGGACGGCTGCAGCTGCAGGTTCCCCGAGGAGGAGGAGGGGGGCTGCGAGCTG CGGGTGAAGTTCAGCAGGAGCGCCGACGCCCCTGCTTACCAGCAGGGCCAGAATCAGCTGTACA ACGAGCTGAATCTGGGCCGGAGGGAGGAGTACGACGTGCTGGACAAGCGGAGGGGCAGGGACCC CGAGATGGGCGGCAAGCCCAGGCGGAAGAACCCCCAGGAGGGGCTGTACAACGAGCTGCAGAAG GACAAGATGGCCGAGGCCTACTCCGAGATCGGCATGAAGGGCGAGAGGCGGAGAGGCAAGGGCC ATGACGGCCTGTACCAGGGCCTGTCCACCGCCACCAAGGACACCTACGACGCCCTGCACATGCA GGCCCTGCCCCCCCGC (SEQ ID NO: 930); ATGGCCCTGCCCGTTACCGCCCTACTCCTGCCCCTGGCCCTCCTGCTCCACGCCGCCAGGCCCC AAGTTCAACTGGTTGAATCCGGGGGCGGGCTGGTGCATGCGGGCGGTTCTCTTCGACTCTCTTG CGCCGCCTCAGGTAGAACCTTCAATACGATGGCTTGGTTTCGGCAAGCACCGGGTAAGGAGCGG GAGTTCGTGGCGGCAATTAGCTGGTCAGGTGGACTGACCTATTACGGAGATTCTGTGAAGGGCC GCTTCACTATATTCCGGGACAATGCGAAGAATCTGGCGTATCTTCAAATGAACTCACTGAAGCC CGAGGACACTGCTGTGTACTCCTGCGCTGCTCGAAGGACTTTCAGGACGGGACTTATAGATACG GTTACAGCGTACGATACTTGGGGGCAGGGAACCCAGGTTACGGTTTCTAGCACCACCACCCCTG CCCCCAGGCCCCCCACCCCCGCCCCCACCATCGCCAGCCAGCCCCTGTCCCTGCGGCCCGAGGC CTGCCGGCCCGCCGCCGGCGGCGCCGTGCACACCCGGGGCCTGGACTTCGCCTGCGACATCTAC ATCTGGGCCCCCCTGGCCGGAACCTGCGGCGTGCTGCTGCTGTCCCTGGTGATCACCCTGTACTGCAAGCGGGGCCGGAAGAAGCTGCTGTACATCTTCAAGCAGCCCTTCATGCGCCCCGTGCAGAC CACCCAGGAGGAGGACGGCTGCAGCTGCAGGTTCCCCGAGGAGGAGGAGGGGGGCTGCGAGCTG CGGGTGAAGTTCAGCAGGAGCGCCGACGCCCCTGCTTACCAGCAGGGCCAGAATCAGCTGTACA ACGAGCTGAATCTGGGCCGGAGGGAGGAGTACGACGTGCTGGACAAGCGGAGGGGCAGGGACCC CGAGATGGGCGGCAAGCCCAGGCGGAAGAACCCCCAGGAGGGGCTGTACAACGAGCTGCAGAAG GACAAGATGGCCGAGGCCTACTCCGAGATCGGCATGAAGGGCGAGAGGCGGAGAGGCAAGGGCC ATGACGGCCTGTACCAGGGCCTGTCCACCGCCACCAAGGACACCTACGACGCCCTGCACATGCA GGCCCTGCCCCCCCGC (SEQ ID NO: 931); ATGGCCCTGCCCGTTACCGCCCTACTCCTGCCCCTGGCCCTCCTGCTCCACGCCGCCAGGCCCC AGGTCCAGCTTGTGGAATCCGGCGGCGGGTTGGTGCAAGCCGGTGATAGCCTGCGCCTTTCTTG CGCGGCTGCTAGTGGGCGCGCTTTGAGCGGCTGGCAAATGGGTTGGTATCGGCAGGCGCCGGGG AAGGAAAGAGAGTTTGTTGCATCCATTTCCATGTCCGATGGGAGTACTAGCTACCAAGATTCTG TCAAGGGGAGATTTACGATCAGCCGCGACAATGCACTTAGTACAATGTCTTTGAGAATGAACAG TCTTAAATCCGAGGACACTGCTATTTACTACTGCCAGGGGCGGTCTAGGTTCGGGTTTGAGTAT TGGGGTCAAGGCACTCAAGTCACAGTCTCTAGTACCACCACCCCTGCCCCCAGGCCCCCCACCC CCGCCCCCACCATCGCCAGCCAGCCCCTGTCCCTGCGGCCCGAGGCCTGCCGGCCCGCCGCCGG CGGCGCCGTGCACACCCGGGGCCTGGACTTCGCCTGCGACATCTACATCTGGGCCCCCCTGGCC GGAACCTGCGGCGTGCTGCTGCTGTCCCTGGTGATCACCCTGTACTGCAAGCGGGGCCGGAAGA AGCTGCTGTACATCTTCAAGCAGCCCTTCATGCGCCCCGTGCAGACCACCCAGGAGGAGGACGG CTGCAGCTGCAGGTTCCCCGAGGAGGAGGAGGGGGGCTGCGAGCTGCGGGTGAAGTTCAGCAGG AGCGCCGACGCCCCTGCTTACCAGCAGGGCCAGAATCAGCTGTACAACGAGCTGAATCTGGGCC GGAGGGAGGAGTACGACGTGCTGGACAAGCGGAGGGGCAGGGACCCCGAGATGGGCGGCAAGCC CAGGCGGAAGAACCCCCAGGAGGGGCTGTACAACGAGCTGCAGAAGGACAAGATGGCCGAGGCC TACTCCGAGATCGGCATGAAGGGCGAGAGGCGGAGAGGCAAGGGCCATGACGGCCTGTACCAGG GCCTGTCCACCGCCACCAAGGACACCTACGACGCCCTGCACATGCAGGCCCTGCCCCCCCGC (SEQ ID NO: 932); ATGGCCCTGCCCGTTACCGCCCTACTCCTGCCCCTGGCCCTCCTGCTCCACGCCGCCAGGCCCC AGGTACAACTCGTAGAAAGCGGTGGGGGCCTTGTTCAGGCAGGGGAGAGCCTCCGGTTGTCTTG CGTCGCTAGCGGTCGAGCCTTGTCAGGACACGGTATGGGGTGGTTCCGACAAGCGCCAGGGAAG GAAAGAGAGTTCGTAGCTGCTATCAGTTGGAGTGGGGTGTCAACTGCTTACGCAGACTCCGTAA AAGGTCGCTTCACGATCAGTAGGGTTAATGCGGAAAACACAGTGTCTGTATCCTTGCAGATGAA CTCACTGAAGCCAGATGATACAGCAGTCTATTTCTGCGCCGCTGGGTTGTATTCCCGCCCGACA ACGGAGCGACGCGACTACATATACTGGGGACAGGGAACACAGGTTACCGTGAGCAGCACCACCA CCCCTGCCCCCAGGCCCCCCACCCCCGCCCCCACCATCGCCAGCCAGCCCCTGTCCCTGCGGCC CGAGGCCTGCCGGCCCGCCGCCGGCGGCGCCGTGCACACCCGGGGCCTGGACTTCGCCTGCGACATCTACATCTGGGCCCCCCTGGCCGGAACCTGCGGCGTGCTGCTGCTGTCCCTGGTGATCACCC TGTACTGCAAGCGGGGCCGGAAGAAGCTGCTGTACATCTTCAAGCAGCCCTTCATGCGCCCCGT GCAGACCACCCAGGAGGAGGACGGCTGCAGCTGCAGGTTCCCCGAGGAGGAGGAGGGGGGCTGC GAGCTGCGGGTGAAGTTCAGCAGGAGCGCCGACGCCCCTGCTTACCAGCAGGGCCAGAATCAGC TGTACAACGAGCTGAATCTGGGCCGGAGGGAGGAGTACGACGTGCTGGACAAGCGGAGGGGCAG GGACCCCGAGATGGGCGGCAAGCCCAGGCGGAAGAACCCCCAGGAGGGGCTGTACAACGAGCTG CAGAAGGACAAGATGGCCGAGGCCTACTCCGAGATCGGCATGAAGGGCGAGAGGCGGAGAGGCA AGGGCCATGACGGCCTGTACCAGGGCCTGTCCACCGCCACCAAGGACACCTACGACGCCCTGCA CATGCAGGCCCTGCCCCCCCGC (SEQ ID NO: 933); ATGGCCCTGCCCGTTACCGCCCTACTCCTGCCCCTGGCCCTCCTGCTCCACGCCGCCAGGCCCC AGGTGCAACTGGTAGAAAGTGGCGGGGGCCTGGTACAAGCGGGAGGCAGCTTGCGGCTCTCTTG CGCGGCGGCGTCCCACACGTTCGATTCTTATACGATGGGTTGGTTCCGACAGGCTCCGGGAAAA GAAAGGGAGTTCGTGGCTGCTGTGAATTGGGATAATGTGAAGAACTACGCAGATCCGGTTAAAG GGCGGTTCACAATCTCTCGAGACAATGTGAAAAACCGCGTGTATTTGCAGATGAATAGCTTGAA ACCCGAAGATACGGCAGTCTACTATTGTGCGGCAGGTACCAATCTGCCGACGAGAGGAAGCGGA TCTTGGGGGCAGGGTACACAAGTTACTGTCTCAAGTACCACCACCCCTGCCCCCAGGCCCCCCA CCCCCGCCCCCACCATCGCCAGCCAGCCCCTGTCCCTGCGGCCCGAGGCCTGCCGGCCCGCCGC CGGCGGCGCCGTGCACACCCGGGGCCTGGACTTCGCCTGCGACATCTACATCTGGGCCCCCCTG GCCGGAACCTGCGGCGTGCTGCTGCTGTCCCTGGTGATCACCCTGTACTGCAAGCGGGGCCGGA AGAAGCTGCTGTACATCTTCAAGCAGCCCTTCATGCGCCCCGTGCAGACCACCCAGGAGGAGGA CGGCTGCAGCTGCAGGTTCCCCGAGGAGGAGGAGGGGGGCTGCGAGCTGCGGGTGAAGTTCAGC AGGAGCGCCGACGCCCCTGCTTACCAGCAGGGCCAGAATCAGCTGTACAACGAGCTGAATCTGG GCCGGAGGGAGGAGTACGACGTGCTGGACAAGCGGAGGGGCAGGGACCCCGAGATGGGCGGCAA GCCCAGGCGGAAGAACCCCCAGGAGGGGCTGTACAACGAGCTGCAGAAGGACAAGATGGCCGAG GCCTACTCCGAGATCGGCATGAAGGGCGAGAGGCGGAGAGGCAAGGGCCATGACGGCCTGTACC AGGGCCTGTCCACCGCCACCAAGGACACCTACGACGCCCTGCACATGCAGGCCCTGCCCCCCCG C (SEQ ID NO: 934); ATGGCCCTGCCCGTTACCGCCCTACTCCTGCCCCTGGCCCTCCTGCTCCACGCCGCCAGGCCCC AAGTCCAACTCGTCGAGTCAGGAGGTGGGCTCGTTCAGGCAGGCGGGAGCCTGAGGTTGAGTTG TGCCGCCGCAAGTCTTACCTTTGATTCATATACTATGGGATGGTTTAGACAGGCGCCAGGTAAA GAAAGAGAGTTCGTAGCAGCAGTTAACTGGGACAACGTAAAGAATTATGCAGATCCAGTAAAGG GTCGCTTTACCATCTCAAGAGATAATGTCAAAAATACGGTGTACCTCCAAATGAACAGTCTGAA GCCTGAGGATACAGCCGTATACTATTGCGCCGCCGGGACCAACCTCCCCACTATAGAGTCAGGG AGTTGGGGGCAGGGCACTCAAGTAACTGTGAGTAGTACCACCACCCCTGCCCCCAGGCCCCCCA CCCCCGCCCCCACCATCGCCAGCCAGCCCCTGTCCCTGCGGCCCGAGGCCTGCCGGCCCGCCGCCGGCGGCGCCGTGCACACCCGGGGCCTGGACTTCGCCTGCGACATCTACATCTGGGCCCCCCTG GCCGGAACCTGCGGCGTGCTGCTGCTGTCCCTGGTGATCACCCTGTACTGCAAGCGGGGCCGGA AGAAGCTGCTGTACATCTTCAAGCAGCCCTTCATGCGCCCCGTGCAGACCACCCAGGAGGAGGA CGGCTGCAGCTGCAGGTTCCCCGAGGAGGAGGAGGGGGGCTGCGAGCTGCGGGTGAAGTTCAGC AGGAGCGCCGACGCCCCTGCTTACCAGCAGGGCCAGAATCAGCTGTACAACGAGCTGAATCTGG GCCGGAGGGAGGAGTACGACGTGCTGGACAAGCGGAGGGGCAGGGACCCCGAGATGGGCGGCAA GCCCAGGCGGAAGAACCCCCAGGAGGGGCTGTACAACGAGCTGCAGAAGGACAAGATGGCCGAG GCCTACTCCGAGATCGGCATGAAGGGCGAGAGGCGGAGAGGCAAGGGCCATGACGGCCTGTACC AGGGCCTGTCCACCGCCACCAAGGACACCTACGACGCCCTGCACATGCAGGCCCTGCCCCCCCG C (SEQ ID NO: 935); ATGGCCCTGCCCGTTACCGCCCTACTCCTGCCCCTGGCCCTCCTGCTCCACGCCGCCAGGCCCC AAGTACAACTTGTTGAGAGCGGGGGAGGATTGGTGCAGGCCGGAGGTTCCCTCCGGCTGTCCTG CGCTGCGTCAGGAAATGGGGTAGATATAGACGACATGGGTTGGTACAGACAGGCACCCGGCAAA CAAAGGGACCTGGTAGCATCTATTACTGCTGGAGGAATTACTAAATACGCCGATTCTGCAAAAG GACGGTTTACGATCAGTCGGGACAACGTAAAGAACACTGTTTACCTCCAGATGAATTCCCTGAA GCCGGAGGACACAGCGACTTACTATTGTTACGCTATCAGACGATTCTACCCTCGCTTCGACTAC TGGGGCCAGGGTACGCAGGTTACGGTTTCATCTACCACCACCCCTGCCCCCAGGCCCCCCACCC CCGCCCCCACCATCGCCAGCCAGCCCCTGTCCCTGCGGCCCGAGGCCTGCCGGCCCGCCGCCGG CGGCGCCGTGCACACCCGGGGCCTGGACTTCGCCTGCGACATCTACATCTGGGCCCCCCTGGCC GGAACCTGCGGCGTGCTGCTGCTGTCCCTGGTGATCACCCTGTACTGCAAGCGGGGCCGGAAGA AGCTGCTGTACATCTTCAAGCAGCCCTTCATGCGCCCCGTGCAGACCACCCAGGAGGAGGACGG CTGCAGCTGCAGGTTCCCCGAGGAGGAGGAGGGGGGCTGCGAGCTGCGGGTGAAGTTCAGCAGG AGCGCCGACGCCCCTGCTTACCAGCAGGGCCAGAATCAGCTGTACAACGAGCTGAATCTGGGCC GGAGGGAGGAGTACGACGTGCTGGACAAGCGGAGGGGCAGGGACCCCGAGATGGGCGGCAAGCC CAGGCGGAAGAACCCCCAGGAGGGGCTGTACAACGAGCTGCAGAAGGACAAGATGGCCGAGGCC TACTCCGAGATCGGCATGAAGGGCGAGAGGCGGAGAGGCAAGGGCCATGACGGCCTGTACCAGG GCCTGTCCACCGCCACCAAGGACACCTACGACGCCCTGCACATGCAGGCCCTGCCCCCCCGC (SEQ ID NO: 936); ATGGCCCTGCCCGTTACCGCCCTACTCCTGCCCCTGGCCCTCCTGCTCCACGCCGCCAGGCCCC AGGTACAGCTCGTCGAATCCGGGGGAGGCTTGGTCCAGGCGGGCGGAAGTCTTAGATTGTCTTG TGCCGCATCTGGGAACGGCGTTGATATTGACGATATGGGGTGGTATCGACAGGCGCCCGGTAAG CAGCGCGATCTGGTTGCCAGCATCACGGCAGGAGGAATCACTAATTATGCGGATAGTGCCAAAG GAAGGTTTACCATCTCTCGGGACAACGTCAAAAATACAGTATATCTTCAGATGAACTCCCTTAA ACCAGAGGATACTGCGACCTATTATTGCTACGCAATACGCCGGTTTTACCCTCGGTTTGACTAC TGGGGTCAAGGGACGCAGGTGACAGTATCATCAACCACCACCCCTGCCCCCAGGCCCCCCACCCCCGCCCCCACCATCGCCAGCCAGCCCCTGTCCCTGCGGCCCGAGGCCTGCCGGCCCGCCGCCGG CGGCGCCGTGCACACCCGGGGCCTGGACTTCGCCTGCGACATCTACATCTGGGCCCCCCTGGCC GGAACCTGCGGCGTGCTGCTGCTGTCCCTGGTGATCACCCTGTACTGCAAGCGGGGCCGGAAGA AGCTGCTGTACATCTTCAAGCAGCCCTTCATGCGCCCCGTGCAGACCACCCAGGAGGAGGACGG CTGCAGCTGCAGGTTCCCCGAGGAGGAGGAGGGGGGCTGCGAGCTGCGGGTGAAGTTCAGCAGG AGCGCCGACGCCCCTGCTTACCAGCAGGGCCAGAATCAGCTGTACAACGAGCTGAATCTGGGCC GGAGGGAGGAGTACGACGTGCTGGACAAGCGGAGGGGCAGGGACCCCGAGATGGGCGGCAAGCC CAGGCGGAAGAACCCCCAGGAGGGGCTGTACAACGAGCTGCAGAAGGACAAGATGGCCGAGGCC TACTCCGAGATCGGCATGAAGGGCGAGAGGCGGAGAGGCAAGGGCCATGACGGCCTGTACCAGG GCCTGTCCACCGCCACCAAGGACACCTACGACGCCCTGCACATGCAGGCCCTGCCCCCCCGC (SEQ ID NO: 937); ATGGCCCTGCCCGTTACCGCCCTACTCCTGCCCCTGGCCCTCCTGCTCCACGCCGCCAGGCCCC AGGTTCAACTGGTCGAGTCCGGTGGAGGCTTGGTGCAAGCGGGTGGTAGTCTGCGGCTGAGCTG CGCTGCTAGTGGTAACGGTGTCGACATCGACGACATGGGATGGTACAGACAGGCACCAGGGAAG CAGAGGGACCTTGTTGCTACAATCACAGCCGGCGGGATAACCAAATACGCAGATTCTGCAAAGG GTCGGTTTACAATTTCACGAGATAATGTAAAGAATACCGTCTATTTGCAGATGAACAGCCTTAA ACCCGAAGATACTGCCACATATTATTGTTACGCCATAAGGCGATTCTATCCCCGCTTCGACTAT TGGGGTCAGGGGACTCAAGTTACTGTTAGCTCCACCACCACCCCTGCCCCCAGGCCCCCCACCC CCGCCCCCACCATCGCCAGCCAGCCCCTGTCCCTGCGGCCCGAGGCCTGCCGGCCCGCCGCCGG CGGCGCCGTGCACACCCGGGGCCTGGACTTCGCCTGCGACATCTACATCTGGGCCCCCCTGGCC GGAACCTGCGGCGTGCTGCTGCTGTCCCTGGTGATCACCCTGTACTGCAAGCGGGGCCGGAAGA AGCTGCTGTACATCTTCAAGCAGCCCTTCATGCGCCCCGTGCAGACCACCCAGGAGGAGGACGG CTGCAGCTGCAGGTTCCCCGAGGAGGAGGAGGGGGGCTGCGAGCTGCGGGTGAAGTTCAGCAGG AGCGCCGACGCCCCTGCTTACCAGCAGGGCCAGAATCAGCTGTACAACGAGCTGAATCTGGGCC GGAGGGAGGAGTACGACGTGCTGGACAAGCGGAGGGGCAGGGACCCCGAGATGGGCGGCAAGCC CAGGCGGAAGAACCCCCAGGAGGGGCTGTACAACGAGCTGCAGAAGGACAAGATGGCCGAGGCC TACTCCGAGATCGGCATGAAGGGCGAGAGGCGGAGAGGCAAGGGCCATGACGGCCTGTACCAGG GCCTGTCCACCGCCACCAAGGACACCTACGACGCCCTGCACATGCAGGCCCTGCCCCCCCGC (SEQ ID NO: 938); ATGGCCCTGCCCGTTACCGCCCTACTCCTGCCCCTGGCCCTCCTGCTCCACGCCGCCAGGCCCC AGGTGCAACTCGTTGAAAGCGGGGGAGGACTCGTGCAAGCGGGAGGATCACTCCGACTGAGTTG TGCTGCTTCAGGGAATGGCGTTGATATAGACGACATGGGTTGGTATCGACAGGCACCCGGAAAG CAACGGGATTTGGTCGCGACTATTACAGCGGGGGGTATTACTAACTATGCGGATAGCGCCAAGG GGCGATTCACTATCTCACGCGATAACGTGAAAAACACCGTATATCTTCAGATGAACAGTTTGAA ACCAGAAGACACCGGTACATACTATTGTTACGCTATCAGAAAATTTTACCCCAGATTTGATTACTGGGGGCAGGGAACGCAGGTTACGGTCAGTAGCACCACCACCCCTGCCCCCAGGCCCCCCACCC CCGCCCCCACCATCGCCAGCCAGCCCCTGTCCCTGCGGCCCGAGGCCTGCCGGCCCGCCGCCGG CGGCGCCGTGCACACCCGGGGCCTGGACTTCGCCTGCGACATCTACATCTGGGCCCCCCTGGCC GGAACCTGCGGCGTGCTGCTGCTGTCCCTGGTGATCACCCTGTACTGCAAGCGGGGCCGGAAGA AGCTGCTGTACATCTTCAAGCAGCCCTTCATGCGCCCCGTGCAGACCACCCAGGAGGAGGACGG CTGCAGCTGCAGGTTCCCCGAGGAGGAGGAGGGGGGCTGCGAGCTGCGGGTGAAGTTCAGCAGG AGCGCCGACGCCCCTGCTTACCAGCAGGGCCAGAATCAGCTGTACAACGAGCTGAATCTGGGCC GGAGGGAGGAGTACGACGTGCTGGACAAGCGGAGGGGCAGGGACCCCGAGATGGGCGGCAAGCC CAGGCGGAAGAACCCCCAGGAGGGGCTGTACAACGAGCTGCAGAAGGACAAGATGGCCGAGGCC TACTCCGAGATCGGCATGAAGGGCGAGAGGCGGAGAGGCAAGGGCCATGACGGCCTGTACCAGG GCCTGTCCACCGCCACCAAGGACACCTACGACGCCCTGCACATGCAGGCCCTGCCCCCCCGC (SEQ ID NO: 939); ATGGCCCTGCCCGTTACCGCCCTACTCCTGCCCCTGGCCCTCCTGCTCCACGCCGCCAGGCCCC AGGTCCAGCTGGTTGAAAGCGGTGGGGGGCTGGTCCAAGCCGGCGGTTCTCTTAGACTTAGCTG CGCCGCGTCTGGTAACATTGTTGACATCGACGACATGGGGTGGTATAGGCAGGCTCCAGGTAAA CAACGAGATTTGGTTGCCTCAATCACAGCGGGGGGTATAACCAAATATGCAGATTCAGCTAAGG GACGATTCACCATTAGCCGAGACAATGTAAAGAACACTGTTAGTTTGCAGATGAACTCACTGAA ACCTGAAGATACGGCGACATATTATTGTTATGCAGTTAGAAAGTATTACCCCAGATTTGACTAT TGGGGCCAAGGCACTCAAGTGACCGTATCCTCTACCACCACCCCTGCCCCCAGGCCCCCCACCC CCGCCCCCACCATCGCCAGCCAGCCCCTGTCCCTGCGGCCCGAGGCCTGCCGGCCCGCCGCCGG CGGCGCCGTGCACACCCGGGGCCTGGACTTCGCCTGCGACATCTACATCTGGGCCCCCCTGGCC GGAACCTGCGGCGTGCTGCTGCTGTCCCTGGTGATCACCCTGTACTGCAAGCGGGGCCGGAAGA AGCTGCTGTACATCTTCAAGCAGCCCTTCATGCGCCCCGTGCAGACCACCCAGGAGGAGGACGG CTGCAGCTGCAGGTTCCCCGAGGAGGAGGAGGGGGGCTGCGAGCTGCGGGTGAAGTTCAGCAGG AGCGCCGACGCCCCTGCTTACCAGCAGGGCCAGAATCAGCTGTACAACGAGCTGAATCTGGGCC GGAGGGAGGAGTACGACGTGCTGGACAAGCGGAGGGGCAGGGACCCCGAGATGGGCGGCAAGCC CAGGCGGAAGAACCCCCAGGAGGGGCTGTACAACGAGCTGCAGAAGGACAAGATGGCCGAGGCC TACTCCGAGATCGGCATGAAGGGCGAGAGGCGGAGAGGCAAGGGCCATGACGGCCTGTACCAGG GCCTGTCCACCGCCACCAAGGACACCTACGACGCCCTGCACATGCAGGCCCTGCCCCCCCGC (SEQ ID NO: 940); ATGGCCCTGCCCGTTACCGCCCTACTCCTGCCCCTGGCCCTCCTGCTCCACGCCGCCAGGCCCC AGGTACAACTTGTCGAATCAGGTGGAGGACTCGTGCAGGCTGGGGGGTCCCTGCGCTTGAGTTG CGCCGCTAGTGGTAGGACATTTTCCAATTACGCCATGGGTTGGTTTAGACAAGCTCCTGGGAAG GAGCGCGAATTCGTGGCTGCAATTAACTGGTCCGGCGGACGCATTTACTATACAGACTCCGTGA AAGGTCGATTTACAATCAGTAGAGACAACGCCAAGAATACGGTTTATCTTCAGATGAACAGTCTTAAACCGGAAGATACTGCCGTGTACTATTGCGCTGCGGGGACGAATTGGTCAATACCACCTGAT TACTGGGGTCAGGGGACGCAGGTAACCGTGAGCTCCACCACCACCCCTGCCCCCAGGCCCCCCA CCCCCGCCCCCACCATCGCCAGCCAGCCCCTGTCCCTGCGGCCCGAGGCCTGCCGGCCCGCCGC CGGCGGCGCCGTGCACACCCGGGGCCTGGACTTCGCCTGCGACATCTACATCTGGGCCCCCCTG GCCGGAACCTGCGGCGTGCTGCTGCTGTCCCTGGTGATCACCCTGTACTGCAAGCGGGGCCGGA AGAAGCTGCTGTACATCTTCAAGCAGCCCTTCATGCGCCCCGTGCAGACCACCCAGGAGGAGGA CGGCTGCAGCTGCAGGTTCCCCGAGGAGGAGGAGGGGGGCTGCGAGCTGCGGGTGAAGTTCAGC AGGAGCGCCGACGCCCCTGCTTACCAGCAGGGCCAGAATCAGCTGTACAACGAGCTGAATCTGG GCCGGAGGGAGGAGTACGACGTGCTGGACAAGCGGAGGGGCAGGGACCCCGAGATGGGCGGCAA GCCCAGGCGGAAGAACCCCCAGGAGGGGCTGTACAACGAGCTGCAGAAGGACAAGATGGCCGAG GCCTACTCCGAGATCGGCATGAAGGGCGAGAGGCGGAGAGGCAAGGGCCATGACGGCCTGTACC AGGGCCTGTCCACCGCCACCAAGGACACCTACGACGCCCTGCACATGCAGGCCCTGCCCCCCCG C (SEQ ID NO: 941); ATGGCCCTGCCCGTTACCGCCCTACTCCTGCCCCTGGCCCTCCTGCTCCACGCCGCCAGGCCCC AAGTACAGCTCGTGGAGTCAGGTGGTGGACTCGTTCAGGCGGGTGGTTCCCTTAGGTTGTCCTG TGCTGCGTCAGGTCGCACGTTCAGCTCCTATGCTATGGGCTGGTTCAGGCAGGCACCGGGGAAG GAGCGAGAATTTGTAGCGGCAATACGATGGAGTGGAGGCTCTACTTATTACGGAGATAGTGTTA AAGGGAGGTTCACTATTTCTAGAGATAATGCGAAAAACACCGTGTATCTCCAAATGAACAGCCT CAAACCTGAAGATACGGCAGTCTACTACTGTGCGGCTGACCCCATTGGCCTCGGATACGAAATG GGAGAGTATGATTACTGGGGTCAAGGTACGCAGGTTACTGTATCAAGTACCACCACCCCTGCCC CCAGGCCCCCCACCCCCGCCCCCACCATCGCCAGCCAGCCCCTGTCCCTGCGGCCCGAGGCCTG CCGGCCCGCCGCCGGCGGCGCCGTGCACACCCGGGGCCTGGACTTCGCCTGCGACATCTACATC TGGGCCCCCCTGGCCGGAACCTGCGGCGTGCTGCTGCTGTCCCTGGTGATCACCCTGTACTGCA AGCGGGGCCGGAAGAAGCTGCTGTACATCTTCAAGCAGCCCTTCATGCGCCCCGTGCAGACCAC CCAGGAGGAGGACGGCTGCAGCTGCAGGTTCCCCGAGGAGGAGGAGGGGGGCTGCGAGCTGCGG GTGAAGTTCAGCAGGAGCGCCGACGCCCCTGCTTACCAGCAGGGCCAGAATCAGCTGTACAACG AGCTGAATCTGGGCCGGAGGGAGGAGTACGACGTGCTGGACAAGCGGAGGGGCAGGGACCCCGA GATGGGCGGCAAGCCCAGGCGGAAGAACCCCCAGGAGGGGCTGTACAACGAGCTGCAGAAGGAC AAGATGGCCGAGGCCTACTCCGAGATCGGCATGAAGGGCGAGAGGCGGAGAGGCAAGGGCCATG ACGGCCTGTACCAGGGCCTGTCCACCGCCACCAAGGACACCTACGACGCCCTGCACATGCAGGC CCTGCCCCCCCGC (SEQ ID NO: 942); ATGGCCCTGCCCGTTACCGCCCTACTCCTGCCCCTGGCCCTCCTGCTCCACGCCGCCAGGCCCC AGGTACAGCTTGTCGAAAGCGGGGGCGGTCTGGTTCAGGCCGGTGGAAGTTTGAGGCTCAGTTG TGCAGCGAGCGGGAGAACCTTCTCCAGTTACGCGATGGGGTGGTTCCGACAGGCGCCAGGGAAG GAGAGAGAATTCGTGGCAGCAATCTCATGGTCCGGCGGAAGCATTTATTATGCGGACTCTGTAAAGGGGCGATTTACAATATCCCGAGACAACGCGAAGAACACAGTATCCCTCCAAATGAATAGCCT GAAGCCTGAAGACACGGCTGTGTACTATTGTGCCGCAGACGGAACGCTCCGCACGCCCATGAAC CTTATTCATTATTGGGGGCAGGGAACCCAAGTGACTGTATCTTCTACCACCACCCCTGCCCCCA GGCCCCCCACCCCCGCCCCCACCATCGCCAGCCAGCCCCTGTCCCTGCGGCCCGAGGCCTGCCG GCCCGCCGCCGGCGGCGCCGTGCACACCCGGGGCCTGGACTTCGCCTGCGACATCTACATCTGG GCCCCCCTGGCCGGAACCTGCGGCGTGCTGCTGCTGTCCCTGGTGATCACCCTGTACTGCAAGC GGGGCCGGAAGAAGCTGCTGTACATCTTCAAGCAGCCCTTCATGCGCCCCGTGCAGACCACCCA GGAGGAGGACGGCTGCAGCTGCAGGTTCCCCGAGGAGGAGGAGGGGGGCTGCGAGCTGCGGGTG AAGTTCAGCAGGAGCGCCGACGCCCCTGCTTACCAGCAGGGCCAGAATCAGCTGTACAACGAGC TGAATCTGGGCCGGAGGGAGGAGTACGACGTGCTGGACAAGCGGAGGGGCAGGGACCCCGAGAT GGGCGGCAAGCCCAGGCGGAAGAACCCCCAGGAGGGGCTGTACAACGAGCTGCAGAAGGACAAG ATGGCCGAGGCCTACTCCGAGATCGGCATGAAGGGCGAGAGGCGGAGAGGCAAGGGCCATGACG GCCTGTACCAGGGCCTGTCCACCGCCACCAAGGACACCTACGACGCCCTGCACATGCAGGCCCT GCCCCCCCGC (SEQ ID NO: 943); ATGGCCCTGCCCGTTACCGCCCTACTCCTGCCCCTGGCCCTCCTGCTCCACGCCGCCAGGCCCC AAGTCCAACTGGTAGAGAGTGGCGGTGGGCTCGTCCAAGCCGGGGGCTCTCTCAGGTTGTCCTG TGCCGCGTCCGGCAGGACCTTCTCAAGTTATGCGATGGGATGGTTCCGACAGGCACCAGGAAAA GAGAGGGAGTTTGTCGCAGCTATTTCATGGTCTGGCGGTAGCACGTATTATGCCAATAGCGTGA AAGGGCGGTTCACGATTAGTCGGGACAATGCGAAAAACACCGTTTATCTGCAAATGAATTCCCT GAAGCCTGAGGACACCGCTGTGTACTACTGCGCTCCTGGCGAAGAAGTAGCAGGCAAGTATTTC CGCCAACTCTATGACTACTGGGGGCAGGGCACACAAGTTACAGTGAGTTCCACCACCACCCCTG CCCCCAGGCCCCCCACCCCCGCCCCCACCATCGCCAGCCAGCCCCTGTCCCTGCGGCCCGAGGC CTGCCGGCCCGCCGCCGGCGGCGCCGTGCACACCCGGGGCCTGGACTTCGCCTGCGACATCTAC ATCTGGGCCCCCCTGGCCGGAACCTGCGGCGTGCTGCTGCTGTCCCTGGTGATCACCCTGTACT GCAAGCGGGGCCGGAAGAAGCTGCTGTACATCTTCAAGCAGCCCTTCATGCGCCCCGTGCAGAC CACCCAGGAGGAGGACGGCTGCAGCTGCAGGTTCCCCGAGGAGGAGGAGGGGGGCTGCGAGCTG CGGGTGAAGTTCAGCAGGAGCGCCGACGCCCCTGCTTACCAGCAGGGCCAGAATCAGCTGTACA ACGAGCTGAATCTGGGCCGGAGGGAGGAGTACGACGTGCTGGACAAGCGGAGGGGCAGGGACCC CGAGATGGGCGGCAAGCCCAGGCGGAAGAACCCCCAGGAGGGGCTGTACAACGAGCTGCAGAAG GACAAGATGGCCGAGGCCTACTCCGAGATCGGCATGAAGGGCGAGAGGCGGAGAGGCAAGGGCC ATGACGGCCTGTACCAGGGCCTGTCCACCGCCACCAAGGACACCTACGACGCCCTGCACATGCA GGCCCTGCCCCCCCGC (SEQ ID NO: 944); ATGGCCCTGCCCGTTACCGCCCTACTCCTGCCCCTGGCCCTCCTGCTCCACGCCGCCAGGCCCC AAGTTCAACTTGTTGAGTCCGGGGGTGGCCTCGTCCAAGCAGGAGGGTCCCTCCGGCTGTCATG CGCGGCTAGCGGTCGGACATTTAGCAGTTATGCGATGGGGTGGTTCCGGCAAGCACCAGGTAAGGAAAGGGAGTTTGTGGCAGACATTTCATGGAGTGGAGGTACGACAAATTATGCAAACAGCGTTA AGGGGCGCTTTACGATTTCCCGAGACAATGCAAAAAACACAGTATATCTGCAGATGAACTCACT CAAGCCGGAAGATACGGCGGTTTACTACTGTGCGCCTGGAGAAGAAGTGGACGGCAAATATTTC CGCCCTCTCTATGATTACTGGGGGCAGGGAACTCAGGTAACCGTAAGCAGTACCACCACCCCTG CCCCCAGGCCCCCCACCCCCGCCCCCACCATCGCCAGCCAGCCCCTGTCCCTGCGGCCCGAGGC CTGCCGGCCCGCCGCCGGCGGCGCCGTGCACACCCGGGGCCTGGACTTCGCCTGCGACATCTAC ATCTGGGCCCCCCTGGCCGGAACCTGCGGCGTGCTGCTGCTGTCCCTGGTGATCACCCTGTACT GCAAGCGGGGCCGGAAGAAGCTGCTGTACATCTTCAAGCAGCCCTTCATGCGCCCCGTGCAGAC CACCCAGGAGGAGGACGGCTGCAGCTGCAGGTTCCCCGAGGAGGAGGAGGGGGGCTGCGAGCTG CGGGTGAAGTTCAGCAGGAGCGCCGACGCCCCTGCTTACCAGCAGGGCCAGAATCAGCTGTACA ACGAGCTGAATCTGGGCCGGAGGGAGGAGTACGACGTGCTGGACAAGCGGAGGGGCAGGGACCC CGAGATGGGCGGCAAGCCCAGGCGGAAGAACCCCCAGGAGGGGCTGTACAACGAGCTGCAGAAG GACAAGATGGCCGAGGCCTACTCCGAGATCGGCATGAAGGGCGAGAGGCGGAGAGGCAAGGGCC ATGACGGCCTGTACCAGGGCCTGTCCACCGCCACCAAGGACACCTACGACGCCCTGCACATGCA GGCCCTGCCCCCCCGC (SEQ ID NO: 945); ATGGCCCTGCCCGTTACCGCCCTACTCCTGCCCCTGGCCCTCCTGCTCCACGCCGCCAGGCCCC AGGTACAACTGGTGGAATCAGGTGGGGGGTTGGTCCAGGCTGGAGGATCATTGCGACTCAGTTG CGCCGCATCAGGGCGAACTTTTTCTACCTATACGATGGGATGGTTTCGGCAAGCCCCCGGTAAA GAACGACAGTTTGTCGCAGCCATTAGTTCCTCAGGAGACTCAACCTACTACACTGATTCCGTGA AAGGCCGGTTTACCATTTCCAGAGATAATGCCAAGAACACTGTTTATCTGCAGATGGACAGCCT GAAGCCCGAGGACACAGCGGTGTATTACTGCGCACCGGGTGAAGAAGTAGCTGGAAAATACTTC CGCGCACTGTATGATTACTGGGGCCAGGGCACTCAAGTTACCGTCTCTAGTACCACCACCCCTG CCCCCAGGCCCCCCACCCCCGCCCCCACCATCGCCAGCCAGCCCCTGTCCCTGCGGCCCGAGGC CTGCCGGCCCGCCGCCGGCGGCGCCGTGCACACCCGGGGCCTGGACTTCGCCTGCGACATCTAC ATCTGGGCCCCCCTGGCCGGAACCTGCGGCGTGCTGCTGCTGTCCCTGGTGATCACCCTGTACT GCAAGCGGGGCCGGAAGAAGCTGCTGTACATCTTCAAGCAGCCCTTCATGCGCCCCGTGCAGAC CACCCAGGAGGAGGACGGCTGCAGCTGCAGGTTCCCCGAGGAGGAGGAGGGGGGCTGCGAGCTG CGGGTGAAGTTCAGCAGGAGCGCCGACGCCCCTGCTTACCAGCAGGGCCAGAATCAGCTGTACA ACGAGCTGAATCTGGGCCGGAGGGAGGAGTACGACGTGCTGGACAAGCGGAGGGGCAGGGACCC CGAGATGGGCGGCAAGCCCAGGCGGAAGAACCCCCAGGAGGGGCTGTACAACGAGCTGCAGAAG GACAAGATGGCCGAGGCCTACTCCGAGATCGGCATGAAGGGCGAGAGGCGGAGAGGCAAGGGCC ATGACGGCCTGTACCAGGGCCTGTCCACCGCCACCAAGGACACCTACGACGCCCTGCACATGCA GGCCCTGCCCCCCCGC (SEQ ID NO: 946); ATGGCCCTGCCCGTTACCGCCCTACTCCTGCCCCTGGCCCTCCTGCTCCACGCCGCCAGGCCCC AAGTCCAGCTTGTAGAAAGCGGTGGCGGTCTCGTTCAAGCCGGTGGAAGCCTCCGGCTTTCATGTGCGGCATCAGGTTCAATTTTCTCCATTAACGCGATGGCATGGTATAGGCAAGCCCCTGGTAAG CAGCGCGAGCTCGTGGCTGTTATCACATCAGGAGGGAGTACTAACTACGCGGATTCTGTTAAAG GAAGATTTACCATTTCCCGCGATAATGCTAAGAATACAGTCTACCTCCAAATGAACTCCCTGAA GCCTGAAGACACTGCCGTGTATTATTGCAATGCTGATCTGGTCTACTACTCAGGCAATCCTGGA GACTATGGTATGGACTACTGGGGAAAGGGGACATTGGTGACTGTCAGTAGTACCACCACCCCTG CCCCCAGGCCCCCCACCCCCGCCCCCACCATCGCCAGCCAGCCCCTGTCCCTGCGGCCCGAGGC CTGCCGGCCCGCCGCCGGCGGCGCCGTGCACACCCGGGGCCTGGACTTCGCCTGCGACATCTAC ATCTGGGCCCCCCTGGCCGGAACCTGCGGCGTGCTGCTGCTGTCCCTGGTGATCACCCTGTACT GCAAGCGGGGCCGGAAGAAGCTGCTGTACATCTTCAAGCAGCCCTTCATGCGCCCCGTGCAGAC CACCCAGGAGGAGGACGGCTGCAGCTGCAGGTTCCCCGAGGAGGAGGAGGGGGGCTGCGAGCTG CGGGTGAAGTTCAGCAGGAGCGCCGACGCCCCTGCTTACCAGCAGGGCCAGAATCAGCTGTACA ACGAGCTGAATCTGGGCCGGAGGGAGGAGTACGACGTGCTGGACAAGCGGAGGGGCAGGGACCC CGAGATGGGCGGCAAGCCCAGGCGGAAGAACCCCCAGGAGGGGCTGTACAACGAGCTGCAGAAG GACAAGATGGCCGAGGCCTACTCCGAGATCGGCATGAAGGGCGAGAGGCGGAGAGGCAAGGGCC ATGACGGCCTGTACCAGGGCCTGTCCACCGCCACCAAGGACACCTACGACGCCCTGCACATGCA GGCCCTGCCCCCCCGC (SEQ ID NO: 947); ATGGCCCTGCCCGTTACCGCCCTACTCCTGCCCCTGGCCCTCCTGCTCCACGCCGCCAGGCCCC AGGTTCAGTTGGTAGAATCCGGCGGTGGATTGGTGCAGGCTGGAGGGTCCTTGAGACTTTCCTG TGTTGCGAGCGGGAGGACGTTTTCAATCAATAACATTAACTGGTATAGACAGGCCCCTGGCAAG GAGCGAGAGTTCGTTGCCACTACCAGATGGCGGGGAGACAGCACTTACTACGCTGACTCTGTGG CCGGTCGATTTACCATATCAAGAGACTCAGCTAAAAATACCGTGTACCTCCAAATGAACTCACT GAAACCAGAGGATACTGCTATATACTATTGCAATGCTAAGGGCGGCGTTGATGTCTGGGGTCAA GGAACCCAGGTAACGGTTTCCAGTACCACCACCCCTGCCCCCAGGCCCCCCACCCCCGCCCCCA CCATCGCCAGCCAGCCCCTGTCCCTGCGGCCCGAGGCCTGCCGGCCCGCCGCCGGCGGCGCCGT GCACACCCGGGGCCTGGACTTCGCCTGCGACATCTACATCTGGGCCCCCCTGGCCGGAACCTGC GGCGTGCTGCTGCTGTCCCTGGTGATCACCCTGTACTGCAAGCGGGGCCGGAAGAAGCTGCTGT ACATCTTCAAGCAGCCCTTCATGCGCCCCGTGCAGACCACCCAGGAGGAGGACGGCTGCAGCTG CAGGTTCCCCGAGGAGGAGGAGGGGGGCTGCGAGCTGCGGGTGAAGTTCAGCAGGAGCGCCGAC GCCCCTGCTTACCAGCAGGGCCAGAATCAGCTGTACAACGAGCTGAATCTGGGCCGGAGGGAGG AGTACGACGTGCTGGACAAGCGGAGGGGCAGGGACCCCGAGATGGGCGGCAAGCCCAGGCGGAA GAACCCCCAGGAGGGGCTGTACAACGAGCTGCAGAAGGACAAGATGGCCGAGGCCTACTCCGAG ATCGGCATGAAGGGCGAGAGGCGGAGAGGCAAGGGCCATGACGGCCTGTACCAGGGCCTGTCCA CCGCCACCAAGGACACCTACGACGCCCTGCACATGCAGGCCCTGCCCCCCCGC (SEQ ID NO: 948); ATGGCCCTGCCCGTTACCGCCCTACTCCTGCCCCTGGCCCTCCTGCTCCACGCCGCCAGGCCCCAGGTACAGCTTGTTGAGTCCGGCGGGGGTCTCGTACAGCCGGGCGGCTCCTTGCGCCTCAGTTG TGCGGCGAGTGGATTCTTGTTCTCACTCTACGCTATGGCATGGGTCCGGCAAGCCCCAGGCAAA GGTCTGGAGTGGGTAAGTGATATAAGCAACGGAGGTGTTACCACAAGATACGCGGATTCAGTAA AAGGCCGGTTTACAATTTCACGAGATAATGCGAAAAATACGTTGTATCTTCAAATGGATAGTCT GACGCCGGGGGATACTGCGGTCTATTACTGTGCTGTTACAACCACGGGCTGGCGGGCAAGAGGC CAAGGGACCCAAGTGACTGTCTCCTCCACCACCACCCCTGCCCCCAGGCCCCCCACCCCCGCCC CCACCATCGCCAGCCAGCCCCTGTCCCTGCGGCCCGAGGCCTGCCGGCCCGCCGCCGGCGGCGC CGTGCACACCCGGGGCCTGGACTTCGCCTGCGACATCTACATCTGGGCCCCCCTGGCCGGAACC TGCGGCGTGCTGCTGCTGTCCCTGGTGATCACCCTGTACTGCAAGCGGGGCCGGAAGAAGCTGC TGTACATCTTCAAGCAGCCCTTCATGCGCCCCGTGCAGACCACCCAGGAGGAGGACGGCTGCAG CTGCAGGTTCCCCGAGGAGGAGGAGGGGGGCTGCGAGCTGCGGGTGAAGTTCAGCAGGAGCGCC GACGCCCCTGCTTACCAGCAGGGCCAGAATCAGCTGTACAACGAGCTGAATCTGGGCCGGAGGG AGGAGTACGACGTGCTGGACAAGCGGAGGGGCAGGGACCCCGAGATGGGCGGCAAGCCCAGGCG GAAGAACCCCCAGGAGGGGCTGTACAACGAGCTGCAGAAGGACAAGATGGCCGAGGCCTACTCC GAGATCGGCATGAAGGGCGAGAGGCGGAGAGGCAAGGGCCATGACGGCCTGTACCAGGGCCTGT CCACCGCCACCAAGGACACCTACGACGCCCTGCACATGCAGGCCCTGCCCCCCCGC (SEQ ID NO: 949); ATGGCCCTGCCCGTTACCGCCCTACTCCTGCCCCTGGCCCTCCTGCTCCACGCCGCCAGGCCCC AGGTCCAACTTGTTGAATCAGGCGGAGGACTCGTTCAGCCTGGAGGCAGCCTGAGGCTTTCTTG CGCCGCTTCAGGAAGCATATTCAGACCAAACGACATGGGCTGGTACCGACAGGCGCCCGGTAAA CAAAGGGAACTCGTGGCAATCATAACGGACGGGGGTATCACAAATTACGCTGCAACGGTAAAGG GGAGGTTTACGATTAGTCGAGACAATGCCAAAAATACAGTGTACCTTCAAATGAACAGCCTCAA ACCGGAGGACACGGCGGTTTATTATTGCAACCTTAATATCCCGTACCCTCGCGTTTCCTCATGG GGCCAGGGAACGCAGGTCACAGTCTCATCTACCACCACCCCTGCCCCCAGGCCCCCCACCCCCG CCCCCACCATCGCCAGCCAGCCCCTGTCCCTGCGGCCCGAGGCCTGCCGGCCCGCCGCCGGCGG CGCCGTGCACACCCGGGGCCTGGACTTCGCCTGCGACATCTACATCTGGGCCCCCCTGGCCGGA ACCTGCGGCGTGCTGCTGCTGTCCCTGGTGATCACCCTGTACTGCAAGCGGGGCCGGAAGAAGC TGCTGTACATCTTCAAGCAGCCCTTCATGCGCCCCGTGCAGACCACCCAGGAGGAGGACGGCTG CAGCTGCAGGTTCCCCGAGGAGGAGGAGGGGGGCTGCGAGCTGCGGGTGAAGTTCAGCAGGAGC GCCGACGCCCCTGCTTACCAGCAGGGCCAGAATCAGCTGTACAACGAGCTGAATCTGGGCCGGA GGGAGGAGTACGACGTGCTGGACAAGCGGAGGGGCAGGGACCCCGAGATGGGCGGCAAGCCCAG GCGGAAGAACCCCCAGGAGGGGCTGTACAACGAGCTGCAGAAGGACAAGATGGCCGAGGCCTAC TCCGAGATCGGCATGAAGGGCGAGAGGCGGAGAGGCAAGGGCCATGACGGCCTGTACCAGGGCC TGTCCACCGCCACCAAGGACACCTACGACGCCCTGCACATGCAGGCCCTGCCCCCCCGC (SEQ ID NO: 950);ATGGCCCTGCCCGTTACCGCCCTACTCCTGCCCCTGGCCCTCCTGCTCCACGCCGCCAGGCCCC AGGTGCAGCTCGTCGAGTCTGGGGGAGGCCTTGTCCAGCCTGGTGGCTCCCTTCGCCTGAGTTG TGCAGCATCTGGGAGTACATTTAACACCATGGCCTGGTTCCGGCAAGCGCCGGGAAAGGAGCGC GAATTCGTGGCGGCCATATCATGGAGCGGCGGATTGACCTATTATGGTGATTCCGTCAAGGGAA GATTCACCATATTCAGGGATAACGCGAAGAATTTGGGCTATCTCCAGATGAATTCCCTTAAACC GGAAGATACTGCGGTATATAGTTGCGCCGCGAGGACAACTTTCCGAACCGGTTTGATCGTAACC GTAACAGCCTATGATACATGGGGTCAAGGTACACAAGTGACAGTCAGTTCCACCACCACCCCTG CCCCCAGGCCCCCCACCCCCGCCCCCACCATCGCCAGCCAGCCCCTGTCCCTGCGGCCCGAGGC CTGCCGGCCCGCCGCCGGCGGCGCCGTGCACACCCGGGGCCTGGACTTCGCCTGCGACATCTAC ATCTGGGCCCCCCTGGCCGGAACCTGCGGCGTGCTGCTGCTGTCCCTGGTGATCACCCTGTACT GCAAGCGGGGCCGGAAGAAGCTGCTGTACATCTTCAAGCAGCCCTTCATGCGCCCCGTGCAGAC CACCCAGGAGGAGGACGGCTGCAGCTGCAGGTTCCCCGAGGAGGAGGAGGGGGGCTGCGAGCTG CGGGTGAAGTTCAGCAGGAGCGCCGACGCCCCTGCTTACCAGCAGGGCCAGAATCAGCTGTACA ACGAGCTGAATCTGGGCCGGAGGGAGGAGTACGACGTGCTGGACAAGCGGAGGGGCAGGGACCC CGAGATGGGCGGCAAGCCCAGGCGGAAGAACCCCCAGGAGGGGCTGTACAACGAGCTGCAGAAG GACAAGATGGCCGAGGCCTACTCCGAGATCGGCATGAAGGGCGAGAGGCGGAGAGGCAAGGGCC ATGACGGCCTGTACCAGGGCCTGTCCACCGCCACCAAGGACACCTACGACGCCCTGCACATGCA GGCCCTGCCCCCCCGC (SEQ ID NO: 951); ATGGCCCTGCCCGTTACCGCCCTACTCCTGCCCCTGGCCCTCCTGCTCCACGCCGCCAGGCCCC AGGTGCAGTTGGTAGAGTCCGGAGGAGGTCTCGTGCAGCCCGGAGGTTCACTCAGACTTTCATG TGTGTTGAGTGGGCGGACGTTTTCTAGTTATGCAATGGGATGGTTCCGGCAAGCGCCGGGCAAA GAAAGAGAGTTCGTGAGTACAATCTCCTTGTCCGGGGGAAGCACATTTTACTCAGGGAGTGCGA AAGGGCGGTTCACGATAAGTAGAGATAACGCCAAAAACACCGTTTATCTCCAGATGAACTCCTT GAAGCCTGAAGACACTGCGGTGTACTACTGCGCTGCACGACCTGTTCTTATTAGCCGGAGCTCA ACAGACTACGCCTATTGGGGTCCGGGAACTCAAGTTACAGTTAGCTCAACCACCACCCCTGCCC CCAGGCCCCCCACCCCCGCCCCCACCATCGCCAGCCAGCCCCTGTCCCTGCGGCCCGAGGCCTG CCGGCCCGCCGCCGGCGGCGCCGTGCACACCCGGGGCCTGGACTTCGCCTGCGACATCTACATC TGGGCCCCCCTGGCCGGAACCTGCGGCGTGCTGCTGCTGTCCCTGGTGATCACCCTGTACTGCA AGCGGGGCCGGAAGAAGCTGCTGTACATCTTCAAGCAGCCCTTCATGCGCCCCGTGCAGACCAC CCAGGAGGAGGACGGCTGCAGCTGCAGGTTCCCCGAGGAGGAGGAGGGGGGCTGCGAGCTGCGG GTGAAGTTCAGCAGGAGCGCCGACGCCCCTGCTTACCAGCAGGGCCAGAATCAGCTGTACAACG AGCTGAATCTGGGCCGGAGGGAGGAGTACGACGTGCTGGACAAGCGGAGGGGCAGGGACCCCGA GATGGGCGGCAAGCCCAGGCGGAAGAACCCCCAGGAGGGGCTGTACAACGAGCTGCAGAAGGAC AAGATGGCCGAGGCCTACTCCGAGATCGGCATGAAGGGCGAGAGGCGGAGAGGCAAGGGCCATG ACGGCCTGTACCAGGGCCTGTCCACCGCCACCAAGGACACCTACGACGCCCTGCACATGCAGGCCCTGCCCCCCCGC (SEQ ID NO: 952); ATGGCCCTGCCCGTTACCGCCCTACTCCTGCCCCTGGCCCTCCTGCTCCACGCCGCCAGGCCCC AGGTTCAACTCGTTGAGTCCGGCGGCGGCCTTGTCCAACCTGGTGGGAGTTTGCGGTTGTCCTG TGTACTTAGCGGCAGAACCTTTAGCTCATACGCGATGGGATGGTTTCGCCAAGCGCCGGGTAAA GAGCGAGAGTTCGTATCAACTATCAGCTTGTCTGGCGGATCAACGTTCTATAGCGGTTCTGCCA AAGGACGGTTCACCATTTCAAGAGACAATGCGAAAAACACTGTATATCTGCAGATGAATAGTCT CAAACCTGAGGACACTGCCGTCTACTATTGTGCTGCTCGGCCAGTTTTGATAAGCCGAAGTAGC ACCGATTATGCCTACTGGGGACCTGGTACTCAGGTGACCGTTTCCAGTACCACCACCCCTGCCC CCAGGCCCCCCACCCCCGCCCCCACCATCGCCAGCCAGCCCCTGTCCCTGCGGCCCGAGGCCTG CCGGCCCGCCGCCGGCGGCGCCGTGCACACCCGGGGCCTGGACTTCGCCTGCGACATCTACATC TGGGCCCCCCTGGCCGGAACCTGCGGCGTGCTGCTGCTGTCCCTGGTGATCACCCTGTACTGCA AGCGGGGCCGGAAGAAGCTGCTGTACATCTTCAAGCAGCCCTTCATGCGCCCCGTGCAGACCAC CCAGGAGGAGGACGGCTGCAGCTGCAGGTTCCCCGAGGAGGAGGAGGGGGGCTGCGAGCTGCGG GTGAAGTTCAGCAGGAGCGCCGACGCCCCTGCTTACCAGCAGGGCCAGAATCAGCTGTACAACG AGCTGAATCTGGGCCGGAGGGAGGAGTACGACGTGCTGGACAAGCGGAGGGGCAGGGACCCCGA GATGGGCGGCAAGCCCAGGCGGAAGAACCCCCAGGAGGGGCTGTACAACGAGCTGCAGAAGGAC AAGATGGCCGAGGCCTACTCCGAGATCGGCATGAAGGGCGAGAGGCGGAGAGGCAAGGGCCATG ACGGCCTGTACCAGGGCCTGTCCACCGCCACCAAGGACACCTACGACGCCCTGCACATGCAGGC CCTGCCCCCCCGC (SEQ ID NO: 953); ATGGCCCTGCCCGTTACCGCCCTACTCCTGCCCCTGGCCCTCCTGCTCCACGCCGCCAGGCCCC AGGTGCAACTCGTAGAAAGCGGGGGTGGGTTGGTTCAAACCGGTGGCTCATTGCGATTGTCCTG CGCGGCATCTGGAAGAACGTTTAGTTCTTATGCGATGGGTTGGTTTAGGCAGGCTCCTGGAAAG GAACGGGAATTTGTCGCCGCAATCACCTGGTCAGGTGGATCCACCTATTACGCAAACAGTGTAA AGGGGCGCTTTACAATCTCTCGGGACAACGCTAAAAATACAGTGGATTTGCAAATGAACAGTCT CAAGCCCGAGGACACAGCAGTCTATTATTGCACTCCTGGAGAAGAAGTAGCCGGTAAGTATTTT AGACCTCTGTATGATTATTGGGGGCAAGGGACGCAAGTTACCGTTTCATCAACCACCACCCCTG CCCCCAGGCCCCCCACCCCCGCCCCCACCATCGCCAGCCAGCCCCTGTCCCTGCGGCCCGAGGC CTGCCGGCCCGCCGCCGGCGGCGCCGTGCACACCCGGGGCCTGGACTTCGCCTGCGACATCTAC ATCTGGGCCCCCCTGGCCGGAACCTGCGGCGTGCTGCTGCTGTCCCTGGTGATCACCCTGTACT GCAAGCGGGGCCGGAAGAAGCTGCTGTACATCTTCAAGCAGCCCTTCATGCGCCCCGTGCAGAC CACCCAGGAGGAGGACGGCTGCAGCTGCAGGTTCCCCGAGGAGGAGGAGGGGGGCTGCGAGCTG CGGGTGAAGTTCAGCAGGAGCGCCGACGCCCCTGCTTACCAGCAGGGCCAGAATCAGCTGTACA ACGAGCTGAATCTGGGCCGGAGGGAGGAGTACGACGTGCTGGACAAGCGGAGGGGCAGGGACCC CGAGATGGGCGGCAAGCCCAGGCGGAAGAACCCCCAGGAGGGGCTGTACAACGAGCTGCAGAAG GACAAGATGGCCGAGGCCTACTCCGAGATCGGCATGAAGGGCGAGAGGCGGAGAGGCAAGGGCCATGACGGCCTGTACCAGGGCCTGTCCACCGCCACCAAGGACACCTACGACGCCCTGCACATGCA GGCCCTGCCCCCCCGC (SEQ ID NO: 954); ATGGCCCTGCCCGTTACCGCCCTACTCCTGCCCCTGGCCCTCCTGCTCCACGCCGCCAGGCCCC AGGTGCAACTGGTTGAGTCCGGCGGTGGCTTGGTACAGCCCGGCGGCAGTCTCCGACTTAGTTG TACGGCGTCAGGTCGCACAATTGCGAGCACGATTATGGGCTGGTACAGACAAACGCCCGGCAAA GAACGGGAATTTGTCGCTATCAGCGCTAGGAGCGGCGATTCCGAATCCTATGCAAGTTCAGTGA AGGATAGGTTTACCATCAGTCGCGATAATGCGAAAAATACCGTCTACCTCCAGATGAACAATTT GAAACCTGAGGACACTGCTATATATTACTGCTACTGGAATACGGGAGCAGGAACCATCTGGGGG CAGGGAACACAAGTGACTGTCTCTTCCACCACCACCCCTGCCCCCAGGCCCCCCACCCCCGCCC CCACCATCGCCAGCCAGCCCCTGTCCCTGCGGCCCGAGGCCTGCCGGCCCGCCGCCGGCGGCGC CGTGCACACCCGGGGCCTGGACTTCGCCTGCGACATCTACATCTGGGCCCCCCTGGCCGGAACC TGCGGCGTGCTGCTGCTGTCCCTGGTGATCACCCTGTACTGCAAGCGGGGCCGGAAGAAGCTGC TGTACATCTTCAAGCAGCCCTTCATGCGCCCCGTGCAGACCACCCAGGAGGAGGACGGCTGCAG CTGCAGGTTCCCCGAGGAGGAGGAGGGGGGCTGCGAGCTGCGGGTGAAGTTCAGCAGGAGCGCC GACGCCCCTGCTTACCAGCAGGGCCAGAATCAGCTGTACAACGAGCTGAATCTGGGCCGGAGGG AGGAGTACGACGTGCTGGACAAGCGGAGGGGCAGGGACCCCGAGATGGGCGGCAAGCCCAGGCG GAAGAACCCCCAGGAGGGGCTGTACAACGAGCTGCAGAAGGACAAGATGGCCGAGGCCTACTCC GAGATCGGCATGAAGGGCGAGAGGCGGAGAGGCAAGGGCCATGACGGCCTGTACCAGGGCCTGT CCACCGCCACCAAGGACACCTACGACGCCCTGCACATGCAGGCCCTGCCCCCCCGC (SEQ ID NO: 955); ATGGCCCTGCCCGTTACCGCCCTACTCCTGCCCCTGGCCCTCCTGCTCCACGCCGCCAGGCCCC AGCTTCAGCTTGTGGAAAGCGGAGGGGGCCTGGTGCAAGCAGGTGGCAGTCTTCGACTCTCATG TGCGGCGTCAGGACGGACTGTCAGTTCATACGCCATGGGCTGGTTCAGGCAGGCACCGGGCAAA GAAAGGGAGTTTGTCGCGGCCATTAGTTGGTCTGGGGGGAGCACTTACTATGCCGATAGTGTTA AGGGTAGATTTACTATTAGTCGCGATAACGCTAAGAACACCGTTTATTTGCAGATGAACTCACT TAAACCAGAGGATACAGCAGTGTACTATTGCGCTGCCGACCCCAGCCTGAGTCGCACCATGGAC GAGATAGGCTCCTGGGGTCAAGGAACGCAGGTCACGGTTTCCTCTACCACCACCCCTGCCCCCA GGCCCCCCACCCCCGCCCCCACCATCGCCAGCCAGCCCCTGTCCCTGCGGCCCGAGGCCTGCCG GCCCGCCGCCGGCGGCGCCGTGCACACCCGGGGCCTGGACTTCGCCTGCGACATCTACATCTGG GCCCCCCTGGCCGGAACCTGCGGCGTGCTGCTGCTGTCCCTGGTGATCACCCTGTACTGCAAGC GGGGCCGGAAGAAGCTGCTGTACATCTTCAAGCAGCCCTTCATGCGCCCCGTGCAGACCACCCA GGAGGAGGACGGCTGCAGCTGCAGGTTCCCCGAGGAGGAGGAGGGGGGCTGCGAGCTGCGGGTG AAGTTCAGCAGGAGCGCCGACGCCCCTGCTTACCAGCAGGGCCAGAATCAGCTGTACAACGAGC TGAATCTGGGCCGGAGGGAGGAGTACGACGTGCTGGACAAGCGGAGGGGCAGGGACCCCGAGAT GGGCGGCAAGCCCAGGCGGAAGAACCCCCAGGAGGGGCTGTACAACGAGCTGCAGAAGGACAAGATGGCCGAGGCCTACTCCGAGATCGGCATGAAGGGCGAGAGGCGGAGAGGCAAGGGCCATGACG GCCTGTACCAGGGCCTGTCCACCGCCACCAAGGACACCTACGACGCCCTGCACATGCAGGCCCT GCCCCCCCGC (SEQ ID NO: 956); ATGGCCCTGCCCGTTACCGCCCTACTCCTGCCCCTGGCCCTCCTGCTCCACGCCGCCAGGCCCC AGGTCCAGTTGGTGGAGAGCGGCGGTGGGTTGGTTCAGGCGGGAGGGTCTCTCAGGCTGAGCTG TGCTGCAAGTGGGAATATCGTCGACATCGACGATATGGGTTGGTACCGCCAAGCACCTGGGAAG CAACGAGATTTGGTTGCATCTATAACCGCAGGCAGAATAACCAAATATGCTGATAGCGCGAAAG GAAGGTTTACAATATCTAGGGATAATGTTAAAAATACCGTTTATCTCCAGATGAACTCACTGAA GCCAGAAGATACCGCGACTTATTACTGTTACGCAATAAGGCGGTCATACCCAAGGTTCGACTAC TGGGGACAGGGGACACAGGTCACAGTGTCAAGCACCACCACCCCTGCCCCCAGGCCCCCCACCC CCGCCCCCACCATCGCCAGCCAGCCCCTGTCCCTGCGGCCCGAGGCCTGCCGGCCCGCCGCCGG CGGCGCCGTGCACACCCGGGGCCTGGACTTCGCCTGCGACATCTACATCTGGGCCCCCCTGGCC GGAACCTGCGGCGTGCTGCTGCTGTCCCTGGTGATCACCCTGTACTGCAAGCGGGGCCGGAAGA AGCTGCTGTACATCTTCAAGCAGCCCTTCATGCGCCCCGTGCAGACCACCCAGGAGGAGGACGG CTGCAGCTGCAGGTTCCCCGAGGAGGAGGAGGGGGGCTGCGAGCTGCGGGTGAAGTTCAGCAGG AGCGCCGACGCCCCTGCTTACCAGCAGGGCCAGAATCAGCTGTACAACGAGCTGAATCTGGGCC GGAGGGAGGAGTACGACGTGCTGGACAAGCGGAGGGGCAGGGACCCCGAGATGGGCGGCAAGCC CAGGCGGAAGAACCCCCAGGAGGGGCTGTACAACGAGCTGCAGAAGGACAAGATGGCCGAGGCC TACTCCGAGATCGGCATGAAGGGCGAGAGGCGGAGAGGCAAGGGCCATGACGGCCTGTACCAGG GCCTGTCCACCGCCACCAAGGACACCTACGACGCCCTGCACATGCAGGCCCTGCCCCCCCGC (SEQ ID NO: 957); ATGGCCCTGCCCGTTACCGCCCTACTCCTGCCCCTGGCCCTCCTGCTCCACGCCGCCAGGCCCC AAGTTCAATTGGTAGAGTCCGGTGGAGGACTGGTCCAACCGGGAGGGTCTTTGCGGTTGTCATG CGCCGCCTCTGGCAGCATTTTTTCTGTGAATGATATGGGTTGGTATCGACAAGCGCCTGGTAAG CAACGGGAACTCGTAGCCGCGATATATTCCGGTGGCTCTACAAATTACGCGGATAGTGTAAAAG GCCGGTTTACCATCTCCCGAGATAATGCTAAGAATACCGTCTATCTTCAAATGAACAGCTTGAA GCCCGAGGACACAGCAGTGTATTATTGCAACGCCGACATTGTAGTGGTCACGACTACCCCTCCG AGTTTCCCTATGCCCTATCGGTTCTTGGAGGTATGGGGTCAGGGAACGCTTGTTACTGTAAGTT CTACCACCACCCCTGCCCCCAGGCCCCCCACCCCCGCCCCCACCATCGCCAGCCAGCCCCTGTC CCTGCGGCCCGAGGCCTGCCGGCCCGCCGCCGGCGGCGCCGTGCACACCCGGGGCCTGGACTTC GCCTGCGACATCTACATCTGGGCCCCCCTGGCCGGAACCTGCGGCGTGCTGCTGCTGTCCCTGG TGATCACCCTGTACTGCAAGCGGGGCCGGAAGAAGCTGCTGTACATCTTCAAGCAGCCCTTCAT GCGCCCCGTGCAGACCACCCAGGAGGAGGACGGCTGCAGCTGCAGGTTCCCCGAGGAGGAGGAG GGGGGCTGCGAGCTGCGGGTGAAGTTCAGCAGGAGCGCCGACGCCCCTGCTTACCAGCAGGGCC AGAATCAGCTGTACAACGAGCTGAATCTGGGCCGGAGGGAGGAGTACGACGTGCTGGACAAGCGGAGGGGCAGGGACCCCGAGATGGGCGGCAAGCCCAGGCGGAAGAACCCCCAGGAGGGGCTGTAC AACGAGCTGCAGAAGGACAAGATGGCCGAGGCCTACTCCGAGATCGGCATGAAGGGCGAGAGGC GGAGAGGCAAGGGCCATGACGGCCTGTACCAGGGCCTGTCCACCGCCACCAAGGACACCTACGA CGCCCTGCACATGCAGGCCCTGCCCCCCCGC (SEQ ID NO: 958); ATGGCCCTGCCCGTTACCGCCCTACTCCTGCCCCTGGCCCTCCTGCTCCACGCCGCCAGGCCCC AGGTTCAGTTGGTTGAATCTGGAGGTGGTCTCGTACAGGTCGGCGGGTCATTGCGGCTGTCCTG CTCTATTAGCAGGAGCATTGCAATTTTTAATTTTATGGCCTGGTATAGGGAGGCCGAAGGGAAG CAGCGGGAACTCGTCGCCTCCATCACTGGCGGGAGTCGACTGTCATATATTGATAGTGTTAAGG GACGCTTCACGGTCAGTAAGGACACAGCTAACAATACACTCGATCTCCAAATGAACTCCCTGCG ACCAGAGGACACCGCCGTGTATCGATGCGCGGCGTCTAGTCCGTTTGCTGGTGAGTTCTGGGGC CAAGGGACCCAGGTAACTGTGTCTTCAACCACCACCCCTGCCCCCAGGCCCCCCACCCCCGCCC CCACCATCGCCAGCCAGCCCCTGTCCCTGCGGCCCGAGGCCTGCCGGCCCGCCGCCGGCGGCGC CGTGCACACCCGGGGCCTGGACTTCGCCTGCGACATCTACATCTGGGCCCCCCTGGCCGGAACC TGCGGCGTGCTGCTGCTGTCCCTGGTGATCACCCTGTACTGCAAGCGGGGCCGGAAGAAGCTGC TGTACATCTTCAAGCAGCCCTTCATGCGCCCCGTGCAGACCACCCAGGAGGAGGACGGCTGCAG CTGCAGGTTCCCCGAGGAGGAGGAGGGGGGCTGCGAGCTGCGGGTGAAGTTCAGCAGGAGCGCC GACGCCCCTGCTTACCAGCAGGGCCAGAATCAGCTGTACAACGAGCTGAATCTGGGCCGGAGGG AGGAGTACGACGTGCTGGACAAGCGGAGGGGCAGGGACCCCGAGATGGGCGGCAAGCCCAGGCG GAAGAACCCCCAGGAGGGGCTGTACAACGAGCTGCAGAAGGACAAGATGGCCGAGGCCTACTCC GAGATCGGCATGAAGGGCGAGAGGCGGAGAGGCAAGGGCCATGACGGCCTGTACCAGGGCCTGT CCACCGCCACCAAGGACACCTACGACGCCCTGCACATGCAGGCCCTGCCCCCCCGC (SEQ ID NO: 959); and ATGGCCCTGCCCGTTACCGCCCTACTCCTGCCCCTGGCCCTCCTGCTCCACGCCGCCAGGCCCC AGGTGCAGCTGGTGGAATCAGGGGGACGCTTGGTTCAAGCAGGGGGTAGCCTTAGGTTGTCTTG TGCGGCAAGTGGGCGGACGTTTAATACAATGGCCTGGTTTCGACAGGCACCTGGAAAGGAAAGG GAATTTGTAGCTGCCATCACCTGGTCCGGGGGGTTGACATACTACGAGGATAGCGTAAAAGGGA GGTTTACAATTTTTCGAGACAACGCAAAAAATTTGGCATACCTTCAGCTCAACTCATTGAAACC CGAGGATACAGCTGTATATTCTTGTGCCGCCCGATCAACTTTTAGGACTGCCCTGGTTAATACT GTTACGGCGTATGACACTTGGGGACAAGGCACCCAAGTGACGGTAAGCTCAACCACCACCCCTG CCCCCAGGCCCCCCACCCCCGCCCCCACCATCGCCAGCCAGCCCCTGTCCCTGCGGCCCGAGGC CTGCCGGCCCGCCGCCGGCGGCGCCGTGCACACCCGGGGCCTGGACTTCGCCTGCGACATCTAC ATCTGGGCCCCCCTGGCCGGAACCTGCGGCGTGCTGCTGCTGTCCCTGGTGATCACCCTGTACT GCAAGCGGGGCCGGAAGAAGCTGCTGTACATCTTCAAGCAGCCCTTCATGCGCCCCGTGCAGAC CACCCAGGAGGAGGACGGCTGCAGCTGCAGGTTCCCCGAGGAGGAGGAGGGGGGCTGCGAGCTG CGGGTGAAGTTCAGCAGGAGCGCCGACGCCCCTGCTTACCAGCAGGGCCAGAATCAGCTGTACAACGAGCTGAATCTGGGCCGGAGGGAGGAGTACGACGTGCTGGACAAGCGGAGGGGCAGGGACCC CGAGATGGGCGGCAAGCCCAGGCGGAAGAACCCCCAGGAGGGGCTGTACAACGAGCTGCAGAAG GACAAGATGGCCGAGGCCTACTCCGAGATCGGCATGAAGGGCGAGAGGCGGAGAGGCAAGGGCC ATGACGGCCTGTACCAGGGCCTGTCCACCGCCACCAAGGACACCTACGACGCCCTGCACATGCA GGCCCTGCCCCCCCGC (SEQ ID NO: 960).

Images